IASLC 2022 World Conference on Lung Cancer

AUGUST 6-9, 2022 | VIENNA, AUSTRIA

CONQUERING THORACIC CANCERS WORLDWIDE

PROGRAM BOOK

IASLC 2022 World Conference on Lung Cancer

August 6-9, 2022 | Vienna, Austria

wclc2022.iaslc.org #WCLC22

ILCN
IASLC LUNG CANCER NEWS

Visit ILCN.org

SCAN TO VIEW

The official news source
of the only global association
dedicated to the multidisciplinary
study of lung cancer

IASLC 2022-23
MEETINGS SCHEDULE

IASLC 2022 North America Conference on Lung Cancer
September 23-25, 2022
Chicago, Illinois
#NACLC22

IASLC 2022 Asia Conference on Lung Cancer
October 27-29, 2022
Nara, Japan
#ACLC22

IASLC 2023 Latin America Conference on Lung Cancer
January 25-27, 2023
Montevideo, Uruguay
#LALCA23

IASLC 2023 Targeted Therapies of Lung Cancer
February 22-25, 2023
Santa Monica, California
#TTLC23

IASLC 2023 World Conference on Lung Cancer
September 9-12, 2023
Singapore
#WCLC23

IASLC.org/Meetings-Webinars

Scan the QR code for information on upcoming meetings and webinars

IASLC
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
Conquering Thoracic Cancers Worldwid

CONNECT WITH US
@IASLC
facebook.com/IASLC
@iaslungcancer
linkedin.com/IASLC
IASLC

*Location and dates subject to change

TABLE OF CONTENTS

1. Welcome

Welcome Messages 7
Conference Summary 10

2. IASLC & WCLC Committees

International Association for the Study of Lung Cancer (IASLC) 13
IASLC Board of Directors 2021 – 2023 14
WCLC Program Committees 14
International Abstract Review Committees 18

3. General Conference Information

Health & Safety Measures at WCLC 2022 23
Registration 25
Virtual Platform and Mobile App 26
Press and Media 26
Information for Invited Faculty and Abstract Presenters 28
Oral Abstract Presenters 29
Mini Oral Presenters 29
Poster Presenters 29
Poster Display Time 30
Presenters in Attendance 30
Poster Setup Time 30
Poster Takedown Time 30
ePosters 30
Invited Speakers and Discussants 30
Onsite Services and General Information 31

4. Continuing Medical Education

Continuing Medical Education 37

5. IASLC & Conference Awards

IASLC Distinguished Service Award Winners 41
IASLC Lectureship Award Winners 44
WCLC 2022 Early Career Education Award Winners 45
WCLC 2022 Developing Nation Education Award Winners 46
IASLC Patient Advocacy Award Winners 47
IASLC Nurse and Allied Health Professional Award Winners 47
Cancer Care Team Award Winners 47

6. Conference Program

Program at a Glance 49
Friday, August 5 51
Saturday, August 6 52
Sunday, August 7 53
Monday, August 8 57
Tuesday, August 9 61
On-Demand Sessions 65
Program by Track 67

7. Daily Scientific Program

Friday, August 5 81
Saturday, August 6 83
Sunday, August 7 87
Monday, August 8 99
Tuesday, August 9 112
On-Demand Sessions 122

8. Poster Sessions

Sunday, August 7 125
Monday, August 8 130

9. ePosters

ePosters 137

10. Author Index

Author Index 171

11. Maps & Floor Plans

Messe Wien Exhibition and Congress Center 219
Foyer D & Hall C 220
Congress Center 221

12. Exhibit & Sponsor Information

Conference Supporters 223
Exhibit Floor Plan 225
Exhibitors Listings 226
Exhibitor & Supporter Descriptions 227

13. Industry Symposia

Saturday, August 6 237
Sunday, August 7 240
Monday, August 8 241

CONFERENCE SECRETARIAT
International Conference Services Ltd. (ICS)

Suite 710, 1201 West Pender Street,
Vancouver, BC, Canada, V6E 2V2

Phone: +1 604 681 2153
Fax: +1 604 681 1049

www.icsevents.com

ICS
International Conference Services

GLOBAL OFFICES
Vancouver, Toronto, Denver,
London, Barcelona, Vienna,
Tokyo, Singapore



1 WELCOME MESSAGES

WELCOME FROM THE MAYOR

City of Vienna

Sehr geehrte Kongressteilnehmerinnen und –teilnehmer!

Als Bürgermeister und Landeshauptmann von Wien ist es mir eine große Ehre und Freude, Sie bei der „2022 World Conference on Lung Cancer“ in Österreichs Bundeshauptstadt begrüßen zu dürfen.
Bei diesem großen und bedeutsamen Netzwerk-Treffen haben Tausende Expertinnen und Experten aus aller Welt die Gelegenheit, ihren neuesten Wissenstand auf dem Gebiet der Thoraxonkologie (Thoracic Onkology) zum Wohle der Patientinnen und Patienten auszutauschen und zu vertiefen.

Ich bin überzeugt davon, dass Sie sich in Wien wohlfühlen werden. Nicht umsonst wurde unsere Millionenstadt erst jüngst wieder von der International Congress and Convention Association (ICCA) zur beliebtesten Kongressstadt der Welt gewählt.

Das hat mehrere Gründe: Zum einen ist Wien mit seinen Parks und Erholungsmöglichkeiten die „grünste Stadt“ der Welt, und zum anderen ist das kulturelle Angebot bei uns – derzeit läuft auch vor dem Wiener Rathaus das weltberühmte Musikfilmfestival - groß und vielfältig.

In diesem Sinne wünsche ich Ihnen einen informativen Kongress und einen abwechslungsreichen Aufenthalt in Wien!

Dear Conference Participants,

As Mayor and Governor of Vienna, it is a great honour and pleasure for me to welcome you to the Austrian capital on occasion of the 2022 World Conference on Lung Cancer.

This large and important network meeting provides thousands of experts from all around the world with an opportunity to exchange and deepen the latest knowledge in the area of thoracic oncology in the interest of the patients.

I am sure that you will enjoy your stay in Vienna as our city has recently been renamed the world’s leading meeting destination in the ranking of the International Congress and Convention Association (ICCA).

There are several reasons for this: with its numerous parks and leisure opportunities Vienna is one of the greenest city in the world but also provides vast cultural offerings such as the current film festival in front of Vienna City Hall.

On this note, I would like to wish you an informative congress and an enjoyable stay in Vienna!

© Stadt Wien/PID, Fotograf Königshofer

Dr. Michael Ludwig
Bürgermeister und Landeshauptmann von Wien
Mayor and Governor of Vienna

WELCOME FROM THE WCLC 2022 CONFERENCE CHAIRS

Dear Colleagues from around the World,
Welcome! Willkommen!

The International Association for the Study of Lung Cancer (IASLC) and the WCLC 2022 Conference Chairs take great pleasure to welcome you to the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) in Vienna. In 2016, the WCLC took place in Vienna for the first time, and much has changed since then. The IASLC now has more than 6,000 members from over 100 countries, and the WCLC has become the premier Conference devoted to all aspects of the management of lung cancer and other thoracic malignancies.

The IASLC 2022 WCLC offers four days of intense scientific activity bringing together more than 4,000 delegates from all fields in basic and clinical sciences related to thoracic malignancies. We are proud to have received 1,474 abstracts which are organized in oral, mini oral, and poster sessions. More than 380 invited lectures, 60 oral and 84 mini oral presentations as well as almost 1,000 posters and ePosters will contribute to the exchange of new information among delegates.

We encourage you to participate actively in the discussions, and also to enjoy the beauty of Vienna – its music, architecture, culture, gastronomy – and to immerse yourself in the ancient imperial traditions along with the modern lifestyle.

To facilitate discussions and networking opportunities we have a mobile app (available in App and Google Play Store), that will allow delegates to ask questions and chat with other participants during the sessions.

Don't miss the opportunity to visit our Poster Viewing reception on Sunday and Monday evening and note that all posters (including ePosters) are available for viewing during networking breaks in the Exhibit Hall.

We also would like to extend our gratitude and thanks to all sponsors and exhibitors for their continued support to WCLC and IASLC. Without them this Conference would not be possible.

Thank you for joining us in Vienna or online. We wish all delegates an enjoyable and productive Conference in this historic and significant region of the world.

Yours sincerely,

Robert Pirker, MD
Austria

Eric Lim, MD
United Kingdom

Françoise Mornex, MD, PhD
France

Silvia Novello, MD, PhD
Italy

Helmut Prosch, MD
Austria

WELCOME FROM THE IASLC PRESIDENT AND CEO

Dear WCLC Participants,

As the President and the CEO of the IASLC, we are thrilled to welcome you to the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) in beautiful Vienna. We are honored that you have chosen to join us for what is sure to be a rigorous, fascinating and collaborative meeting.

This year marks the 23rd WCLC, serving as a unique moment to pause and reflect on how this meeting and the thoracic oncology field have evolved over the past four decades. During that time, we've seen extraordinary progress in the field of lung cancer diagnosis and treatment, with the discovery of new biomarkers, new screening techniques and the rise of precision medicine leading to improvements in overall mortality and quality of life for patients.

Throughout its long history, the WCLC has played a strong role in facilitating that progress – providing a platform for sharing cutting-edge research, creating space for new collaborations and partnerships, connecting established researchers with young investigators and serving as a foundational meeting for health care professionals (representing the full spectrum of the multidisciplinary team), patients and advocates who have dedicated their lives to conquering these challenging diseases. This enduring importance is illustrated in how the WCLC has evolved over time – growing from a gathering of approximately 100 colleagues in the late-1970s to an expansive conference that regularly attracts over 7,500 international participants. Such growth in size, impact and relevance did not happen by accident. We are grateful to our previous WCLC conference presidents, organizers and participants. Additionally, we want to honor our past and current board members, as well as former CEOs Heine H. Hansen, Paul A. Bunn Jr. and Fred R. Hirsch for their leadership of the IASLC – from its formative years to the present day.

But while the story of the WCLC is well-established, we know that we must always be looking to the future if we are to continue making inroads in the treatment of thoracic cancers. That is why for WCLC 2022 we are proud to announce that the conference organizers have put together an incredible scientific program that includes almost 1,480 abstracts. We want to thank them for their hard work, and we are especially grateful for the dedication and leadership of our Conference Chairs: Drs. Robert Pirker, Eric Lim, Françoise Mornex, Silvia Novello, and Helmut Prosch. The program is organized in to 17+ specialized tracks and covers the latest advances in biology, prevention, screening, staging and treatment. With its ground-breaking plenaries, interactive breakfast sessions, research abstracts and specialized sessions, we have no doubt that you will find WCLC 2022 to be an exceptional educational experience.

Thank you for attending WCLC 2022 and thank you for your engagement with the IASLC. We hope you enjoy the meeting; have the opportunity to explore Vienna and the surrounding countryside; find opportunities to develop new relationships and collaborations; and, finally gain novel skills and insights that can be applied to improving the lives of thoracic cancer patients – both in your local communities and worldwide. Like so much of what the IASLC does, the success of the WCLC hinges on the passion, commitment and engagement of those who attend it. In short, your participation is one of the main reasons for why the event has remained the world's leading thoracic cancer conference for over 40 years. We also encourage you to participate in the IASLC Steps Challenge, which is a seven-day virtual walk-a-thon that will raise money to support Research Grants. We appreciate you being a part of our ongoing story.

Heather Wakelee, MD

President,
International Association for the Study of Lung Cancer (IASLC)

Karen Kelly, MD

Chief Executive Officer,
International Association for the Study of Lung Cancer (IASLC)



Messe Wien Exhibition and Congress Center
Foyer D Entrance, Messepl. 1, 1021 Wien, Austria

Closest Metro Station: U2 Station Krieau

ONSITE REGISTRATION

Foyer D, Ground Level, (U2 Station Krieau)
Messe Wien Exhibition & Congress Center

Friday, August 5, 2022	07:30 - 18:00
Saturday, August 6, 2022	07:00 - 20:30
Sunday, August 7, 2022	06:30 - 19:00
Monday, August 8, 2022	07:00 - 19:00
Tuesday, August 9, 2022	07:00 - 16:00

SPEAKER PREVIEW ROOM & LOUNGE

VIP Lounge D, Upper Level, Messe Wien Exhibition & Congress Center

Friday, August 5, 2022	14:00 - 18:00
Saturday, August 6, 2022	07:00 - 19:30
Sunday, August 7, 2022	07:00 - 16:30
Monday, August 8, 2022	07:00 - 16:30
Tuesday, August 9, 2022	07:00 - 15:45

EXHIBITION HALL

Hall B, Ground Level, Messe Wien Exhibition & Congress Center

Saturday, August 6, 2022 **(Welcome Reception)**	19:45 - 21:00
Sunday, August 7, 2022	09:45 - 19:00
Monday, August 8, 2022	09:45 - 19:00
Tuesday, August 9, 2022	09:45 - 14:15

COAT & BAGGAGE CHECK

Foyer D, Ground Level, Messe Wien Exhibition & Congress Center

Friday, August 5, 2022	08:00 - 17:00
Saturday, August 6, 2022	07:00 - 22:00
Sunday, August 7, 2022	06:30 - 20:00
Monday, August 8, 2022	07:00 - 20:00
Tuesday, August 9, 2022	07:00 - 17:30

MEDIA WORK ROOM

Piazza, Upper Level, Messe Wien Exhibition & Congress Center

Saturday, August 6, 2022	08:00 - 18:00
Sunday, August 7, 2022	08:00 - 18:00
Monday, August 8, 2022	08:00 - 18:00
Tuesday, August 9, 2022	08:00 - 18:00

IASLC BUSINESS MEETING

Strauss 3, Ground Level, Messe Wien Exhibition & Congress Center

Tuesday, August 9, 2022	10:00 - 10:45

IASLC AWARD CEREMONY

Lehar 1, Ground Level, Messe Wien Exhibition & Congress Center

Saturday, August 6, 2022	17:00 – 17:45

2 IASLC & WCLC COMMITTEES

IASLC & WCLC COMMITTEES

International Association for the Study of Lung Cancer (IASLC)

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes nearly 8,000 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the *Journal of Thoracic Oncology*, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

- To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
- To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public
- To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

IASLC

999 17th Street, Suite 200 - Denver, Colorado 80202-2725

Phone: 1-855-GO-IASLC (1-855-464-2752)

IASLC Staff

Karen Kelly
Chief Executive Officer

John Skadow
Chief Financial Officer

Matt Yeingst
Chief Development Officer

Tessa Baxter
ILC Foundation Coordinator / Project Manager

Becky Bunn
Senior Advisor, Scientific Relations

Mya Burns
Associate Director, Conferences

Casey Connolly
Scientific Affairs Specialist

Bailey Creamer
Editorial Assistant

Kathy Doherty
Director, Human Resources

Ken Harrell
Database Administrator

O'Ryan Jackson
Administrative Assistant

Vun Sin Lim
Editorial Consultant JTO Clinical and Research Reports

Sara Lindsey Patton
Patient Advocacy Specialist

Katie Maher
Member Experience Specialist

Sunhee Malinowski
Account Manager

Jan Mazotti
Associate Director, Marketing and Communications

Karen Muth
Executive Assistant and Board Liaison

Rodrigo Sagastegui
Marketing Specialist

Mary Todd
Managing Editor, JTO & JTO CRR

Kelsey Wood
Associate Director, Member Experience

Kelly Wright
Member Experience Coordinator

Murry Wynes, PhD
Senior Advisor, Scientific Affairs

Kexin Yu
Accountant

Flavia Zarcula
Corporate Relations Manager

IASLC BOARD OF DIRECTORS 2021 – 2023

OFFICERS:

President
Heather Wakelee, United States

Past-President
Tetsuya Mitsudomi, Japan

President-Elect
Paul Van Schil, Belgium

Secretary
Andrea Bezjak, Canada

Treasurer
Erik Thunnissen, Netherlands

Chief Executive Officer
Karen Kelly, United States

BOARD OF DIRECTORS:

Joachim Aerts	*Netherlands*
Carlos Gil Moreira Ferreira	*Brazil*
Jhanelle Gray	*United States*
Roy Herbst	*United States*
Young Tae Kim	*South Korea*
Morten Quist	*Denmark*
Lecia Sequist	*United States*
Ming-Sound Tsao	*Canada*
Paula Ugalde	*United States*
Caicun Zhou	*China*

WCLC PROGRAM COMMITTEES

WCLC CONFERENCE CHAIRS:

Robert Pirker, Austria
Eric Lim, United Kingdom
Françoise Mornex, France
Silvia Novello, Italy
Helmut Prosch, Austria

EARLY DETECTION AND SCREENING:

Mario Silva, Chair, Italy
Monica Castro, Co-Chair, Argentina
Ivy Elkins, United States
John Field, United Kingdom
Anna Kerpel-Fronius, Hungary
Annette McWilliams, Australia
Ugo Pastorino, Italy
Nir Peled, Israel
Ricardo Sales Santos, Brazil

EARLY STAGE NON-SMALL CELL LUNG CANCER – NEOADJUVANT AND ADJUVANT SYSTEMIC THERAPY (MULTI-MODALITY TREATMENT, IMMUNOTHERAPY, MOLECULAR TARGETED TREATMENTS):

Mariano Provencio, Chair, Spain
Natasha Leighl, Co-Chair, Canada
Jamie Chaft, United States
Rafal Dziadziusko, Poland
Enriqueta Felip, Spain
Nicolas Girard, France
Stephanie Saw, Singapore
Yi Long Wu, China
Caicun Zhou, China

EARLY STAGE NON-SMALL CELL LUNG CANCER – RADIOTHERAPY AND OTHER ABLATIVE TECHNIQUES:

Lizza Hendriks, Chair, Netherlands
Shankar Siva, Co-Chair, Australia
Yong Chan Ahn, South Korea
Kevin Chua Lee Min, Singapore
Yasushi Nagata, Japan
Umberto Ricardi, Italy
Rocco Trisolini, Italy
Maria Werner-Wasik, United States

WCLC PROGRAM COMMITTEES

EARLY STAGE NON-SMALL CELL LUNG CANCER – SURGERY:

Masahiro Tsuboi, Chair, Japan
Giulia Veronesi, Co-Chair, Italy
Alessandro Brunelli, United Kingdom
Jessica Donington, United States
Mir Ali Reza Hoda, Austria
Young Tae Kim, South Korea
Katherine Kuhns, United States
Valerie Rusch, United States
Alan Sihoe, Hong Kong
Jonathan Spicer, Canada
Ricardo Terra, Brazil
Wen-Zhao Zhong, China
Jie Wang, China

EPIDEMIOLOGY:

Paolo Boffetta, Chair, Italy
Christine Berg, Co-Chair, United States
Hermann Brenner, Germany
David Christiani, United States
Rayjean Hung, Canada
Mattias Johansson, France
Qing Lan, United States
Adonina Tardon, Spain

GLOBAL HEALTH, HEALTH SERVICES RESEARCH, AND HEALTH ECONOMICS:

Clarissa Mathias, Chair, Brazil
Suresh Senan, Co-Chair, Netherlands
Fabrice Barlesi, France
Digambar Behera, India
Peter Berzinec, Slovakia
Caleb Egwuenu, Nigeria
Tewodros Haile, Ethiopia
Mohana Roy, United States
Martin Sebastian, Germany
Chunxia Su, China

LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER – CHEMORADIOTHERAPY AND RADIOTHERAPY:

Andrea Bezjak, Chair, Canada
Matthias Guckenberger, Co-Chair, Switzerland
Dirk de Ruysscher, Netherlands
Wilfried Eberhardt, Germany
Ken Harada, Japan
Ross Soo, Singapore
Anna Wrona, Poland
Milada Zemanova, Czech Republic
Zheng-Fei Zhu, China

LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER – NEOADJUVANT AND ADJUVANT THERAPY:

Luis Paz-Ares, Chair, Spain
Virginie Westeel, Co-Chair, France
Oscar Arrieta, Mexico
Christophe Dooms, Germany
Maximilian Hochmair, Austria
Julia Judd, United States
Thomas Newsom-Davis, United Kingdom
Qing Zhou, China

LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER - SURGERY:

Shanda Blackmon, Chair, United States
Andrea Bille, Co-Chair, United Kingdom
Margaret Blair Marshall, United States
Oleg Pikin, Russia
Geatano Rocco, United States
Brendon Stiles, United States
Hauke Winter, Germany

MANAGEMENT OF LUNG CANCER IN THE ERA OF COVID-19:

Marina Garassino, Chair, United States
Christian Grohe, Co-Chair, Germany
Alfredo Addeo, Switzerland
Leanne Ashrafian, United Kingdom
Jackie Fenemore, United Kingdom
Abdul Rahman Jazieh, Saudi Arabia
Eldsamira Mascarenhas, Brazil

MESOTHELIOMA, THYMOMA, AND OTHER THORACIC MALIGNANCIES:

Paul Baas, Chair, Netherlands
Dean Fennell, Co-Chair, United Kingdom
Leah Backhus, United States

WCLC PROGRAM COMMITTEES

Paolo Bironzo, Italy
Joseph Friedberg, United States
Ritu Gill, United States
Raffit Hassan, United States
Marko Jakopovic, Croatia
Anna Nowak, Australia
Jordi Remon, Spain
Enrico Ruffini, Italy
Arnaud Scherpereel, France
Leah Taylor, United Kingdom
David Waller, United Kingdom

METASTATIC NON-SMALL CELL LUNG CANCER – IMMUNOTHERAPY:

Pilar Garrido, Chair, Spain
Sanjay Popat, Co-Chair, United Kingdom
Charu Aggarwal, United States
Michael Boyer, Australia
Federico Cappuzzo, Italy
Shun Lu, China
Martin Reck, Germany
Kostas Syrigos, Greece
Daniel Tan, Singapore

METASTATIC NON-SMALL CELL LUNG CANCER – MOLECULAR TARGETED TREATMENTS:

Benjamin Besse, Chair, France
Lorenza Landi, Co-Chair, Italy
Joachim Aerts, Netherlands
Odd Terje Brustugun, Norway
Andrew Ciupek, United States
Baohui Han, China
Pasi Jänne, United States
Helena Linardou, Greece
Laura Mezquita, Spain
Amanda Tufman, Germany

METASTATIC NON-SMALL CELL LUNG CANCER – OLIGOMETASTATIC DISEASE:

Anne-Marie Dingemans, Chair, Netherlands
Fiona McDonald, Co-Chair, United Kingdom
Mara Antonoff, United States
Saulius Cicenas, Lithuania
Simon Ekman, Sweden
Yesim Eralp, Turkey
Jorge Gomez, United States
Hans Hoffmann, Germany
Isabelle Opitz, Switzerland
Ben Slotman, Netherlands

METASTATIC NON-SMALL CELL LUNG CANCER – PALLIATIVE CHEMOTHERAPY:

Giorgio Scagliotti, Chair, Italy
Navneet Singh, Co-Chair, India
Antonio Araujo, Portugal
Sofia Baka, Greece
Khaled Kamal, Egypt

METASTATIC NON-SMALL CELL LUNG CANCER – PALLIATIVE RADIOTHERAPY:

Fiona Hegi-Johnson, Chair, Australia
Sara Ramella, Co-Chair, Italy
Jeff Bradley, United States
Karin Dieckmann, Austria
Jill Feldman, United States
Andrea Filippi, Italy
Kristin Higgins, United States
Billy Loo, United States
Alexandra Louie, Canada

NURSING AND ALLIED HEALTH PROFESSIONALS:

Maria Ftanou, Chair, Australia
Michelle Turner, Co-Chair, United States
Somaya Abou-Abdou, Egypt
Melissa Culligan, United States
Jacqui Frowen, Australia
Nazanin Nouriany, Canada
Morten Quist, Denmark
Alison Homes Tisch, United States

PALLIATIVE AND SUPPORTIVE CARE:

Alberto Chiappori, Chair, United States
Jose Belderbos, Co-Chair, Netherlands

WCLC PROGRAM COMMITTEES

Semra Bilaceroglu, Turkey
Emilio Bria, Italy
Joe Y. Chang, United States
Andreas Charalambous, Greece
Satoko Kono, Japan
Manali Patel, United States
Kavitha Ramchandran, United States

PATIENT ADVOCACY:

Christina Sit, Chair, Canada
Stefania Vallone, Co-Chair, Spain
Anne-Marie Baird, Ireland
Lorraine Dallas, United Kingdom
Merel Hennink, Netherlands
Shani Shilo, Israel
Ewelina Szmytke, Poland

PATHOLOGY:

Sylvia Lantuejoul, Chair, France
Keith Kerr, Co-Chair, United Kingdom
Sanja Dacic, United States
Patrick Micke, Sweden
Yuko Minami, Japan
Andrew Nicholson, United Kingdom
Masayuki Noguchi, Japan
Helmut Popper, Austria
Fernando Lopez Rios, Spain
Ales Ryska, Czech Republic
Erik Thunnissen, Netherlands

PULMONOLOGY, RADIOLOGY AND STAGING:

Jin Mo Goo, Chair, South Korea
Daniele Gompelmann, Co-Chair, Austria
Hisao Asamura, Japan
Wentao Fang, China
Kwun Meng Fong, Australia
Rudolf Huber, Germany
Ankush Jajodia, India
Edith Marom, Israel
Lucia Viola, Colombia

SMALL CELL LUNG CANCER AND NEURO-ENDOCRINE TUMOURS:

Raffaele Califano, Chair, United Kingdom
Melissa L. Johnson, Co-Chair, United States
Andrea Ardizzoni, Italy
Corinne Favire-Finn, United Kingdom
Guyla Ostoros, Hungary
Upal Basu Roy, United States
Miyako Satouchi, Japan
Egbert Smit, Netherlands
Jens Benn Sorensen, Denmark
Sumitra Thongprasert, Thailand

TOBACCO CONTROL AND RISK REDUCTION:

Jacek Jassem, Chair, Poland
Bill Evans, Co-Chair, Canada
May Myat Cho, Thailand
Nagla Abdel Karim, United States
Judith (Jodi) Prochaska, United States
Matthew Steliga, United States
Emily Stone, Australia
Ning Wu, China
Xiuyi Zhi, China

TUMOUR BIOLOGY AND BIOMARKERS:

Caroline Dive, Chair, United Kingdom
Kurt Schalper, Co-Chair, United States
Prasad Adusumilli, United States
Martin Filipits, Austria
Philippe Joubert, Canada
Umberto Malapelle, Italy
Amy Moore, United States
Kenneth O'Byrne, Australia
Sandra Ortiz-Cuaran, France
Christian Rolfo, United States
Jie Wang, China

INTERNATIONAL ABSTRACT REVIEW COMMITTEES

Nagla Abdel Karim, United States
Somaya Abou-Abdou, Egypt
Alfredo Addeo, Switzerland
Prasad Adusumilli, United States
Joachim Aerts, Netherlands
Charu Aggarwal, United States
Yong Chan Ahn, South Korea
Mara Antonoff, United States
Antonio Araujo, Portugal
Andrea Ardizzoni, Italy
Oscar Arrieta, Mexico
Hisao Asamura, Japan
Leanne Ashrafian, United Kingdom
Fredrick Asirwa, Kenya
Paul Baas, Netherlands
Leah Backhus, United States
Anne-Marie Baird, Ireland
Haval Balata, United Kingdom
David Baldwin, United Kingdom
Upal Basu Roy, United States
Mary Beth Beasley, United States
Digambar Behera, India
Jose Belderbos, Netherlands
Sabina Berezowska, Switzerland
Christine Berg, United States
Eric Bernicker, United States
Pietro Bertoglio, Italy
Peter Berzinec, Slovakia
Ricardo Beyruti, Brazil
Semra Bilaceroglu, Turkey
Andrea Bille, United Kingdom
Paolo Bironzo, Italy
Paolo Boffetta, Italy
Alain Borczuk, United States
Andrea Borondy Kitts, United States
Souheil Boubia, France
Michael Boyer, Australia
Jeff Bradley, United States
Luka Brcic, Austria
Emilio Bria, Italy
Caitlin Broderick, Australia
Alessandro Brunelli, United Kingdom
Odd Terje Brustugun, Norway
Lukas Bubendorf, Switzerland
Guoping Cai, United States
Raffaele Califano, United Kingdom
Federico Cappuzzo, Italy
Giuseppe Cardillo, Italy
Monica Castro, Argentina
Milena Cavic, Serbia
Joe Y. Chang, United States
Andreas Charalambous, Cyprus
Alberto Chiappori, United States
May Myat Cho, Thailand
Ricardo Terra, United States
Teh-Ying Chou, Taiwan
Kevin Chua Lee Min, Singapore
Jin-Haeng Chung, South Korea
Saulius Cicenas, Lithuania
Andrew Ciupek, United States
Wendy Cooper, Australia
Sanja Dacic, United States
Roselle De Guzman, Philippines
Marc de Perrot, Canada
Dirk de Ruysscher, Netherlands
Karin Dieckmann, Austria
Anne-Marie Dingemans, Netherlands
Caroline Dive, United Kingdom
Jessica Donington, United States
Christophe Dooms, Germany
Carolyn Dresler, United States
Elizabeth Dudnik, Israel
Mary Duffy, Australia
Wilfried Eberhardt, Germany
Simon Ekman, Sweden
Ivy Elkins, United States
Yesim Eralp, Turkey
Jeremy John Erasmus, United States
Bill Evans, Canada
Wentao Fang, China
Nicholas Faris, United States
Babalola Faseru, United States

Joelle Fathi, United States
Corinne Favire-Finn, United Kingdom
Jill Feldman, United States
Enriqueta Felip, Spain
Emanuela Felley-Bosco, Switzerland
Dean Fennell, United Kingdom
John Field, United Kingdom
Martin Filipits, Austria
Andrea Filippi, Italy
Pier Luigi Filosso, Italy
Kwun Meng Fong, Australia
Patrick Forde, United States
Joseph Friedberg, United States
Jacqui Frowen, Australia
Maria Ftanou, Australia
Francoise Galateau-Salle, France
Marina Garassino, United States
Pilar Garrido, Spain
Oliver Gautschi, Czech Republic
Ritu Gill, United States
Nicolas Girard, France
Ioannis Gkiozos, Greece
Daniela Gompelmann, Austria
Maciej Goniewicz, United States
Jin Mo Goo, South Korea
Jhanelle Gray, United States
Christian Grohe, Germany
Matthias Guckenberger, Switzerland
Tewodros Haile, Ethiopia
Baohui Han, China
Yuchen Han, China
Ken Harada, Japan
Seiki Hasegawa, Japan
Raffit Hassan, United States
Hidetoshi Hayashi, Japan
Fiona Hegi-Johnson, Australia
Lizza Hendriks, Netherlands
Merel Hennink, Netherlands
Kristin Higgins, United States
Maximilian Hochmair, Austria
Mir Ali Reza Hoda, Austria
Hans Hoffmann, Germany
Alison Holmes Tisch, United States
Rudolf M. Huber, Germany
David Hwang, Canada
Mauricio Infante, United States
Deepali Jain, India
Ankush Jajodia, India
Marko Jakopovic, Croatia
Seung Hun Jang, South Korea
Pasi Janne, United States
Jacek Jassem, Poland
James Jett, United States
Long Jiang, China
Mattias Johansson, France
Melissa L. Johnson, United States
Philippe Joubert, Canada
Ayten Kayi Cangir, Turkey
Kemp Kernstine, United States
Anna Kerpel-Fronius, Hungary
Hong Kwan Kim, South Korea
Yeol Kim, South Korea
Young Tae Kim, South Korea
Hedy Lee Kindler, United States
Nicole Kiss, Australia
Mark Klein, United States
Peter Kneuertz, United States
Robert Kratzke, United States
Kaoru Kubota, Japan
Stephen Lam, Canada
Stepanie Land, United States
Lorenza Landi, Italy
Natasha Leighl, Canada
Whitney Lewis, United States
Yolande Lievens, Belgium
Eric Lim, United Kingdom
Helena Linardou, Greece
Herbert Loong, Hong Kong
Fernando Lopez, Spain
Alexandra Louie, Canada
Shun Lu, China
Gustavo Lyons, Argentina
Umberto Malapelle, Italy
Nabanita Mandal, India
Aaron Mansfield, United States
Mirella Marino, Italy
Edith Marom, Israel
Thomas Marron, United States

Margaret Blair Marshall, United States
Eldsamira Mascarenhas, Brazil
Clarissa Mathias, Brazil
José Matilla, Spain
Daisuke Matsubara, Japan
Fiona McDonald, United Kingdom
Sara McLaughlin-Barrett, Australia
Annette McWilliams, Australia
Laura Mezquita, Spain
Patrick Micke, Sweden
Andrzej Milewski, Poland
Yuko Minami, Japan
Mari Mino-Kenudson, United States
Deebya Mishra, Nepal
Tetsuya Mitsudomi, Japan
Drew Moghanaki, United States
Luis Montuenga, Spain
Amy Moore, United States
Carlos gil Moreira Ferreira, Brazil
Merel Nissenberg Mountain, United States
Sudish Murthy, United States
Yasushi Nagata, Japan
Ursula Nestle, Switzerland
Thomas Newsom-Davis, United Kingdom
Andrew Nicholson, United Kingdom
Kim Norris, United States
Nazanin Nouriany, Canada
Junichi Soh, Japan
Anna Nowak, Australia
Kenneth O'Byrne, Australia
Emma O'Dowd, United Kingdom
Sandra Ortiz-Cuaran, France
Raymond U. Osarogiagbon, United States
Gyula Ostoros, Hungary
Marcin Ostrowski, Poland
Harvey Pass, United States
Manali Patel, United States
Hofman Paul, France
Luis Paz Ares, Spain
Tobias Peikert, United States
Nir Peled, Israel
Oleg Pikin, Russia
Claudia Poleri, Argentina
Sanjay Popat, United Kingdom
Helmut Popper, Austria
Helmut Prosch, Austria
Mariano Provencio, Spain
Paul Martin Putora, Switzerland
Morten Quist, Denmark
Kavitha Ramchandran, United States
Sara Ramella, Italy
Ramón Rami-Porta, Spain
Martin Reck, Germany
Natasha Rekhtman, United States
Jordi Remon, Spain
Joshua Reuss, United States
Umberto Ricardi, Italy
Maureen Rigney, United States
Andreas Rimner, United States
Geatano Rocco, United States
Anja Roden, United States
Christian Rolfo, United States
Mohana Roy, United States
John Ruckdeschel, United States
Enrico Ruffini, Italy
Valerie Rusch, United States
Ales Ryska, Czech Republic
Witold Rzyman, Poland
Ricardo Sales Santos, Brazil
Rachel Sanborn, United States
Jacob Sands, United States
Beth Sandy, United States
Edgardo Santos, United States
Anjali Saqi, United States
Miyako Satouchi, Japan
Stephanie Saw, Singapore
Giorgio Scagliotti, Italy
Kurt Schalper, United States
Arnaud Scherpereel, France
Jun Nakajima, Italy
Martin Sebastian, Germany
Yoshitaka Sekido, Japan
Suresh Senan, Netherlands
Claudia Henschke, Spain
Anant Mohan, United States
Abhishek Shankar, India
Shani Shilo, Israel
Hyo Sup Shim, South Korea

Lynette Sholl, United States
Elaine Shum, United States
Alan Sihoe, Hong Kong
Mario Silva, Italy
Navneet Singh, India
Christina Sit, Canada
Shankar Siva, Australia
Ben Slotman, Netherlands
Matthew Smeltzer, United States
Egbert Smit, Netherlands
Ross Soo, Singapore
Jonathan Spicer, Canada
Matthew Steliga, United States
Daniel Sterman, United States
Conor Steuer, United States
Brendon Stiles, United States
Emily Stone, Australia
Chunxia Su, China
Francisco Suarez, Chile
J. Marie Suga, United States
Kostas Syrigos, Greece
Adonina Tardon, Spain
Erik Thunnissen, Netherlands
Betty Tong, United States
William Travis, United States
Rocco Trisolini, Italy
Ming Tsao, Canada
Yasuhiro Tsutani, Japan
Amanda Tufman, Germany
Akif Turna, Turkey
James Huang, United States
Michelle Turner, United States
Paula Ugalde, Canada
Stefania Vallone, Italy
Jan Van Meerbeeck, Belgium
Paul Van Schil, Belgium
Luigi Ventura, Italy
Giulia Veronesi, Italy
Lucia Viola, Colombia
Jan Von Der Thussen, Netherlands
David Waller, United Kingdom
Jie Wang, China
Shun-ichi Watanabe, Japan
Stefan Watzka, Austria
Annikka Weissferdt, United States
Virginie Westeel, France
Paul Wheatley-Price, Canada
Kahren White, Australia
Hauke Winter, Germany
Ignacio Wistuba, United States
Ning Wu, China
Yi Long Wu, China
Chi-Fu Yang, United States
Gail Darling, United States
Dawei Yang, China
David Yankelevitz, United States
Yasushi Yatabe, Japan
Sonam Puri, United States
Milada Zemanova, Czech Republic
Caicun Zhou, China
Qing Zhou, China
Zheng-fei Zhu, China

3 GENERAL INFORMATION

HEALTH & SAFETY MEASURES AT WCLC 2022

WCLC 2022 will be hosted as an in-person meeting in Vienna, Austria at the Messe Wien Convention & Exhibition Center. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to Vienna, all necessary precautions will be taken to ensure a safe environment throughout the Conference.

The following measures are in place and enforced on-site to achieve this commitment (applicable to all staff, delegates, exhibitors, sponsors, and guests):

Vaccination

All in-person attendees at WCLC 2022 must be fully vaccinated against COVID-19 by the time of the Conference. Fully vaccinated refers to completing the approved first 2 vaccines, as per the guidelines of their country of residence.

All participants, including attendees, speakers, staff, and suppliers will be asked to present proof of full vaccination and photo ID with a matching name prior to entry into the Conference Venue.

Access will be denied if proper proof of full vaccination is not provided. Proof of a negative test will NOT be a substitute for vaccination. Accepted Forms of Proof: (Note: Proof of vaccination must match the Attendee's name)

- Copy of an official certificate from your Country/State/Province
- Photo of the official certificate
- Digital PDF or document of the official certificate on a mobile device
- Accepted Vaccines: as per approved guidelines from the country of residence

If you cannot or choose not to comply with the IASLC health and safety protocols, or if you are unable to come to Vienna, please join us virtually for live-streamed sessions, Q&A, and other interactive features.

If you will not be fully vaccinated by the time of the Conference and are registered for the in-person meeting, you may change your registration to virtual-only by sending an email request to **WCLC2022-registration@icsevents.com**.

Mask Requirement

Masks will be required to be worn at all times in all WCLC 2022 session rooms and at networking events.

The only time masks may be removed is when you are eating, drinking, taking medication, or presenting. The mask mandate will be strictly enforced by security. There will be masks available at the Registration Desk, located in Foyer D of the Messe Convention Centre & Exhibition Center for the convenience of attendees.

We strongly recommend all participants administer self-tests at least 24 hours prior to coming on-site to the venue. An onsite testing facility will be available free of charge to all delegates.

By registering to attend, you agree that:

- You will not attend if you have any COVID-19 symptoms
- If during your attendance you develop any COVID-19 symptoms, you will immediately:
- Self-isolate;
  - Comply with all local/national government restrictions; and
  - Inform the WCLC 2022 Conference Secretariat by email (**WCLC2022-Registration@icsevents.com**).

IASLC and their suppliers will in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.

THE BiTE® UNIVERSE IS EXPANDING

WITH THE GOAL OF TARGETING MULTIPLE TUMOR TYPES

Amgen is contributing to the advancement of cancer treatment with the investigational BiTE® immuno-oncology platform. This versatile technology is engineered to deliver off-the-shelf therapies that direct patients' own T cells to target tumor-associated antigens, activating their cytotoxic potential.[1,2] Currently being investigated in multiple tumor types and extended half-life therapies, BiTE® technology is designed to close the space between patients' T cells and tumors.[1,3]

Learn more about the BiTE® platform by visiting the Amgen medical booth

WE'RE BRINGING BiTE TO THE FIGHT™

BiTE, Bispecific T-cell Engager.

AMGEN®

Oncology

Advancing oncology at the speed of life™

BCMA, B-cell maturation antigen; CD, cluster of differentiation; DLL3, delta-like ligand 3; FLT3, FMS-like tyrosine kinase 3; MUC17, mucin 17; PSMA, prostate-specific membrane antigen.

References: 1. Baeuerle PA, Kufer P, Bargou R. *Curr Opin Mol Ther*. 2009;11:22-30. **2.** Frankel SR, Baeuerle PA. *Curr Opin Chem Biol*. 2013;17:385-392. **3.** Amgen. Amgen Pipeline. Accessed March 31, 2022.

© 2022 Amgen Inc. All rights reserved.
SC-ELMAC-CP-00038 4/22

REGISTRATION LOCATION

Foyer D, Ground Level, Messe Wien Exhibition & Congress Center

HOURS OF OPERATION

Friday, August 5, 2022	07:30 - 18:00
Saturday, August 6, 2022	07:00 - 20:30
Sunday, August 7, 2022	06:30 - 19:00
Monday, August 8, 2022	07:00 - 19:00
Tuesday, August 9, 2022	07:00 - 16:00

REGISTRATION MATERIALS:

Registration Materials Include:

- Name Badge
- Ribbons (if applicable)
- Mini Pocket Program
- Printed Conference Program (only if printed version selected during registration)
- Public Transportation Ticket

NAME BADGES:

Delegates and guests are requested to wear their name badge at all times in order to participate in the Scientific Sessions, Networking Events and Exhibition.

DELEGATE HELP AND VISIT VIENNA DESK

Foyer D, Ground Level, Messe Wien Exhibition & Congress Center

HOURS OF OPERATION

Friday, August 5, 2022	07:30 - 18:00
Saturday, August 6, 2022	07:00 - 20:30
Sunday, August 7, 2022	06:30 - 19:00
Monday, August 8, 2022	07:00 - 19:00
Tuesday, August 9, 2022	07:00 - 16:00

Visit the Help Desk for Information on the scientific sessions and networking events. Information on Vienna tours and attractions, restaurant reservations and general information can be found at the Visit Vienna Desk.

VIRTUAL PLATFORM / MOBILE APP HELP DESK

Foyer D, Ground Level, Messe Wien Exhibition & Congress Center

Visit the Virtual Platform and Mobile App Help Desk for information on watching sessions online, asking questions, sending connection requests, or downloading conference resources.

If you have log-in related questions, you can get help here as well.

HOURS OF OPERATION

Friday, August 5, 2022	07:30 - 18:00
Saturday, August 6, 2022	07:00 - 20:30
Sunday, August 7, 2022	06:30 - 19:00
Monday, August 8, 2022	07:00 - 19:00
Tuesday, August 9, 2022	07:00 - 16:00

PRESS AND MEDIA / MEDIA WORK ROOM

Piazza, Upper Level, Messe Wien Exhibition & Congress Center

HOURS OF OPERATION

Saturday, August 6, 2022	08:00 - 18:00
Sunday, August 7, 2022	08:00 - 18:00
Monday, August 8, 2022	08:00 - 18:00
Tuesday, August 9, 2022	08:00 - 18:00

PRESS CONFERENCES

Schubert 5/6, Upper Level, Messe Wien Exhibition & Congress Center

SCHEDULE TIME

Sunday, August 7, 2022	10:05 - 10:45
Monday, August 8, 2022	10:25 - 11:00
Tuesday, August 9, 2022	10:05 - 10:45

Press releases will be posted on the Conference website at the conclusion of each Conference day. The Press Conferences will be live streamed. The link will be made available to all registered Press & Media Representatives.

PRESS AND MEDIA REGISTRATION AND ACCESS

Press and Media passes are issued to journalists, including photographers and freelance journalists, after providing proof of accreditation. Pre-registration form and proof of accreditation must be submitted prior to the Conference. Press and Media representatives are required to check in at the regular Registration Counters when they arrive on-site.

PRESS RELEASE POLICY

Press releases that feature data or events involving the WCLC should include the full name of the meeting, specifically: **IASLC 2022 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer**. Further, we respectfully request that the release include the official conference hashtag: **#WCLC22.** To learn more, please visit **www.iaslc.org**.

Abstracts selected for inclusion in the WCLC press program will be kept under embargo until either the time of the presentation or the beginning of the WCLC press conference in which it is presented, whichever comes first. All abstracts covered in the WCLC press program will receive a press release.

All other abstracts have been available since Tuesday, July 12, 2022 on the Conference website at **wclc2022.iaslc.org**

All abstracts, including those presented in the press program, will be published as an online supplement to the *Journal of Thoracic Oncology (JTO)*.

SOCIAL MEDIA POLICY

Organizations may use social media to disseminate news and information regarding abstracts being presented at the WCLC. All information distributed through social media channels must adhere to the IASLC's embargo policy. Please use the IASLC's World Conference hashtag, **#WCLC22** in any social media posts. Members of the media are permitted to photograph and transmit/share on any social media platform any presentation's slides without approval from the presenter and/or the IASLC unless explicitly forbidden. However, authors retain the copyright to their full slide presentations and all copyright laws.

INTERVIEW POLICY

For an in-person meeting, all interviews outside of press conferences must be arranged in advance with interviewees and must take place in IASLC approved and designated rooms, with an IASLC meeting backdrop. No last-minute or hallway interviews are permitted inside the conference facility, IASLC staff are available to help schedule interviews and a limited number of designated interview rooms are available, complimentary to credentialed media and may be scheduled for up to two hours. Sign up is required.

For questions, please see the IASLC staff in the Media Room.

Media organizations filming a large amount of video content must contact the IASLC in advance **CMartin@DavidJamesGroup.com** and must meet the following requirements:

1. All filming must take place in one designated spot (contact the IASLC for that location).
2. No filming of sessions is allowed.
3. All filming must be done in front of backdrop which includes any of the below linked images of the IASLC logo. This may be co-branded to have your logo as well, as long as the IASLC logo is visible in the final footage.
4. All filming must include the official name of the Conference "IASLC 2022 World Conference on Lung Cancer" in the questions asked of the interviewees, and acknowledgement must be given to the fact that the interview was conducted at the WCLC.
5. Any footage placed on your website must include a reference to the IASLC World Conference on Lung Cancer.
6. If possible, you may also include the Conference hashtag: **#WCLC22**

VIDEO, PHOTOGRAPHY AND AUDIO RECORDING POLICY

Photography, videotaping and audio recording are allowed for news coverage only in the following area/events:

- Press Conference / Media Availability
- Interview rooms
- Other designated locations (with IASLC approval)
- Recording in common areas requires permission and/or an IASLC staff escort

LIVE COVERAGE POLICY

We welcome the coverage of the event. Please contact us ahead of time to arrange this. An authorized representative of any press vehicle requiring electrical service or external cabling must be available to coordinate logistical details with the IASLC. Live coverage is restricted to designated areas or an area approved by IASLC staff and is on a first-come, first-served basis.

PRESENTATION SLIDES AND POSTER RELEASE POLICY

All presentation slides including audio or video recordings as well as the electronic poster files will be released on the virtual platform within 24 hours after the presentation, but only after the talk or the poster has been presented at the Conference.

MEDIA LIST POLICY

The IASLC does not release media lists for the IASLC World Conference on Lung Cancer.

INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS

DISCLOSURE INFORMATION

All invited speakers as well as oral and mini oral abstract presenters must include a slide with their financial disclosure information. Without a disclosure slide you will not be allowed to present!

PRESENTATION SLIDE TEMPLATE

All invited speakers as well as oral and mini oral abstract presenters are strongly encouraged to use the IASLC/WCLC presentation slide template for their presentation.

LANGUAGE GUIDE

Please review the IASLC Language Guide and ASCO Language of Respect to review guidelines on presentation best practices to promote the use of language that respects the dignity of people diagnosed with lung cancer.

To review the guideline, please visit at
https://wclc2022.iaslc.org/presenter-resources/

REGISTRATION

Invited Faculty

'Invited Faculty' Registration Counter (Session Chairs, Invited Speakers, Abstract Discussants)

Abstract Presenters

Pre-Registered Delegates Counter

SPEAKER PREVIEW ROOM & LOUNGE

VIP Lounge D, Upper Level, Messe Wien Exhibition & Congress Center

HOURS OF OPERATION

Friday, August 5, 2022	14:00 - 18:00
Saturday, August 6, 2022	07:00 - 19:30
Sunday, August 7, 2022	07:00 - 16:30
Monday, August 8, 2022	07:00 - 16:30
Tuesday, August 9, 2022	07:00 - 15:45

All invited speakers as well as oral and mini oral abstract presenters are encouraged to report to the Speaker Preview Room & Lounge at least 24 hours prior to their scheduled presentation to preview their slides and ensure all fonts appear as expected and all sound/video clips are working properly.

Due to CME regulations, changes to previously submitted and reviewed slides can only be allowed in exceptional circumstances.

NO FILE SUBMISSIONS WILL BE ACCEPTED IN THE SESSION ROOMS.

ORAL ABSTRACT PRESENTERS

- You will have a total of 10 minutes; 8 minutes of presentation, followed by 2 minutes time for questions from the audience. Time limits will be strictly enforced.
- You are asked to prepare a PPT Presentation with **maximum 10 slides** in **16:9 format** (not including title, author and disclosure slide).
- Please be in room for your session 10 minutes before the start time of the session. The session Chairs will start and end strictly on time.
- The presenting author must control all content.
- Slides, abstracts, and handouts cannot contain advertising, QR codes, corporate logos, trade names, or product-group messages of an ACCME-defined ineligible company.
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

MINI ORAL ABSTRACT PRESENTERS

- You will have a total of 5 minutes. Time limits will be strictly enforced.
- You are asked to prepare a PPT Presentation with **maximum 5 slides** in **16:9 format** (not including title, author and disclosure slide).
- Please be in room for your session 10 minutes before the start time of the session. The session Chairs will start and end strictly on time.
- The presenting author must control all content.
- Slides, abstracts, and handouts cannot contain advertising, QR codes, corporate logos, trade names, or product-group messages of an ACCME-defined ineligible company.
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

POSTER PRESENTERS

Poster Presenters are asked to prepare and print their poster(s) for display at the Conference (double sided cohesive tapes will be provided in the Exhibit Hall). The maximum poster size is: 1900mm (wide) x 1040mm (high) – landscape format. Poster Presentations/ Boards are located in the **Exhibit Hall (Hall B), Ground Level**, and each Poster Board is identified by a professionally lettered sign with the assigned Poster Number. The Poster Board Number corresponds with the pre-assigned Poster Number provided in your confirmation letter and printed in the Abstract Book and this Conference Program.

POSTER DISPLAY TIME

Posters for both Poster Sessions (P1 and P2) will be on display for the entire duration of the Conference.

Sunday, August 7, 2022	09:45 - 19:00
Monday, August 8, 2022	09:45 - 19:00
Tuesday, August 9, 2022	09:45 - 14:15

PRESENTERS IN ATTENDANCE

Poster Session P1
Sunday, August 7, 2022 17:00 - 19:00

Poster Session P2
Monday, August 8, 2022 17:15 - 19:00

Poster Presenters **MUST** place their poster(s) and be present during their assigned Poster Viewing Session. Presenting authors who do not comply may be at risk of having their abstract(s) rejected at future WCLC conferences.

POSTER SETUP TIME

Sunday, August 7, 2022 07:00 - 08:30

POSTER TAKEDOWN TIME

Tuesday, August 9, 2022 13:30 – 14:15

Any posters not removed by the end of Poster Takedown time will be discarded by management.

ePOSTERS

ePosters will be available for delegates to view in the exhibit hall during exhibit hall opening hours.

- You are asked to prepare a PPT Presentation with one (1) slide in 16:9 format.
- All e-Posters will be displayed on a 60-inch digital screen.

INVITED SPEAKERS AND DISCUSSANTS

- Employees of ACCME-defined **ineligible companies** are prohibited from presenting educational content for Continuing Medical Education.
- You are asked to prepare a PPT Presentation in **16:9 format**.
- Please be in room for your session 10 minutes before the start time of the session. The session Chairs will start and end strictly on time.
- The presenting author must control all content.
- Slides, abstracts, and handouts cannot contain advertising, QR codes, corporate logos, trade names, or product-group messages of an ACCME-defined **ineligible company**.
- All presenters MUST include statement disclosing any conflict of interest as the first slide of your presentation.
- The duration of presentation was provided in your invitation letter. If you are unsure of the length of your presentation, please contact **wclc2022-speakers@icsevents.com**.

ONSITE SERVICES AND GENERAL INFORMATION

IASLC MEETINGS & CONFERENCES MOBILE APP

Download the free IASLC Meetings and Conferences mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan and exhibitor biographies, and general Conference and venue information on our easy-to-use app!

The app is compatible with all iOS devices and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts.

Search for: IASLC Meetings & Conferences

IASLC WCLC 2022 VIRTUAL PLATFORM

All sessions will be audio recorded and made available on the Virtual Platform and the Mobile App within 24 hours. The Virtual Platform and Mobile App also include presentation slides, abstracts and posters.

Log-in details are sent to your registered email. If you need assistance, you can visit the Virtual Platform / Mobile App Help Desk in Foyer D, Ground Level or send an email to **wclc2022-registration@icsevents.com.**

GET THE WCLC 2022 VIRTUAL PLATFORM AT **MEETINGSAPP.IASLC.ORG/EVENT/WCLC2022**
All accepted abstracts are also included in the IASLC Meetings & Conferences Mobile App.

Available on the App Store

ANDROID APP ON Google play

APP STORE

ANDROID

IASLC SOCIAL MEDIA ACCOUNTS

- facebook.com/IASLC
- @IASLC
- IASLC
- IASLC
- iaslungcancer

ABSTRACTS

Abstracts selected for IASLC WCLC are presented in Oral, Mini Oral and Poster Sessions. The top rated abstracts featuring groundbreaking trials will be presented in the Presidential Symposium on Monday, August 8, 08:30 – 10:20.

All accepted and confirmed abstracts are published in a supplement of the *Journal of Thoracic Oncology* and on the Conference Website prior to IASLC 2022 WCLC.

ABSTRACTS ONLINE

Attendees are invited to view the abstracts available on the Conference website, the Mobile App and the Virtual Platform. You may search for abstracts, topics, presenters, and keywords. You can bookmark presentations and sessions building your own personal conference calendar.

ACCREDITATION

Please refer to CME Information on page 36 (CME Page) in this book for further information.

ATTIRE

Business casual is appropriate for all sessions and networking events. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

ATM

There are two ATM machines located in the Mall Area – One is located between Hall C and Foyer D, the other is close to the café between Hall A and Hall B.

BADGES AND ACCESS CONTROL

You will be required to wear your badge at all times within the venue.

BREAKFAST

The Conference does NOT provide breakfast except for the Interactive Breakfast Sessions (ticketed sessions) from Sunday – Tuesday from 07:30 – 08:15 or as otherwise indicated in the program.

CELL PHONES

As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CERTIFICATE OF ATTENDANCE

International attendees can request a 'Certificate of Attendance' by completing the Conference evaluation form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

CHARGING STATION

Charging Station is located in the Exhibit Hall (Hall B) allowing delegates to power up their cell phones, tablets, and other electronic devices for free.

COAT AND BAGGAGE CHECK

Foyer D, Ground Level, Messe Wien Exhibition & Congress Center

OPENING HOURS

Friday, August 5, 2022	08:00 - 17:00
Saturday, August 6, 2022	07:00 - 22:00
Sunday, August 7, 2022	06:30 - 20:00
Monday, August 8, 2022	07:00 - 20:00
Tuesday, August 9, 2022	07:00 - 17:30

DELEGATE LOUNGES

Exhibit Hall, Hall B, Ground Level, Messe Wien Exhibition & Congress Center

Delegate Lounges are available and located in the Exhibit Hall (Hall B). These lounges are specifically designed to provide a comfortable seating area for delegates to rest, conduct brief meetings or network with colleagues.

IASLC Membership Lounge
Reserved for IASLC Members

Patient Advocacy Lounge
Reserved for Patients, Survivors, Caregivers/ Partners, and Patient Advocates

Collaborative Meeting Space
Public space for a quick meeting for all delegates

EMERGENCY SERVICES AND FIRST AID

Dial **133** for police, **122** for Fire, and **144** for Ambulance service. Please have the number of your embassy with you when travelling. In case of fire at the Messe Wien, use the stairs and NOT the elevator for exit. Please follow the Messe Wien's instructions in case of emergency.

The first aid room is located in ARZT Room in Foyer CC, Ground Floor.

INTERNET CAFÉ

Exhibit Hall, Hall B, Ground Level, Messe Wien Exhibition & Congress Center

Keep in touch with home and office! Computers with internet and printers are available to delegates on a complimentary basis. The Internet Café is open during Exhibit Hall Hours. Internet sessions are limited to 15 minutes per delegate.

MOTHERS / PRAYER ROOM

Mothers / Prayer Room, Ground Level, Messe Wien Exhibition & Congress Center

IASLC is offering delegates the use of a private nursing room and the use of a multifaith prayer room located on the ground level next to Strauss 3.

LOST AND FOUND

The lost and found collection point is at the Registration Counter. Every object found around the Conference premises (by security, cleaning staff or attendees) is eventually delivered and centralized to the Registration Counter at the end of the day.

MEDIA WORK ROOM

Piazza, Upper Level, Messe Wien Exhibition & Congress Center

Workstations with internet access and copy machine will be available to press and media representatives. Support staff will also take reservations for the use of **Interview Room 1 & 2**.

OVERFLOW ROOMS

An overflow viewing area has been set up in **Lehar 2, 3 & 4**.

PARKING

Public car parking is available at multi-storey car park D / access via Trabrennstraße 3, 1020 Wien/ GPS-Coordinates: 48.212802, 16.412057 / entrance height on the ground floor: 3 meters; first floor: 2,10 meters. The parking fee is € 3.00 for the first hour and € 3.50 for every additional hour (incl VAT).

POSTERS ONLINE

All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in the Exhibit Hall (Hall B). In addition to the printed poster, each presenter is required to submit an electronic version of their poster to be made available in the Virtual Platform at **MEETINGSAPP.IASLC.ORG/EVENT/WCLC2022** and the Mobile App (available in the App and Google Play Store), which, is free of charge to all delegates.

PUBLIC TRANSPORTATION

We strongly recommend that you take public transportation whenever possible. Vienna offers efficient public transportation networks. For assistance, please visit the Delegate Help and Visit Vienna Desk in Foyer D, Ground Level, Messe Wien Exhibition & Congress Center.

All in-person delegates will receive a ticket for complimentary use of the public transportation system for the duration of the Conference with their registration materials.

RESTAURANTS

There are plenty of restaurant choices in Vienna and within walking distance from the Messe Wien Exhibition & Congress Center. The staff at the Delegate Help Desk will be happy to assist with recommendations and bookings.

SMOKING

The Messe Wien Exhibition & Congress Center is a smoke-free environment. All public areas, rental space, corridors, loading docks, exhibit halls, and parking lots are designated non-smoking. The Messe Wien Exhibition & Congress Center is required to enforce the no-smoking rules.

SPEAKER PREVIEW ROOM & LOUNGE

VIP Lounge D, Upper Level, Messe Wien Exhibition & Congress Center

All presenters are required to preview their slides at least 24 hours prior to their scheduled presentation to ensure compatibility with the Conference AV Equipment.

SPEAKER PREVIEW ROOM & LOUNGE	
Friday, August 5, 2022	14:00 - 18:00
Saturday, August 6, 2022	07:00 - 19:30
Sunday, August 7, 2022	07:00 - 16:30
Monday, August 8, 2022	07:00 - 16:30
Tuesday, August 9, 2022	07:00 - 15:45

VIRTUAL PLATFORM

The WCLC 2022 Virtual Platform is included in your registration and can be accessed through **MEETINGSAPP.IASLC.ORG/EVENT/WCLC2022**

Your personal Virtual Platform Log-in information will be sent to your registered email prior to the Conference. Should you need assistance to Log-in to the Virtual Platform, please contact **wclc2022-registration@icsevents.com**

ANDROID

APP STORE

WIRELESS INTERNET

Premium Attendee Wireless Internet Access is provided throughout the Messe Wien Exhibition & Congress Center. This service is suited for attendee general usage such as checking email social media, and web surfing. Users are restricted from Virtual Private Networks (VPN), Remote Desktop Protocols (RDP) and peer to peer protocols.

Wireless network is optimized to be used by devised operation in the 5GHz radio band (802.11 a/n ac). Although the service will be offered in the 2.4GHz radio band (802.11 g/n) the service is provided best effort due to the high levels of contention and interference present on the radio band.

To connect to the Wi-Fi, connect to:

Network:
WCLC2022

DISCLAIMER

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.

Join the IASLC Today!

Scan the QR code & enter

WCLCNewMember2022

to receive half off membership dues for one year.

IASLC

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

Conquering Thoracic Cancers Worldwid



4 CONTINUING MEDICAL EDUCATION

CONTINUING MEDICAL EDUCATION (CME)

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.

In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined **ineligible companies**. All disclosures are reviewed to identify relevant financial relationships and any conflicts of interest which are mitigated before the individual can assume their role in the activity.

ACCREDITATION AND CREDIT STATEMENT

The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IASLC designates this "other activity" (a live conference offered in a hybrid format including recorded virtual participation) for a maximum of *57.25 AMA PRA Category 1 Credit(s)*™.

GOAL & PURPOSE

The IASLC 2022 World Conference on Lung Cancer (WCLC 2022) is the world's largest international conference for clinicians, researchers, and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the conference offers opportunities for learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 20 educational tracks and over 300 global experts as invited speakers, WCLC 2022 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumour biomarkers, clinical trials, targeted therapies, liquid biopsy, lung cancer screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts, and posters.

TARGET AUDIENCE

The 2022 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Examine scientific advances in thoracic cancer including the pathogenesis, biology, and mechanisms of drug interactions that can be used to make evidence-based diagnosis and treatment decisions.
2. Synthesize cutting edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
3. Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
4. Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
5. Collaborate on multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
6. Engage and empower patients to become active participants in their treatment.

OFFICIAL LANGUAGE

The official language of the IASLC 2022 World Conference on Lung Cancer is English.

DISCLAIMER

The information presented at the IASLC 2022 World Conference on Lung Cancer is that of the contributing faculty and does not necessarily

represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

HOW TO RECEIVE A CME CERTIFICATION (PHYSICIANS ONLY)

Physicians are entitled to receive a CME certificate after completing the Conference evaluation survey. A link to this survey will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, physicians have the option to print or save their CME certificate.

CME certificates will reflect the number of accredited sessions attended. CME accredited activities are designated in the program guide. The deadline for claiming CME credit is **December 31, 2022**.

Please direct any certificate inquiries to: **cme@iaslc.org**

HOW TO RECEIVE A CERTIFICATE OF ATTENDANCE (NON-PHYSICIANS)

Non-physicians are entitled to receive a "Certificate of Attendance". To claim a Certificate of Attendance, non-physicians must first complete the Conference evaluation survey. A survey link will be emailed to all attendees at the conclusion of the Conference; the survey can also be accessed from the Conference website. After submitting the survey, attendees may print or save their Certificate of Attendance. **The deadline for receiving a Certificate of Attendance is December 31, 2022.**

Please direct any certificate inquiries to: **cme@iaslc.org**

LUNG CANCER CONSIDERED

with **Dr. Stephen Liu** and **Dr. Narjust Florez**

The official podcast of the IASLC.

Tune in each month for conversations with the researchers, healthcare professionals, patients and advocates from around the world who are making a difference in the treatment of thoracic cancers.

Find new podcast episodes at
IASLC.org/Lung-Cancer-Considered

Simply scan the QR Code and
start listening today.

Lung Cancer Considered
is funded in part by:
AstraZeneca,
Bristol Myers Squibb,
Lilly Oncology, and
Merck KGaA.

5 | IASLC & CONFERENCE AWARDS

IASLC Distinguished Service Awards

2022 Joseph W. Cullen Prevention / Early Detection Award

Edward Patz, MD

Dr. Edward Patz is a thoracic radiologist with a long-standing interest in early lung cancer detection, molecular diagnostics, and novel therapeutic strategies. Dr. Patz has been studying lung cancer for over 25 years, and has been involved with numerous clinical trials including the National Lung Cancer Screening Trial (NLST). Dr. Patz was on the ACRIN-NLST Executive Committee, helped design and was the Chair of the ACRIN-NLST Biomarker Committee, and have been involved with many other lung cancer initiatives, including the IASLC staging project.

Dr. Patz has also been the principal investigator of a basic science laboratory that currently has projects on clonal evolution of tumours, cell-free plasma DNA as biomarkers for early detection, and the role of inflammation in cancer. While remaining focused on early cancer detection and treatment, his out-of-the-box type of approach has required him to explore and integrate a broad spectrum of different disciplines. As below, this work has resulted in a number of seminal publications and impact on patient care, but this is an amazingly complex challenge that requires innovative strategies. His experience as both a clinical and basic science researcher, particularly in lung cancer biology, provides a unique perspective to help move these innovative types of translational projects forward with the ultimate goal to improve patient care and outcomes.

2022 Mary J. Matthews Pathology / Translational Research Award

Rafael Rosell, MD, PhD

Dr. Rafael Rosell is Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona, Barcelona, Spain), Chief Scientific Officer, Chairman and Founder of Pangaea Oncology SL (Barcelona), Chief Medical Officer and President of the Dr Rosell Oncology Institute (IOR), Quirón Dexeus, General de Catalunya & Sagrat Cor Univ. Hospitals (Barcelona), and Founder and President of the Molecular Oncology Research Foundation (Barcelona). He is Founder and Director of International Relations and Projects, Spanish Lung Cancer Group (SLCG), member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP) and on the Foundation Board of the ETOP- International Breast Cancer Study Group (IBCSG). He is also a Panel member of the ASCO Clinical Practice Living Guidelines- Systemic Therapy for Stage IV NSCLC.

Dr. Rosell's contributions to translational medical oncology, with particular emphasis in the field of non-small-cell lung cancer with EGFR mutations, have earned him international renown. Dr. Rosell is fully dedicated to the improvement of lung cancer therapy. His current research programs include continued investigation in translational/preclinical research, liquid biopsy, and novel technologies with NGS. In 2018, he was selected to participate in The European Liquid Biopsy Academy (ELBA).

IASLC Distinguished Service Awards

2022 Paul A. Bunn, Jr. Scientific Award

James Chih-Hsin Yang, MD, PhD

James Chih-Hsin Yang, MD, PhD, received his MD from National Taiwan University (NTU) in Taipei in 1986 and completed his PhD degree at the Graduate Institute of Clinical Medicine, NTU, in 2000. He completed his internal medicine residency at the NTU Hospital. Between 1992 and 1995, he undertook medical oncology fellowship training for early phase cancer trials and new cancer drug development at the National Cancer Institute at Bethesda, Maryland. He has been a staff member in the Department of Oncology at the NTU Hospital since 1995 and chair the Department of Oncology between 2015-2020. He was appointed as the superintendent (Director) of the NTU Cancer Center hospital in Aug 2020, Director of NTU Cancer Research Center in Aug 2021. He is the President of Taiwan Oncology Society since Sep 2021, the President of Taiwan Association for the Study of Lung Cancer since April 2022.

Dr Yang's research focuses on lung cancer treatment and the mechanism of resistance of chemotherapy, targeted therapy and immunotherapy. Dr Yang is a leader in lung cancer new drug development. He and other Asian investigators have established EGFR TKI as the front-line treatment for lung cancer patients with EGFR mutation (IPASS study). He is also the principal investigator of several studies that led to the global approval of the 2nd-generation irreversible EGFR TKI, afatinib, and contributed to the development of 3rd-generation EGFR TKI, osimertinib. His studies were highly focused on various approach to improve the treatment outcome of EGFR mutation positive patients. He contributed and established the standards for the treatment of uncommon EGFR mutations patients and leptomeningeal metastasis patients. His clinical research included EGFR TKI combination with chemotherapy, targeted therapies and immunotherapy. He has published more than 300 papers in peer-reviewed journals such as New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Lancet Respiratory Medicine, Cancer Discovery and Journal of Thoracic Oncology etc. He served more than 15 years as associate editor of Journal of Thoracic Oncology. He received many awards such as the 2nd Kobayashi Foundation Cancer Research Award from the Asian Clinical Oncology Society in 2012, the distinguished research award of the Taiwan National Science Council 2012-2015, the TECO award for biotechnology in 2015, distinguished research award of the Ministry of Science and Technology, Taiwan, from 2016-2018 and Academic Award from Taiwan Ministry of Education in 2018; Outstanding Scholar Award, Foundation For the Advancement of Outstanding Scholarship 2019 Aug -2021 Jan. Chair Professor Award, Taiwan Ministry of Education, 2021 Feb to 2024 Jan and Chair Professor of National Taiwan University in 2021. He is also the highly cited researcher of 2019, 2020, 2021 in Clinical Medicine category awarded by Clarivate Analytics (Web of Science Group). He gave numerous speech in international conferences, including many oral presentations of study reports in ASCO, ESMO and World Conference on Lung Cancer.

IASLC Distinguished Service Awards

2022 The Adi F. Gazdar IASLC Merit Award

Valerie Rusch, MD

Dr. Valerie W. Rusch is Attending Thoracic Surgeon, Vice Chair of Clinical Research, Department of Surgery and Member, Memorial Sloan-Kettering Cancer Center in New York, where she holds the Miner Family Chair in Intrathoracic Cancers. After residencies in general and cardiothoracic surgery at the University of Washington, she was a Faculty Associate at the MD Anderson Cancer Center, then a faculty member at the University of Washington. She moved to MSKCC in 1989, where she served as Chief of Thoracic Surgery from 2000 to 2013. Dr. Rusch's career has been devoted to thoracic surgical oncology, to clinical and translational research, and she has been PI for multiple NCI-sponsored Cooperative Group clinical trials. Dr. Rusch is a Past President of the American College of Surgeons, and has held leadership positions in ASCO, the Society for Thoracic Surgeons, the American Association for Thoracic Surgery, and the International Association for the Study of Lung Cancer. She has served as a Director and Chair of the American Board of Thoracic Surgery. Dr. Rusch is the recipient of multiple teaching awards, is author on more than 450 peer-reviewed publications, holds more than 50 visiting professorships and has delivered more than 400 invited lectures.

DISTINGUISHED SERVICE AWARD WINNERS

Year	Adi F. Gazdar IASLC Merit Award (Formerly IASLC Merit Award)	IASLC Mary J. Matthews Pathology/ Transational Research Award	IASLC Joseph W. Cullen Prevention/ Early Detection Award	IASLC Paul A. Bunn, Jr. Scientific Award (Formerly IASLC Scientific Award)
2021	Michael Boyer	Deepali Jain	Gabriella Sozzi	David P. Carbone
2020	Alex A. Adjei	Caroline Dive	Pan-Chyr Yang	Joan H. Schiller
2019	Hisao Asamura	Andrew Nicholson	Denise R. Aberle	Charles Rudin
2018	Françoise Mornex	Ignacio I. Wistuba	Fadlo Khuri Nise Yamaguchi	Charles Swanton
2017	Ramon Rami-Porta	Yasushi Yatabe	Carolyn Dresley	Tony Mok
2016	Sumitra Thongprasert Keunchil Park	Keith Kerr	Ugo Pastorino	Roy Herbst
2015	Harvey Pass	Ming Tsao	Jacek Jassem	Yi-Long Wu
2013	James Jett	Tetsuya Mitsudomi	Pieter Postmus	David R. Gandara
2011	David Ball	Philip Hasleton	John Field	Nagahiro Saijo
2009	Giorgio V. Scagliotti	Masayuki Noguchi	Stephen Lam	Bruce Johnson Tom Lynch
2007	Peter Goldstraw	Fred R. Hirsch	James Mulshine	Frances Shepherd
2005	Harubumi Kato	Elisabeth Brambilla	Nigel Gray	Thierry LeChevalier
2003	Paul A. Bunn, Jr.	Adi Gazdar		Paul Van Houtte
2000	Desmond Carney	Yokio Shimosato		Daniel C. Ihde
1997	Heine H. Hansen	William Travis	Clifford Douglas	John D. Minna
1994	Y. Shimosato N. Bleehen	Geno Saccamanno	Jesse Steinfeld	Robert J. Ginsberg
1991	Clifton F. Mountain			

IASLC LECTURESHIP AWARD WINNERS

The IASLC International Lectureship Award Winners will receive their award at the IASLC Award Ceremony on **Saturday, August 6, 17:00 – 17:45**, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center. Each award winner will give their presentation at the following assigned Lectureship Award Sessions:

LA01 – Lectureship Award Session 1
Sunday, August 7, 13:15 – 14:15
Hall C1, Ground Level

IASLC Lectureship Award for Tobacco Control and Smoking Cessation
RAY OSAROGIAGBON, UNITED STATES
Medical Oncology

Tsuguo Naruke Lectureship Award for Surgery
WENZHAO ZHONG, CHINA
Thoracic Surgery

Daniel C. Ihde Lectureship Award for Medical Oncology
PATRICK FORDE, UNITED STATES
Medical Oncology

LA02 – Lectureship Award Session 2
Monday, August 8, 13:30 - 14:30
Hall C1, Ground Level

Robert J. Ginsberg Lectureship Award for Surgery
ISABELLE OPITZ, SWITZERLAND
Thoracic Surgery

James D. Cox Lectureship Award for Radiation Oncology
YUKO NAKAYAMA, JAPAN
Radiation Oncology

Heine H. Hansen Lectureship Award for Small Cell Lung Cancer
STEPHEN V LIU, UNITED STATES
Medical Oncology

LA03 – Lectureship Award Session 3
Tuesday, August 9, 13:15 – 14:15
Hall C1, Ground Level

Fred R. Hirsch Lectureship Award for Translational Research
LUKAS BUBENDORF, SWITZERLAND
Pathologist

IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)
ANNE FRASER, NEW ZEALAND
Nursing

Clifton F. Mountain Lectureship Award for Staging
CLARISSA MATHIAS, BRAZIL
Medical Oncology

IASLC ACADEMY PARTICIPANTS

The IASLC Academy Participants will be acknowledged and honored during the IASLC Award Ceremony on **Saturday, August 6, 17:00 – 17:45**, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

MIHAELA ALDEA
Gustave Roussy, France

CARLOS CABRERA
UOMi Cancer Center, Spain

NICOLE CARRIEL
Hospital Dr. Gustavo Fricke, Chile

GUILHERME HARADA
Memorial Sloan-Kettering Cancer Center, United States

BRIAN S HENICK
Herbert Irving Comprehensive Cancer Center, United States

HASHIM ISMAIL
Travancore Medical College, India

KEIGO KOBAYASHI
National Cancer Centre Singapore, Singapore

KONSTANTINOS LEVENTAKOS
Mayo Clinic, United States

JOSEPH MURRAY
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States

CORAL OLAZAGASTI
University of Miami Health System, United States

MANGLIO RIZZO
Hospital Universitario Austral, Argentina

GIOVANNI ROSSI
IRCCS Ospedale Policlinico San Martino, Italy

STEPHANIE PEI LI SAW
National Cancer Centre Singapore, Singapore

ILIT TURGEMAN
Emek Medical Center, Israel

BARLIZ WAISSENGRIN
Tel Aviv Medical Center, Israel

WCLC 2022 EARLY CAREER EDUCATION AWARD WINNERS

The WCLC 2022 Early Career Education Award Winners will receive their award during the IASLC Award Ceremony on **Saturday, August 6, 17:00 – 17:45**, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

NICOLAS ALCALA
International Agency for Research on Cancer / World Health Organization, France
MA02.03: The Evolution of Lung Neuro-endocrine Tumors

MARTA CASARRUBIOS
Hospital Puerta de Hierro Majadahonda, Spain
OA02.03: Tumor Bulk-RNA Seq Identifies Patients at High Risk Of Progression in Non-Complete Pathological Responders from NADIM Trial

KEVIN CHUA
National Cancer Centre Singapore, Singapore
P2.13-02: Dynamic Tracking of Bespoke Circulating Tumour DNA During Multi-Modality Therapy for Locally Advanced NSCLC (LA-NSCLC)

LAURENT DERCLE
Columbia University Medical Center / Herbert Irving Cancer Center (CUMC / HICCC), United States
P2.12-03: External Validation of A Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial

SIMON HEEKE
UT MD Anderson Cancer Center, United States
MA01.03: Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using A Robust Machine Learning Approach

ARVIND KUMAR
Icahn School of Medicine at Mount Sinai, United States
OA02.04: Multimodal Management of T4 N2 Non-Small-Cell Lung Cancer with Additional Ipsilateral Pulmonary Nodules

JENNIFER MARKS
Georgetown University, United States
MA05.08: MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History

ÉMILIE MATHIAN
International Agency for Research on Cancer (IARC-WHO), France
MA01.07: From Molecular to Histological Characterization of Lung Carcinoids via Computer Vision and Spatial Genomics

ALBERTO TRAVERSO
Maastro Clinic, Netherlands
P1.15-01: Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy with Radiomics

HANA ZAHED
International Agency for Research on Cancer (IARC / WHO), France
MA11.05: The Blood Proteome of Imminent Lung Cancer

WCLC 2022 DEVELOPING NATION EDUCATION AWARD WINNERS

The WCLC 2022 Developing Nation Education Award Winners will receive their award during the IASLC Award Ceremony on **Saturday, August 6, 17:00 – 17:45**, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

AMIYA AGRAWAL
Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India

MA09.03: Response of Palliative Radiotherapy in Bone Metastases of Lung Cancer - Results of Prospective Longitudnal Study from India

LEEN AL-KRAIMEEN
Jordan University of Science and Technology, Jordan

EP08.02-096: Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis

EP16.01-008: The Effect of Cytochrome P450 Family 4 Subfamily B Member 1 (CYP4B1) on Lung Adenocarcinoma (LUAD) Immune Microenvironment

RUI FU
School of Medicine, South China University of Technology, Guangdong Lung Cancer Institute, China

EP16.02-024: Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer

CHENCHEN GUO
Cas Center for Excellence in Molecular Cell Science, Shanghai, China

EP14.02-005: Therapeutic targeting Mevalonate-Geranylgeranyl Diphosphate Pathway with Statins Overcomes Chemotherapy-resistance in SCLC

CHINMAY HARIDAS
Shri Vasantrao Naik Government Medical College, Yavatmal, India

EP14.05-003: Recent Stage Shifts and Changes in the Treatment of Stage I Small Cell Lung Cancer in the United States

DEBAPRIYA MONDAL
Tata Medical Center, India

EP08.02-040: Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event

EP16.02-006: Evaluation of Carcinoembryonic Antigen (CEA) as Predictive Marker in Patients with Metastatic Non-small Cell Lung Cancer

AMBER RATHOR
All India Institute of Medical Sciences, India

EP11.01-011: Clinical Application of Liquid Biopsy for assessing Early EGFR mutation detection in Non-Small Cell Lung Carcinoma

SEBAWE SYAJ
Jordan University of Science and Technology, Jordan

EP02.04-008: Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Non-small Cell Lung Cancer (NSCLC): a Systematic Review and Meta-analysis

EP05.03-010: Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: a Systematic Review and Meta-analysis

SAURAV VERMA
Vardhman Mahavir Medical College and Safdarjung Hospital, India

P2.02-03: A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer

IASLC PATIENT ADVOCACY AWARD WINNERS

The IASLC Patient Advocacy Award Winner will receive their award during the IASLC Award Ceremony on **Saturday, August 6, 17:00 – 17:45**, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

MaryAnn Bradley
Canada

Seamus Cotter
Ireland

Dusty Joy Donaldson
United States

IASLC NURSE AND ALLIED HEALTH PROFESSIONAL AWARD WINNERS

The IASLC Nurse and Allied Health Professional Award Winners will receive their award during the IASLC Award Ceremony on **Saturday, August 6, 17:00 – 17:45**, at Lehar 1, Congress Center, Ground Level, Messe Wien Exhibition & Congress Center.

LAKEDIA BANKS
Va Palo Alto Health Care System, United States
EP04.02-003: Improving Supportive Care for Patients with Thoracic Cancer

IMANUELY BORCHARDT
Grupo Oncoclinicas, Brazil
OA08.03: Do in Screening-Calf Circumference and Muscle Strength is Predictive of Outcomes in Lung Cancer Treatment.

AMANDA MOORE
The University of Texas at Austin, United States
EP05.02-013: Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC

ANDREJA SAJNIC
Department for Respiratory Diseases Jordanovac, University Hospital Center, Croatia
P02.04-01: Lung Cancer Patient Experience Survey from Twelfth Central and Eastern Europe Countries

CANCER CARE TEAM AWARD WINNERS

Latin America Regional Winner
Instituto Nacional del Tórax in Providencia, Chile

North America Regional Winner
Baptist Cancer Center in Memphis, TN

Asia / Rest of the World Regional Winner
Shanghai Pulmonary Hospital Affiliated to Tonji University, Shanghai, China

6 CONFERENCE PROGRAM

PROGRAM AT A GLANCE



Ticketed Event IASLC CME Accredited

PROGRAM AT A GLANCE

Monday
August 8, 2022

- Concurrent Interactive Breakfast Sessions (07:30 - 08:15)
- Plenary 3: Presidential Symposium (08:30 - 10:20)
- Break (10:20 - 11:00)
- Press Conference (10:25 - 11:00)
- Concurrent Abstract Sessions (11:00 - 12:00)
- Concurrent Education Sessions (11:00 - 12:00)
- Concurrent Abstract Sessions (12:15 - 13:15)
- Concurrent Education Sessions (12:15 - 13:15)
- Concurrent Industry Symposia (13:30 - 14:30)
- Lunch Break (13:30 - 14:30)
- Lectureship Awards Session (13:30 - 14:30)
- Concurrent Abstract Sessions (14:45 - 15:45)
- Concurrent Education Sessions (14:45 - 15:45)
- Concurrent Abstract Sessions (16:00 - 17:00)
- Concurrent Education Sessions (16:00 - 17:00)
- Poster Session with Presenters Stand By (17:15 - 19:00)
- Concurrent Industry Symposia (18:00 - 19:00)
- Faculty Dinner (19:30 - 22:30) *BY INVITE ONLY*

Tuesday
August 9, 2022

- Concurrent Interactive Breakfast Sessions (07:30 - 08:15)
- Plenary Session 4 (08:30 - 10:00)
- IASLC Business Meeting (10:00 - 10:45)
- Break (10:00 - 10:45)
- Press Conference (10:05 - 10:45)
- Concurrent Abstract Sessions (10:45 - 11:45)
- Concurrent Education Sessions (10:45 - 11:45)
- Concurrent Abstract Sessions (12:00 - 13:00)
- Concurrent Education Sessions (12:00 - 13:00)
- Lunch Break (13:15 - 14:15)
- Lectureship Awards Session (13:15 to 14:15)
- Concurrent Abstract Sessions (14:30 - 15:30)
- Concurrent Education Sessions (14:30 - 15:30)
- Closing Plenary 5 (15:45 - 16:45)

Ticketed Event IASLC CME Accredited

SESSION OVERVIEW

Friday, August 5, 2022

09:00 - 16:00

WS02: IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening

TICKETED SESSION

Strauss 3

EP	ePosters	**MA**	Mini Oral Session
ES	Educational Session	**OA**	Oral Session
IBS	Interactive Breakfast Session (Ticketed Session)	**P**	Posters
IS	Industry Symposium	**PL**	Plenary Session
LA	Lectureship Awards	**WS**	Workshop

SESSION OVERVIEW

Saturday, August 6, 2022

08:00 - 11:30	**WS03 Early Career & First Time Attendee Session** Lehar 1 LIGHT BREAKFAST PROVIDED
08:00 - 12:00	**WS04 IASLC/IMIG Workshop - The Future of Mesothelioma Treatment** Lehar 4
09:00 - 11:00	**WS05 Social Media + Communications Workshop** Lehar 2
12:00 - 17:00	**WS06 Nurse & AHP + ITONF Joint Workshop** LIGHT LUNCH REFRESHMENTS PROVIDED Lehar 3
15:00 - 16:30	**WS07 LATAM Workshop** Lehar 2
17:00 - 17:45	**AC01 IASLC Awards Ceremony** Lehar 1
18:15 - 19:45	**PL01 Opening Plenary 1: Immunotherapy & Vaccines** LIVE-STREAM Hall C1
19:45 - 21:00	**Welcome Reception** Hall B, Exhibit Hall

EP	ePosters	**MA**	Mini Oral Session
ES	Educational Session	**OA**	Oral Session
IBS	Interactive Breakfast Session (Ticketed Session)	**P**	Posters
IS	Industry Symposium	**PL**	Plenary Session
LA	Lectureship Awards	**WS**	Workshop

SESSION OVERVIEW

Sunday, August 7, 2022

07:30 - 08:15

IBS01 Lung Cancer Screening: From Lung Cancer to Multiple Comorbidities

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 1

Track: Early Detection and Screening

07:30 - 08:15

IBS02 SABR versus Surgery for Operable Lung Cancer

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Hall C8

Track: Early Stage Non-Small Cell Lung Cancer - Radiotherapy and Other Ablative Techniques

---

07:30 - 08:15

IBS03 Real World Discussion about Testing in Low Income Countries

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 2

Track: Global Health, Health Services Research, and Health Economics

---

07:30 - 08:15

IBS04 The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Strauss 3

Track: Nursing and Allied Health Professionals

07:30 - 08:15

IBS05 Controversies in Management of Locally Advanced NSCLC

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 3

Track: Locally Advanced Non-Small Cell Lung Cancer

07:30 - 08:15

IBS06 Which Therapy for Which MPM Patient?

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 4

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

---

08:30 - 10:00

PL02 Plenary 2: Multidisciplinary Approach to the Oligo Paradigm

IASLC CME ACCREDITED | LIVE-STREAM

Hall C1

10:00 - 10:45

Networking Break

LIGHT REFRESHMENTS PROVIDED

Hall B, Exhibit Hall

10:05 - 10:45

PC02 Press Conference

Schubert 5/6

10:45 - 11:45

ES01 Implementation and Continuous Optimization of Lung Cancer Screening

IASLC CME ACCREDITED

Hall C1

Track: Early Detection and Screening

SESSION OVERVIEW

Sunday, August 7, 2022

10:45 - 11:45	**ES02 Management of Lung Cancer in the Era of COVID-19** IASLC CME ACCREDITED Hall C2 Track: Management of Lung Cancer in the Era of COVID-19
10:45 - 11:45	**ES03 Synchronous Oligometastatic NSCLC: Practical Implications** IASLC CME ACCREDITED Strauss 1/2 Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
10:45 - 11:45	**MA01 Molecular Subtypes and Prognostic Factors for SCLC and Neuro-endocrine Tumours** Hall C7 Track: Small Cell Lung Cancer and Neuro-endocrine Tumours
10:45 - 11:45	**MA02 Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics** Hall C8 Track: Tumour Biology and Biomarkers
10:45 - 11:45	**OA01 Real World Data to Guide Our Daily Needs** Strauss 3 Track: Global Health, Health Services Research, and Health Economics
12:00 - 13:00	**ES04 Current Status of Lung Cancer Screening Worldwide** IASLC CME ACCREDITED Hall C1 Track: Early Detection and Screening
12:00 - 13:00	**ES05 Oncogenic Alterations and Beyond - Novel Treatments** IASLC CME ACCREDITED Hall C2 Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
12:00 - 13:00	**ES06 Symptom Management in Lung Cancer** IASLC CME ACCREDITED Lehar 1 Track: Palliative and Supportive Care
12:00 - 13:00	**ES07 Impact of Tumour Plasticity and Molecular/Immune Adaptations in Treatment Sensitivity and Resistance** IASLC CME ACCREDITED Strauss 1/2 Track: Tumour Biology and Biomarkers
12:00 - 13:00	**MA03 Predicting Outcome in Patients with Early Disease NSCLC** Hall C8 Track: Early Stage Stage Non-small Cell Lung Cancer

SESSION OVERVIEW

Sunday, August 7, 2022

12:00 - 13:00	**OA02 From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment** Hall C7 Track: Locally Advanced Non-small Lung Cancer
13:15 - 14:15	**LA01 Lectureship Awards - Sunday** LIVE-STREAM Hall C1
13:15 - 14:45	**Networking Lunch** LIGHT LUNCH REFRESHMENTS PROVIDED Hall B, Exhibit Hall
14:00 - 15:30	**MTE01 Meet the Editor** Committee Room 1
14:30 - 15:30	**ES08 Sublobar Resection: Oncological Outcome and Advantages** IASLC CME ACCREDITED Hall C1 Track: Early Stage Metastatic Non-small Cell Lung Cancer - Molecular Targted Treatments - Surgery
14:30 - 15:30	**ES09 Technology Innovations** IASLC CME ACCREDITED Hall C2
14:30 - 15:30	**ES10 Problems and Controversies in Thoracic Tumours** IASLC CME ACCREDITED Strauss 1/2 Track: Pathology
14:30 - 15:30	**ES11 Joint ESTRO Session - Integration of Radiotherapy for Optimal Patient Outcomes** IASLC CME ACCREDITED Lehar 1
14:30 - 15:30	**MA04 Pulmonology, Radiology, and Staging** Strauss 3 Track: Pulmonology, Radiology, and Staging
14:30 - 15:30	**OA03 Molecular Targeted Treatments** Hall C7 Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
14:30 - 15:30	**OA04 Mesothelioma Under the Looking Glass** Hall C8 Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

SESSION OVERVIEW

Sunday, August 7, 2022

15:45 - 16:45	**ES12 Surgical Issues in Multimodality Treatments for Early Stage NSCLC** IASLC CME ACCREDITED Hall C1 Track: Early Stage Non-small Cell Lung Cancer - Surgery
15:45 - 16:45	**ES13 Mesothelioma** IASLC CME ACCREDITED Hall C2 Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies
15:45 - 16:45	**ES14 Think, Think, Think.....The Importance of Thinking Holistically When Caring for Lung Cancer Patients** IASLC CME ACCREDITED Lehar 1 Track: Nursing and Allied Health Professionals
15:45 - 16:45	**ES15 Is Cytotoxic Chemotherapy in NSCLC Management Only Palliative?** IASLC CME ACCREDITED Strauss 1/2 Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
15:45 - 16:45	**MA05 Immune Landscape and Molecular Profiling of Lung Cancer** Hall C8 Track: Tumour Biology and Biomarkers
15:45 - 16:45	**OA05 The Granularity of Lung Cancer Screening Implementation** Hall C7 Track: Early Detection and Screening
17:00 - 19:00	**Poster Viewing Reception - Poster Session P1 Presenters in Attendance (Stand By Their Posters)** LIGHT REFRESHMENTS PROVIDED Hall B, Exhibit Hall
18:00 - 18:30	**Editorial Reception (By Invitation Only)** Messe Wien, Ground Floor, Pavilion Restaurant
19:30 - 22:30	**International Lung Cancer Foundation Benefit Supporting Early Career Researchers** TICKETED NETWORKING EVENT Please refer to the ILCF Benefit Supporting Early Career Researchers Ticket for more information.

EP	ePosters	**MA**	Mini Oral Session
ES	Educational Session	**OA**	Oral Session
IBS	Interactive Breakfast Session (Ticketed Session)	**P**	Posters
IS	Industry Symposium	**PL**	Plenary Session
LA	Lectureship Awards	**WS**	Workshop

SESSION OVERVIEW

Monday, August 8, 2022

07:30 - 08:15

IBS07 Interactive Multidisciplinary Thoracic Tumour Board

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 1
Track: Early Stage Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)

07:30 - 08:15

IBS08 Chemotherapy Still Remains a Key Component of Treatment for Majority of Patients with Metastatic NSCLC in the Era of Immune-Oncology

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Hall C8
Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

---

07:30 - 08:15

IBS09 Inequities in Access to Lung Cancer Care across the World

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Struass 3
Track: Patient Advocacy

07:30 - 08:15

IBS10 In Situ IO Biomarkers

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 2
Track: Pathology

07:30 - 08:15

IBS11 E-Cigarettes Are an Effective Smoking Cessation Aid

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 3
Track: Tobacco Control and Risk Reduction

07:30 - 08:15

IBS12 Mediastinal Staging

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 4
Track: Pulmonology, Radiology, and Staging

08:30 - 10:20

PL03 Plenary 3: Presidential Symposium – Top Rated Abstracts

IASLC CME ACCREDITED | LIVE-STREAM

Hall C1

10:20 - 11:00

Networking Break

LIGHT REFRESHMENTS PROVIDED

Hall B, Exhibit Hall

10:25 - 11:00

PC03: Press Conference

Schubert 5/6

11:00 - 12:00

ES16 Pushing the Boundaries in Lung Ablative Therapies

IASLC CME ACCREDITED

Hall C1
Track: Early Stage Non-Small Cell Lung Cancer - Radiotherapy and Other Ablative Techniques

---

SESSION OVERVIEW

Monday, August 8, 2022

11:00 - 12:00	**ES17 Cost and Accessibility to Lung Cancer Drugs - Pathways to Improvement** IASLC CME ACCREDITED Hall C2 Track: Global Health, Health Services Research, and Health Economics
11:00 - 12:00	**ES18 Management of Pulmonary Nodules** IASLC CME ACCREDITED Strauss 1/2 Track: Pulmonology, Radiology, and Staging
11:00 - 12:00	**OA06 Impact of COVID-19 on Cancer Management and Protection from Vaccines** Lehar 1 Track: Management of Lung Cancer in the Era of COVID-19
11:00 - 12:00	**OA07 Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?** Hall C7 Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
11:00 - 12:00	**OA08 Multidisciplinary Care of the Lung Cancer Patient** Strauss 3 Track: Nursing and Allied Health Professionals
12:15 - 13:15	**ES19 Toxicity Avoidance in SABR for Early Stage NSCLC** IASLC CME ACCREDITED Hall C1 Track: Early Stage Non-Small Cell Lung Cancer - Radiotherapy and Other Ablative Techniques
12:15 - 13:15	**ES20 Management of Lung Cancer in the Era of COVID-19 II** IASLC CME ACCREDITED Hall C2 Track: Management of Lung Cancer in the Era of COVID-19
12:15 - 13:15	**ES21 Problems and Controversies in Lung Tumours** IASLC CME ACCREDITED Strauss 1/2 Track: Pathology
112:15 - 13:15	**MA06 Resectable and Unresectable Locally Advanced Lung Cancer** Lehar 1 Track: Locally Advanced Non-small Cell Lung Cancer
12:15 - 13:15	**MA07 Overcoming Resistance to EGFR Inhibitors** Hall C7 Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

SESSION OVERVIEW

Monday 8 August, 2022

12:15 - 13:15	**MA08 Patient Advocacy and Patient Preferences** Strauss 3 Track: Patient Advocacy
13:30 – 14:30	**LA02 Lectureship Awards - Monday** LIVE-STREAM Hall C1
13:30 - 14:30	**Networking Lunch** LIGHT LUNCH REFRESHMENTS PROVIDED Hall B, Exhibit Hall
14:45 - 15:45	**ES22 Lung Cancer in Individuals Without A Smoking History** IASLC CME ACCREDITED Hall C1 Track: Epidemiology
14:45 - 15:45	**ES23 Optimizing Radio-Chemo-Immunotherapy for Locally Advanced NSCLC** IASLC CME ACCREDITED Hall C2 Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
14:45 - 15:45	**ES24 Palliative Care Integration and QOL in Advanced Lung Cancer** IASLC CME ACCREDITED Strauss 1/2 Track: Palliative and Supportive Care
14:45 - 15:45	**MA09 Palliative Radiotherapy: The Changing Landscape with Immunotherapy and Targeted Therapies** Hall C7 Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy
14:45 - 15:45	**MA10 Updates in Thymoma** Hall C8 Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies
14:45 - 15:45	**OA09 Precision Immunotherapy via Modulation of the Tumour Microenvironment** Lehar 1 Track: Tumour Biology and Biomarkers
14:45 - 15:45	**OA10 Strategies to Integrate Smoking Cessation and Cancer Care** Strauss 3 Track: Tobacco Control and Risk Reduction

SESSION OVERVIEW

Monday, August 8, 2022

16:00 – 17:00	**ES25 Clinical Issues with Immunotherapy in Non-small Cell Lung Cancer** IASLC CME ACCREDITED Hall C1 Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
16:00 – 17:00	**ES26 Thymoma** IASLC CME ACCREDITED Hall C2 Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies
16:00 – 17:00	**ES27 Joint Global Lung Cancer Coalition and International Association for the Study of Lung Cancer Session - Breaking Down Roadblocks to Lung Cancer Care in 2022** IASLC CME ACCREDITED Strauss 1/2 Track: Patient Advocacy incl. Joint Session with GLCC
16:00 – 17:00	**MA11 Optimization of Technologies for Lung Cancer Screening: Population Selection and Nodule Handling** Lehar 1 Track: Early Detection and Screening
16:00 – 17:00	**OA11 Optimal Patient Selection for Local Therapy in Stage IV NSCLC** Hall C7 Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
16:00 – 17:00	**OA12 Novel Combination Strategies for SCLC** Hall C8 Track: Small Cell Lung Cancer and Neuro-endocrine Tumours
17:15 - 19:00	**Poster Viewing Reception** LIGHT REFRESHMENTS PROVIDED Hall B, Exhibit Hall
19:30 - 22:30	**Faculty Dinner (By Invitation Only)** Please refer to the Faculty Dinner Ticket for more information

EP	ePosters	**MA**	Mini Oral Session
ES	Educational Session	**OA**	Oral Session
IBS	Interactive Breakfast Session (Ticketed Session)	**P**	Posters
IS	Industry Symposium	**PL**	Plenary Session
LA	Lectureship Awards	**WS**	Workshop

SESSION OVERVIEW

Tuesday, August 9, 2022

07:30 - 08:15

IBS13 CNS Involvement in Oncogene-Driven and Not-Oncogene-Driven Disease: Optimal Management

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 1

Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

---

07:30 - 08:15

IBS14 Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Strauss 3

Track: Palliative and Supportive Care

07:30 - 08:15

IBS15 Should We Offer PCI and Consolidation Thoracic RT to Patients Treated with First-Line Chemo-Immunotherapy?

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Hall C8

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

07:30 - 08:15

IBS16 A Guide for the Perplexed: How to Use Lung Cancer Risk Models Efficiently for Screening

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 2

Track: Early Detection and Screening

07:30 - 08:15

IBS17 Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?

IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Lehar 3

Track: Tumour Biology and Biomarkers

07:30 - 08:15

IBS18 Women in Thoracic Oncology

IASLC CME ACCREDITED | LIGHT BREAKFAST PROVIDED

Lehar 4

08:30 - 10:00

PL04 Plenary 4: Artificial Intelligence in Lung Cancer

IASLC CME ACCREDITED | LIVE-STREAM

Hall C1

10:00 - 10:45

IASLC Business Meeting

LIGHT REFRESHMENTS PROVIDED

Strauss 3

10:00 - 10:45

Networking Break

LIGHT REFRESHMENTS PROVIDED

Hall B, Exhibit Hall

10:05 - 10:45

PC04 - Press Conference

Schubert 5/6

SESSION OVERVIEW

Tuesday, August 9, 2022

10:45 - 11:45	**ES28 Neoadjuvant and Adjuvant Treatment of NSCLC in 2022** IASLC CME ACCREDITED Hall C1 Track: Early Stage Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)
10:45 - 11:45	**ES29 Palliative Radiotherapy in Metastatic NSCLC: State of the Art in an Era of New Hope** IASLC CME ACCREDITED Hall C2 Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy
10:45 - 11:45	**ES30 Leveraging the Power of Immunotherapy for SCLC** IASLC CME ACCREDITED Strauss 1/2 Track: Small Cell Lung Cancer and Neuro-endocrine Tumours
10:45 - 11:45	**ES31 Survivorship across the Cancer Continuum for Patients Treated with Immunotherapies and Targeted Therapies** IASLC CME ACCREDITED Lehar 1 Track: Nursing and Allied Health Professionals
10:45 - 11:45	**MA12 Pathology: Tumour Diagnostics** Hall C7 Track: Pathology
10:45 - 11:45	**OA13 Evolving Epidemiology of Lung Cancer Beyond Tobacco** Hall C8 Track: Epidemiology
12:00 - 13:00	**ES32 Beyond Tobacco: Environmental Risk Factors for Lung Cancer** IASLC CME ACCREDITED Hall C1 Track: Epidemiology
12:00 - 13:00	**ES33 Management of Oligometastatic and Multi-Focal Lung Cancer** IASLC CME ACCREDITED Hall C2 Track: Locally Advanced Non-small Cell Lung Cancer - Oligometastatic
12:00 - 13:00	**ES34 Updates in Radiology, Pulmonology, and Staging** IASLC CME ACCREDITED Strauss 1/2 Track: Pulmonology, Radiology, and Staging

SESSION OVERVIEW

Tuesday, 9 August, 2022

12:00 - 13:00	**ES35 High-Plex Spatial Technologies for Molecular Tumour Analysis and Single-Cell Studies in Thoracic Oncology Research and Future Clinical Uses** IASLC CME ACCREDITED Lehar 1 Track: Tumour Biology and Biomarkers
12:00 - 13:00	**MA13 Update on ROS1 Inhibitors and New Pathways** Hall C7 Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
12:00 - 13:00	**OA14 New Techniques to Improve Outcome in Early Stage NSCLC Patients Treated with Surgery or Radiotherapy** Hall C8 Track: Early Stage Non-small Cell Lung Cancer
13:15 - 14:15	**LA03 Lectureship Awards - Tuesday** LIVE-STREAM Hall C1
13:15 - 14:15	**Networking Lunch** LIGHT LUNCH REFRESHMENTS PROVIDED Hall B, Exhibit Hall
14:30 - 15:30	**ES36 Revisiting the Perioperative Management of NSCLC** IASLC CME ACCREDITED Hall C1 Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
14:30 - 15:30	**ES37 What Lung Cancer Clinicians Need to Know about Tobacco** IASLC CME ACCREDITED Hall C2 Track: Tobacco Control and Risk Reduction
14:30 - 15:30	**ES38 Optimising the Management of SCLC and Neuro-endocrine Tumours** IASLC CME ACCREDITED Strauss 1/2 Track: Small Cell Lung Cancer and Neuro-endocrine Tumours
14:30 - 15:30	**ES39 Role of Novel Biomarkers and Technologies in Optimal Diagnosis and Disease Management: Focus on Liquid Biopsies and Advanced Tissue Diagnostics** IASLC CME ACCREDITED Lehar 1 Track: Tumour Biology and Biomarkers
14:30 - 15:30	**MA14 Palliative and Supportive Care - The Forgotten Trade** Strauss 3 Track: Palliative and Supportive Care

SESSION OVERVIEW

Tuesday, 9 August, 2022

14:30 - 15:30

OA15 Patient Selection in Advanced NSCLC Immunotherapy
Hall C7
Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

15:45 - 16:45

PL05 Closing Plenary 5: Access to Drugs
IASLC CME ACCREDITED | LIVE-STREAM
Hall C1

EP	ePosters	**MA**	Mini Oral Session
ES	Educational Session	**OA**	Oral Session
IBS	Interactive Breakfast Session (Ticketed Session)	**P**	Posters
IS	Industry Symposium	**PL**	Plenary Session
LA	Lectureship Awards	**WS**	Workshop

ON-DEMAND SESSIONS

These on-demand sessions are available exclusively on the virtual platform.

WS08	Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC
HOD01	Highlights of the Day - Sunday
HOD02	Highlights of the Day - Monday
HOD03	Highlights of the Day - Tuesday

Immunohistochemistry is an extremely valuable and powerful technique for pathologic diagnosis.

Published by the IASLC and its Pathology Committee, the IHC Atlas takes a comprehensive look at diagnostic IHC and its role in thoracic pathology.

The IHC Atlas is a useful reference for anyone interested in thoracic tumor diagnostics, from basic researchers to practicing oncologists. All pathologists should have access to these best practices. The Atlas is available in multiple languages.

Visit the IASLC booth or scan the QR code to order your copy today!

IASLC
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

Coming Soon!
IASLC Atlas on Molecular Biomarker Testing for Targeted Therapy
Available at #TTLC23

PROGRAM BY TRACK

Early Detection and Screening

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS01	**Lung Cancer Screening: From Lung Cancer to Multiple Comorbidities** TICKETED SESSION IASLC CME ACCREDITED	Lehar 1
Sunday, August 7, 2022	10:45 - 11:45	Education Session	ES01	**Implementation and Continuous Optimization of Lung Cancer Screening** IASLC CME ACCREDITED	Hall C1
Sunday, August 7, 2022	12:00 - 13:00	Education Session	ES04	**Current Status of Lung Cancer Screening Worldwide** IASLC CME ACCREDITED	Hall C1
Sunday, August 7, 2022	15:45 - 16:45	Oral Session	OA05	**The Granularity of Lung Cancer Screening Implementation**	Hall C7
Monday, August 8, 2022	16:00 – 17:00	Mini Oral Session	MA11	**Optimization of Technologies for Lung Cancer Screening: Population Selection and Nodule Handling**	Lehar 1
Tuesday, August 9, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS16	**A Guide for the Perplexed: How to Use Lung Cancer Risk Models Efficiently for Screening** TICKETED SESSION IASLC CME ACCREDITED	Lehar 2

Early Stage Non-small Cell Lung Cancer

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	12:00 - 13:00	Mini Oral Session	MA03	**Predicting Outcome in Patients with Early Disease NSCLC**	Hall C8
Tuesday, August 9, 2022	12:00 - 13:00	Oral Session	OA14	**New Techniques to Improve Outcome in Early Stage NSCLC Patients Treated with Surgery or Radiotherapy**	Hall C8

Early Stage Non-small Cell Lung Cancer – Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)

Date	Time	Session Type	#	Session Title	Room
Monday, August 8, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS07	**Interactive Multidisciplinary Thoracic Tumour Board** TICKETED SESSION IASLC CME ACCREDITED	Lehar 1
Tuesday, August 9, 2022	10:45 - 11:45	Education Session	ES28	**Neoadjuvant and Adjuvant Treatment of NSCLC in 2022** IASLC CME ACCREDITED	Hall C1

Early Stage Non-small Cell Lung Cancer – Radiotherapy and Other Ablative Techniques

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS02	**SABR versus Surgery for Operable Lung Cancer** TICKETED SESSION IASLC CME ACCREDITED	Hall C8
Monday, August 8, 2022	11:00 – 12:00	Education Session	ES16	**Pushing the Boundaries in Lung Ablative Therapies** IASLC CME ACCREDITED	Hall C1
Monday, August 8, 2022	12:15 – 13:15	Education Session	ES19	**Toxicity Avoidance in SABR for Early Stage NSCLC** IASLC CME ACCREDITED	Hall C1

Early Stage Non-small Cell Lung Cancer – Surgery

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	14:30 - 15:30	Education Session	ES08	**Sublobar Resection: Oncological Outcome and Advantages** IASLC CME ACCREDITED	Hall C1
Sunday, August 7, 2022	15:45 - 16:45	Education Session	ES12	**Surgical Issues in Multimodality Treatments for Early Stage NSCLC** IASLC CME ACCREDITED	Hall C1

Epidemiology

Date	Time	Session Type	#	Session Title	Room
Monday, August 8, 2022	14:45 – 15:45	Education Session	ES22	**Lung Cancer in Individuals Without A Smoking History** IASLC CME ACCREDITED	Hall C1
Tuesday, August 9, 2022	10:45 - 11:45	Oral Session	OA13	**Evolving Epidemiology of Lung Cancer Beyond Tobacco**	Hall C8
Tuesday, August 9, 2022	12:00 - 13:00	Education Session	ES32	**Beyond Tobacco: Environmental Risk Factors for Lung Cancer** IASLC CME ACCREDITED	Hall C1

Global Health, Health Services Research, and Health Economics

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS03	**Real World Discussion about Testing in Low Income Countries** TICKETED SESSION IASLC CME ACCREDITED	Lehar 2
Sunday, August 7, 2022	10:45 - 11:45	Oral Session	OA01	**Real World Data to Guide Our Daily Needs**	Strauss 3
Monday, August 8, 2022	11:00 – 12:00	Education Session	ES17	**Cost and Accessibility to Lung Cancer Drugs - Pathways to Improvement** IASLC CME ACCREDITED	Hall C2

Locally Advanced Non-small Cell Lung Cancer

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS05	**Controversies in Management of Locally Advanced NSCLC** TICKETED SESSION IASLC CME ACCREDITED	Hall C8
Sunday, August 7, 2022	12:00 - 13:00	Oral Session	OA02	**From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment**	Hall C8
Monday, August 8, 2022	12:15 – 13:15	Mini Oral Session	MA06	**Resectable and Unresectable Locally Advanced Lung Cancer**	Lehar 1

Locally Advanced Non-small Cell Lung Cancer – Chemoradiotherapy and Radiotherapy

Date	Time	Session Type	#	Session Title	Room
Monday, August 8, 2022	14:45 – 15:45	Education Session	**ES23**	**Optimizing Radio-Chemo-Immunotherapy for Locally Advanced NSCLC** IASLC CME ACCREDITED	Hall C2

Locally Advanced Non-small Cell Lung Cancer – Neoadjuvant and Adjuvant Therapy

Date	Time	Session Type	#	Session Title	Room
Tuesday, August 9, 2022	14:30 - 15:30	Education Session	**ES36**	**Revisiting the Perioperative Management of NSCLC** IASLC CME ACCREDITED	Hall C1

Locally Advanced Non-small Cell Lung Cancer – Oligometastatic

Date	Time	Session Type	#	Session Title	Room
Tuesday, August 9, 2022	12:00 - 13:00	Education Session	**ES33**	**Management of Oligometastatic and Multi-Focal Lung Cancer** IASLC CME ACCREDITED	Hall C2

Management of Lung Cancer in the Era of COVID-19

Date	Time	Session Type	#	Session Title	
Sunday, August 7, 2022	10:45 - 11:45	Education Session	**ES02**	**Management of Lung Cancer in the Era of COVID-19** IASLC CME ACCREDITED	Hall C2
Monday, August 8, 2022	11:00 – 12:00	Oral Session	**OA06**	**Impact of COVID-19 on Cancer Management and Protection from Vaccines**	Lehar 1
Monday, August 8, 2022	12:15 – 13:15	Education Session	**ES20**	**Management of Lung Cancer in the Era of COVID-19 II** IASLC CME ACCREDITED	Hall C2

Mesothelioma, Thymoma, and Other Thoracic Malignancies

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS06	**Which Therapy for Which MPM Patient?** TICKETED SESSION IASLC CME ACCREDITED	Lehar 4
Sunday, August 7, 2022	14:30 - 15:30	Oral Session	OA04	**Mesothelioma Under the Looking Glass**	Hall C8
Sunday, August 7, 2022	15:45 - 16:45	Education Session	ES13	**Mesothelioma** IASLC CME ACCREDITED	Hall C2
Monday, August 8, 2022	14:45 – 15:45	Mini Oral Session	MA10	**Updates in Thymoma**	Hall C8
Monday, August 8, 2022	16:00 – 17:00	Education Session	ES26	**Thymoma** IASLC CME ACCREDITED	Hall C2

Metastatic Non-small Cell Lung Cancer - Immunotherapy

Date	Time	Session Type	#	Session Title	Room
Monday, August 8, 2022	16:00 – 17:00	Education Session	ES25	**Clinical Issues with Immunotherapy in Non-small Cell Lung Cancer** IASLC CME ACCREDITED	Hall C1
Tuesday, August 9, 2022	14:30 - 15:30	Mini Oral Session	OA15	**Patient Selection in Advanced NSCLC Immunotherapy**	Hall C7

Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	12:00 - 13:00	Education Session	ES05	**Oncogenic Alterations and Beyond - Novel Treatments** IASLC CME ACCREDITED	Hall C7
Sunday, August 7, 2022	14:30 - 15:30	Oral Session	OA03	**Molecular Targeted Treatments**	Hall C7
Monday, August 8, 2022	12:15 – 13:15	Mini Oral Session	MA07	**Overcoming Resistance to EGFR Inhibitors**	Hall C7
Tuesday, August 9, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS13	**CNS Involvement in Oncogene-Driven and Not-Oncogene-Driven Disease: Optimal Management** TICKETED SESSION IASLC CME ACCREDITED	Lehar 1
Tuesday, August 9, 2022	12:00 - 13:00	Mini Oral Session	MA13	**Update on ROS1 Inhibitors and New Pathways**	Hall C7

Metastatic Non-small Cell Lung Cancer – Oligometastatic Disease

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	10:45 - 11:45	Education Session	**ES03**	**Synchronous Oligometastatic NSCLC: Practical Implications** IASLC CME ACCREDITED	Strauss 1/2
Monday, August 8, 2022	16:00 – 17:00	Oral Session	**OA11**	**Optimal Patient Selection for Local Therapy in Stage IV NSCLC**	Hall C7

Metastatic Non-small Cell Lung Cancer – Palliative Chemotherapy

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	15:45 - 16:45	Education Session	**ES15**	**Is Cytotoxic Chemotherapy in NSCLC Management Only Palliative?** IASLC CME ACCREDITED	Strauss 1/2
Monday, August 8, 2022	07:30 - 08:15	Interactive Breakfast Session	**IBS08**	**Chemotherapy Still Remains a Key Component of Treatment for Majority of Patients with Metastatic NSCLC in the Era of Immune-Oncology** TICKETED SESSION IASLC CME ACCREDITED	Hall C8
Monday, August 8, 2022	11:00 – 12:00	Oral Session	**OA07**	**Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?**	Hall C7

Metastatic Non-small Cell Lung Cancer – Palliative Radiotherapy

Date	Time	Session Type	#	Session Title	Room
Monday, August 8, 2022	14:45 – 15:45	Mini Oral Session	**MA09**	**Palliative Radiotherapy: The Changing Landscape with Immunotherapy and Targeted Therapies**	Hall C7
Tuesday, August 9, 2022	10:45 - 11:45	Education Session	**ES29**	**Palliative Radiotherapy in Metastatic NSCLC: State of the Art in an Era of New Hope** IASLC CME ACCREDITED	Hall C2

Nursing and Allied Health Professionals

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS04	**The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy** TICKETED SESSION IASLC CME ACCREDITED	Strauss 3
Sunday, August 7, 2022	15:45 - 16:45	Education Session	ES14	**Think, Think, Think.....The Importance of Thinking Holistically When Caring for Lung Cancer Patients** IASLC CME ACCREDITED	Lehar 1
Monday, August 8, 2022	11:00 – 12:00	Oral Session	OA08	**Multidisciplinary Care of the Lung Cancer Patient**	Strauss 3
Tuesday, August 9, 2022	10:45 - 11:45	Education Session	ES31	**Survivorship across the Cancer Continuum for Patients Treated with Immunotherapies and Targeted Therapies** IASLC CME ACCREDITED	Lehar 1

Palliative and Supportive Care

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	12:00 - 13:00	Education Session	ES06	**Symptom Management in Lung Cancer** IASLC CME ACCREDITED	Lehar 1
Monday, August 8, 2022	14:45- 15:45	Education Session	ES24	**Palliative Care Integration and QOL in Advanced Lung Cancer** IASLC CME ACCREDITED	Strauss 1/2
Tuesday, August 9, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS14	**Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies** TICKETED SESSION IASLC CME ACCREDITED	Strauss 3
Tuesday, August 9, 2022	14:30 - 15:30	Mini Oral Session	MA14	**Palliative and Supportive Care - The Forgotten Trade**	Strauss 3

Pathology

Date	Time	Session Type	#	Session Title	Room
Saturday August 6, 2022	14:30 - 15:30	Education Session	ES10	**Problems and Controversies in Thoracic Tumours** IASLC CME ACCREDITED	Strauss 1/2
Monday, August 8, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS10	**In Situ IO Biomarkers** TICKETED SESSION IASLC CME ACCREDITED	Lehar 2
Monday, August 8, 2022	12:15 – 13:15	Education Session	ES21	**Problems and Controversies in Lung Tumours** IASLC CME ACCREDITED	Strauss 1/2
Tuesday, August 9, 2022	10:45 - 11:45	Mini Oral Session	MA12	**Pathology: Tumour Diagnostics**	Hall C7

Patient Advocacy

Date	Time	Session Type	#	Session Title	Room
Monday, August 8, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS09	**Inequities in Access to Lung Cancer Care across the World** TICKETED SESSION IASLC CME ACCREDITED	Strauss 3
Monday, August 8, 2022	12:15- 13:15	Mini Oral Session	MA08	**Patient Advocacy and Patient Preferences**	Strauss 3
Monday, August 8, 2022	16:00 – 17:00	Education Session	ES27	**Joint Global Lung Cancer Coalition and International Association for the Study of Lung Cancer Session - Breaking Down Roadblocks to Lung Cancer Care in 2022** IASLC CME ACCREDITED	Strauss 1/2

Pulmonology, Radiology, and Staging

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	14:30 - 15:30	Mini Oral Session	MA04	**Pulmonology, Radiology, and Staging**	Strauss 3
Monday, August 8, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS12	**Mediastinal Staging** TICKETED SESSION IASLC CME ACCREDITED	Lehar 4
Monday, August 8, 2022	10:45 - 11:45	Education Session	ES18	**Management of Pulmonary Nodules** IASLC CME ACCREDITED	Strauss 1/2
Tuesday, August 9, 2022	12:00 - 13:00	Education Session	ES34	**Updates in Radiology, Pulmonology, and Staging** IASLC CME ACCREDITED	Strauss 1/2

Small Cell Lung Cancer and Neuro-endocrine Tumours

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	10:45 - 11:45	Mini Oral Session	MA01	**Molecular Subtypes and Prognostic Factors for SCLC and Neuro-endocrine Tumors**	Hall C7
Monday, August 8, 2022	16:00 – 17:00	Oral Session	OA12	**Novel Combination Strategies for SCLC**	Hall C8
Tuesday, August 9, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS15	**Should We Offer PCI and Consolidation Thoracic RT to Patients Treated with First-Line Chemo-Immunotherapy?** TICKETED SESSION IASLC CME ACCREDITED	Hall C8
Tuesday, August 9, 2022	10:45 - 11:45	Education Session	ES30	**Leveraging the Power of Immunotherapy for SCLC** IASLC CME ACCREDITED	Strauss 1/2
Tuesday, August 9, 2022	14:30 - 15:30	Education Session	ES38	**Optimising the Management of SCLC and Neuro-endocrine Tumours** IASLC CME ACCREDITED	Strauss 1/2

Tobacco Control and Risk Reduction

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS11	**E-Cigarettes Are an Effective Smoking Cessation Aid** TICKETED SESSION IASLC CME ACCREDITED	Lehar 3
Monday, August 8, 2022	14:45 – 15:45	Oral Session	OA10	**Strategies to Integrate Smoking Cessation and Cancer Care**	Strauss 3
Tuesday, August 9, 2022	14:30 - 15:30	Education Session	ES37	**What Lung Cancer Clinicians Need to Know about Tobacco** IASLC CME ACCREDITED	Hall C2

Tumour Biology and Biomarkers

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	10:45 - 11:45	Mini Oral Session	**MA02**	**Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics**	Hall C8
Sunday, August 7, 2022	12:00 - 13:00	Education Session	**ES07**	**Impact of Tumor Plasticity and Molecular/Immune Adaptations in Treatment Sensitivity and Resistance** IASLC CME ACCREDITED	Strauss 1/2
Sunday, August 7, 2022	15:45 - 16:45	Oral Session	**MA05**	**Immune Landscape and Molecular Profiling of Lung Cancer**	Hall C8
Monday, August 8, 2022	14:45 – 15:45	Oral Session	**OA09**	**Precision Immunotherapy via Modulation of the Tumor Microenvironment**	Lehar 1
Tuesday, August 9, 2022	07:30 - 08:15	Interactive Breakfast Session	**IBS17**	**Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?** TICKETED SESSION IASLC CME ACCREDITED	Lehar 3
Tuesday, August 9, 2022	12:00 - 13:00	Education Session	**ES35**	**High-Plex Spatial Technologies for Molecular Tumor Analysis and Single-Cell Studies in Thoracic Oncology Research and Future Clinical Uses** IASLC CME ACCREDITED	Lehar 1
Tuesday, August 9, 2022	14:30 - 15:30	Education Session	**ES39**	**Role of Novel Biomarkers and Technologies in Optimal Diagnosis and Disease Management: Focus on Liquid Biopsies and Advanced Tissue Diagnostics** IASLC CME ACCREDITED	Lehar 1

Others

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	14:30 - 15:30	Education Session	ES09	**Technology Innovations** IASLC CME ACCREDITED	Hall C2
Sunday, August 7, 2022	14:30 - 15:30	Education Session	ES11	**Joint IASLC-ESTRO Session - Integration of Radiotherapy for Optimal Patient Outcomes**	Lehar 1
Tuesday, August 8, 2022	07:30 - 08:15	Interactive Breakfast Session	IBS18	**Women in Thoracic Oncology** IASLC CME ACCREDITED	Lehar 4

Workshops

Date	Time	Session Type	#	Session Title	Room
Friday August 5, 2022	09:00 - 16:00	Workshop	WS02	**IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening** TICKETED SESSION	Strauss 3
Saturday August 6, 2022	08:00 - 11:30	Workshop	WS03	**Early Career & First Time Attendee Session**	Lehar 1
Saturday August 6, 2022	08:00 - 12:00	Workshop	WS04	**IASLC/IMIG Workshop - The Future of Mesothelioma Treatment**	Lehar 4
Saturday August 6, 2022	09:00 - 11:00	Workshop	WS05	**Social Media + Communications Workshop**	Lehar 2
Saturday August 6, 2022	12:00 - 17:00	Workshop	WS06	**Nurse & AHP + ITONF Joint Workshop**	Lehar 3
Saturday August 6, 2022	15:00 - 16:30	Workshop	WS07	**LATAM Workshop**	Lehar 2
On-Demand	On-Demand	Workshop	WS08	**Joint IASLC-CSCO-CAALC Session (On-Demand)**	On-Demand

Plenary Sessions

Date	Time	Session Type	#	Session Title	Room
Saturday August 6, 2022	18:15 - 19:45	Plenary	**PL01**	**Opening Plenary 1: Immunotherapy & Vaccines** LIVE-STREAM	Hall C1
Sunday, August 7, 2022	08:30 - 10:00	Plenary	**PL02**	**Plenary 2: Multidisciplinary Approach to the Oligo Paradigm** LIVE-STREAM	Hall C1
Monday, August 8, 2022	08:30 - 10:20	Plenary	**PL03**	**Plenary 3: Presidential Symposium – Top Rated Abstracts** LIVE-STREAM	Hall C1
Tuesday, August 9, 2022	08:30 - 10:00	Plenary	**PL04**	**Plenary 4: Artificial Intelligence in Lung Cancer** LIVE-STREAM	Hall C1
Tuesday, August 9, 2022	15:45 - 16:45	Plenary	**PL05**	**Closing Plenary 5: Access to Drugs** LIVE-STREAM	Hall C1

Lectureship Awards

Date	Time	Session Type	#	Session Title	Room
Sunday August 7, 2022	13:15 - 14:15	Lectureship Awards	**LA01**	**Lectureship Awards - Sunday** LIVE-STREAM	Hall C1
Monday, August 8, 2022	13:30 - 14:30	Lectureship Awards	**LA02**	**Lectureship Awards - Monday** LIVE-STREAM	Hall C1
Tuesday, August 9, 2022	13:15 - 14:15	Lectureship Awards	**LA03**	**Lectureship Awards - Tuesday** LIVE-STREAM	Hall C1

IASLC Awards Ceremony

Date	Time	Session Type	#	Session Title	Room
Saturday August 6, 2022	17:00 - 17:45	Awards Ceremony	**AC01**	**IASLC Awards Ceremony**	Lehar 1

IASLC Business Meeting

Date	Time	Session Type	#	Session Title	Room
Tuesday, August 9, 2022	10:00 - 10:45	Business Meeting	-	**IASLC Business Meeting**	Strauss 3

Meet the Editor

Date	Time	Session Type	#	Session Title	Room
Sunday, August 7, 2022	14:00 - 15:30	Meet the Editor	**MTE01**	**Meet the Editor**	Committee Room 1

Remaking medicine, starting in lung cancer

EQRx™

EQ-NP-0007 06/2022

Clinical OLYMPICS™

A GAMIFIED SATELLITE SYMPOSIUM DURING THE IASLC 2022 WORLD CONFERENCE ON LUNG CANCER

HARNESSING THE FULL POTENTIAL OF FRONTLINE IMMUNOTHERAPY IN ADVANCED NSCLC

COMPETE TO WIN.

LET THE CLINICAL GAMES BEGIN!

EXPERT FACULTY

Jared M. Weiss, MD
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States

Prof. MUDr. Aleš Ryška, MD, PhD
Charles University
Hradec Králové University Hospital
Prague, Czech Republic

Mihaela Aldea, MD, PhD
Paris-Saclay University
Gustave Roussy
Villejuif, France

SUNDAY, 7 AUGUST 2022 | 18:00 – 19:00

Mess Wien Exhibition & Congress Center Hall C7

Register Now!
RMEI.com/WCLC2022

EVENT #1: Use of Biomarker Testing in Advanced NSCLC

EVENT #2: Selecting Frontline Immunotherapy in Advanced NSCLC

EVENT #3: Managing Immunotherapy-Related Adverse Events in NSCLC

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

RMEI MEDICAL EDUCATION FOR BETTER OUTCOMES This educational activity was independently developed by RMEI Medical Education, LLC. All faculty and planner relevant financial relationships were identified and mitigated and RMEI Medical Education, LLC has reviewed the content and determined it to be fair, balanced, and without commercial bias.

This program was approved by the IASLC 2022 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2022 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

7 DAILY SCIENTIFIC PROGRAM

DAILY SCIENTIFIC PROGRAM - FRIDAY, AUGUST 5

09:00 - 16:00
WS02: IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening

STRAUSS 3 | TICKETED SESSION

Chairs: Chunxue Bai, China, David Baldwin, United Kingdom, Ella Kazerooni, United States, Stephen Lam, Canada, Annette McWilliams, Australia, Harry de Koning, Netherlands

09:00 – 09:12
WS02.01 / WS02.02 / WS02.03 / WS02.04 / WS02.05 / WS02.06 Session Introduction
Chunxue Bai, China, David Baldwin, United Kingdom, Ella Kazerooni, United States, Stephen Lam, Canada, Annette Mcwilliams, Australia, Harry de Koning, Netherlands

09:12 – 09:15
WS02.07 / WS02.08 Session 1 Welcome
Ella Kazerooni, United States, Stephen Lam, Canada

09:15 – 09:25
WS02.09 Key Elements for Successful Implementation of a National Screening Program - The Taiwan Experience
Pan Chyr Yang, Taiwan

09:25 – 09:35
WS02.10 LungPlan (Financial Modeling to Secure Resources for Lung Screening and Nodule Management Program)
Ella Kazerooni, United States

09:35 – 09:45
WS02.11 LungPlan (Financial Modeling to Secure Resources for Lung Screening and Nodule Management Program)
Robert Smith, United States

09:45 – 09:55
WS02.12 Optimal Smoking Cessation Strategy
Matthew Peters, Australia

09:55 – 10:25
WS02.13 Panel Discussion & Live Q&A

10:25 – 10:40 WS02.14 Break

10:40 – 10:45
WS02.15 / WS02.16 Session 2 Welcome
David Baldwin, United Kingdom, Annette Mcwilliams, Australia

10:45 – 10:55
WS02.17 Training, Assessment and Standardized Cad-Based Reporting - The British Columbia Lung Screening Program
Stephen Lam, Canada

10:55 – 11:05
WS02.18 IASLC Education Resource Initiative
Natthaya Triphuridet, Thailand

11:05 – 11:15
WS02.19 Quality Assurance of Radiology Reporting: PERFECTS
Yan Chen, United Kingdom

11:15 – 11:25
WS02.20 CAD/AI in Screening Interpretation: From Detection through Management
Mathijs Oudkerk, Netherlands

11:25 – 11:55
WS02.21 Panel Discussion & Live Q&A

11:55 – 12:55
WS02.22 Lunch Break

12:55 – 13:10
WS02.23 / WS02.24 Welcome Back/Q&A from Morning Sessions
Stephen Lam, Canada, Harry de Koning, Netherlands

13:10 – 13:20
WS02.25 Assessing Lung Cancer Risk from a Single Chest CT
Marjolein Heuvelmans, Netherlands

13:20 – 13:30
WS02.26 Personalized Risk Assessment Using Blood and Imaging Biomarkers
Hilary Robbins, France

13:30 – 13:40
WS02.27 Deep Learning Approach to Optimize the Lung Cancer Screening Interval
Ping Hu, United States

13:40 – 13:50
WS02.28 Future Directions Using AI Technologies for Early Lung Cancer Detection
Georg Langs, Austria

13:50 – 14:20
WS02.29 Panel Discussion & Live Q&A

14:20 – 14:30
WS02.30 Break

14:30 – 14:35
WS02.31 / WS02.32 Session 4 Welcome
Ella Kazerooni, United States, Harry de Koning, Netherlands

14:35 – 14:45
WS02.33 Mass Screening Using AI and Liquid Biopsy in China
Chunxue Bai, China

14:45 – 14:55
WS02.34 Incidental Lung Nodules - An Opportunity to Advance Early Lung Cancer Detection
Raymond Osarogiagbon, United States

14:55 – 15:05
WS02.35 Benchmarks for Diagnostic Workup of Early Lung Cancer
Annette McWilliams, Australia

15:05 – 15:15
WS02.36 Additional Findings in Lung Cancer Screening
David Baldwin, United Kingdom

15:15 – 15:40
WS02.37 Panel Discussion & Live Q&A

15:40 – 15:50
WS02.38 Workshop Summary/Conclusion
John Field, United Kingdom

DAILY SCIENTIFIC PROGRAM - SATURDAY, AUGUST 6

08:00 – 11:30
WS03: Early Career & First Time Attendee Session

LEHAR 1

Chairs: Karen Kelly, United States, Heather Wakelee, United States

07:30 - 08:00 LIGHT BREAKFAST PROVIDED
WS03.01 / WS03.02 Session Introduction
Karen Kelly, United States, Heather Wakelee, United States

08:10 - 08:25
WS03.03 Introduction to the IASLC - Why You Should Be a Member
Karen Kelly, United States

08:25 - 08:40
WS03.04 Making the Most of WCLC: A Guide for First Time Attendees
Jarushka Naidoo, Ireland

08:40 - 08:55
WS03.05 Planning a Career in Lung Cancer - Bench to Bedside and Educational
Anne-Marie Dingemans, Netherlands

08:55 - 09:10
WS03.06 Planning a Career in Lung Cancer - Sponsored and Academic Trials
Ross Soo, Singapore

09:10 - 09:25
WS03.07 Planning a Career in Lung Cancer - A New Era of Trial Designs
Simon Ekman, Sweden

09:25 - 09:55
WS03.08 Break

09:55 - 10:10
WS03.09 Principles to Get Your Paper Published
Alex Adjei, United States

10:10 - 10:25
WS03.10 How to Give a Great Presentation
Pasi Janne, United States

10:25 - 10:40
WS03.11 Role of IASLC in Developing Countries
Clarissa Mathias, Brazil

10:40 - 10:55
WS03.12 Early Career Researcher Experience
Alessandro Russo, Italy

10:55 - 11:30
WS03.13 Live Q&A

08:00 – 12:00
WS04: IASLC/IMIG Workshop - The Future of Mesothelioma Treatment

LEHAR 4

Chair(s): Kenneth O'Byrne, Australia, Arnaud Scherpereel, France

08:00 - 08:05
WS04.01 / WS04.02 Session Introduction
Kenneth O'Byrne, Australia, Arnaud Scherpereel, France

08:05 - 08:20
WS04.03 Surgery with Immunotherapy
Maria Pagano, Italy

08:20 - 08:40
WS04.04 Personalizing Immunotherapy
Ibiayi Dagogo-Jack, United States

08:40 - 08:50
WS04.05 Discussant
Dean Fennell, United Kingdom

08:50 - 09:00
WS04.06 Live Q&A

09:00 - 09:30
WS04.07 Biology
Yoshitaka Sekido, Japan

09:30 - 09:50
WS04.09 What Is the Price We Pay for New Treatments and How Do We Manage Them?
Françoise Galateau-Salle, France

09:50 - 10:00
WS04.10 Live Q&A

10:00 - 12:00
WS04.11 / WS04.11 / WS04.12/ WS04.13 / WS04.14/ WS04.15 / WS04.16 / WS04.17/ WS04.18 Panel - Everything You Wanted to Know About Mesothelioma but Were Afraid to Ask
Dean Fennell, United Kingdom, Paul Baas, Netherlands, Patrick Forde, United States, Arnaud Scherpereel, France, Andreas Rimner, United States, Isabelle Opitz, Switzerland, Hedy Kindler, United States

09:00 – 10:00
WS05: Social Media + Communications Workshop

LEHAR 2

Chair(s): Brendon Stiles, United States, Jarushka Naidoo, Ireland

09:00 - 09:05
WS05.01 / WS05.02 Introduction & Live Tweeting Session
Brendon Stiles, United States, Jarushka Naidoo, Ireland

09:05 - 09:10
WS05.03 How to Work with Hospital, Institution, Communications Staff Members. Or Oncology Trade Journal Editor Perspectives
Chris Martin, United States

09:10 - 09:15
WS05.04 Building a Personal Brand on Social Media
Stephen Liu, United States

09:15 - 09:20
WS05.05 Promoting Your Research through Traditional and Social Media Networks
Matthew Smeltzer, United States

09:20 - 09:25
WS05.06 Engaging in Latin America
Jose Corona-Cruz, Mexico

09:25 - 09:30
WS05.07 Engaging in Asia
Vun-Sin Lim, Hong Kong

09:30 - 09:35
WS05.08 How to Give the Perfect Interview (Traditional Approach to Media/Trade Interviews)
Karen Reckamp, United States

09:35 - 09:40
WS05.09 Using Podcast to Promote Your Message and Disseminate Research
Narjust Florez, United States

09:40 - 09:45
WS05.10 Use of Social Media and Communications Channels for Patient Advocacy
Janet Freeman-Daily, United States

09:45 - 09:50
WS05.11 Wrap Up

09:50 - 10:10
WS05.12 Networking

12:00 – 17:00
WS06: Nurse & AHP + ITONF Joint Workshop

LEHAR 3

Chair(s): Mary Duffy, Australia, Maria Ftanou, Australia, Jacqui Frowen, Australia

12:00 - 12:30
WS06.01 ITONF AGM - ITONF Membership
Mary Duffy, Australia

12:30 - 13:00
WS06.02 Lunch/Networking/Poster Viewing

13:00 - 13:10
WS06.03 / WS06.04 Welcome
Mary Duffy, Australia, Maria Ftanou, Australia

13:10 - 13:15
WS06.05 Session Introduction
Jacqui Frowen, Australia

13:15 - 13:30 WS06.06
Targeted Therapy in NSCLC - New Frontiers
Marianne Davies, United States

13:30 - 13:45
WS06.07 Beyond Treating the Disease, Addressing the Person We Care For - Symptom Management, Palliative Care, Survivorship
Polly Dufton, Australia

13:45 - 14:00
WS06.08 Unlocking the Secrets of Immunotherapy - What Clinicians Need to Know
Michelle Turner, United States

14:00 - 14:10
WS06.09 Live Q&A

14:10 - 14:30
WS06.10 Refreshment Break/Networking/Poster Viewing

14:30 - 14:35
WS06.11 Session Introduction
Melanie Rabbets, Australia

14:35 - 14:50
WS06.12 Stigma & Shame Still an Issue in Lung Cancer?
Maria Ftanou, Australia

14:50 - 15:05
WS06.13 Enhancing Health Literacy Amongst Care Givers of People with Lung Cancer
Simon Dunne, Ireland

15:05 - 15:20
WS06.14 Supporting Children of Parents & Grandparents with Lung Cancer
Elena Schiena, Australia

15:20 - 15:302
WS06.15 / WS07.02 Live Q&A

15:30 - 15:50
WS06.16 Networking Break/Poster Viewing

15:50 - 15:55
WS06.17 Session Introduction
Andreas Charalambous, Cyprus

15:55 - 16:10
WS06.18 Working across Borders, Egypt & ITONF's Educational Modules
Mary Duffy, Australia

16:10 - 16:20
WS06.19 Clinician Professional & Academic Development - From Bedside to Bench: Getting Involved in Research - A Practical Approach
Morten Quist, Denmark

16:20 - 16:30
WS06.20 Clinician Professional & Academic Development - From Bedside to Bench: The Grant Application Process
Jacqui Frowen, Australia

16:30 - 16:40
WS06.21 Clinician Professional & Academic Development - From Bedside to Bench: Getting Published

16:40 - 16:50
WS06.22 Clinician Professional & Academic Development - From Bedside to Bench: Getting Involved in Clinical Practice Guidelines Development
Marianne Davies, United States

16:50 - 17:00
WS06.23 Successfully Navigating the WCLC2022 Program Summary & Close
Morten Quist, Denmark

15:00 – 16:30
WS07: LATAM Workshop

LEHAR 2

Chair(s): Clarissa Mathias, Brazil, Lucia Viola, Columbia

15:00 – 15:02
WS07.01 / WS07.02 Session Introduction
Clarissa Mathias, Brazil, Luica Viola, Colombia

15:02 - 15:12
WS07.03 Effect of Mirtazapine on Energy Intake in Patients with Anorexia Associated with NSCLC
Oscar Arrieta, Mexico, Oscar Arrieta, Mexico

15:12 - 15:22
WS07.04 KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients
Maritza Ramos-Ramirez, Mexico

15:22 - 15:32
WS07.05 Artificial Intelligence in Lung Cancer Screening: Accuracy and Predictive Value
Ricardo Santos, Brazil

15:32 - 15:42
WS07.06 Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression
Pedro Aguiar Jr, Brazil

15:42 - 15:52
WS07.07 Discussant
Andres Cardona, Colombia

15:52 – 16:02
WS07.08 Ancestry and Somatic Mutations in Lung Cancer in Latin America
Ticiana Leal, United States

16:02 – 16:12
WS07.09 Challenges of Implementing Lung Cancer Screening in Latin Countries
Ricardo Sales Santos, Brazil

16:12 – 16:22
WS07.10 Lung Cancer Disparities in Molecular Testing and Therapy Outcome in Hispanics in LATAM
Luis Raez, United States

16:22 – 16:30
WS07.11 Live Q&A

17:00 – 17:45
AC01: IASLC Awards Ceremony

LEHAR 1

18:15 – 19:45
PL01: Opening Plenary 1: Immunotherapy & Vaccines

HALL C1 LIVE-STREAM

Chair(s): Silvia Novello, Italy, Robert Pirker, Austria, Eric Lim, United Kingdom, Françoise Mornex, France, Helmut Prosch, Austria

18:15 – 18:20
PL01.01 / PL01.02 / PL01.03 / PL01.04 / PL01.05 Welcome and Introduction
Silvia Novello, Italy, Robert Pirker, Austria, Eric Lim, United Kingdom, Françoise Mornex, France, Helmut Prosch, Austria

18:20 - 18:25
PL01.06 Welcome Address - IASLC President
Heather Wakelee, United States

18:25 - 18:27
PL01.07 Welcome Address - IASLC Past President
Tetsuya Mitsudomi, Japan

18:30 – 18:55
PL01.09 IASLC Distinguished Service Award Presentations

18:55 – 19: 10
PL01.10 "We'll Do the Best We Can for as Long as We Can" and Other Assumptions I Hope We'll Make Obsolete in My Lifetime
Annabelle Gurwitch, United States

19:10 – 19:25
PL01.11 Immune Checkpoint Inhibitors
Julie Brahmer, United States

19:25 – 19:45
PL01.12 mRNA Vaccines for Prevention or Treatment of Disease
Christoph Huber, Austria

19:45 – 21:00
Welcome Reception

HALL B, EXHIBIT HALL

Light refreshments and beverages will be served.

DAILY SCIENTIFIC PROGRAM - SUNDAY, AUGUST 7

07:30 – 08:15
IBS01: Lung Cancer Screening: From Lung Cancer to Multiple Comorbidities

Track: Early Detection and Screening

LEHAR 1 | IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 08:15
IBS01.01 Net Benefit of Lung Cancer Screening: Much More Than Lung Cancer
John K. Field, United Kingdom

07:30 – 08:15
IBS02: SABR versus Surgery for Operable Lung Cancer

Track: Early Stage Non-small Cell Lung Cancer - Radiotherapy and Other Ablative Techniques

HALL C8

07:30 - 08:10
IBS02.01 / IBS02.02 SABR versus Surgery for Operable Lung Cancer
Famke Schneiders, Netherlands, Hiran Chrishantha Fernando, United States

08:10 - 08:15
IBS02.03 Live Q&A

07:30 – 08:15
IBS03: Real World Discussion about Testing in Low Income Countries

Track: Global Health, Health Services Research, and Health Economics

LEHAR 2 | IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 – 08:00
IBS03.01 / IBS03.02 Real World Discussion about Testing in Low Income Countries
Rodrigo Dientsmann, Brazil, Thanyanan Baisamut, Thailand

08:00 - 08:15
IBS03.03 Live Q&A

07:30 – 08:15
IBS04: The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy

Track: Nursing and Allied Health Professionals

STRAUSS 3 | IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 07:45
IBS04.01 The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy - Shared Presentation Nurse and Patient Advocate
Jennifer King, United States

07:45 - 08:00
IBS04.02 The Survivorship Experience for People Treated with Immunotherapy or Targeted Therapy - Shared Presentation Nurse and Consumer
Anne Fraser, New Zealand

08:00 - 08:15
IBS04.03 Live Q&A

07:30 – 08:15 IBS05: Controversies in Management of Locally Advanced NSCLC

Track: Locally Advanced Non-small Cell Lung Cancer

LEHAR 3 | IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 07:45
IBS05.01 Controversies in Management of Locally Advanced NSCLC
Gerry Hanna, United Kingdom

07:45 - 08:00
IBS05.02 Defining Resectability in Locally Advanced Lung Cancer
Clemens Aigner, Germany

08:00 - 08:15
IBS05.03 Live Q&A

07:30 – 08:15 IBS06: Which Therapy for Which MPM Patient?

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

LEHAR 4 | IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 07:45
IBS06.02 Local Treatments for Meso - Surgery
Marc De Perrot, Canada

07:45 - 08:00
IBS06.03 Local Treatments for Meso - Radiotherapy
Andreas Rimner, United States

08:00 - 08:15
IBS06.04 Live Q&A

08:30 – 10:00
PL02: Plenary 2: Multidisciplinary Approach to the Oligo Paradigm

HALL C1 | IASLC CME ACCREDITED | LIVE-STREAM

Chair(s): Francoise Mornex, France, Hisao Asamura, Japan

08:30 - 08:32
PL02.01 / PL02.02 Session Introduction
Francoise Mornex, France, Hisao Asamura, Japan

08:32 - 08:40
PL02.03 Definitions of Oligometastatic Disease - Concept, Definitions, Different Clinical Situations
Anne-Marie Dingemans, Netherlands

08:40 - 08:48
PL02.04 Definitions of Oligometastatic Disease - Concept, Definitions, Different Clinical Situations
Mathias Guckenberger, Switzerland

08:48 - 08:56
PL02.05 Definitions of Oligometastatic Disease - Biological Bases and Specificities
John Heymach, United States

08:56 - 09:06
PL02.06 Radical Modalities for De Novo Oligometastatic Disease - Role and Timing of Systemic Therapy
Delphine Antoni, France

09:06 - 09:16
PL02.07 Radical Modalities for De Novo Oligometastatic Disease - Local Consolidation - Surgery
Mara Antonoff, United States

09:16 - 09:26
PL02.08 Radical Modalities for De Novo Oligometastatic Disease - Local Consolidation - Radiation Oncology
Daniel Gomez, United States

09:26 - 09:36
PL02.09 Radical Modalities for De Novo Oligometastatic Disease - Local Consolidation - Interventional Radiology
Miltiadis Krokidis, Greece

09:36 - 09:43
PL02.10 Radical Management of Induced Oligometastatic Disease - Multi-modality Management
Eric Lim, United Kingdom

09:43 - 09:53
PL02.11 Patient Perspectives for Radical Management of Advanced Disease: When is it Enough/Too Much?
Lavina Magee, United Kingdom

09:53 - 10:00
PL02.12 Round Table

10:00 – 10:45
Networking Break

HALL B, EXHIBIT HALL

Light refreshments and beverages will be served.

10:05 – 10:45
PC02: Press Conference

SCHUBERT 5/6

10:45 – 11:45
ES01: Implementation and Continuous Optimization of Lung Cancer Screening

Track: Early Detection and Screening

HALL C1 | IASLC CME ACCREDITED

Chair(s): Mario Silva, Italy, Marjolein Heuvelmans, Netherlands

10:45 – 10:47
ES01.01 / ES01.02 Session Introduction
Mario Silva, Italy, Marjolein Heuvelmans, Netherlands

10:47 – 10:59
ES01.03 Scalability of Excellence: Continuous Refinement of Screening Scheme
Annette McWilliams, Australia

10:59 – 11:11
ES01.04 Strategies for Recruitment: Risk Profile, Engagement, Adherence
Hilary Robbins, France

11:11 - 11:23
ES01.05 LCS: Pulmonary and Extrapulmonary Findings
Sam Janes, United Kingdom

11:23 - 11:35
ES01.06 US-Preventive Services Task Force LCS Recommendations in Community Based Health Care Systems
Katharine Rendle, United States

11:35 - 11:45
ES01.07 Live Q&A

10:45 – 11:45
ES02: Management of Lung Cancer in the Era of COVID-19

Track: Management of Lung Cancer in the Era of COVID-19

HALL C2 IASLC CME ACCREDITED

Chair(s): Marina Garassino, United States, Christian Grohe, Germany

10:45 - 10:47
ES02.01 /ES02.02 Session Introduction
Marina Garassino, United States, Christian Grohe, Germany

10:47 -10:59
ES02.03 Impact of the COVID-19 Pandemic on Lung Cancer Diagnosis and Screening
Betty Tong, United States

10:59 - 11:11
ES02.04 Impact of the COVID-19 Pandemic on Surgery
Leanne Ashrafian, United Kingdom

11:11 - 11:23
ES02.05 Impact of the COVID-19 Pandemic on Radiotherapy
Umberto Ricardi, Italy

11:23 - 11:35
ES02.06 Impact of the COVID-19 Pandemic on Systemic Treatment
Wilfried Eberhardt, Germany

11:35 - 11:45
ES02.07 Live Q&A

10:45 – 11:45
ES03: Synchronous Oligometastatic NSCLC: Practical Implications

Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Daniel Tan, Singapore, Hans Hoffmann, Germany

10:45 - 10:47
ES03.01 / ES03.02 Session Introduction
Daniel Tan, Singapore, Hans Hoffmann, Germany

10:47 - 10:59
ES03.03 Synchronous Oligometastatic NSCLC 2022 Where Are We Now
Jeffrey Bradley, United States

10:59 -11:11
ES03.04 Concept 1: Brain Only Disease
Paul Martin Putora, Switzerland

11:11 - 11:23
ES03.05 Concept 2: Bulky Thoracic Disease
Ben Solomon, Australia

11:23 – 11:35
ES03.06 Concept 3: cT1bN0, Single Adrenal Met: Surgery or Radiotherapy; Sequencing with Systemic Treatment
Isabelle Opitz, Switzerland

11:35 - 11:45
ES03.07 Live Q&A

10:45 – 11:45
MA01: Molecular Subtypes and Prognostic Factors for SCLC and Neuro-endocrine Tumours

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

HALL C7

Chair(s): Fabio Pagni, Italy, Ferdinando Skoulidis, United States

10:45 - 10:47
MA01.01 / MA01.02 Session Introduction
Fabio Pagni, Italy, Ferdinandos Skoulidis, United States

10:47 - 10:52
MA01.03 Exploiting DNA Methylation for Classification of SCLC Subtypes from Liquid Biopsies Using a Robust Machine Learning Approach
Simon Heeke, United States

10:52 - 10:57
MA01.04 Molecular Subtypes of Surgically Resected Small Cell Lung Cancer: Expression Pattern and Prognostic Relevance
Zsolt Megyesfalvi, Hungary

10:57 - 11:02
MA01.05 Immuno-microenvironment (TIME) Heterogeneity of Small Cell Lung Cancer (SCLC) Stratified by Molecular Subtypes
Jiyan Dong, China

11:02 - 11:12
MA01.06 Discussant
Kenneth O'Byrne, Australia

11:12 - 11:17
MA01.07 From Molecular to Histological Characterization of Lung Carcinoids via Computer Vision and Spatial Genomics
Émilie Mathian, France

11:17 - 11:22
MA01.08 Impact of [18F]FDG PET/CT-derived Metabolic Parameters on Outcomes in Extensive-stage SCLC
Giuseppe Lamberti, Italy

11:22 - 11:27
MA01.09 Characterising Aggressive Pulmonary Carcinoids Through Integrative Omics Analysis Within the lungNENomics Project
Alexandra Sexton-Oates, France

11:27 - 11:37
MA01.10 Discussant
Michael Boyer, Australia

11:37 - 11:45
MA01.11 Live Q&A

10:45 – 11:45
MA02: Molecular Underpinnings of Lung Cancer Histological Differentiation and Targeted Therapeutics

Track: Tumour Biology and Biomarkers

HALL C8

Chair(s): Erik Thunnissen, Netherlands, Rafael Rosell, Spain

10:45 - 10:47
MA02.01 / MA02.02 Session Introduction
Erik Thunnissen, Netherlands, Rafael Rosell, Spain

10:47 - 10:52
MA02.03 The Evolution of Lung Neuro-endocrine Tumours
Nicolas Alcala, France

10:52 - 10:57
MA02.04 Molecular Drivers and Therapeutic Targets for Neuro-endocrine Transformation in Lung Cancer
Triparna Sen, United States

10:57 - 11:02
MA02.05 Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
Jie Huang, China

11:02 – 11:12
MA02.06 Discussant
Yuko Minami, Japan

11:12 - 11:17
MA02.07 Aurora A Kinase Inhibition with VIC-1911Potentiates KRASG12C Inhibitor and Overcomes Resistance to Sotorasib in Lung Cancer
Jong Woo Lee, United States

11:17 - 11:22
MA02.08 Trametinib Inhibition of MEK1 2 Upregulates PD-L1 Expression in KRAS-Mutant NSCLC Through ID1 Downregulation
Ander Puyalto, Spain

11:22 - 11:27
MA02.09 Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC
Giuseppe Lamberti, United States

11:27 - 11:37
MA02.10 Discussant
Sally Lau, United States

11:37 - 11:45
MA02.11 Live Q&A

10:45 – 11:45
OA01: Real World Data to Guide Our Daily Needs

Track: Global Health, Health Services Research, and Health Economics

STRAUSS 3

Chair(s): Gyula Ostoros, Hungary, Oscar Arrieta, Mexico

10:45 - 10:47
OA01.01 / OA01.02 Session Introduction
Gyula Ostoros, Hungary, Oscar Arrieta, Mexico

10:47 - 10:57
OA01.03 Lung Cancer in Victoria: Association Between Stage-Specific Receipt of Guideline-Concordant Treatment and Survival
Sanuki Tissera, Australia

10:57 - 11:07
OA01.04 Persisting Gaps in Optimal Care of Stage III Non-Small Cell Lung Cancer: An Australian Patterns of Care Analysis
Robert Stirling, Australia

11:07 - 11:17
OA01.05 Socio-economic Inequalities in NSCLC Treatment During the Era of Tumour Biomarker Guided Therapy: A Population-based Study
Ruth Norris, United Kingdom

11:17 - 11:27
OA01.06 Project PEER: A Longitudinal Real-World Study to Understand the Experience of Patients With Lung Cancer and Their Caregivers
Upal Basu Roy, United States

11:17 - 11:27
OA01.07 Discussant
Tatiane Montella, Brazil

11:37 - 11:55
OA01.08 Live Q&A

12:00 – 13:00
ES04: Current Status of Lung Cancer Screening Worldwide

Track: Early Detection and Screening

HALL C1 IASLC CME ACCREDITED

Chair(s): Torsten Blum, Germany, Ricardo Sales Santos, Brazil, Mónica Castro, Argentina

12:00 – 12:03
ES04.01 / ES04.02 / ES04.03 Session Introduction
Torsten Blum, Germany, Ricardo Sales Santos, Brazil, Mónica Castro, Argentina

12:03 - 12:15
ES04.04 Europe: International Network for Continuous Evidence-Based Optimization of LCS
Matthijs Oudkerk, Netherlands

12:15 - 12:27
ES04.05 Lung Cancer Screening in Asia for Individuals Without a Smoking History
Pan Chyr Yang, Taiwan

12:27 - 12:39
ES04.06 Argentinean National Consensus on LCS; Barriers and Challenges to Implement It in the Context of Latinoamerica LCS Situation
Iris Boyeras Navarro, Argentina

12:39 - 12:51
ES04.07 Gender Differences in Lung Cancer Screening
Narjust Florez (Duma), United States

12:51 – 13:00
ES04.08 Live Q&A

12:00 – 13:00
ES05: Oncogenic Alterations and Beyond - Novel Treatments

Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

HALL C2 IASLC CME ACCREDITED

Chair(s): Caicun Zhou, China, Helena Linardou, Greece

12:00 – 12:02
ES05.01 / ES05.02 Session Introduction
Caicun Zhou, China, Helena Linardou, Greece

12:02 - 12:14
ES05.03 Targeting Rarer Events in Known Targets: EGFR Exon20 (EGFR, HER2)
Giannis Mountzios, Greece

12:14 - 12:26
ES05.04 All You Need to Know About KRAS
Odd Terje Brustugun, Norway

12:26 - 12:38
ES05.05 Antibody-Drug Conjugates - Where We Stand Today?
Bob T. Li, United States

12:38 - 12:50
ES05.06 HRD/DDR in Lung Cancer: Role and Therapeutic Implications
Lauren Byers, United States

12:50 - 13:00
ES05.07 Live Q&A

12:00 – 13:00
ES06: Symptom Management in Lung Cancer

Track: Palliative and Supportive Care

LEHAR 1 IASLC CME ACCREDITED

Chair(s): Alberto Chiappori, United States, Sara Ramella, Italy

12:00 - 12:02
ES06.01 / ES06.02 Session Introduction
Alberto Chiappori, United States, Sara Ramella, Italy

12:02 – 12:14
ES06.03 The Management of Symptoms with Patients Reported Outcome
Emilio Bria, Italy

12:14 - 12:26
ES06.04 Interventional Pulmonology for Managing Dyspnea in Lung Cancer
Semra Bilaceroglu, Turkey

12:26 - 12:38
ES06.05 Palliative Radiotherapy in the Era of Targeted and Immunotherapy
Lucyna Kepka, Poland

12:38 - 12:50
ES06.06 Self-Care for the Clinician Caring for Advanced Cancer Patients: Compassion Fatigue and Burnout
Maria Ftanou, Australia

12:50 - 12:55
ES06.07 Innovative Technology/Tools for Smoking Cessation
Lawson Eng, Canada

12:55 - 13:00
ES06.08 Live Q&A

12:00 – 13:00
ES07: Impact of Tumour Plasticity and Molecular/Immune Adaptations in Treatment Sensitivity and Resistance

Track: **Tumour Biology and Biomarkers**

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Benjamin Besse, France, YUnited Kingdomo Minami,Japan

12:00 – 12:02
ES07.01 / ES07.02 Session Introduction
Benjamin Besse, France, Yuko Minami, Japan

12:02 – 12:14
ES07.03 NSCLC Persister Cells and Their Role in Treatment Resistance and Disease Progression
Trever Bivona, United States

12:14 - 12:26
ES07.04 Biological Role and Actionability of Molecular/Immune Alterations after Acquired Resistance to Single-Agent and Combination Therapies (Focus on EMT, Includes SCLC)
Sandra Ortiz-Cuaran, France

12:26 - 12:38
ES07.05 Tumour Cell Plasticity and Histological/ Molecular Changes: Focus On Transition from NSCLC to SCLC
Triparna Sen, United States

12:38 - 12:50
ES07.06 Biological Advances in SCLC: Molecular Subtypes, Anti-tumour Immune Responses and Impact on Therapeutics
Helmut Popper, Austria

12:50 - 13:00
ES07.07 Live Q&A

12:00 – 13:00
MA03: Predicting Outcomes in Patients with Early Disease NSCLC

Track: **Early Stage Non-small Cell Lung Cancer**

HALL C8

Chair: Devayani Niyogi, India

12:00 – 12:02
MA03.01 / MA03.02 Session Introduction
Devayani Niyogi, India

12:02 - 12:07
MA03.03 Predicting Occult Lymph Node Metastasis in Patients With Clinical Stage IA Non-small Cell Lung Cancer: A Prospective Cohort Study
Junghee Lee, South Korea

12:07 – 12:12
MA03.04 An Integrated Deep Learning Method to Predict Lung Cancer Recurrence Risk for Resected Stage IA NSCLC
Peng Huang, United States

12:12 - 12:17
MA03.05 EGFR mutation Is Not a Risk Factor for Postoperative Recurrence of Lung Adenocarcinoma on Long Follow-up of a Multi-Institutional Cohort
Yuki Matsumura, Japan

12:17 - 12:27
MA03.06 Discussant
Betty Tong, United States

12:27 - 12:32
MA03.07 Accurate Intraoperative Diagnosis of Spread Through Air Spaces (STAS) Using a Cryo Embedding Medium Inflation Method
Takashi Eguchi, Japan

12:32 - 12:37
MA03.08 Survival Impact of Benchmarking Lung Cancer Surgeons' Performance by Quality Metrics
Meredith Ray, United States

12:37 - 12:42
MA03.09 Real-World Acute Toxicity and 90-day Mortality in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy.
Nienke Wolfhagen, Netherlands

12:42 - 12:52
MA03.10 Discussant
Young Tae Kim, South Korea

12:52 - 13:00
MA03.11 Live Q&A

12:00 – 13:00
OA02: From Locally Advanced to Unresectable NSCLC: Improvement of Multimodality Treatment

Track: Locally Advanced Non-small Cell Lung Cancer

HALL C7

Chair(s): Isabelle Opitz, Switzerland, Luis Paz-Ares, Spain

12:00 – 12:02
OA02.01 / OA02.02 Session Introduction
Isabelle Opitz, Switzerland, Luis Paz-Ares, Spain

12:02 - 12:12
OA02.03 Tumour Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
Marta Casarrubios, Spain

12:12 - 12:22
OA02.04 Multimodal Management of T4 N2 Non-small-cell Lung Cancer with Additional Ipsilateral Pulmonary Nodules
Arvind Kumar, South Korea

12:22 - 12:32
OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
Yi-Long Wu, China

12:32 - 12:42
OA02.06 Discussant
Linda Martin, United States

12:42 - 13:00
OA02.07 Live Q&A

13:15 – 14:15
LA01: Lectureship Awards - Sunday

HALL C1 LIVE-STREAM

Chair(s): Keunchil Park, South Korea, Paul A. Bunn, Jr., United States

13:15 - 13:17
LA01.01 / L01.02 Session Introduction
Keunchil Park, South Korea, Paul A. Bunn, Jr., United States

13:17 - 13:32
LA01.03 IASLC Lectureship Award for Smoking Cessation and Tobacco Control
Raymond Osarogiagbon, United States

13:32 - 13:47
LA01.04 Tsuguo Naruke Lectureship Award for Surgery
Wenzhao Zhong, China

13:47 - 14:02
LA01.05 Daniel C. Ihde Lectureship Award for Medical Oncology
Patrick Forde, United States

14:02 – 14:15
LA01.06 Live Q&A

13:15 – 14:15 Networking Lunch

HALL B, EXHIBIT HALL

Complimentary food and beverages will be served.

14:00 – 15:30
MTE01: Meet the Editor

COMMITTEE ROOM 1

14:00 - 15:30
MTE01.01 Meet the Editor
Alex Adjei, United States

14:30 – 15:30
ES08: Sublobar Resection: Oncological Outcome and Advantages

Track: Early Stage Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments - Surgery

HALL C1 IASLC CME ACCREDITED

Chair(s): Masahiro Tsuboi, Japan, Monica Casiraghi, Italy

14:30 – 14:32
ES08.01 / ES08.02 Session Introduction
Masahiro Tsuboi, Japan, Monica Casiraghi, Italy

14:32 - 14:44
ES08.03 Patients Selection for Segmentectomy
Hisao Asamura, Japan

14:44 - 14:56
ES08.04 Occult Lymph Nodes Metastasis During Segmentectomy: What to Do
Keiju Aokage, Japan

14:56 - 15:08
ES08.05 Are There Benefits of Sublobar Resection Including Lung Function
Nasser Khaled Altorki, United States

15:08 - 15:20
ES08.06 Management of Multifocal GGO
In Kyu Park, South Korea

15:20 – 15:30
ES08.07 Live Q&A

14:30 – 15:30
ES09: Technology Innovations

HALL C2 IASLC CME ACCREDITED

Chair(s): Joe Chang, United States, Wieland Voigt, Germany

14:30 – 14:32
ES09.01 / ES09.02 Session Introduction
Joe Chang, United States, Wieland Voigt, Germany

14:32 - 14:44
ES09.03 New Radiotherapy Machines, Techniques and Results
Suresh Senan, Netherlands

14:44 - 14:56
ES09.04 How to Improve Lung Tolerance to Radiation in the Setting of Combined Modality Treatment
Andrea Bezjak, Canada

14:56 - 15:08
ES09.05 Machine Learning in Cancer Imaging: The Power of Pooling Data
Philippe Lambin, Netherlands

15:08 - 15:20
ES09.06 Robotic Surgery
Diego Gonzalez Rivas, Spain

15:20 – 15:30
ES09.07 Live Q&A

14:30 – 15:30
ES10: Problems and Controversies in Thoracic Tumours

Track: **Pathology**

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Keith Kerr, United Kingdom, Wendy Cooper, Australia

14:30 – 14:32
ES10.01 / ES10.02 Session Introduction
Keith Kerr, United Kingdom, Wendy Cooper, Australia

14:32 - 14:44
ES10.03 Undifferentiated Epithelioid Tumour in a Biopsy
Andrew Nicholson, United Kingdom

14:44 - 14:56
ES10.04 Undifferentiated Spindle Tumour in a Biopsy
Sabina Berezowska, Switzerland

14:56 - 15:08
ES10.05 How To Maximize Biomarker Information From a Small Sample
Kuniko Sunami, Japan

15:08 - 15:20
ES10.06 Grading Lung Cancer - Where Are We Now
Andre Moreira, United States

15:20 - 15:30
ES10.07 Live Q&A

14:30 – 15:30
ES11: Joint IASLC-ESTRO Session - Integration of Radiotherapy for Optimal Patient Outcomes

LEHAR 1 IASLC CME ACCREDITED

Chair(s): Alexander Louie, Canada, Corinne Faivre-Finn, United Kingdom

14:30 – 14:32
ES11.01 / ES11.02 Session Introduction
Alexander Louie, Canada, Corinne Faivre-Finn, United Kingdom

14:32 – 14:44
ES11.03 What Is the Role of Radiotherapy in the Immunotherapy Era for Resectable NSCLC?
Shankar Siva, Australia

14:44 - 14:56
ES11.05 How Do We Address the Challenge of Pneumonitis in the Multimodality Radical Treatment Era?
Andrew Bang, Canada

14:56 - 15:08
ES11.06 The Increasing Role of Re-Irradiation: How Do We Keep It Safe?
Sara Ramella, Italy

15:08 - 15:30
ES11.07 Live Q&A

14:30 – 15:30
MA04: Pulmonology, Radiology, and Staging

Track: Pulmonology, Radiology, and Staging

STRAUSS 3

Chair(s): Mir Ali Reza Hoda, Austria, Pieter Postmus, Netherlands

14:30 – 14:32
MA04.01 / MA04.02 Session Introduction
Mir Alireza Hoda, Austria, Pieter Postmus, Netherlands

14:32 - 14:37
MA04.03 Reconsidering T Classification for T3/T4 Non-small Cell Lung Cancer with Additional Nodule(s)
Fang Wang, China

14:37 – 14:42
MA04.04 The Ground-Glass Component Status Combined with the Clinical T Descriptor Predicts Prognosis and Genomic Alterations in NSCLC
Yukihiro Yoshida, Japan

14:42 - 14:47
MA04.05 T3 Defining Features Influence Long Term Survival after Resection of T3N0M0 NSCLC
Paula Ugalde Figueroa, United States

14:31 - 14:57
MA04.06 Discussant
Frank Detterbeck, United States

14:57 - 15:02
MA04.07 A Controlled Study of Pathological T-staging and Imaging T-staging of NSCLC Based on Artificial Intelligence
Yuanyong Wang, China

15:02 - 15:07
MA04.08 Navigation Bronchoscopy Mediated Sentinel Lymph Node Procedure: an Explorative Study in Ex-vivo Lung Cancer Specimens
Desi Ter Woerds, Netherlands

15:07 - 15:12
MA04.09 The Incidence and Predictors of Unsuspected Brain Metastases in Patients with Stage IA NSCLC
Camille Mathey-Andrews, United States

15:12 - 15:22
MA04.10 Discussant
Rudolf Huber, Germany

15:22 - 15:30
MA04.11 Live Q&A

14:30 – 15:40
OA03: Molecular Targeted Treatments

Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

HALL C7

Chair(s): Andrew Ciupek, United States, David Gandara, United States

14:30 – 14:32
OA03.01 / OA03.02 Session Introduction
Andrew Ciupek, United States, David Gandara, United States

14:32 - 14:42
OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumours
Gerald Falchook, United States

14:42 - 14:52
OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
Adrian Sacher, Canada

14:52 - 15:02
OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
Michael Thomas, Germany

15:02 - 15:12
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
Bob Li, United States

15:12 - 15:22
OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
Shun Lu, China

15:22 – 15:32
OA03.08 Discussant
Helena Linardou, Greece

15:32 - 15:40
OA03.09 Live Q&A

14:30 – 15:40
OA04: Mesothelioma Under the Looking Glass

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

HALL C8

Chair(s): Joachim Aerts, Netherlands, Anne Tsao, United States

14:30 - 14:32
OA04.01 / OA04.02 Session Introduction
Joachim Aerts, Netherlands, Anne Tsao, United States

14:32 - 14:42
OA04.03 Multi-omic Analysis of Malignant Pleural Mesothelioma PDXs Reveal Pathway Alterations and Therapeutic Targets
Triparna Sen, United States

14:42 - 14:52
OA04.04 Association of Novel microRNAs With Diagnosis and Histology of Malignant Pleural Mesothelioma
Michaela Kirschner, Switzerland

14:52 - 15:02
OA04.05 MESOMICS Project: Using Whole-Genome Sequencing Data to Fill the Gaps in Malignant Pleural Mesothelioma Molecular Studies
Nicolas Alcala, France

15:02 - 15:12
OA04.06 PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)
Li-Anne Douma, Netherlands

15:12 – 15:22
OA04.07 Discussant
Giovanni Ceresoli, Italy

15:22 - 15:40
OA04.08 Live Q&A

15:45 – 16:45
ES12: Surgical Issues in Multimodality Treatments for Early Stage NSCLC

Track: Early Stage Non-small Cell Lung Cancer - Surgery

HALL C1 IASLC CME ACCREDITED

Chair(s): Tomaz Stupnik, Slovenia, Mir Ali Reza Hoda, Austria

15:45 – 15:47
ES12.01 / ES12.02 Session Introduction
Tomaz Stupnik, Slovenia, Mir Ali Reza Hoda, Austria

15:47 - 15:59
ES12.03 The Role of Minimally Invasive Surgery in Multimodality Setting
Alan Sihoe, Hong Kong

15:59 - 16:11
ES12.04 Surgical Challenges of Neoadjuvant Immunotherapy
Valerie Rusch, United States

16:11 - 16:23
ES12.05 Assessment of Resectability after Chemotherapy with Immunocheckpoint Inhibitor or Molecular Targeted Therapies
Giulia Veronesi, Italy

16:23 - 16:35
ES12.06 Optimum Surgical Staging and Tissue Acquisition for Adjuvant Immunotherapy and Targeted Treatments
Paula Ugalde, United States

16:35 - 16:45
ES12.07 Live Q&A

15:45 – 16:45
ES13: Mesothelioma

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

HALL C2 IASLC CME ACCREDITED

Chair(s): Paolo Bironzo, Italy, Leah Backhus, United States

15:45 – 15:47
ES13.01 / ES13.02 Session Introduction
Paolo Bironzo, Italy, Leah Backhus, United States

15:47 - 15:59
ES13.03 Update in the Pathologic Diagnosis in Mesothelioma
Françoise Galateau-Salle, France

15:59 - 16:11
ES13.04 First Line Treatment: Optimal Choice for Which Patient?
Wanda Cui, Australia

16:11 - 16:23
ES13.05 Second Line and Beyond
Dean Fennell, United Kingdom

16:23 - 16:35
ES13.06 Targeted Therapy and Experimental Drugs
Raffit Hassan, United States

16:35 - 16:45
ES13.07 Live Q&A

15:45 – 16:45
ES14: Think, Think, Think?..The Importance of Thinking Holistically When Caring for Lung Cancer Patients

Track: **Nursing and Allied Health Professionals**

LEHAR 1 IASLC CME ACCREDITED

Chair(s): Anne Fraser, New Zealand, Andreas Charalambous, Cyprus

15:45 – 15:47
ES14.01 / ES14.02 Session Introduction
Anne Fraser, New Zealand, Andreas Charalambous, Cyprus

15:47 - 15:59
ES14.03 Information Needs of Carers of People with Lung Cancer
Simon Dunne, Ireland

15:59 - 16:11
ES14.04 Interventions to Improve Cancer Survivorship among Indigenous Peoples and Communities
Marianne Davies, United States

16:11 - 16:23
ES14.05 Interventions to Limit the Impacts of Parental Lung Cancer Impact on Children
Elena Schiena, Australia

16:23 - 16:35
ES14.06 Treating People with Comorbid Dementia: Implications for Cancer Care
Lorna McWilliams, United Kingdom

16:35 – 16:45
ES14.07 Live Q&A

15:45 – 16:45
ES15: Is Cytotoxic Chemotherapy in NSCLC Management Only Palliative?

Track: **Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy**

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Navneet Singh, India, Khaled Kamal, Egypt

15:45 – 15:47
ES15.01 / ES15.02 Session Introduction
Navneet Singh, India, Khaled Kamal, Egypt

15:52 - 16:04
ES15.03 Can Chemotherapy Agents Be Personalized in NSCLC?
David Planchard, France

16:04 - 16:16
ES15.04 Second-Line Chemotherapy Following First-Line Mono-Immunotherapy in High PD-L1 (TPS≥50%) Advanced/Metastatic NSCLC
Sara Pilotto, Italy

16:16 - 16:28
ES15.05 The Future of Cytotoxics in the Management of NSCLC
Sofia Baka, Greece

16:28 - 16:40
ES15.06 Chemotherapy in Elderly NSCLC Patients: How to Play It Safe?
Rajwanth Veluswamy, United States

15:47 - 15:52
ES15.07 Impact of Smoking on Clinical Outcomes of Systemic Therapies
Enrica Capelletto, Italy

16:40 - 16:45
ES15.08 Live Q&A

15:45 – 16:45
MA05: Immune Landscape and Molecular Profiling of Lung Cancer

Track: **Tumour Biology and Biomarkers**

HALL C8

Chair(s): Luis Paz-Ares, Spain, Tina Cascone, United States

15:45 - 15:47
MA05.01 / MA05.02 Session Introduction
Luis Paz-Ares, Spain, Tina Cascone, United States

15:47 - 15:52
MA05.03 Utilization of Genomic Mutation Signature to Predict the Immunotherapy Response in Non-small Cell Lung Cancer
Wenbin Li, China

15:52 - 15:57
MA05.04 Multiplex Phenotyping Reveals Spatial Immune Patterns in NSCLC
Max Backman, Sweden

16:12 - 16:17
MA05.05 Analysis of CREBBP as a Potential Biomarker for Immune Checkpoint Therapy in Solid Tumours and Its Correlation With Immune Microenvironment
Xiaoli Liu, China

16:02 - 16:12
MA05.06 Discussant
Fabio Pagni, Italy

15:57 - 16:02
MA05.07 Intertumoural Molecular Heterogeneity of Non-small Cell Lung Cancer With MET Exon 14 Skipping
Yuchen Han, China

16:17 - 16:22
MA05.08 MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History
Jennifer Marks, United States

16:22 - 16:27
MA05.09 Genomic Mapping of Metastatic Organotropism: Analysis of 2326 Primary and Organ-Specific Metastases in Lung Adenocarcinoma
Harry Lengel, United States

16:27 - 16:37
MA05.10 Discussant
Giulia Pasello, Italy

16:37 – 16:45
MA05.11 Live Q&A

15:45 – 16:45
OA05: The Granularity of Lung Cancer Screening Implementation

Track: Early Detection and Screening

HALL C7

Chair(s): Arjun Nair, United Kingdom, Ella Kazerooni, United States

15:45 - 15:47
OA05.01 / OA05.02 Session Introduction
Arjun Nair, United Kingdom, Ella Kazerooni, United States

15:47 - 15:57
OA05.03 Incidence, Timing, and Survival of Second Primary Lung Cancer in Patients in the National Lung Screening Trial
Alexandra Potter, United States

15:57 - 16:07
OA05.04 A Comparison of Stage- and Histology-Specific CT Sensitivity in the NELSON Trial and the NLST
Koen de Nijs, Netherlands

16:07 - 16:17
OA05.05 China Lung Cancer Screening (CLUS) Version 1.0: Mortality, Survival and Incidence Rates with Long-Term Follow-up
Fangfei Qian, China

16:17 - 16:27
OA05.06 Early Diagnosis of Lung Cancer Among Younger vs. Older Adults: Widening Disparities in the Era of Lung Cancer Screening
Alexandra Potter, United States

16:27 – 16:37
OA05.07 The Granularity of Lung Cancer Screening Implementation
Anand Devaraj, United Kingdom

16:37 - 16:45
OA05.08 Live Q&A

17:00 – 19:00
Poster Viewing Reception
Poster Session P1 Presenters in Attendance

HALL B, EXHIBIT HALL

Complimentary food and beverage will be served.

18:00 – 18:30
Editorial Reception (By Invitation Only)

MESSE WIEN, GROUND LEVEL, PAVILION RESTAURANT

19:30 – 22:30
International Lung Cancer Foundation Benefit Supporting Early Career Researchers

Please refer to your International Lung Cancer Foundation Benefit Supporting Early Career Researchers ticket for more information.

TICKETED NETWORKING EVENT

DAILY SCIENTIFIC PROGRAM - MONDAY, AUGUST 8

07:30 – 08:15
IBS07: Interactive Multidisciplinary Thoracic Tumour Board

Track: **Early Stage Non-small Cell Lung Cancer?-Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)**

LEHAR 1 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 08:15
IBS07.01 Interactive Multidisciplinary Thoracic Tumour Board
Stephen Liu, United States

07:30 – 08:15
IBS08: Chemotherapy Still Remains a Key Component of Treatment for Majority of Patients with Metastatic NSCLC in the Era of Immune-Oncology

Track: **Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy**

HALL C8 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 07:45
IBS08.01 In Favor
Takayuki Takahama, Japan

07:45 - 08:00
IBS08.02 Against
Mirjana Rajer, Slovenia

08:00 - 08:15
IBS08.03 Live Q&A

07:30 – 08:15
IBS09: Inequities in Access to Lung Cancer Care across the World

Track: **Patient Advocacy**

STRAUSS 3 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

Chair(s): Stefania Vallone, Italy, Merel Hennink, Netherlands

07:30 - 07:32
IBS09.01 / IBS09.02 Session Introduction
Stefania Vallone, Italy, Merel Hennink, Netherlands

07:32 - 07:56
IBS09.03 / IBS09.04 / IBS09.05 Growing Inequality: Care and Access to New Treatments
Ebele Mbanugo, United States, Karla Ruiz de Castilla, Peru, Nabanita Mandal, India

07:56 - 08:06
IBS09.06 Opportunities to Equalize Access to Treatment: Cost, Health Technology Assessment (HTA) And Logistics
Christina Sit, Canada

08:06 - 08:15
IBS09.07 Live Q&A

07:30 – 08:15
IBS10: In Situ IO Biomarkers

Track: **Pathology**

LEHAR 2 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 – 08:00
IBS10.01 / IBS10.02Pathology, Immunotherapy and the TME
Sanja Dacic, United States, Patrick Micke, Sweden

08:00 - 08:15
IBS10.03 Live Q&A

07:30 – 08:15
IBS11: E-Cigarettes Are an Effective Smoking Cessation Aid

Track: **Tobacco Control and Risk Reduction**

LEHAR 3 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 07:45
IBS11.01 Pro
Matt Evison, United Kingdom

07:45 - 08:00
IBS11.02 Con
Emily Stone, Australia

08:00 - 08:15
IBS11.03 Live Q&A

07:30 – 08:15
IBS12: Mediastinal Staging

Track: **Pulmonology, Radiology, and Staging**

LEHAR 4 | IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 07:42
IBS12.01 Mediastinal Staging: Pulmonologist's Perspective
Sylvia Guetz, Germany

07:42 - 07:54
IBS12.02 Mediastinal Staging: Surgeon's Perspective
Joshua Sonett, United States

07:54 - 08:15
IBS12.03 Live Q&A

08:30 – 10:20
PL03: Plenary 3: Presidential Symposium - Top Rated Abstracts

HALL C1 | IASLC CME ACCREDITED | LIVE-STREAM

Chair(s): Heather Wakelee, United States, Eric Lim, United Kingdom

08:30 - 08:30
PL03.01 / PL03.02 Session Introduction
Heather Wakelee, United States, Eric Lim, United Kingdom

08:30 - 08:40
PL03.03 Personalised Smoking Cessation Support in a Lung Cancer Screening Programme: The Yorkshire Enhanced Stop Smoking Study (YESS)
Rachael Murray, United Kingdom

08:40 - 08:50
PL03.04 Discussant
Jacek Jassem, Poland

08:50 - 08:55
PL03.05 Live Q&A

08:55 - 09:05
PL03.06 Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA = 2 cm Non-small Cell Lung Cancer (NSCLC): Results From an International Randomized Phase III Trial (CALGB 140503 [Alliance])
Nasser Khaled Altorki, United States

09:05 - 09:15
PL03.07 Discussant
Hisashi Saji, Japan

09:15 - 09:20
PL03.08 Live Q&A

09:20 - 09:30
PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
Enriqueta Felip, Spain

09:30 - 09:40
PL03.10 Discussant
Benjamin Besse, France

09:40 - 09:45
PL03.11 Live Q&A

09:45 - 09:55
PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
Mariano Provencio, Spain

09:55 - 10:05
PL03.13 Discussant
Masahiro Tsuboi, Japan

10:05 - 10:15
PL03.14 Discussant
Corinne Faivre-Finn, United Kingdom

10:15 - 10:20
PL03.15 Live Q&A

10:20 – 11:00
Networking Break

HALL B, EXHIBIT HALL

Light refreshments and beverages will be served.

10:25 – 11:00
PC03: Press Conference

SCHUBERT 5/6

11:00 – 12:00
ES16: Pushing the Boundaries in Lung Ablative Therapies

Track: **Early Stage Non-small Cell Lung Cancer-Radiotherapy and Other Ablative Techniques**

HALL C1 | IASLC CME ACCREDITED

Chair(s): Yasushi Nagata, Japan, Ursula Nestle, Germany

11:00 - 11:02
ES16.01 / ES16.02 Session Introduction
Yasushi Nagata, Japan, Ursula Nestle, Germany

11:02 - 11:14
ES16.03 SABR and ICI Combinations
Stephanie Kroeze, Switzerland

11:14 - 11:26
ES16.04 New Radiotherapy Approaches (MRI-Linac, Protons, Single Fraction)
Yong Chan Ahn, South Korea

11:26 - 11:38
ES16.05 Thermal Ablation: Stand-Alone or Prior to Lung SBRT?
Percy Lee, United States

11:38 - 11:50
ES16.06 Re-Irradiation: Which Are the Possibilities? A Practical Guide
Kevin Chua, Singapore

11:50 - 12:00
ES16.07 Live Q&A

11:00 – 12:00
ES17: Cost and Accessibility to Lung Cancer Drugs - Pathways to Improvement

Track: Global Health, Health Services Research, and Health Economics

HALL C1 IASLC CME ACCREDITED

Chair(s): David R. Gandara, United States

11:00 - 11:02
ES17.02 Session Introduction
David R. Gandara, United States

11:07 - 11:19
ES17.03 WHO Essential List: Is This a Possible Road to Follow?
Gilberto Lopes, United States

11:19 - 11:31
ES17.04 Bringing Research to the Forefront of Care? Lessons Learned
Clarissa Mathias, Brazil

11:31 - 11:43
ES17.05 Incorporation of China Innovative Anti-cancer Drugs - What Have We Learned?
Yuankai Shi, China

11:43 - 11:55
ES17.06 Role of Advocacies and Scientific Societies in Improving Cancer Care in Low Income Countries
Alina Comanescu, Romania

11:02 - 11:07
ES17.07 The Role of Social Media in Supporting Tobacco Control
Nagla Abdel Karim, United States

11:55 - 12:00
ES17.08 Live Q&A

11:00 – 12:00
ES18: Management of Pulmonary Nodules

Track: Pulmonology, Radiology, and Staging

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Edith Marom, Israel, Wentao Fang, China

11:00 - 11:02
ES18.01 / ES18.02 Session Introduction
Edith Marom, Israel, Wentao Fang, China

11:02 - 11:14
ES18.03 Preneoplasia Management Strategies
Seung Hun Jang, South Korea

11:14 - 11:26
ES18.04 Nodule Measurements: Diameter vs. Volume
Ritu Gill, United States

11:26 - 11:38
ES18.05 Biopsy and Localization of Nodules
Yeun-Chung Chang, Taiwan

11:38 - 11:50
ES18.06 Managing Indeterminate Pulmonary Nodules: Current Best Practice
Hans-Ulrich Kauczor, Germany

11:50 - 12:00
ES18.07 Live Q&A

11:00 – 12:00
OA06: Impact of COVID-19 on Cancer Management and Protection from Vaccines

Track: Management of Lung Cancer in the Era of COVID-19

LEHAR 1

Chair(s): Marina Garassino, United States, Christian Grohe, Germany

11:00 - 11:02
OA06.01 / OA06.02 Session Introduction
Marina Garassino, United States, Christian Grohe, Germany

11:02 - 11:12
OA06.03 Serological Response to SARS-CoV-2 Vaccination in Patients Lung Cancer: A Mount Sinai-Led Prospective Matched Controlled Study
Philip Mack, United States

11:12 - 11:22
OA06.04 Immune Response after SARS-CoV-2 Vaccination in Lung Cancer Patients. Update of the Covid Lung Vaccine Cohort
Ainhoa Hernandez, Spain

11:22 - 11:32
OA06.05 Impact of COVID-19 Pandemic on Proportion and Treatment Patterns for Stage I Non-small Cell Lung Cancer in the Netherlands
Nienke Wolfhagen, Netherlands

11:32 - 11:42
OA06.06 Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis
Amit Kulkarni, United States

11:42 - 11:52
OA06.07 Stereotactic Ablative Radiotherapy Before Resection to Avoid Delay for Early-Stage LunG Cancer or OligomEts
Biniam Kidane, Canada

11:52 - 12:02
OA06.08 Discussant
Marina Garassino, United States

12:02 - 12:10
OA06.09 Live Q&A

11:00 – 12:00
OA07: Is There Still a Role for Chemotherapy Alone in the Management of NSCLC?

Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

HALL C7

Chair(s): Lubos Petruzelka, Czech Republic, Pilar Garrido, Spain

11:00 - 11:02
OA07.01 / OA07.02 Session Introduction
Lubos Petruzelka, Czech Republic, Pilar Garrido, Spain

11:02 - 11:12
OA07.03 Association Between Genetic Variation in the ATP-binding Cassette Transporter ABCC10 and nab-PTX Treatment in Japanese Cohort
Minoru Horiuchi, Japan

11:12 - 11:22
OA07.04 Overall Survival in Patients With Advanced NSCLC Receiving Taxane-Containing Regimen After Exposure to Immunotherapy and Platinum-Doublet
Stephen Liu, United States

11:22 - 11:32
OA07.05 Gemcitabine Plus Platinum Chemotherapy Re-challenge in Metastatic Pulmonary Lymphoepithelioma-like Carcinoma
Gavin Cheung, Hong Kong

11:32 - 11:42
OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
Edouard Auclin, France

11:42 - 11:52
OA07.07 Discussant
Navneet Singh, India

11:52 - 12:00
OA07.08 Live Q&A

11:00 – 12:00
OA08: Multidisciplinary Care of the Lung Cancer Patient

Track: Nursing and Allied Health Professionals

STRAUSS 3

Chair(s): Shankar Siva, Australia, Sun Min Lim, South Korea

11:00 - 11:02
OA08.01 / OA08.02Session Introduction
Shankar Siva, Australia, Sun Min Lim, South Korea

11:02 - 11:12
OA08.03 Do in Screening - Calf Circumference and Muscle Strength is Predictive of Outcomes in Lung Cancer Treatment.
Imanuely Borchardt Borchardt, Brazil

11:12 - 11:22
OA08.04 The Impact of Video-fluoroscopic Swallow Assessment on Dysphagia Management in Lung Cancer
Ashton Brower, United Kingdom

11:22 - 11:32
OA08.05 A Quality Improvement Project Determining if Dietitian Input with the UHS Lung Oncology Team Improved Patient Outcomes.
Ann-Marie Jones, United Kingdom

11:32 - 11:42
OA08.06 Implementation of a Nurse-led Geriatric Oncology Assessment Model in the Lung Cancer Care Pathway
Polly Dufton, Australia

11:42 - 11:52
OA08.07 Discussant
Jacqui Frowen, Australia

11:52 - 12:00
OA08.08 Live Q&A

12:15 – 13:15
ES19: Toxicity Avoidance in SABR for Early Stage NSCLC

Track: Early Stage Non-small Cell Lung Cancer?-Radiotherapy and Other Ablative Techniques

HALL C1 | IASLC CME ACCREDITED

Chair(s): Lizza Hendriks, Netherlands, Shankar Siva, Australia

12:15 - 12:17
ES19.01 / ES19.02 Session Introduction
Lizza Hendriks, Netherlands, Shankar Siva, Australia

12:17 - 12:29
ES19.03 SABR in the Ultracentral Lesions
Kevin Franks, United Kingdom

12:29 - 12:41
ES19.04 Heart Matters in Lung SABR
Pamela Samson, United States

12:41 - 12:53
ES19.05 SABR in Patients with Interstitial Lung Disease
Yeon Sil Kim, South Korea

12:53 - 13:05
ES19.06 Chest Wall Myositis, Pleuritis and Rib Fracture
Maria Werner-Wasik, United States

13:05 - 13:15
ES19.07 Live Q&A

12:15 – 13:15
ES20: Management of Lung Cancer in the Era of COVID-19 II

Track: Management of Lung Cancer in the Era of COVID-19

HALL C2 | IASLC CME ACCREDITED

Chair(s): Andrea Bezjak, Canada, Milena Cavic, Serbia

12:15 - 12:17
ES20.01 / ES20.02 Session Introduction
Andrea Bezjak, Canada, Milena Cavic, Serbia

12:17 - 12:29
ES20.03 COVID-19 and Its Complications in Patients With Lung Cancer
Kwun Fong, Australia

12:29 - 12:41
ES20.04 Impact of COVID-19 on Lung Cancer and Mesothelioma Specialist Nurses
Sarah Hargreaves, United Kingdom

12:41 - 12:53
ES20.05 Intensive Care for Lung Cancer Patients
Erwin GrasmUnited Kingdom-Siegl, Austria

12:53 - 13:05
ES20.06 Telemedicine in 2021: Pros and Cons
Howard (Jack) West, United States

13:05 - 13:15
ES20.07 Live Q&A

12:15 – 13:15
ES21: Problems and Controversies in Lung Tumours

Track: Pathology

STRAUSS 1/2 | IASLC CME ACCREDITED

Chair(s): Jin-Haeng Chung, South Korea, Sylvie Lantuejoul, France

12:15 - 12:17
ES21.01 / ES21.02 Session Introduction
Jin-Haeng Chung, South Korea, Sylvie Lantuejoul, France

12:17 - 12:29
ES21.03 G3NET/Supracarcinoids
Mauro Papotti, Italy

12:29 - 12:41
ES21.04 SCLC Subtypes
Natasha Rekhtman, United States

12:41 - 12:53
ES21.05 LCNEC: Where Are We with Diagnosis?
Teodora Radonic, Netherlands

12:53 - 13:05
ES21.06 Molecular Profiling and Biomarkers in Lung NET. Any Closer?
Alexandra Sexton-Oates, France

13:05 - 13:15
ES21.07 Live Q&A

12:15 – 13:15
MA06: Resectable and Unresectable Locally Advanced Lung Cancer

Track: Locally Advanced Non-small Cell Lung Cancer

LEHAR 1

Chair(s): Saulius Cicenas, Lithuania, Celine Mascaux, France

12:15 - 12:17
MA06.01 / MA06.02 Session Introduction
Saulius Cicenas, Lithuania, Celine Mascaux, France

12:17 - 12:22
MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
Atocha Romero, Spain

12:22 - 12:27
MA06.04 Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study (WJOG11619L)
Motoko Tachihara, Japan

12:27 - 12:32
MA06.05 Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC
Greg Durm, United States

12:32 - 12:42
MA06.06 Discussant
Andrea Bille, United Kingdom

12:42 - 12:47
MA06.07 Molecular Typing of pN2 Lung Adenocarcinoma: A Retrospective Study Based on Transcriptome Sequencing
Jianfei Zhu, China

12:47 - 12:52
MA06.08 Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC
Wilfried Eberhardt, Germany

12:52 - 12:57
MA06.09 Deep Learning for Predicting MPR to Neoadjuvant Immunotherapy in NSCLC
Yifan Zhong, China

12:57 - 13:07
MA06.10 Discussant
Dawn Owen, United States

13:07 - 13:15
MA06.11 Live Q&A

12:15 – 13:15
MA07: Overcoming Resistance to EGFR Inhibitors

Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

HALL C7

Chair(s): Dana Lucia Stanculeanu, Romania, Ross Soo, Singapore

12:15 - 12:17
MA07.01 / MA07.02 Session Introduction
Dana Lucia Stanculeanu, Romania, Ross Soo, Singapore

12:17 - 12:22
MA07.03 Real-world Landscape of EGFR C797X Mutation as a Resistance Mechanism to Osimertinib in Non-small Cell Lung Cancer
Suresh Ramalingam, United States

12:22 - 12:27
MA07.04 Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
Melina Marmarelis, United States

12:27 - 12:32
MA07.05 Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
Jonathan Goldman, United States

12:32 - 12:42
MA07.06 Discussant
Laura Mezquita, Spain

12:42 - 12:47
MA07.07 Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA
Laura Mezquita, Spain

12:47 - 12:52
MA07.08 JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC
Byoung Chul Cho, South Korea

12:52 - 12:57
MA07.09 BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study
Sun Min Lim, South Korea

12:57 - 13:07
MA07.10 Discussant
Pasi Jänne, United States

13:07 - 13:15
MA07.11 Live Q&A

12:15 – 13:15
MA08: Patient Advocacy and Patient Preferences

Track: **Patient Advocacy**

STRAUSS 3

Chair(s): Merel Hennink, Netherlands, Ewelina Szmytke, Poland

12:15 - 12:17
MA08.01 / MA08.02 Session Introduction
Merel Hennink, Netherlands, Ewelina Szmytke, Poland

12:17 - 12:22
MA08.03 Breathe Anew: Designing and Testing the Feasibility of a Novel Intervention for Lung Cancer Survivorship
Yogita S. Patel, Canada

12:22 - 12:27
MA08.04 Initial Steps in Creating a Patient-Centric Addendum to Clinical Trial Informed Consent Forms
Bellinda King-Kallimanis, United States

12:27 - 12:32
MA08.05 Advancing Education and Advocacy for the Small Cell Lung Cancer Community
Jennifer King, United States

12:32 - 12:42
MA08.06 Discussant
Lorraine Dallas, United Kingdom

12:42 - 12:47
MA08.07 Understanding Lung Cancer Patients' Preferences in Speaking to Their Treatment Team: Insights from a Global Patient Experience Survey
Jackie Fenemore, United Kingdom

12:47 - 12:52
MA08.08 Impact of Lung Cancer on Quality of Life - A European Perspective
Anne-Marie Baird, Ireland

12:52 - 12:57
MA08.09 The Role of Social Media as a Platform for Patient-Led Support Groups
Maryann Bradley, Canada

12:57 - 13:07
MA08.10 Discussant
Hiroaki Akamatsu, Japan

13:07 - 13:15
MA08.11 Live Q&A

13:30 – 14:30
LA02: Lectureship Awards - Monday

HALL C1 LIVE-STREAM

Chair(s): Frances Shepherd, Canada, Giorgio Scagliotti, Italy

13:30 - 13:32
LA02.01 / LA02.02 Session Introduction
Frances Shepherd, Canada, Giorgio Scagliotti, Italy

13:32 - 13:47
LA02.03 Robert J. Ginsberg Lectureship Award for Surgery
Isabelle Opitz, Switzerland

13:47 - 14:02
LA02.04 James D. Cox Lectureship Award for Radiation Oncology
Yuko Nakayama, Japan

14:02 - 14:17
LA02.05 Heine H. Hansen Lectureship Award for Small Cell Lung Cancer
Stephen Liu, United States

14:17 - 14:30
LA02.06 Live Q&A

13:30 – 14:30
Networking Lunch

HALL B, EXHIBIT HALL

Complimentary food and beverages will be served.

14:45 – 15:45
ES22: Lung Cancer in Individuals Without A Smoking History

Track: **Epidemiology**

HALL C1 IASLC CME ACCREDITED

Chair(s): Rayjean Hung, Canada, Mattias Johansson, France

14:45 - 14:47
ES22.01 / ES22.02 Session Introduction
Rayjean Hung, Canada, Mattias Johansson, France

14:47 - 14:59
ES22.03 Epidemiological Risk Factors for Lung Cancer Beyond Smoking History
Michelle C. Turner, Spain

14:59 - 15:11
ES22.04 Radon and Lung Cancer
Alberto Ruano Ravina, Spain

15:11 - 15:23
ES22.05 SHERLOCK-LUNG: Somatic Characterizations for Individuals Without a Smoking History
Zhibin Hu, China

15:23 - 15:35
ES22.06 The Advocates Perspective on Lung Cancer in Individuals Without a Smoking History
Upal Basu Roy, United States

15:35 - 15:45
ES22.07 Live Q&A

14:45 – 15:45
ES23: Optimizing Radio-Chemo-Immunotherapy for Locally Advanced NSCLC

Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

HALL C2 IASLC CME ACCREDITED

Chair(s): Billy Loo, United States, Jose Belderbos, Netherlands

14:45 - 14:47
ES23.01 / ES23.02 Session Introduction
Billy Loo, United States, Jose Belderbos, Netherlands

14:47 - 14:59
ES23.03 Early Integration of Immune Checkpoint Inhibition into Radio-Chemotherapy
Willemijin Theelen, Netherlands

14:59 - 15:11
ES23.04 Management of Patients with Oncogenic Driver Mutations
Ross Soo, Singapore

15:11 - 15:23
ES23.05 Next-Generation Radiotherapy in the Era of Immunotherapy
Ken Harada, Japan

15:23 - 15:35
ES23.06 Diagnosis and Management of Pneumonitis after Radio-Chemo-Immunotherapy
Alexander Louie, Canada

15:35 - 15:45
ES23.07 Live Q&A

14:45 – 15:45
ES24: Palliative Care Integration and QOL in Advanced Lung Cancer

Track: Palliative and Supportive Care

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Charu Aggarwal, United States, Karin Dieckmann, Austria

14:45 - 14:47
ES24.01 / ES24.02 Session Introduction
Charu Aggarwal, United States, Karin Dieckmann, Austria

14:47 - 14:59
ES24.03 Early Palliative Care in Advanced Non-small-Cell Lung Cancer
Jennifer Temel, United States

14:59 - 15:11
ES24.04 Treatment Decision-Making for Patients with Complicated Bone Metastases
Thanyanan Baisamut, Thailand

15:11 - 15:23
ES24.05 What Is the Role of Supporting Care to Improve Checkpoint Inhibitor Tolerance?
Mirjana Rajer, Slovenia

15:23 - 15:35
ES24.06 The Management of Pain in Lung Cancer: Pharmacological Interventions
Marliese Alexander, Australia

15:35 - 15:45
ES24.07 Live Q&A

14:45 – 15:45
MA09: Palliative Radiotherapy: The Changing Landscape with Immunotherapy and Targeted Therapies

Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy

HALL C7

Chair(s): Milada Zemanova, Czech Republic, David Ball, Australia

14:45 - 14:47
MA09.01 / MA09.02 Session Introduction
Milada Zemanova, Czech Republic, David Ball, Australia

14:47 - 14:52
MA09.03 Response of Palliative Radiotherapy in Bone Metastases of Lung Cancer - Results of Prospective Longitudnal Study from India
Amiya Agrawal, India

14:52 - 14:57
MA09.04 First-line PD-1 Inhibitors and Chemotherapy Combined with or without Radiotherapy in Advanced Non-small-cell Lung Cancer
Xiaorong Dong, China

14:57 - 15:02
MA09.05 Increased PD-L1 Tracer Uptake in Recently-irradiated Lesions in NSCLC: Preliminary Results of a Phase 0 Trial (ImmunoPET) of a Novel PET Tracer
Michael Macmanus, Australia

15:02 - 15:12
MA09.06 Discussant
Kristin Higgins, United States

15:12 - 15:17
MA09.07 Understanding Outcomes of Patients with Metastatic Non-Small Cell Lung Carcinoma Undergoing Whole Brain vs Stereotactic Radiotherapy
Dhruv Abhi, United Kingdom

15:17 - 15:22
MA09.08 Radiotherapy Improves Outcomes to Immunotherapy in Patients with Stage III and IV NSCLC
Haihua Yang, China

15:22 - 15:27
MA09.09 Perilesional Edema and Size of Brain Metastases as Prognostic and Predictive Factors to Local Therapy in Advanced Non-small-Cell Lung Cancer
Oscar Arrieta, Mexico

15:27 - 15:27
MA09.10 Discussant
Ursula Nestle, Germany

15:27 - 15:35
MA09.11 Live Q&A

14:45 – 15:45
MA10: Updates in Thymoma

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies

HALL C8

Chair(s): Noboru Yamamoto, Japan, Paul van Houtte, Belgium

14:45 - 14:47
MA10.01 / MA10.02 Session Introduction
Noboru Yamamoto, Japan, Paul van Houtte, Belgium

14:47 - 14:52
MA10.03 Is Thoracoscopic Thymectomy Safe and Oncologically Sound in Large Thymic Tumours?
Venkataramani Karthik, India

14:52 - 14:57
MA10.04 Long-term Follow-up Study of Thymic Epithelial Tumours. Report of the Updated Nation-wide Database in Japan
Meinoshin Okumura, Japan

14:57 - 15:02
MA10.05 High Levels of CD47 Expression in Thymic Epithelial Tumours
Thomas Yang Sun, United States

15:02 - 15:12
MA10.06 Discussant
Joachim Aerts, Netherlands

15:12 - 15:17
MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)
Claudia Proto, Italy

15:17 - 15:22
MA10.08 Activated Pathways of Myastenia Gravis in Thymic Epithelial (TETs)
Jose Benítez, France

15:22 - 15:27
MA10.09 Outcomes of Induction Therapy Followed by Surgical Resection for Advanced Thymic Tumour
Sumin Shin, South Korea

15:27 - 15:37
MA10.10 Discussant
Alessandra Curioni-Fontecedro, Switzerland

15:37 - 15:45
MA10.11 Live Q&A

14:45 – 15:45
OA09: Precision Immunotherapy via Modulation of the Tumour Microenvironment

Track: Tumour Biology and Biomarkers

LEHAR 1

Chair(s): Kurt Schalper, United States, Umberto Malapelle, Italy

14:45 - 14:47
OA09.01 / OA09.02 Session Introduction
Kurt Schalper, United States, Umberto Malapelle, Italy

14:47 - 14:57
OA09.03 Single Cell Analyses Reveal Effects of Immunosenescence Cells in Neoadjuvant Immunotherapy of Lung Squamous cell Carcinoma Patients
Tao Wang, China

14:57 - 15:07
OA09.04 Spatial Mapping and Clinical Significance of the LAG-3/FGL1 Pathway in Non-small Cell Lung Cancer Using High-Dimensional Tissue Imaging
Shruti Desai, United States

15:07 - 15:17
OA09.05 Neoadjuvant IL-15-PDL1 Antibody Promotes T cell Memory and Decreases Metastatic Recurrence in Resectable NSCLC
Jonathan Villena-Vargas, United States

15:17 - 15:27
OA09.06 Vascular Leakage Promotes Immunosuppression and is Associated with Reduced Patient Survival in Non-Small Cell Lung Cancer
Emmanuel Nwadozi, Sweden

15:27 - 15:37
OA09.07 Discussant
Umberto Malapelle, Italy

15:37 - 15:45
OA09.08 Live Q&A

14:45 – 15:45
OA10: Strategies to Integrate Smoking Cessation and Cancer Care

Track: Tobacco Control and Risk Reduction

STRAUSS 3

Chair(s): Enrica Capelletto, Italy, Manfred Neuberger, Austria

14:45 - 14:47
OA10.01 / OA10.02 Session Introduction
Enrica Capelletto, Italy, Manfred Neuberger, Austria

14:47 - 14:57
OA10.03 A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting
Randi Williams, United States

14:57 - 15:07
OA10.04 Opt-out Outperforms Opt-in Smoking Cessation Treatment One-month Post Randomization
Babalola Faseru, United States

15:07 - 15:17
OA10.05 Integrating Smoking Cessation into LDCT Lung Cancer Screening. Results of the Ontario, Canada, Pilot
Bill Evans, Canada

15:17 - 15:27
OA10.06 An Unconventional Financial Incentive Based Feasibility Trial for Smoking Cessation
Gregory Holt, United States

15:27 - 15:37
OA10.07 Discussant
Patrizia Froesch, Switzerland

15:37 - 15:55
OA10.08 Live Q&A

16:00 – 17:00
ES25: Clinical Issues with Immunotherapy in Non-small Cell Lung Cancer

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

HALL C1 IASLC CME ACCREDITED

Chair(s): Martin Reck, Germany, Sanjay Popat, United Kingdom

16:00 - 16:02
ES25.01 / ES25.02 Session Introduction
Martin Reck, Germany, Sanjay Popat, United Kingdom

16:02 - 16:14
ES25.03 First-Line Choice in PD-L1 Positive Patients
Filiz Oezkan, Germany

16:14 - 16:26
ES25.04 First-Line Choice in PD-L1 Negative Patients
Delvys Rodriguez-Abreu, Spain

16:26 - 16:38
ES25.05 Second-Line Options in Immune-Pretreated Patients
Keunchil Park, South Korea

16:38 - 16:50
ES25.06 Immunotherapy in Oncogene-Addicted NSCLC
Francesco Passiglia, Italy

16:50 - 17:00
ES25.07 Live Q&A

16:00 – 17:00
ES26: Thymoma

Track: **Mesothelioma, Thymoma, and Other Thoracic Malignancies**

HALL C2 | IASLC CME ACCREDITED

Chair(s): Joachim Aerts, Netherlands, David Waller, United Kingdom

16:00 - 16:02
ES26.01 / ES26.02 Session Introduction
Joachim Aerts, Netherlands, David Waller, United Kingdom

16:02 - 16:14
ES26.03 Pathological Staging of Thymic Epithelial Tumours
Anja Roden, United States

16:14 - 16:26
ES26.04 How to Implement Surgery in the Multimodality Therapy of Thymic Epithelial Tumours
Enrico Ruffini, Italy

16:26 - 16:38
ES26.05 Risks and Options of IO Therapy in Thymic Epithelial Tumours
Chen Zhao, United States

16:38 - 16:50
ES26.06 Indications for Radiation Therapy
Anna Wrona, Poland

16:50 - 17:00
ES26.07
Live Q&A

16:00 – 17:00
ES27: Joint Global Lung Cancer Coalition and International Association for the Study of Lung Cancer Session - Breaking Down Roadblocks to Lung Cancer Care in 2022

Track: **Patient Advocacy**

HALL C2 | IASLC CME ACCREDITED

Chair(s): Carolyn Aldige, United States, David Baldwin, United Kingdom

16:00 - 16:02
ES27.01 / ES27.02 Session Introduction
Carolyn Aldige, United States, David Baldwin, United Kingdom

16:02 - 16:12
ES27.03 Mitigating the Effects of COVID - How Does Lung Cancer Recover?
David Baldwin, United Kingdom

16:12 - 16:22
ES27.04 Lung Cancer Screening - From Pilots to Programs and the Effects of Patient Advocacy
Shani Shilo, Israel

16:22 - 16:32
ES27.05 Lung Cancer Screening - From Pilots to Programs
Matthew Peters, Australia

16:32 - 16:42
ES27.06 Lung Cancer Patient Experience - The Impact of COVID
Merel Hennink, Netherlands

16:42 - 16:52
ES27.07 Optimising Telehealth for the Lung Cancer Patient
Lauren Pretorius, South Africa

16:52 - 17:00
ES27.08 Live Q&A

16:00 – 17:00
MA11: Optimization of Technologies for Lung Cancer Screening: Population Selection and Nodule Handling

Track: **Early Detection and Screening**

LEHAR 1

Chair(s): Anna Kerpel-Fronius, Hungary, Annemiek Snoeckx, Belgium

16:00 - 16:02
MA11.01 / MA11.02 Session Introduction
Anna Kerpel-Fronius, Hungary, Annemiek Snoeckx, Belgium

16:02 - 16:07
MA11.03 Updated Cost-Effectiveness Analysis of Lung Cancer Screening for Australia, Capturing Differences in the Impact of NELSON and NLST Outcomes
Preston Ngo, Australia

16:07 - 16:12
MA11.04 Genetic Variants of HUNT Lung Cancer Model Improve Lung Cancer Risk Assessment Over Clinical Models
Olav Toai Duc Nguyen, Norway

16:12 - 16:17
MA11.05 The Blood Proteome of Imminent Lung Cancer
Hana Zahed, France

16:17 - 16:27
MA11.06 Discussant
Carole Ridge, United Kingdom

16:27 - 16:32
MA11.07 The ELIC Distributed Database and Computation Environment for Analyses of Lung Cancer Screening LDCTs Across the World
Stephen Lam, Canada

16:32 - 16:37
MA11.08 Value of Computer Aided Diagnosis on Radiologists' Workflow and Recommendation for Reporting Lung Cancer Screening LDCT
Ren Yuan, Canada

16:37 - 16:42
MA11.09 Artificial Intelligence in Lung Cancer Screening: Accuracy and Predictive Value
Ricardo Santos, Brazil

16:42 - 16:52
MA11.10 Discussant
Arjun Nair, United Kingdom

16:52 - 17:00
MA11.11 Live Q&A

16:00 – 17:00
OA11: Optimal Patient Selection for Local Therapy in Stage IV NSCLC

Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease

HALL C7

Chair(s): Pablo Munoz-Schuffenegger, Chile, Mariana Brandao, Belgium

16:00 - 16:02
OA11.01 / OA11.02 Session Introduction
Pablo Munoz-Schuffenegger, Chile, Mariana Brandao, Belgium

16:02 - 16:12
OA11.03 Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Non-Small Cell Lung Cancer: A Marker of Better Prognosis
Peter Zhan, United States

16:12 - 16:22 OA11.04
The Factors Associated With Reduced Risk of Progression in Patients With Oligometastatic NSCLC Treated With Local Ablative Radiotherapy
Gowoon Yang, South Korea

16:22 - 16:32
OA11.05 Treatment Strategies Based on Different Oligoprogressive Patterns after Immunotherapy Resistance in Advanced NSCLC
Shun Lu, China

16:32 - 16:42
OA11.06 Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis
Xiaorong Dong, China

16:42 - 16:52
OA11.07 Discussant
Digambar Behera, India

16:52 - 17:00
OA11.08 Live Q&A

16:00 – 17:00
OA12: Novel and Combination Strategies for SCLC

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

HALL C8

Chair(s): Alessandra Curioni-Fontecedro, Switzerland, Kostas Syrigos, Greece

16:00 - 16:02
OA12.01 / OA12.02 Session Introduction
Alessandra Curioni-Fontecedro, Switzerland, Kostas Syrigos, Greece

16:02 - 16:12
OA12.03 Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Jonathan Goldman, United States

16:12 - 16:22
OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial.
Dwight Owen, United States

16:22 - 16:32
OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
Hossein Borghaei, United States

16:32 - 16:42
OA12.06 First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
Charles Rudin, United States

16:42 - 16:52
OA12.07 Discussant
Virginie Westeel, France

16:52 - 17:00
OA12.08 Live Q&A

17:15 – 19:00
Poster Viewing Reception
Poster Session P2 Presenters in Attendance

HALL B, EXHIBIT HALL

Complimentary food and beverage will be served.

19:30 – 22:30
Faculty Dinner (By Invitation Only)

Please refer to your Faculty Dinner ticket for more information.

DAILY SCIENTIFIC PROGRAM - TUESDAY, AUGUST 9

07:30 – 08:15
IBS13: CNS Involvement in Oncogene-Driven and Not-Oncogene-Driven Disease: Optimal Management

Track: **Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments**

LEHAR 1 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 08:00
IBS13.01 CNS Involvement in Oncogene-Driven and Not-Oncogene-Driven Disease: Optimal Management
Rifaquat Rahman, United States

08:00 - 08:15
IBS13.02 Live Q&A

07:30 – 08:15
IBS14: Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies

Track: **Palliative and Supportive Care**

STRAUSS 3 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 08:00
IBS14.01 Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies
Krisztina Bogos, Hungary

08:00 - 08:15
IBS14.02 Live Q&A

07:30 – 08:15
IBS15: Should We Offer PCI and Consolidation Thoracic RT to Patients Treated with First-Line Chemo-Immunotherapy?

Track: **Small Cell Lung Cancer and Neuro-endocrine Tumours**

HALL C8 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 07:45
IBS15.01 No
Gyula Ostoros, Hungary

07:45 - 08:00
IBS15.02 Yes
Corinne Faivre-Finn, United Kingdom

08:00 - 08:15
IBS15.03 Live Q&A

07:30 – 08:15
IBS16: A Guide for the Perplexed: How to Use Lung Cancer Risk Models Efficiently for Screening

Track: **Early Detection and Screening**

LEHAR 2 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 - 08:15
IBS16.01 A Guide for the Perplexed: How to Use Lung Cancer Risk Models Efficiently for Screening
Martin Tammemagi, Canada

07:30 – 08:15
IBS17: Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?

Track: **Tumour Biology and Biomarkers**

LEHAR 3 IASLC CME ACCREDITED | TICKETED SESSION | LIGHT BREAKFAST PROVIDED

07:30 – 08:00
IBS17.01 / IBS17.02 Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?
Fred R. Hirsch, United States, Solange Peters, Switzerland

08:00 - 08:15
IBS17.03 Live Q&A

07:30 – 08:15
IBS18: Women in Thoracic Oncology

LEHAR 4 IASLC CME ACCREDITED | LIGHT BREAKFAST PROVIDED

Chair(s): Françoise Mornex, France, Silvia Novello, Italy, Narjust Florez, United States

07:30 - 07:33
IBS18.01 / IBS18.02 / IBS18.03 Session Introduction
Françoise Mornex, France, Silvia Novello, Italy, Narjust Florez, United States

07:33 – 07:35
IBS18.04 President Welcome
Heather Wakelee, United States

07:35 – 07:45
IBS18.05 / IBS18.06 / IBS18.07 / IBS18.08 / IBS18.09/ IBS18.11/ IBS18.12 / IBS18.13 / IBS18.14 Panel Discussion - Thriving during a Global Crisis
Narjust Florez, United States, Heather Wakelee, United States, Silvia Novello, Italy, Clarissa Mathias, Brazil, Françoise Mornex, France, Karen Kelly, United States, Enriqueta Felip, Spain, Roselle De Guzman, Philippines, Feng-Ming Spring Kong, Hong Kong

07:45 – 08:15
Round Table
Moderators: Anne-Marie Dingemans, Netherlands, Deepali Jain, India, Aki Kobayashi, Japan, Vun-Sin Lim, Hong Kong, Natasha Leighl, Canada

Topics:

1. **Career Transitions - Finding a New Job**
2. **Negotiating Salary and Beyond (Vacation, Rooms in Clinic, Days of Clinic, RVU Target)**
3. **Finding Mentors beyond Your Institution / How to Identify Suitable Mentors in General**
4. **Systematic Approaches to Wellness (Changing the Work Environment)**
5. **Building a Career beyond Clinical Care and Research - Admin, Education, etc**
6. **Finding Your Niche - What Fills Your Cup?**
7. **Social Media - How to Get Involved**

08:30 – 10:00
PL04: Plenary 4: Artificial Intelligence in Lung Cancer

HALL C1 | IASLC CME ACCREDITED | LIVE-STREAM

Chair(s): Andrea Bezjak, Canada, Helmut Prosch, Austria

08:30 - 08:32
PL04.01 / PL04.02 Session Introduction
Andrea Bezjak, Canada, Helmut Prosch, Austria

08:32 - 08:52
PL04.03 AI in Pathology
Douglas Hartman, United States

08:52 - 09:12
PL04.04 AI in Radiology
Fergus Gleeson, United Kingdom

09:12 - 09:32
PL04.05 AI in Radiotherapy
Jean-Emmanuel Bibault, France

09:32 - 09:52
PL04.06 The Promise of Big Data
Georg Langs, Austria

09:52 - 10:00
PL04.07 Live Q&A

10:00 – 10:45
IASLC Business Meeting

STRAUSS 3 | LIGHT REFRESHMENTS PROVIDED

10:00 – 10:45
Networking Break

HALL B, EXHIBIT HALL

Light refreshments and beverages will be served.

10:05 – 10:45
PC04: Press Conference

SCHUBERT 5/6

10:45 – 11:45
ES28: Neoadjuvant and Adjuvant Treatment of NSCLC in 2022

Track: Early Stage Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Systemic Therapy (Multi-Modality Treatment, Immunotherapy, Molecular Targeted Treatments)

HALL C1 | IASLC CME ACCREDITED

Chair(s): Tina Cascone, United States, Mariano Provencio, Spain

10:45 - 10:47
ES28.01 / ES28.02 Session Introduction
Tina Cascone, United States, Mariano Provencio, Spain

10:47 - 10:59
ES28.03 Surgical Techniques to Optimize Uptake of Adjuvant Treatment
Thomas D'Amico, United States

10:59 - 11:11
ES28.04 Standardisation of Pathological Assessment with Novel Neoadjuvant Therapies
Yasushi Yatabe, Japan

11:11 - 11:23
ES28.05 How Does MRD Status Affect Decisions on Adjuvant Therapy?
Federico Cappuzzo, Italy

11:23 - 11:35
ES28.06 Neoadjuvant EGFR TKI Trials
Julia Rotow, United States

11:35 - 11:45
ES28.07 Live Q&A

10:45 – 11:45
ES29: Palliative Radiotherapy in Metastatic NSCLC: State of the Art in an Era of New Hope

Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy

HALL C2 IASLC CME ACCREDITED

Chair(s): Fiona Hegi-Johnson, Australia, Joachim Widder, Austria

10:45 - 10:47
ES29.01 / ES29.02 Session Introduction
Fiona Hegi-Johnson, Australia, Joachim Widder, Austria

10:47 - 10:59
ES29.03 Radiotherapy of Brain Mets: Which Technique for Which Tumour?
Yu Yang Soon, Australia

10:59 - 11:11
ES29.04 Management of Brain Mets: What Is the Current Role of Radiotherapy in an Era of Effective Systemic Therapies?
Margot Lehman, Australia

11:11 - 11:23
ES29.05 The Clinical Integration of Radiotherapy and Systemic Therapy in Metastatic Disease
Shilo Lefresne, Canada

11:23 - 11:35
ES29.06 Radiobiology of Palliative Radiotherapy: Integration with Emerging Systemic Therapies
Magnus Dillon, United Kingdom

11:35 - 11:40
ES29.07 Is There an Inexpensive, Effective Alternative to Nicotine Replacement Therapy (NRT)?
Magdalena Cedzynska, Poland

11:40 - 11:45
ES29.08 Live Q&A

10:45 – 11:45
ES30: Leveraging the Power of Immunotherapy for SCLC

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Giorgio Scagliotti, Italy, Raffaele Califano, United Kingdom

10:45 - 10:47
ES30.01 / ES30.02 Session Introduction
Giorgio Scagliotti, Italy, Raffaele Califano, United Kingdom

10:47 - 10:59
ES30.03 Transcriptional Subtypes and Impact of Immune Checkpoint Inhibitors
Christine Hann, United States

10:59 - 11:11
ES30.04 State of the Art and Perspectives in Limited Stage SCLC
Sumitra Thongprasert, Thailand

11:11 - 11:23
ES30.05 Novel Strategies Other Than IO in the Front-Line Setting
Jens Benn Sørensen, Denmark

11:23 - 11:35
ES30.06 Novel Immunotherapies Beyond PD-(L1) and CTLA-4 Inhibition
Egbert Smit, Netherlands

11:35 - 11:45
ES30.07 Live Q&A

10:45 – 11:45
ES31: Survivorship across the Cancer Continuum for Patients Treated with Immunotherapies and Targeted Therapies

Track: Nursing and Allied Health Professionals

LEHAR 1 IASLC CME ACCREDITED

Chair(s): Nazanin Nouriany, Canada, Morten Quist, Denmark

10:45 - 10:47
ES31.01 / ES31.02 Session Introduction
Nazanin Nouriany, Canada, Morten Quist, Denmark

10:47 - 10:59
ES31.03 Long-Term Immunotherapy Survivors of Advanced Non-small Cell Lung Cancer: The Survivorship Experience
Michelle Turner, United States

10:59 - 11:11
ES31.04 Survivorship and Financial Toxicity in Lung Cancer
Paula Shepherd, United Kingdom

11:11 - 11:23
ES31.05 Fear of Cancer Progression in Patients Treated with Novel Therapies
Fiona Lynch, Australia

11:23 - 11:35
ES31.06 Impact of Body Composition, Nutritional and Inflammatory Status on Outcome of Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Ilaria Trestini, Italy

11:35 - 11:45
ES31.07 Live Q&A

10:45 – 11:45
MA12: Pathology: Tumour Diagnostics

Track: **Pathology**

HALL C7

Chair(s): Aleks Ryska, Czech Republic, Deepali Jain, India

10:45 - 10:47
MA12.01 / MA12.02 Session Introduction
Aleks Ryszka, Czech Republic, Deepali Jain, India

10:47 - 10:52
MA12.03 Mechanims of Immune Evasion in Patients With KRAS-Mutant Lung Adenocarcinoma: A Role of MAPK Pathway Activation
Dwayne Naves, Netherlands

10:52 - 10:57
MA12.04 SAKK 16/14: CD8 T Cell Positioning Correlates with Survivalin Stage IIIA(N2) NSCLC After Neoadjuvant Immunotherapy
Sacha Rothschild, Switzerland

10:57 - 11:02
MA12.05 Economic Impact of Delaying Care With Single-Gene Testing Versus Next-Generation Sequencing in Non-small Cell Lung Cancer
Brandon Sheffield, Canada

11:02 - 11:12
MA12.06 Discussant
Ming-Sound Tsao, Canada

11:12 - 11:17
MA12.07 Defining Morphologic Features of Invasion in Pulmonarynon-MucinoUnited Statesdenocarcinoma With Lepidic Growth
Erik Thunnissen, Netherlands

11:17 - 11:22
MA12.08 Pagetoid Growth of Squamous Cell Carcinoma with a Subsolid Component
Federica Filipello, Italy

11:22 - 11:27
MA12.09 Frequency and Detectability of Uncommon EGFR Mutations in NSCLC
Hazel O'Sullivan, United Kingdom

11:27 - 11:37
MA12.10 Discussant
Mari Mino-Kenudson, United States

11:37 - 11:45
MA12.11 Live Q&A

10:45 – 11:45
OA13: Evolving Epidemiology of Lung Cancer Beyond Tobacco

Track: **Epidemiology**

HALL C8

Chair(s): Matthew Warkentin, Canada, Hilary Robbins, France

10:45 - 10:47
OA13.01 / OA13.02 Session Introduction
Matthew Warkentin, Canada, Hilary Robbins, France

10:47 - 10:57
OA13.03 Evaluation of Outdoor Air Pollution Exposure (PM2.5) In Female Non-smoking Lung Cancer Patients
Renelle Myers, Canada

10:57 - 11:07
OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study
Miguel Garcia, Canada

11:07 - 11:17
OA13.05 Lung Cancer Risk Prediction Nomogram in Chinese Female Non-smokers
Lanwei Guo, China

11:17 - 11:27
OA13.06 Changing Patterns of Lung Cancer Histology in an Asbestos Exposed Population
Chellan Kumarasamy, Australia

11:27 - 11:37
OA13.07 Discussant
Chang-Chuan Chan, Taiwan

11:37 - 11:45
OA13.08 Live Q&A

12:00 – 13:00
ES32: Beyond Tobacco: Environmental Risk Factors for Lung Cancer

Track: Epidemiology

HALL C1 IASLC CME ACCREDITED

Chair(s): Christine D Berg, United States, Paolo Boffetta, United Kingdom

12:00 - 12:02
ES32.01 / ES32.02 Session Introduction
Christine Berg, United States, Paolo Boffetta, United States

12:02 - 12:14
ES32.03 Outdoor Particulate Air Pollution
Pawan Kumar Singh, India

12:14 - 12:26
ES32.04 What Changes Are Needed to Reach WHO Particulate Matter Standards: Particular Emphasis on Power Generation and Transportation
Paolo Boffetta, United States

12:26 - 12:38
ES32.05 Indoor Air Pollution, Genetic Susceptibility, and Lung Cancer among Women in Asia Without a Smoking History
Chunxia Su, China

12:38 - 12:50
ES32.06 Effects of Climate Change: Treatment Delays during Natural Disasters Lessen Lung Cancer Patient Survival
Roselle De Guzman, Philippines

12:50 - 13:00
ES32.07 Live Q&A

12:00 – 13:00
ES33: Management of Oligometastatic and Multi-Focal Lung Cancer

Track: Locally Advanced Non-small Cell Lung Cancer - Oligometastatic

HALL C2 IASLC CME ACCREDITED

Chair: Alexander Louie, Canada

12:00 - 12:02
ES33.01 / ES33.02 Session Introduction
Alexander Louie, Canada

12:02 - 12:14
ES33.03 Role of Ablation in Multifocal or Oligometastatic Lung Carcinoma
Carole Ridge, United Kingdom

12:14 - 12:26
ES33.04 Surgery for Oligometastatic and Multi-Focal Lung Cancer
Loretta Erhunmwunsee, United States

12:26 - 12:38
ES33.05 Radiation for Oligometastatic Lung Cancer
Fiona Hegi Johnson, Australia

12:38 - 12:50
ES33.06 Multimodality Management of Multi-Focal Lung Cancer
Walter Weder, Switzerland

12:50 - 13:00
ES33.07 Live Q&A

12:00 – 13:00
ES34: Updates in Radiology, Pulmonology, and Staging

Track: Pulmonology, Radiology, and Staging

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Lynette Teo, Singapore, David Carbone, United States

12:00 - 12:02
ES34.01 / ES34.02 Session Introduction
Lynette Teo, Singapore, David Carbone, United States

12:02 - 12:14
ES34.03 Advances in Lung Cancer Imaging
Jin Mo Goo, South Korea

12:14 - 12:26
ES34.04 Diagnostic and Interventional Bronchoscopy: Updates and Future
Daniela Gompelmann, Austria

12:26 - 12:38
ES34.05 TNM Staging: Essential and Other Emerging Concepts
David Carbone, United States

12:38 - 12:50
ES34.06 Inclusion of Molecular/Genetic Factors in the TNM Staging System, Is It Possible?
David Carbone, United States

12:50 - 13:00
ES34.07 Live Q&A

12:00 – 13:00
ES35: High-Plex Spatial Technologies for Molecular Tumour Analysis and Single-Cell Studies in Thoracic Oncology Research and Future Clinical Uses

Track: Tumour Biology and Biomarkers

LEHAR 1 IASLC CME ACCREDITED

Chair(s): Martin Filipits, Austria, Caroline Dive, United Kingdom

12:00 - 12:02
ES35.01 / ES35.02 Session Introduction
Martin Filipits, Austria, Caroline Dive, United Kingdom

12:02 - 12:14
ES35.03 Discovery of Predictive Biomarkers for Immunotherapy Using Deep Spatial Tissue Analysis in Lung Cancer
David Rimm, United States

12:14 - 12:26
ES35.04 Single-Cell Transciptomics to Study Immunotherapy Responses in Resectable Non-small Cell Lung Cancer
Kellie Smith, United States

12:26 - 12:38
ES35.05 Computational Approaches to Analyze and Interpret High-Plex Spatial and Single-Cell Molecular Tumour Studies
Melissa Davies, Australia

12:38 - 12:50
ES35.06 A Multi-Omics Approach for Delineating Tissue Signatures of Immunotherapy Response in Lung Cancer
Arutha Kulasinghe, Australia

12:50 - 13:00
ES35.07 Live Q&A

12:00 – 13:00
MA13: Update on ROS1 Inhibitors and New Pathways

Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

HALL C7

Chair(s): Lorenza Landi, Italy, Jii Bum Lee, South Korea

12:00 - 12:02
MA13.01 / MA13.02 Session Introduction
Lorenza Landi, Italy, Jii Bum Lee, South Korea

12:02 - 12:07
MA13.03 Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies
Sai-Hong Ou, United States

12:07 - 12:12
MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
Yun Fan, China

12:12 - 12:17
MA13.05 TA0953/HM06, a Novel RET-specific Inhibitor Effective in Extracranial and CNS Disease Models of NSCLC with RETfusions
Romel Somwar, United States

12:17 - 12:27
MA13.06 Discussant
Lorenza Landi, Italy

12:27 - 12:32
MA13.07 TROPION-Lung02: Initial Results for Datopotamab Deruxtecan Plus Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
Benjamin Levy, United States

12:32 - 12:37
MA13.08 A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation
Jonathan Riess, United States

12:37 - 12:42
MA13.09 Time from Immune Checkpoint Inhibitor to Sotorasib Use Correlates with Risk of Hepatotoxicity in Non-small Cell Lung Cancer
Sagar Rakshit, United States

12:42 - 12:52
MA13.10 Discussant
Paolo Bironzo, Italy

12:52 - 13:00
MA13.11 Live Q&A

12:00 – 13:00
OA14: New Techniques to Improve Outcome in Early Stage NSCLC Patients Treated with Surgery or Radiotherapy

Track: Early Stage Non-small Cell Lung Cancer

HALL C8

Chair(s): Paul Van Schil, Belgium. Fabio Moraes, Canada

12:00 - 12:02
OA14.01 / OA14.02 Session Introduction
Paul van Schil, Belgium, Fabio Moraes, Canada

12:02 - 12:12
OA14.04 Chest Wall Toxicity after Individualized Stereotactic Ablative Radiotherapy for Lung Tumours
Brianna Lau, United States

12:12 - 12:22
OA14.05 Intraoperative Molecular Imaging Guided Resection of CEACAM5+ Lung Tumours: First In-Human SGM-101 Lung Cancer Surgical Trial
Feredun Azari, United States

12:22 - 12:32
OA14.06 T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing
Filiz Oezkan, Germany

12:32 - 12:42
OA14.07 Discussant
Brendon Stiles, United States

12:42 - 13:00
OA14.08 Live Q&A

13:15 – 14:15
LA03: Lectureship Awards - Tuesday

HALL C1 LIVE-STREAM

Chair(s): Ross Soo, Singapore, David Carbone, United States

13:15 - 13:17
LA03.01 / LA03.02 Session Introduction
Ross Soo, Singapore, David Carbone, United States

13:17 - 13:32
LA03.03 Fred R. Hirsch Lectureship Award for Translational Research
Lukas Bubendorf, Switzerland

13:32 - 13:47
LA03.04 IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)
Anne Fraser, New Zealand

13:47 - 14:02
LA03.05 Clifton F. Mountain Lectureship Award for Staging
Clarissa Mathias, Brazil

14:02 - 14:15
LA03.06 Live Q&A

13:15 – 14:15
Networking Lunch

HALL B, EXHIBIT HALL

Complimentary food and beverages will be served.

14:30 – 15:30
ES36: Revisiting the Perioperative Management of NSCLC

Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

HALL C1 IASLC CME ACCREDITED

Chair(s): Yasushi Goto, Japan, Virginie Westeel, France

14:30 - 14:32
ES36.01 / ES36.02 Session Introduction
Yasushi Goto, Japan, Virginie Westeel, France

14:32 - 14:44
ES36.03 Reshaping Perioperative Treatment With the Emergence of Immunotherapy
Enriqueta Felip, Spain

14:44 - 14:56
ES36.04 Neoadjuvant versus Upfront Surgery - Which Surgical Endpoints Are Most Relevant?
Jonathan Spicer, Canada

14:56 - 15:08
ES36.05 Role of Perioperative Radiotherapy in the Era of Immunotherapy
Sameera Kumar, United States

15:08 - 15:20
ES36.06 Perioperative Targeted Therapy
Wen-Zhao Zhong, China

15:20 - 15:30
ES36.07 Live Q&A

14:30 – 15:30
ES37: What Lung Cancer Clinicians Need to Know about Tobacco

Track: **Tobacco Control and Risk Reduction**

HALL C2 IASLC CME ACCREDITED

Chair(s): May Myat Cho, Thailand, Magdalena Cedzynska, Poland

14:30 - 14:32
ES37.01 / ES37.02 Session Introduction
May Myat Cho, France, Magdalena Cedzynska, Poland

14:32 - 14:44
ES37.03 Biologic Perturbations Induced by Tobacco Smoke
Srikumar Chellappan, United States

14:44 - 14:56
ES37.04 Does Quitting Smoking after a Diagnosis of Lung Cancer Improve Survival?
Jacek Jassem, Poland

14:56 - 15:08
ES37.05 How Best to Talk With Your Patient About Tobacco Use
Joelle Fathi, United States

15:08 - 15:20
ES37.06 Implementing Smoking Cessation within Cancer Centers
William Evans, Canada

15:20 - 15:25
ES37.07 Smoking Cessation: A Component of High Quality Thoracic Surgery
Christian Finley, Canada

15:25 - 15:30
ES37.08 Live Q&A

14:30 – 15:30
ES38: Optimising the Management of SCLC and Neuro-endocrine Tumours

Track: **Small Cell Lung Cancer and Neuro-endocrine Tumours**

STRAUSS 1/2 IASLC CME ACCREDITED

Chair(s): Feng Ming Spring Kong, Hong Kong, Nevena Secen, Serbia

14:30 - 14:32
ES38.01 / ES38.02 Session Introduction
Feng-Ming Spring Kong, Hong Kong, Nevena Secen, Serbia

14:32 - 14:47
ES38.03 What's the Best Management for CNS Metastases in the Era of IO?
Inga Grills, United States

14:47 - 15:02
ES38.04 Treatment of Relapsed/Refractory SCLC: Old and New Drugs
Charles Rudin, United States

15:02 - 15:17
ES38.05 How Should We Treat Pulmonary Large-Cell Neuro-endocrine Carcinomas?
Andrea Ardizzoni, Italy

15:17 - 15:30
ES38.06 Live Q&A

14:30 – 15:30
ES39: Role of Novel Biomarkers and Technologies in Optimal Diagnosis and Disease Management: Focus on Liquid Biopsies And Advanced Tissue Diagnostics

Track: **Tumour Biology and Biomarkers**

LEHAR 1 IASLC CME ACCREDITED

Chair(s): Umberto Malapelle, Italy, Christian Rolfo, United States

14:30 - 14:32
ES39.01 / ES39.02 Session Introduction
Umberto Malapelle, Italy, Christian Rolfo, United States

14:32 - 14:44
ES39.03 Advances and Role of CTCs for Lung Cancer Diagnosis and Treatment (Early and Advanced: NSCLC and SCLC)
Caroline Dive, United Kingdom

14:44 - 14:56
ES39.04 Optimal Use of ctDNA Analysis Lung Cancer Diagnosis, Response Assessment and Monitoring
Christian Rolfo, United States

14:56 - 15:08
ES39.05 Biomarker Analysis of the Tumour Microenvironment and Tumour-Immune Cell Interactions Using High-Plex Spatial and Single-Cell Studies
Junko Tanizaki, Japan

15:08 - 15:20
ES39.06 Advanced Tumour-Based and Circulating Diagnositics in Early Stage Disease
Lillian Siu, Canada

15:20 - 15:30
ES39.07 Live Q&A

14:30 – 15:30
MA14: Palliative and Supportive Care - The Forgotten Trade

Track: Palliative and Supportive Care

STRAUSS 3

Chair(s): Maria Werner-Wasik, United States, Satoko Kono, Japan

14:30 - 14:32
MA14.01 / MA14.02 Session Introduction
Maria Werner-Wasik, United States, Satoko Kono, Japan

14:32 - 14:37
MA14.03 Effect of Mirtazapine on Energy Intake in Patients with Anorexia Associated with NSCLC
Oscar Arrieta, Mexico

14:37 - 14:42
MA14.04 Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study
Narjust Duma, United States

14:42 - 14:47
MA14.05 A Double-blind Phase III Trial of Denosumab Biosimilar QL1206 vs Denosumab in Bone Metastatic Tumour: Lung Cancer Cohort Data
Yan Huang, China

14:47 - 14:57
MA14.06 Discussant
Karin Dieckmann, Austria

14:57 - 15:02
MA14.07 The Use of Medical Cannabis Concomitantly with Immune-Check Point Inhibitors (ICI) in Non Small Cell Lung Cancer (NSCLC): A Sigh of Relief?
Barliz Waissengrin, Israel

15:02 - 15:07
MA14.08 Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving PD-1 Inhibitors for Metastatic NSCLC
Christopher Poletes, Ireland

15:07 - 15:12
MA14.09 Lower Paraspinous Muscle Index at First Thoracentesis is Associated with Poor Survival in Non-Small Cell Lung Cancer
Candice Wilshire, United States

15:12 - 15:22
MA14.10 Discussant
Devayani Niyogi, India

15:22 - 15:35
MA14.11 Live Q&A

14:30 – 15:30
OA15: Patient Selection in Advanced NSCLC Immunotherapy

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

HALL C7

Chair(s): Pilar Garrido, Spain, António Araújo, Portugal

14:30 - 14:32
OA15.01 / OA15.02 Session Introduction
Pilar Garrido, Spain, António Araújo, Portugal

14:32 - 14:42
OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
Martin Reck, Germany

14:42 - 14:52
OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
Solange Peters, Switzerland

14:52 - 15:02
OA15.05 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed Phase 2 Study in NSCLC Patients Who Progressed on Anti-PD-(L)1 Therapy
Benjamin Besse, France

15:02 - 15:12
OA15.06 Pooled Analysis of Outcomes With Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
Delvys Rodriguez-Abreu, Spain

15:12 - 15:22
OA15.07 Discussant
Puey Ling Chia, Singapore

15:22 - 15:30
OA15.08 Live Q&A

15:45 – 16:45
PL05: Closing Plenary 5: Access to Drugs

HALL C1 | IASLC CME ACCREDITED | LIVE-STREAM

Chair(s): Yi-Long Wu, China, Clarissa Mathias, Brazil

15:45 - 15:47
PL05.01 / PL05.02 Session Introduction
Yi-Long Wu, China, Clarissa Mathias, Brazil

15:47 - 16:02
PL05.03 How to Double Lung Cancer Survival within 5 Years
Giorgio Scagliotti, Italy

16:02 - 16:17
PL05.04 Access to Drugs
Nir Peled, Israel

16:17 - 16:32
PL05.05 Drug Development in the 21st Century
Francesco Pignatti, Netherlands

16:32 - 16:45
PL05.06 Closing Remarks

DAILY SCIENTIFIC PROGRAM - ON-DEMAND SESSIONS

These on-demand sessions are available exclusively on the virtual platform.

WS08:
Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC

ON-DEMAND

Chair(s): Yi-Long, Wu, China, Chunxue Bai, China, Caicun Zhou, Karen Kelly, United States

10 mins
WS08.01 / WS08.02 / WS08.03 / WS08.04
Session Introduction
Yi-Long, Wu, China, Chunxue Bai, China, Caicun Zhou, Karen Kelly, United States

20 mins
WS08.05 Minimal Residual Disease (MRD) Negative: Potential for Cure in Resected Oncogene Driven NSCLC? Chinese Perspective
Jia-Tao, China

20 mins
WS08.06 Could MRD Change Our Clinical Practice? North American Perspective
Aadel A. Chaudhuri, United States

20 mins
WS08.07 How to Use Liquid Biopsy to Monitor Treatment Efficacy for Advanced Driven NSCLC
Jie Hu, China

20 mins
WS08.08 Liquid Biopsy for Advanced Oncogene Driven NSCLC. European Perspective
Martin Filipits, Austria

10 mins
WS08.09 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
Si-Yang Liu, China

10 mins
WS08.10 Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
Xuxinyi Ling, China

5 mins
WS08.11 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp)
Yun Fan

20 mins
WS08.12 Discussant for Oral Abstracts
Sai-Hong Ou, United States

WS08.13 Activity of aPD1-MSLN-CART Cells Against Metastatic Lung Cancer in a Phase 1 Trial
Xiaorong Dong, China

WS08.14
Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-Negative NSCLC
Lin Wu, China

WS08.15
Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Jun Zhao, China

WS08.16
The Increase of Blood Intratumor Heterogeneity is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC
Juan Zhou, China

WS08.17
Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
Wenbin Li, China

15 mins
WS08.18 Discussant for Poster 1 – 5
Xiaorong Dong, China

WS08.19
Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
Yao-Bin Lin, China

WS08.20
Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
Yuan Li, China

WS08.21
Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
Wen-Fang Tang, China

WS08.22
Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-arm, Phase 2 Trial (Renaissance Study)
Shi Yan, China

WS08.23
Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
Shu Lu, China

15 mins
WS08.24 Discussant for Poster 6 – 10
Ming Fang Zhao, China

HOD01: Highlights of the Day - Sunday

ON-DEMAND

15 mins
HOD01.01 Surgery
Eveline Internullo, United Kingdom

15 mins
HOD01.02 Radiation Oncology
Megan Daly, United States

15 mins
HOD01.03 Pulmonology
Torsten Blum, Germany

15 mins
HOD01.04 Medical Oncology
Niels Reinmuth, Germany

HOD02: Highlights of the Day - Monday

ON-DEMAND

15 mins
HOD02.01 Surgery
Cecilia Pompili, Italy

15 mins
HOD02.02 Radiation Oncology
Jan Nyman, Sweden

15 mins
HOD02.03 Pulmonology
Joanna Chorostowska-Wynimko, Poland

15 mins
HOD02.04 Medical Oncology
Miyako Satouchi, Japan

HOD03: Highlights of the Day – Tuesday

ON-DEMAND

15 mins
HOD03.01 Surgery + Early Stage
Aki Kobayashi, Japan

15 mins
HOD03.02 Pathology + Epidemiology
Fernando Lopez-Rios, Spain

15 mins
HOD02.03 Pulmonology
Joanna Chorostowska-Wynimko, Poland

15 mins
HOD02.04 Medical Oncology
Alexander Drilon, United States

8 POSTER SESSIONS

Poster will be displayed in the Exhibit Hall, Hall B, Messe Wien Exhibition and Congress Center starting **Sunday, August 7** at **09:45** until **Tuesday, August 9** at **14:15**.

Poster Viewing Reception with Presenters in Attendance by Day

POSTER SESSIONS - SUNDAY, AUGUST 7, 2022 17:00 – 19:00

P1.01 Early Detection and Screening – Biomarkers

P1.01-01 **Comparison between Protein and Autoantibody Biomarkers for the Early Detection of Lung Cancer**
Xiaoshuang Feng, France

P1.02 Early Detection and Screening - Implementation

P1.02-02 **Current Status, Challenges and Perspectives of Lung Cancer Screening in Low- and Middle-Income Countries**
Milena Cavic, Serbia

P1.02-03 **Budget Impact Analysis of Volume CT Lung Cancer Screening Based on NELSON Study Outcomes in Europe**
Xuanqi Pan, Netherlands

P1.02-04 **Spatial Access to Lung Screening in British Columbia, Canada**
Stephen Lam, Canada

P1.03 Early Detection and Screening - Pulmonary Nodule

P1.03-01 **Do We Follow Incidental Lung Nodules Appropriately? A Retrospective Study**
Jasleen Pannu, United States

P1.04 Early Detection and Screening - Risk Stratification

P1.04-01 **Risk Stratification for Personalised Screening Intervals: Performance of PLCOm2012NoRace at Second Round of Manchester LHC**
Patrick Bradley, United Kingdom

P1.04-02 **Optimizing Screening Frequency and Interval Using a Deep Learning Algorithm**
Stephen Lam, Canada

P1.04-03 **Independent Validation of the Maisonneuve Lung Cancer Risk Model to Optimize Screening Interval in High-risk Individuals**
Giulia Veronesi, Italy

P1.05 Early Stage Non-small Cell - Biomarkers

P1.05-01 **Phase II Study of ctDNA Directed Consolidation Durvalumab After Induction and Concurrent Durvalumab with SABR for Stage I NSCLC**
Islam Mohamed, Canada

P1.05-02 **Mutations in CREBBP are Associated with Local Failure after Lung Stereotactic Body Radiation Therapy**
Victor Ng, United States

P1.06 Early Stage Non-small Cell - Systemic Therapy

P1.06-01 **Adjuvant Osimertinib vs Placebo in Completely Resected Stage IA2-IA3 EGFR-mutated NSCLC: The ADAURA2 Phase III Study**
Toon Van Der Gronde, United States

P1.07 Epidemiology

P1.07-01 **Early Detection Plus Timely Surgery Remains the Standard despite Advances in Immunotherapy**
Emanuela Taioli, United States

P1.07-02 **Personal and Family HiStory of CANcer in Patients with Non-small Cell Lung Cancer: Preliminary Data of the SCAN Study**
Juan Carlos Laguna, Spain

P1.08 Global Health, Health Services Research, and Health Economics - Cost Issues

P1.08.01 **Updated Costs and Survival Expectations for Stage IV Lung Cancer in Australia**
Preston Ngo, Australia

P1.09 Global Health, Health Services Research, and Health Economics - Support to Patients and Staff

P1.09-01 **The Lung Cancer Patient Experience and Care Pathway: A Multi-Country Survey**
Pauline Frank, Msc, Switzerland

P1.09-02 **Real-world Clinical Characteristics and Treatment Patterns of METExon 14 Skipping Mutation in Advanced/Metastatic NSCLC**
Xiuning Le, United States

P1.09-03 **Multidisciplinary Thoracic Tumours Board Survey in Spain**
Bartomeu Massutí, Spain

P1.10 Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

P1.10-01 **Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)**
Aarthi Gopinathan, United Kingdom

P1.10-02 **ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation**
Fiona Hegi-Johnson, Australia

P1.10-03 **A Deep Learning Auto-Segmentation Tool for Cardiac Substructures in 4D Radiotherapy Planning for Locally Advanced Lung Cancer**
Gerard Walls, United Kingdom

P1.10-04 **Impact of Radiation Dose to the Immune Cells in Unresectable or Stage III Non-Small Cell Lung Cancer in the Durvalumab Era**
Neal Mccall, United States

P1.11 Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

P1.11-01 **Cobolimab With Dostarlimab and Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung**
Hye Ryun Kim, South Korea

P1.11-02 **Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C**
Baohui Han, China

P1.12 Management of Lung Cancer in the Era of COVID-19

P1.12-01 **Lung Cancer Screening in the COVID-19 Era: Understanding Program-Level Impact**
Andrew Ciupek, United States

P1.12-02 **The Impact of COVID-19 on Quality of Care for Lung Cancer - Analyses of Prospective Clinical Data from The EnRICH Cohort**
Bea Brown, Australia

P1.12-03 **Computed Tomography-based Artificial Intelligence System in the Diagnosis of COVID-19**
Yusuf Kahya, Turkey

P1.12-04 **The FLARE Score and Circulating Neutrophils Are Associated with Poor Covid-19 Outcomes in Patients with Thoracic Cancers**
Laura Mezquita, Spain

P1.12-05 **Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st Wave)**
Yu Zhi Zhang, United Kingdom

P1.13 Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

P1.13-01 **Preoperative Chemotherapy Induces Epithelial-Mesenchymal Transition Which Reduces Survival After Surgery for Mesothelioma**
Luigi Ventura, United Kingdom

P1.13-02 **Quantitative Assessment Using MR in Malignant Pleural Mesothelioma**
Ritu Gill, United States

P1.14 Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical

P1.14-01 **Transcriptomic Analysis of Malignant Pleural Mesothelioma (MPM) Reveals Insights for Basic Research and Preclinical Testing**
Alexander Laure, Switzerland

P1.14-02 **Implantable Cytokine Factories for Eradication of Malignant Pleural Mesothelioma (MPM) Tumours in Mice**
Amanda Nash, United States

P1.14-03 **Characterization of Tumour Immune Microenvironment and Its Prognostic Value in Patients with Surgically Resected Thymic Epithelial Tumours**
Haojie Si, China

P1.14-04 **Silencing ADAR1 Abrogates Mesothelioma Tumourigenicity**
Robert Kratzke, United States

P1.14-05 **TROP2 Expression and SN38 Antitumour Activity in Malignant Pleural Mesothelioma Cells**
Luca Hegedüs, Germany

P1.15 Metastatic Non-small Cell Lung Cancer – Immunotherapy

P1.15-01 **Differential Diagnosis of Pneumonitis in Metastatic NSCLC (Non-Small Cell Lung Cancer) Patients Receiving Immunotherapy With Radiomics**
Alberto Traverso, Netherlands

P1.15-02 **Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors**
Claudia Proto, Italy

P1.15-03 **Clinical Outcomes Among Patients With Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity**
Federica Pecci, United States

P1.15-04 **Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer**
Giulia Mazzaschi, Italy

P1.15-05 **Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial)**
Martin Reck, Germany

P1.15-06 **Immune-Checkpoint Inhibitors-Related Colitis in Advanced Non-small Cell Lung Cancer Patients: A Real-World Analysis**
Martina Lorenzi, Italy

P1.15-07 **Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1**
Melina Marmarelis, United States

P1.15-08 **Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer**
Michael Boyer, Australia

P1.15-09 **First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.**
Mariano Provencio-Pulla, Spain

P1.15-10 **Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada**
Sze Wh Samuel Chan, Canada

P1.15-11 **Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study**
Myung-Ju Ahn, South Korea

P1.15-12 **Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1**
Saadettin Kilickap, Turkey

P1.15-13 **Immune Escape Mechanisms Mediated by B-Catenin in Non-small Cell Lung Cancer**
Satoshi Muto, Japan

P1.16 Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

P1.16-01 **Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)**
Byoung Chul Cho, South Korea

P1.16-02 **Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale**
Laura Mezquita, Spain

P1.16-03 **Managing Cardiotoxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors (TKIs)**
Luis Raez, United States

P1.16-04 **Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors**
Niels Reinmuth, Germany

POSTER SESSIONS - MONDAY, AUGUST 8, 2022 17:15 – 19:00

P2.01 Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease

P2.01-01 **Association Between Clinical Outcomes and Local Treatment in Stage IV Non-small Cell Lung Cancer Patients With Single Extrathoracic Metastasis**
Seung Joon Kim, South Korea

P2.01-02 **Delivery of Concurrent Extracranial Stereotactic Body Radiotherapy With Osimertinib for Oligoprogressive EGFR Mutated Stage IV NSCLC**
Eyal Tsur, Israel

P2.02 Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

P2.02-01 **Value of Albumin-to-Globulin Ratio for Survival Prediction in Advanced Stage Non-Small Cell Lung Cancer Treated with Chemotherapy**
Chaichana Chantharakhit, Thailand

P2.02-02 **A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy**
Ralph Millett, United States

P2.02-03 **A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer**
Saurav Verma, India

P2.03 Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy

P2.03-01 **Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT**
Fiona Hegi-Johnson, Australia

P2.04 Nursing and Allied Health Professionals

P2.04-01 **Lung Cancer Patient Experience Survey from Twelfth Central and Eastern Europe Countries**
Andreja Sajnic, Croatia

P2.04-02 **Psychosocial Burdens in Cancer Caregivership, an Updated Overview**
Csaba Dégi, Romania

P2.04-03 **Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumours and their Care-Givers**
Paolo Bironzo, Italy

P2.04-05 **Is Opioid Use in the Management of Stage III Non-Small Cell Lung Cancer Patients Necessary?**
Ulrike Gorgens, United States

P2.05 Palliative and Supportive Care

P2.05-01 **The Effect of Treadmill Training on Cardiopulmonary, Health-related Quality of Life in Lung Cancer with Lobectomy**
Kyung-Lim Joa, South Korea

P2.06 Pathology - Tumour Diagnostics

P2.06-01 **Skip Hilar Lymph Node Metastasis in Non-Small Cell Lung Cancer Has Similar Survival to N0 Disease: Need for a change in the pN sub-classification?**
Ismail Sarbay, Turkey

P2.07 Pathology - Tumour Genomics

P2.07-01 **Deep-Learning Based Prediction of c-MET Status from Digitized H&E-Stained Non-Small Cell Lung Cancer Tissue Samples**
Bahar Rahsepar, United States

P2.07-02 **RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC**
Susana Hernandez, Spain

P2.08 Patient Advocacy

P2.08-01 **Real-world barriers to clinical trial enrollment as reported by U.S. lung cancer patients and community cancer centers**
Andrew Ciupek, United States

P2.08-02 **Burning the Candle at Both Ends-Sleep Quality Before and After Chemotherapy in Lung Cancer Patients - A Systematic Review and Meta-Analysis**
Andrew Jeklin, Australia

P2.08-03 **Patient Reported Lung Cancer Care Team Satisfaction and Treatment Dynamics, Based on the Online MyHealthTeams Survey**
Dianna Cronin, United States

P2.08-04 **Patient Reported Impact of Lung Cancer Symptoms and Treatment on Mental Health and Quality of Life, Based on the Online MyHealthTeams Survey**
Dianna Cronin, United States

P2.08-05 **Lung Cancer Patients' Willingness to Attend a Screening Appointment or Lung Health Check: Insights from a Global Patient Experience Survey**
Jackie Fenemore, United Kingdom

P2.08-06 **Patient Involvement in Decision-Making around Their Treatment and Care: Findings from a Global Patient Experience Survey**
Jackie Fenemore, United Kingdom

P2.08-07 **The Campaign to End Lung Cancer Stigma: The ACS National Lung Cancer Roundtable Efforts to Confront and Extinguish Lung Cancer Stigma**
Dusty Donaldson, United States

P2.08-08 **Where Have All the Lung Cancer Support Groups Gone?**
Maureen Rigney, United States

P2.08-09 **Adaptation of Empathic Communication Skills Training for Oncology Care Providers to Reduce Lung Cancer Stigma**
Jamie Ostroff, United States

P2.09 Pulmonology, Radiology, and Staging

P2.09-01 **MRI-based Radiomic Signature to Predict Pathologic High-grade Pattern in Lung Adenocarcinoma**
Harim Kim, South Korea

P2.09-02 **Clinical Nodal (cN) Category Is Independently Prognostic for Overall Survival in Unresectable Advanced/Metastatic Lung Cancer**
Navneet Singh, India

P2.09-03 **A Radiomics Approach Using Baseline CT Can Predict Response to 1st-Line Pembrolizumab in Advanced NSCLC with High PD-L1**
Ren Yuan, Canada

P2.10 Small Cell Lung Cancer and Neuro-endocrine Tumours

P2.10-01 **Transcriptional Diversity of Emerging Cell Populations in Refractory Small Cell Lung Cancer Biopsies and Xenografts**
C. Allison Stewart, United States

P2.10-02 **EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer**
Balazs Halmos, United States

P2.10-03 **High-dose Thoracic Radiotherapy Improves the Overall Survival of Oligo-Metastatic Extensive-Stage Small Cell Lung Cancer**
Zhengfei Zhu, China

P2.10-04 **Immunologic Subtype of Small Cell Lung Carcinoma Dictates Susceptibility to NK Cell-Mediated Cytotoxicity**
Navin Mahadevan, United States

P2.10-05 **Circulating CD3+CD56+ Cells as a Biomarker for Immunotherapy in SCLC.**
Vito Longo, Italy

P2.11 Tobacco Control and Risk Reduction

P2.11-01 **Awareness of Lung Cancer Risk Factors in Palestine: Current Situation and Future Directions**
Ahmad Mansour, Palestine

P2.11-02 **New Assay for Smoking Status based on 3D Imaging of Pulmonary Macrophages**
Michael Meyer, United States

P2.11-03 **Smoking Prevention Intervention With School Classes in University Hospital by Thoracic Surgeon und Pulmonologist**
Sven Hillinger, Switzerland

P2.12 Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

P2.12-01 **Intratumoural Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)**
Angelo Porciuncula, United States

P2.12-02 **Immune-Cell Distribution Between Tumour Edge and Center Affects Lung Cancer Aggressiveness - Multiplex Immunofluorescence**
Takashi Eguchi, Japan

P2.12-03 **External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients With Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial**
Laurent Dercle, United States

P2.12-04 **The Role of Serum Proteomic Signature in Predicting Survival in PD-L1 Low Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor (ICI)**
Youjin Oh, United States

P2.12-05 **Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes with PD-L1 Blockade to Reverse Type-2Mediated Immunosuppression**
Thomas Marron, United States

P2.13 Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

P2.13-01 **Low EV miR-30c Levels as Biomarker of Increased Tumour Autophagy and Chemoradiotherapy Resistance in Locally Advanced NSCLC**
Diego de Miguel Perez, United States

P2.13-02 **Dynamic Tracking of Bespoke Circulating Tumour DNA During Multi-Modality Therapy for Locally Advanced NSCLC (LA-NSCLC)**
Kevin Chua, Singapore

P2.13-03 **Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer**
Per Hydbring, Sweden

P2.14 Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics

P2.14-01 **Clinical Utility of Reflex to Tissue-based Comprehensive Genomic Profiling (CGP) After Negative Liquid Biopsy (LBx) in NSCLC**
Khaled Tolba, United States

P2.14-02 **TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial**
Lorenza Landi, Italy

P2.14-03 **Restored Ubiquitination and Degradation of Exon 14 Skipped MET with Proteolysis Targeting Chimeras**
Aaron Mansfield, United States

P2.14-04 **Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches**
Sara Hijazo-Pechero, Spain

P2.15-01 **Digital Pathology Uncovers Multi-Omic Hallmarks of Lung Cancer in Histopathology Images**
Maria Guramare, United States

JTO CLINICAL AND RESEARCH REPORTS

The official open access journal of the IASLC

Editor-in-Chief:
Alex A. Adjei, MD, PhD, FACP
Chairman, Taussig Cancer Institute – Cleveland Clinic, Cleveland, OH USA

JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of lung Cancer. It complements the *Journal of Thoracic Oncology* by offering authors a gold open access publication option and publishing the following article types in particular:

- Phase I trials
- Well performed single-arm phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports



IASLC INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

Now indexed in PubMed Central

visit jtocrr.org

Learn more at JTOCRR.org

ELSEVIER

IASLC

Lace up your sneakers and get ready to Step it Up for Research by joining our First Annual IASLC Steps Challenge!

The Steps Challenge is a virtual walk-a-thon, held in conjunction with WCLC, to raise money for lung cancer research. Register Today!

Scan the QR code for information.

If you're signed up, *be sure to stop by the IASLC booth to grab your* ***participant pin!***

STEP IT UP FOR RESEARCH

IASLC STEPS CHALLENGE 2022

Vienna, Austria

9 | EPOSTERS

ePOSTERS

EP01.01 - Early Detection and Screening – Biomarkers
EP01.02 - Early Detection and Screening – Dissemination
EP01.03 - Early Detection and Screening – Implementation
EP01.04 - Early Detection and Screening - Implementation Quality Control
EP01.05 - Early Detection and Screening - Pulmonary Nodule
EP01.06 - Early Detection and Screening - Risk Stratification
EP01.07 - Early Detection and Screening - Work Up
EP02.01 - Early Stage Non-small Cell Lung Cancer – Biomarkers
EP02.02 - Early Stage Non-small Cell Lung Cancer – Radiotherapy
EP02.03 - Early Stage Non-small Cell Lung Cancer – Surgery
EP02.04 - Early Stage Non-small Cell Lung Cancer - Systemic Therapy
EP03.01 – Epidemiology
EP04.01 - Global Health, Health Services Research, and Health Economics - Cost Issues
EP04.02 - Global Health, Health Services Research, and Health Economics - Support to Patients and Staff
EP05.01 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
EP05.02 - Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy
EP05.03 - Locally Advanced Non-small Cell Lung Cancer – Surgery
EP06.01 - Management of Lung Cancer in the Era of COVID-19
EP07.01 - Mesothelioma, Thymoma, and Other Thoracic Malignancies – Clinical
EP07.02 - Mesothelioma, Thymoma, and Other Thoracic Malignancies – Preclinical
EP07.03 - Mesothelioma, Thymoma, and Other Thoracic Malignancies – Thymoma
EP08.01 - Metastatic Non-small Cell Lung Cancer – Immunotherapy
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
EP08.03 - Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease
EP08.04 - Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy
EP08.05 - Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy
EP09.01 - Nursing and Allied Health Professionals
EP10.01 - Palliative and Supportive Care
EP11.01 - Pathology - Genomics & Analytics
EP11.02 - Pathology - New Technology
EP11.03 - Pathology - Tumour Biology
EP11.04 - Pathology - Tumour Diagnostics
EP12.01 - Patient Advocacy
EP13.01 - Pulmonology, Radiology, and Staging
EP14.01 - Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC
EP14.02 - Small Cell Lung Cancer and Neuro-endocrine Tumours - Preclinical/Translational
EP14.03 - Small Cell Lung Cancer and Neuro-endocrine Tumours – RT
EP14.04 - Small Cell Lung Cancer and Neuro-endocrine Tumours – RW
EP14.05 - Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC
EP15.01 - Tobacco Control and Risk Reduction
EP16.01 - Tumour Biology and Biomarkers - Immune Biology & Immunotherapy
EP16.02 - Tumour Biology and Biomarkers - Minimally Invasive Biomarkers
EP16.03 - Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics
EP16.04 - Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

EP01.01

Track: Early Detection and Screening – Biomarkers

EP01.01-001 Circulating Tumour Cells-Based Radiobiological Model Improves the Indeterminate Pulmonary Solid Nodules Diagnosis
Mengmeng Zhao, China

EP01.01-002 Challenges in the Use of NLST Image Data for Quantitative Algorithm Development
Artit Jirapatnakul, United States

EP01.01-003 DELFI-L101: Development of a Blood-Based Assay That Evaluates Cell-Free DNA Fragmentation Patterns to Detect Lung Cancer
Peter Bach, United States

EP01.01-004 The Correlation Between Exhaled Volatile Organic Compounds Using Breath Analyzer and Interleukin-23 (IL-23) in Lung Cancer
Raden Dicky Listiandoko, Indonesia

EP01.01-005 Increased Levels of mRNAs and miRNAs Associated with Imminent and Advanced Lung Cancer
Ilona Urbarova, Norway

EP01.01-006 Sensitive Detection of Lung Cancer Using a Multiomic Plasma Cell-Free DNA Sequencing Assay
Jing Shan Lim, United States

EP01.01-007 Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients
Joana Espiga De Macedo, Portugal

EP01.01-008 Expression of PD-L1 mRNA and Its Epigenetic Regulators: MicroRNA-17, -93 and -142 in Early Stages NSCLC Patients' Plasma
Natalia Krzyzanowska, Poland

EP01.01-009 Common MicroRNAs in Pre-diagnostic Serum Associated with Lung Cancer in Two Cohorts up to Eight Years Before Diagnosis: A HUNT Study
Oluf Røe, Norway

EP01.01-010 Graphene Based Activity Sensors Detect All Stages of Lung Cancer Using an Evolutionary Machine Learning Algorithm Approach
Paul Dempsey, United States

EP01.01-011 Utility of Arm-level cfDNA Fragment Size Distribution in the Early Detection of Lung Cancer and Pan Cancer
Lifeng Wang, China

EP01.01-012 Clinical and Molecular Features of Chinese Early-stage Multiple Primary Lung Cancer Patients
Yongjie Wang, China

EP01.02

Track: Early Detection and Screening - Dissemination

EP01.02-001 Citizens' Perspective on Combination Screening for Lung Cancer, COPD and CVD
Carina Behr, Netherlands

EP01.02-002 Awareness of Palestinians about Lung Cancer Symptoms: A National Cross-sectional Study
Hanan Abukmail, Palestine

EP01.02-003 Lung Cancer Screening: A Systematic Review of Knowledge Translation Interventions
Paul Dawkins, New Zealand

EP01.02-004 Education Messages and Strategies About Lung Cancer Screening: A Systematic Review
Rachael Dodd, Australia

EP01.02-005 Exploring Individuals' Views on Invitation to Lung Cancer Screening: Developing a Tailored Approach
Rachael Murray, United Kingdom

EP01.02-006 Excuse Me? Patient Perceptions of Lung Cancer Screening Results
Rayan Ihle, United States

EP01.02-007 It's Not How You Start, It's How You Finish: Patient Motivators to Follow Low-Dose Screening Recommendations
Rayan Ihle, United States

EP01.02-008 Pocket Nodules, An Innovative Patient Education Tool to Explain Lung Nodules
Theresa Roelke, United States

EP01.03

Track: Early Detection and Screening - Implementation

EP01.03-001 Māori Perspectives on a Potential Lung Cancer Screening Programme Aotearoa NZ: An Indigenous People's Perspective.
Anne Fraser, New Zealand

EP01.03-002 Implementation of the International Lung Screen Trial (ILST) in Catalonia: A Cost Analysis study
Antoni Rosell, Spain

EP01.03-003 AI Detection of Emphysema in an Ultra-Low Dose CT Lung Cancer Screening Program
Chellan Kumarasamy, Australia

EP01.03-004 Should We Screen for Lung Cancer? A 10-Country Analysis Identifying Key Decision-Making Factors
Charlotte Poon, United Kingdom

EP01.03-005 Current status of High-risk Smokers Participating in Population-based National Lung Cancer Screening Program in Korea
Eunkyo Kang, South Korea

EP01.03-006 Potential Drivers of Lung Cancer Screening Participation in Australia: A Qualitative Study to Inform Future Implementation
Emily Stone, Australia

EP01.03-007 Lung Cancer Screening Use Among Screening-Eligible Adults With Disability in the United States: Evidence From Population-Based Data
Hermine Poghosyan, United States

EP01.03-008 Lung Cancer Screening Patients Experiences and Satisfaction: Quantitative and Qualitative Findings From a Survey Study
Jaileene Perez-Morales, United States

EP01.03-009 Cost-effectiveness of Lung Cancer Screening in New Zealand Varies by Ethnicity
Peter Sandiford, United Kingdom

EP01.03-010 China Lung Cancer Screening Study (CLUS) Version 2.0: Study Design and Baseline Screening Results
Fangfei Qian, China

EP01.03-011 Clinical Features and Surgical Outcomes of Young Patients with Ground Glass Opacity Featured Lung Adenocarcinoma
Rirong Qu, China

EP01.03-012 Acceptability and Feasibility of Lung Cancer Screening in Australia: The View of Key Stakeholders
Rachael Dodd, Australia

EP01.03-013 A Pilot Study of Lung Cancer Screening with Low Dose CT in Georgia (One Centre Experience and Preliminary Data).
Salome Kukava, Georgia

EP01.04

Track: Early Detection and Screening - Implementation Quality Control

EP01.04-001 A Programmatic Approach to Improve Efficiency in Lung Cancer Screening
Brendon Stiles, United States

EP01.04-002 The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program
Iakovos Toumazis, United States

EP01.04-003 Effectiveness of Cloud-based Computer Aided Quality Control System in Korean National Lung Cancer Screening
Ji-Youn Song, South Korea

EP01.04-004 Overcoming the Barriers to Lung Cancer Screening using a Systemwide Approach
Michael Gieske, United States

EP01.04-005 Quantitative Characteristics in Global CT Lung Cancer Screening Populations Using the ELIC Distributed Database and Computation Environment
Stephen Lam, Canada

EP01.04-006 Clinical Scores, Biomarkers and It Tools in Lung Cancer Screening - Can an Integrated Approach Overcome Current Challenges?
Wieland Voigt, Germany

EP01.05

Track: Early Detection and Screening - Pulmonary Nodule

EP01.05-001 Radiomics to Increase the Effectiveness of Lung Cancer Screening Programs. Radiolung Preliminary Results
Antoni Rosell, Spain

EP01.05-002 Role of the Lung Cancer Screening MDT in the Manchester Lung Health Check Programme
Avik Ghoshal, United Kingdom

EP01.05-003 Changes of Repeated Lung Cancer Screening Results and Affected Factors; Analysis of Korean National Lung Cancer Screening Program
Eunkyo Kang, South Korea

EP01.05-004 Trial in Progress: An Observational Study for Management of Lung Nodules across Latin America (DOuBLED Study)
Felipe Da Costa, Brazil

EP01.05-005 The Accuracy of Baseline Low-dose CT Lung Cancer Screening: A Systematic Review and Meta-analysis
Lanwei Guo, China

EP01.05-006 Influenza Season Influence on Incidence and Outcome of Nodules in the NELSON Trial
Harriet Lancaster, Netherlands

EP01.05-007 Radiomics Based Machine Learning Model for Sub-cm Lung Nodule Malignancy Diagnosis in the PanCan Screening Study
Ian Janzen, Canada

EP01.05-008 Pre-Trial Validation of a Risk Prediction Model for Pulmonary Nodules Trained on a Nested Case-Control Study with No External Cohort
Michael Kammer, United States

EP01.05-009 Simulation-Based Sample Size Estimation for an Early Detection of Lung Cancer Clinical Utility Trial in Indeterminate Pulmonary Nodules
Michael Kammer, United States

EP01.05-010 Using a Pattern Submodel Approach to Predict Lung Cancer in High-Risk Lung Nodule Clinics
Valerie Welty, United States

EP01.05-011 Radiologic Features of Nodules Attached to the Mediastinal or Diaphragmatic Pleura
Yeqing Zhu, United States

EP01.06

Track: Early Detection and Screening - Risk Stratification

EP01.06-001 Lung Cancer after First Primary Breast Cancer: Risk Factors and Results of Treatment
Camilla Vanni, Italy

EP01.06-002 Impact of Immediate AI Enabled Patient Triage to Chest CT on the Lung Cancer Pathway: LungIMPACT
David Baldwin, United Kingdom

EP01.06-003 Female Asian Nonsmoker Screening Study (FANSS): Exploring Lung Cancer Screening in a High Risk Population
Elaine Shum, United States

EP01.06-004 Eliciting Quantitative Smoking History by the Use of Natural Language Processing
John Ruckdeschel, United States

EP01.06-005 Assessment of Cardiovascular Risk in the Non Screening Radically Treated Lung Cancer Cohort
Marius Theiveehathasan, United Kingdom

EP01.06-006 Impact of Low Dose CT Screening on Cause of Death in Different Socio-Economic Groups
Michael Davies, United Kingdom

EP01.06-007 The Impact of Modified Screening Eligibility Criteria on Race and Sex Disparities in Lung Cancer Screening
Matthew Smeltzer, United States

EP01.06-008 Low Dose CT Screening in Asian Female-Never-Smokers is as Efficacious as in Asian Male-Ever-Smokers. A Systemic Review and Meta-Analysis
Natthaya Triphuridet, Thailand

EP01.06-009 Frequency of Lung Adenocarcinoma in Patients With Growing Nonsolid and Part-Solid Nodules With Solid Component ≤5 mm
Natthaya Triphuridet, Thailand

EP01.07

Track: Early Detection and Screening - Work Up

EP01.07-001 Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial
Kasper Guldbrandsen, Denmark

EP01.07-002 Objectives and Design of the ACR Lung Cancer Screening CT Incidental Findings - Quick Reference Guide
Michael Gieske, United States

EP01.07-003 Accuracy of Cytological Diagnosis for Malignant Nodule in Participants With Nonsolid Nodules and Part-Solid Nodules With Solid Component≤5 mm
Natthaya Triphuridet, Thailand

EP01.07-004 FDG-PET-CT for Staging Screen Detected Lung Cancer
Renelle Meyers, Canada

EP01.07-005 Combined Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced MRI for Diagnosing Indeterminate Pulmonary Nodules
Fang Wu, China

EP01.07-006 Incidence and Resource Burden for the Management of CT Detected Ground Glass Opacities at a Tertiary Lung Cancer Service in the United Kingdom
Muhammad Ashraf, United Kingdom

EP02.01

Track: Early Stage Non-small Cell Lung Cancer - Biomarkers

EP02.01-001 Plasma Cell-Free DNA as a Point-of-Care Wellbeing Biomarker for Early-Stage Non-Small Cell Lung Cancer Patients
Anna Mcguire, Canada

EP02.01-002 Development of Circulating and Tissue Biomarkers Predicting Immune Phenotype and Response to Immunotherapy in NSCLC.
Brian Henderson, Ireland

EP02.01-003 Predictive Role of Novel Grading System on Adjuvant Chemotherapy in Early Resected Lung Adenocarcinoma Based on EGFR Mutation Status
Yiming He, China

EP02.01-004 Application of a Genomic Assay for Risk Stratification of Resected NSCLC in a Community Cancer Center Setting, a Pilot Study
Hiroshi Yamagata, United States

EP02.01-005 The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma
Ken Onodera, Japan

EP02.01-006 Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Real-World Impact on Survival
Kohei Hashimoto, Japan

EP02.01-007 Clinicopathologic and Prognostic Features of Early Resected Lung Adenocarcinoma Characterized With Uncommon EGFR Mutation
Shenghui Li, China

EP02.01-008 Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas
Luka Brcic, Austria

EP02.01-009 PD-L1 Expression in Biopsies and Surgical Specimens of Lung Cancer: Impact of Biopsy Methods and Neoadjuvant Therapy
Mir Alireza Hoda, Austria

EP02.01-010 Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumour Fail to Predict Nodal Upstaging in Early-Stage Lung Cancer
Oezlem Okumus, Germany

EP02.01-011 Immune-related Histologic Phenotype in Pretreatment Tumour Biopsy Predicts Efficacy of Neoadjuvant Anti-PD-1 Treatment in Squamous Lung Cancer
Pei Yuan, China

EP02.01-012 PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation
Yi-Fan Qi, China

EP02.01-013 Real World Treatment Patterns, Prevalence and Outcomes in Patients with KRAS Mutated Non Small Cell Lung Cancer in Southwestern Ontario
Sara Kuruvilla, Canada

EP02.01-014 Prognostic Classification of Early-Stage Lung Cancer Using Preoperative Prealbumin and D-dimer Levels
Takashi Yamamichi, Japan

EP02.01-015 Computer-Aided Volumetry by Multidetector Computed Tomography is Efficient for Prognostic Prediction of Early-Stage Solid Lung Cancers
Taketo Kato, Japan

EP02.01-016 Molecular Alterations and Clinical Prognostic Factors in Resectable Non-Small Lung Cancer
Thanaporn Thamrongjirapat, Thailand

EP02.01-017 The Role of Adjuvant Chemotherapy for Stage II/III Lung Adenocarcinoma Based on Epidermal Growth Factor Receptor Mutation Status
Yasuhiro Tsutani, Japan

EP02.01-018 EGFR Mutations Promote Lung Adenocarcinoma From Adenocarcinoma in Situ to Minimally Invasive Carcinoma to Invasive Adenocarcinoma
Jianfei Zhu, China

EP02.02

Track: Early Stage Non-small Cell Lung Cancer - Radiotherapy

EP02.02-001 Genome-wide Analysis and Dynamic Changes of Human Non-small Cell Lung Carcinoma Cells After Radiation
Yajing Du, China

EP02.02-002 Increased Utilization of Stereotactic Body Radiotherapy Has Decreased Treatment Disparities for Early-Stage NSCLC
Ashwin Ganesh, United States

EP02.02-003 Mean Lung Dose Correlates with Volume of Radiation-Induced Lung Injury in Patients Treated with SABR for Lung Cancer
Angus Killean, United Kingdom

EP02.02-004 Clinical Outcomes Following Photon-Based and Proton-Based Stereotactic Body Radiation Therapy for Early Stage Lung Cancer
Bong Kyung Bae, South Korea

EP02.02-005 Changes in PFT Parameters and Correlation with Symptomatic Pulmonary Toxicity Following SBRT For Early Stage Lung Cancer
Bong Kyung Bae, South Korea

EP02.02-006 Differing Doses: The Effects of Radiation Dose Calculation Algorithms on Local Control in Early-Stage Lung Cancer
Bradley Ackerson, United States

EP02.02-007 Correlation between Biological Equivalent Dose and Radiological Changes after Lung Stereotactic Ablative Radiation Therapy
Carla Cases Copestake, Spain

EP02.02-008 Transbronchial Microwave Ablation of Lung Nodules - Good Safety Profile and Promising Mid-Term Results
Wing Yan Joyce Chan, China

EP02.02-009 Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancer, Cyberknife-M6 Experience
Süreyya Sarihan, Turkey

EP02.02-010 Histology Impacts Time-to-Treatment on Lung SBRT Outcomes
Gregory Videtic, United States

EP02.03

Track: Early Stage Non-small Cell Lung Cancer - Surgery

EP02.03-001 The Role of Completion Lobectomy Following Sublobar Resection in Patients with T1 Non-Small Cell Lung Cancer
Akif Turna, Turkey

EP02.03-002 Impact of Society and National Guidelines on Patient Selection for Lung Cancer Surgery in the United Kingdom from 2008 to 2013
Chiara Proli, United Kingdom

EP02.03-003 Survival of Patients with Interstitial Lung Disease Who Undergoing Lung Cancer Surgery: A Propensity Score Matching Study
Sang Hoon Lee, South Korea

EP02.03-004 Association Between Sarcopenia and Outcomes of Lung Cancer Surgery in Old-Age Patients: Interim Analysis of Prospective Cohort Study
Hyeoksang Woo, South Korea

EP02.03-005 Perioperative Factors That Predict or Are Associated With Prolonged Air Leaks After Robotic-Assisted Pulmonary Lobectomy
Eric Toloza, United States

EP02.03-006 Oncological Outcome And Surgical Instruments in VATS Lobectomy For Early Stage Lung Cancer
Federico Femia, Italy

EP02.03-007 Seeds of Gold. Triple Contrast Marking in Hybrid Operative Room for All-in One Diagnostic and Therapeutic Precision Surgery
Francesco Guerrera, Italy

EP02.03-008 Combined Robotic Assisted Thoracic Surgery (CRATS)
Eric Anderson, United States

EP02.03-009 Real-world Disease-Free Survival as a Predictor of Overall Survival in Resected Early-Stage Non-Small Cell Lung Cancer
Howard West, United States

EP02.03-010 Intrapulmonary and Hilar Lymph Node Dissection Performed by the Surgical Team: Impact on Pathological Stage of NSCLC
Jefferso Gross, Brazil

EP02.03-011 Timeliness of Surgery for Early-Stage Lung Cancer: Perspectives from Surgeons and Patients
Jeffrey Zhu, United States

EP02.03-012 Peri-operative and Oncologic Outcomes after Robotic-Assisted Segmentectomy at a NCI-designated Cancer Center
Jobelle Joyce Anne Baldonado, United States

EP02.03-013 Should Visceral Pleural Invasion Be Prognostic Factor in Early-Stage Lung Adenocarcinoma With Tumour Size 3cm or Less?
Kisung Park, South Korea

EP02.03-014 Pulmonary Segmentectomy via Minimally Invasive Open Surgery: An Analysis From a Japanese High-Volume Hospital
Kazuo Nakagawa, Japan

EP02.03-015 Fully Robotic Arm Robot Assisted Lung Surgery Exploration
Taiyang Liuru, China

EP02.03-016 Dynamics of Recurrence After Curative Resection of Non-small Cell Lung Cancer
Masaya Yotsukura, Japan

EP02.03-017 Novel Intraoperative CT-Guided Marking Using O-Arm in Video-Assisted Thoracoscopic Surgery
Yoshimitsu Hirai, Japan

EP02.03-018 Intermittent Chest Tube Clamping Shortens Chest Tube Duration After Lung Cancer Surgery: An Open-label, Randomized Controlled Trial
Nan Wu, China

EP02.03-019 T3 Non Small Cell Lung Cancer with Satellite Nodules: A Multicentric Analysis.
Pietro Bertoglio, Italy

EP02.03-020 Patient Outcomes Following Salvage Lung Cancer Surgery Post Definitive Chemotherapy or Radiation
Riley Bowker, Canada

EP02.03-021 Uncertain Resection for Localized cN0M0 Non Small Cell-Lung Cancer: The Crucial Prognosis of Suboptimal Lymph Node Assessment
Romain Vergé, France

EP02.03-022 Evolution of Lung Cancer Resection Quality: A Prospective Staggered Implementation Quality Improvement Study
Ray Osarogiagbon, United States

EP02.03-023 Decreasing Time to Definitive Therapy with MIDAS: Minimally Invasive Diagnosis and Surgery
Patrick Ross, United States

EP02.03-024 Clinical and Prognostic Impact of Pleural Adhesions during Lung Cancer Surgery
Satoshi Shiono, Japan

EP02.03-025 Long-Term Oncological Outcomes and Risk Factors of Recurrence After Segmentectomy for Primary Lung Cancer
Shinsuke Uchida, Japan

EP02.03-026 Is Ratio of Surgical Margin to Nodule Size a Prognostic Factor in Stage 1 Adenocarcinoma?
Tiffany Melissa Ergin, Turkey

EP02.03-027 After Surgery Factors Affecting Relapse in Early Stage Non Small Cell Lung Cancer
Tiffany Ergin, Turkey

EP02.03-028 Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumour Spread through Air Spaces
Eunjue Yi, South Korea

EP02.03-029 Prognostic Factors in Curative Intent Stage I lung Adenocarcinoma: Hospital's Cancer Registry Based Analysis
Vinícius Silva, Brazil

EP02.04

Track: Early Stage Non-small Cell Lung Cancer - Systemic Therapy

EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)
Alessandro Leonetti, Italy

EP02.04-002 Synergy of Local Treatment with Pulsed Electric Fields and Anti-PD1 Checkpoint Blockade
Chiara Pastori, United States

EP02.04-003 A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases
Ishjot Litt, Canada

EP02.04-004 Time to Surgery After Neoadjuvant Immunotherapy: Not a Day Too Soon
Nathan Mynard, United States

EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC
Jay Lee, United States

EP02.04-006 Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Preoperative Chemotherapy
Lei Deng, United States

EP02.04-007 Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)
Patrick Forde, United States

EP02.04-008 Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Non-small Cell Lung Cancer (NSCLC): a systematic review and meta-analysis
Sebawe Syaj, Jordan

EP02.04-009 Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC
Tedi Hoxha, Canada

EP02.04-010 Clinical Outcomes After Neoadjuvant Tislelizumab plus Chemotherapy in Resectable Stage IIIA-B NSCLC: A Retrospective Study
Xiangyang Cheng, China

EP03.01

Track: Epidemiology

EP03.01-001 Is Airflow Limitation a CausalFactor for Lung Squamous Cell Carcinoma? Evidence from Mendelian RandomizationAnalysis
Qing Zhang, China

EP03.01-002 Co-occurring Mutations, Smoking Status and Prognosis of Early-stage Resected NSCLCs with EGFR Mutations
Alison Moore, Canada

EP03.01-003 Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)
Clarissa Mathias, Brazil

EP03.01-004 Impact of Covid-19 Pandemic in Lung Cancer Patients in Albania
Daniela Xhemalaj, Albania

EP03.01-005 Clinicopathological Features of ROS1-rearranged Adenocarcinomas: A Single Institutional Experience Spanning Four Years From India
Aruna Nambirajan, India

EP03.01-006 Familial Aggregation in Non-small Cell Lung Cancer - An Observational Study
Sindhura Durga Chitikela, India

EP03.01-007 Comprehensive Genomic Profile of Advanced Lung Cancer in a Region With the Worst Human Development Index in Brazil
Eldsamira Mascarenhas, Brazil

EP03.01-008 Shift in Lung Cancer Stage at Diagnosis during the COVID-19 Pandemic in New York City
Emanuela Taioli, United States

EP03.01-009 BrainMets-Cross-Sectional Study To Identify The Presence Of Brain Metastasis At Diagnosis Of Advanced NSCLC EGFRm in Portuguese Patients
Maria Teixeira, Portugal

EP03.01-010 Clinicopathological Characteristics of Non-Small Cell Lung Cancer patients in the United Arab Emirates and Correlation with Their Outcomes
Fathi Azribi, United Arab Emirates

EP03.01-011 Prevalence of KRASMutations in Treatment-naïve Non-small Cell Lung Cancer Patients in Hong Kong
James Ho, China

EP03.01-012 Characterization of Lung Cancer in Patients With High Familial Aggregation of Cancer: Preliminary Data From the SCAN Study
Juan Carlos Laguna, Spain

EP03.01-013 Improving the Risk Estimation for Second Primary Lung Cancer after Lung Cancer by Taking Histologic Subtype into Account
Marian Eberl, Germany

EP03.01-014 Results From the BEWELL Study: Black Raspberry Nectar for the Prevention of Lung Cancer (NCT04267874)
Marisa Bittoni, United States

EP03.01-015 Disease-Free Survival and Clinical Characteristics in Early-Stage NSCLC Patients From a Danish Cohort
Peter Meldgaard, Denmark

EP03.01-016 The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration
Sara Moore, Canada

EP03.01-017 Epidemiology of Lung Cancer in Northern Serbia During the Past Ten Years
Tomi Kovacevic, Serbia

EP04.01

Track: Global Health, Health Services Research, and Health Economics - Cost Issues

EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience
Abhenil Mittal, Canada

EP04.01-002 Costs of Locoregional and Metastatic Recurrences in Patients with Resectable Stage II-III NSCLC in Spain
Amelia Insa, Spain

EP04.01-003 Is It Time for a New Paradigm in Care of Young Cancer Patients? A Retrospective Study
Andreina Vasconcelos, Portugal

EP04.01-004 Interim Feedback on Pilot Public Facing Website for Cancer Clinical Trial Patient-Reported Symptom Data: Project Patient Voice
Bellinda King-Kallimanis, United States

EP04.01-005 Lung Cancer Diagnosis Following Emergency Admission: Diagnostic and Therapeutic Pathways and Outcomes Within an Italian Cancer Center
Carlo Genova, Italy

EP04.01-006 A Systematic Review (SR) of Cost-effectiveness Analysis (CEA) of ALK Inhibitors (iALK) in Advance Non-small Cell Lung Cancer (NSCLC)
Carolina Gabay, Argentina

EP04.01-007 Impact of Precision Medicine Methods on First-Line Therapies in Metastatic Non-Small Cell Lung Cancer
Chetan Vakkalagadda, United States

EP04.01-008 Factors Impacting Time from Biopsy to Initiation of Treatment for Advanced NSCLC at an Academic Hospital and Affiliate Hospitals
Chetan Vakkalagadda, United States

EP04.01-009 Performance Indicators of Lung Cancer MDT at a Regional Center: Disagreements Between Trust and NLCA Data
Qudratullah Qudratullah, United Kingdom

EP04.01-010 Addressing Barriers to Lung Cancer Care for Diverse Populations through Patient Navigation: The University of Miami Experience
Estelamari Rodriguez, United States

EP04.01-011 Diagnostic Approach and Treatment of Lung Cancer Patients in Portugal: Portuguese Lung Cancer Study Group Survey
Fernanda Estevinho, Portugal

EP04.01-012 Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data
Heidi Andersén, Finland

EP04.01-013 Frailty Index Predicts Treatment Outcomes in Older Adults with Lung Cancer
James Fletcher, Australia

EP04.01-014 Adherence to Treatment Recommendations From Multidisciplinary Tumour Boards
Julia Roeper, Germany

EP04.01-015 Lung Cancer after Solid Organ Transplantation - A Claims Data Analysis
Julia Walter, Germany

EP04.01-016 First Comprehensive Lung Cancer Long-Term Survivorship Analysis - Late Toxicities and Overall Survival
Martin Metzenmacher, Germany

EP04.01-017 Cost-Effectiveness of Atezolizumab for Adjuvant Treatment of Patients with Stage II-IIIA PD-L1+ Non-small Cell Lung Cancer
Millie Das, United States

EP04.01-018 Medical Oncology and Radiation Oncology Consultation in Non-small Cell Lung Cancer (NSCLC). A Population-Based Study Using Administrative Data
Michela Febbraro, Canada

EP04.01-019 Into the Wild: Assessing Acute Care for Lung Cancer Patients, A Cohort Study to Improve Cancer Care at Emergency Department
Mariano Provencio, Spain

EP04.01-020 Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center
Myriam Nait Ajjou, Canada

EP04.01-021 Cancer Clinical Quality Registries: A Systematic Review of the Utilisation and Effectiveness of Knowledge Translation Interventions
Paul Dawkins, New Zealand

EP04.01-022 Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression
Pedro Aguiar Jr, Brazil

EP04.01-023 Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry (ANZLCR)
Rob Stirling, Australia

EP04.01-024 Influence of Lung Diagnostic Assessment Program on Health Resource Utilization in Lung Cancer in Southeastern Ontario, Canada
Shahad Alghamdi, Canada

EP04.01-025 Implementation of Electronic Patient Reported Outcomes in Routine Cancer Care
Shalini Vinod, Australia

EP04.01-026 Cone-Beam CT Guided Navigation Bronchoscopy: a Cost-Effective Modality for the Diagnosis of Pulmonary Nodules
Stephan Kops, Netherlands

EP04.01-027 Pain and Interventions in Stage IV Non-Small Cell Lung Cancer: A Province-Wide Analysis
Vivian Tan, Canada

EP04.01-029 Reduction of ER Visits of Lung Cancer Patients Through Care Interventions in Day-To-Day Clinical Service: Experience of a Thoracic Unit in México
Saul Campos-Gomez, Mexico

EP04.02

Track: Global Health, Health Services Research, and Health Economics - Support to Patients and Staff

EP04.02-001 Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival
Chelsea Ford-Sahibzada, Canada

EP04.02-002 International Consensus on Actions to Improve Lung Cancer Survival: Delphi Method in the International Cancer Benchmarking Partnership
Christian Finley, Canada

EP04.02-003 Improving Supportive Care for Patients with Thoracic Cancer
Lakedia Banks, United States

EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer
Lucy Corke, Canada

EP04.02-005 First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival
Martin Metzenmacher, Germany

EP04.02-006 Burn-Out Syndrome: Neglected Syndrome Among Health Care Professionals Managing Lung Cancer Patients
Tomi Kovacevic, Serbia

EP04.02-007 First Comprehensive Lung Cancer Long-Term Survivorship Program- Competing Risks
Sascha Nadjm, Germany

EP05.01

Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

EP05.01-001 Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity
Andres Cardona, Colombia

EP05.01-002 Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy
Ashwini Arunachalam, United States

EP05.01-003 First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area
Chihhsi Kuo, Taiwan

EP05.01-004 Induction Chemoimmunotherapy before Definitive Chemoradiotherapy for Large-Volume Unresectable Locally Advanced NSCLC
Yu Wang, China

EP05.01-005 Impact of Antibiotic Use Before Definitive Concurrent Chemoradiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Youling Gong, China

EP05.01-006 Population Kinetic Assessment of Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
David Stewart, Canada

EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC)
Gerard Walls, United Kingdom

EP05.01-008 The Scottish Inflammatory Prognostic Score predicts survival in non-small cell lung cancer treated with chemoradiotherapy
Grace Ball, United Kingdom

EP05.01-009 A Clinical Outcome Comparison of IMRT and VMAT in Stage II and III NSCLC Irradiated with Radical Intent
Jose Belderbos, Netherlands

EP05.01-010 External Validation of Two Prediction Models for Severe Radiation-induced Lymphopenia during Concurrent Chemoradiotherapy for Lung Cancer
Jose Belderbos, Netherlands

EP05.01-011 Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience.
Joel Rivera Concepcion, United States

EP05.01-012 Avoiding Cardiac Toxicity in Lung Cancer Radiotherapy (ACcoLade) Trial - Initial Results
Kathryn Banfill, United Kingdom

EP05.01-013 Increased C-reactive Protein after Chemoradiotherapy and Immunotherapy in Locally Advanced Non-small Lung Cancer Indicates Worse Survival
Karmen Stanic, Slovenia

EP05.01-014 Circulating Tumour DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer
Emily Lebow, United States

EP05.01-015 Validate Radiomics Features and XGBoost Model in Radiation Pneumonitis (RP) Prediction in Patients with Primary Lung Cancer: A MultiCenter Study
Jiali Liu, China

EP05.01-016 Radiation Recall Pneumonitis (RRP) Induced by Immune Checkpoint Inhibitors (ICIs) after Thoracic Radiotherapy for Lung Cancer
Xiaotong Lu, China

EP05.01-017 Exploring the Benefits of Adaptive Radiotherapy in NSCLC-patients
Marie Tvilum, Denmark

EP05.01-018 Chemoradiotherapy Followed by Durvalumab in Unresectable Locally Advanced NSCLC- A Single Institution Experience in Croatia
Marko Jakopović, Croatia

EP05.01-019 4D CT Ventilation Image-Guided Lung Functional Avoidance Radiotherapy: A Single-Arm Prospective Pilot Clinical Trial
Megan Daly, United States

EP05.01-020 Unanticipated Radiation Re-planning for Stage III Non-small Cell Lung Cancer
Melinda Mushonga, Canada

EP05.01-021 Radiation Dose to Cardiac Substructures and the Incidence of Cardiac Events in Patients with Stage III NSCLC Receiving CCRT
Meng Welliver, United States

EP05.01-022 Evaluation of the Management of Stage III NSCLC at Mohamed IV Center for Cancer Treatment Casablanca
Maryam Zaouit, Morocco

EP05.01-023 Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial
Nicholas Bucknell, Australia

EP05.01-024 Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study
Paolo Bironzo, Italy

EP05.01-025 Planned Interim Analysis of a Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer
Andreas Rimner, United States

EP05.01-026 Carboplatin Dose Calculations for Patients with Lung Cancer: Significant Dose Differences Found Depending on Dosing Equation
Seçkin Akgül, Australia

EP05.01-027 Uncertain Resection of pN2 NSCLC Patients-survival Analysis of Postoperative Radiotherapy and Driver Gene Mutations
Qianyue Deng, China

EP05.01-028 Thoracic Radiotherapy of Baseline Severe Pulmonary Dysfunction NSCLC Patients and Predictive Analysis for Acute Radiation Pneumonitis
Qianyue Deng, China

EP05.01-029 Association between DNA Repair Gene Pathway SNPs and Tumour Response in NSCLC Patients Receiving Radiotherapy: A Meta-Analysis
Timothy Shun Man Chu, United Kingdom

EP05.01-030 CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315
Wilfried Eberhardt, Germany

EP05.01-031 Lysimachia Capillipes Capilliposide C Enhances the Radiosensitivity of Lung Cancer by Promoting ERRFI1 via Inhibiting Phosphorylation of STAT3
Kan Wu, China

EP05.01-032 The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
Yeonsil Kim, South Korea

EP05.01-033 Stimulation CT-Based Radiomics Predict Radiation Pneumonitis after Chemoradiotherapy in Locally Advanced NSCLC
Haihua Yang, China

EP05.01-036 Role of Nanoparticle Polymeric Micellar Paclitaxel in Reducing Toxicity and Enhancing Efficacy in Non-small Cell Lung Cancer
Baohui Han, China

EP05.02

Track: Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

EP05.02-001 Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort
Amanda Gibson, Canada

EP05.02-002 Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?
Blanca Tavara, Spain

EP05.02-003 Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting.
Blanca Tavara, Spain

EP05.02-004 Could Fifty Percent Tumour Viability Be a Good Prognostic Factor?
Ezgi Cesur, Turkey

EP05.02-005 Is Immunotherapy Safer Than Radiotherapy in Combination With Chemotherapy in Neoadjuvant Therapy?
Ezgi Cesur, Turkey

EP05.02-006 Neoadjuvant DS-8201 for Stage III Non-small Cell Lung Cancer with HER2 20ins
Huizhao Hong, China

EP05.02-007 Impact Of Fibrinogen Levels and mGPS on Survival of Stage III/N2 NSCLC Patients Treated with Neoadjuvant Therapy and Radical Surgery
Katharina Sinn, Austria

EP05.02-008 Phase II Trial of Neoadjuvant Icotinib Plus Chemotherapy for Stage II-IIIB EGFR-mutant Non-small-Cell Lung Cancer
Fang-Liang Lu, China

EP05.02-009 Aumolertinib Versus Erlotinib/ Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)
Wenhua Liang, China

EP05.02-010 Robotic-Assisted Thoracic Surgery Following Neoadjuvant Chemoimmunotherapy in Patients with Stage III Non-small Cell Lung Cancer
Min Li, China

EP05.02-011 Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer
Yao-Bin Lin, China

EP05.02-012 Chemoradiotherapy versus Chemotherapy in Neoadjuvant Settings for Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC) Patients
Marah Akhdar, Jordan

EP05.02-013 Immune-Related Adverse Effects and Durvalumab Treatment Patterns in VHA Patients with Unresectable Stage III NSCLC
Amanda Moore, United States

EP05.02-014 Neoadjuvant Toripalimab Combination in Patients with Stage IIB-IIIB NSCLC: A Single-Arm, Phase 2 Trial (Renaissance Study)
Shi Yan, China

EP05.02-015 Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-small-Cell Lung Cancer: Optimizing Outcomes throughout the Trajectory of Care.
Severin Schmid, Germany

EP05.02-016 Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation
Yu Zhang, China

EP05.02-017 Prognostic Factors Following Induction Therapy for N2 Lung Cancer
Takashi Inoue, Japan

EP05.02-019 Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network
Yohann Pilon, Canada

EP05.02-020 IL-9Stimulates Anti-tumour Immune Response and Facilitates Checkpoint Blockade in Lung Cancer
Yuqian Feng, Hong Kong

EP05.02-021 An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC
Yongchang Zhang, China

EP05.02-022 Thoracic Radiotherapy May Increase the Risk of Treatment-induced Pneumonitis after Immune Checkpoint Inhibitors: A Meta-Analysis
Feng-Ming Kong, Hong Kong

EP05.03

Track: Locally Advanced Non-small Cell Lung Cancer - Surgery

EP05.03-001 Impact of Neoadjuvant Chemo/radiotherapy Followed by Surgical Resection on T4N0-1 Non-Small Cell Lung Cancer
Akif Turna, Turkey

EP05.03-002 Pulmonary Artery Reconstruction for Lung Cancer With N1 Vessel Infiltration: Is It Justified?
Camilla Vanni, Italy

EP05.03-003 Superior Sulcus (Pancoast) Tumours: A 11-Year Single-Centre Experience
Catarina Moita, Portugal

EP05.03-004 Risk Prediction of Multiple-station N2 Metastasis in Patients with Clinical Single-station N2 Non-small Cell Lung Cancer
Joon Young Kim, South Korea

EP05.03-005 Clinical Impact of Histologic Type in Patients with Surgically Resected Stage II and III Non-small Cell Lung Cancer
Hyeong Ryul Kim, South Korea

EP05.03-006 Real-World Treatment Pathways In Stage III Non-Small Cell Lung Cancer in Portugal (PICTuRE): An Interim Analysis Of Surgical Patients
Maria Teixeira, Portugal

EP05.03-007 Comparison of Surgical Methods in Patients Receiving Neoadjuvant Treatment; Thoracoscopy vs. thoracotomy
Ezgi Cesur, Turkey

EP05.03-008 Surgery after First-Line Alectinib for (Locally) Advanced ALK-rearranged NSCLC: Pathological Response and Peri-Operative Results
Filippo Lococo, Italy

EP05.03-009 Prognostic Impact of Tumour Volume Doubling Time for Resected Squamous Cell Carcinoma of the Lung
Kenta Nakahashi, Japan

EP05.03-010 Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: A Systematic Review and Meta-analysis
Shadi Hamouri, Jordan

EP05.03-011 Bilateral Orthotopic Lung Transplantation for a Patient with Advanced Invasive Mucinous Adenocarcinoma
Young Kwang Chae, United States

EP05.03-012 Deep Learning-based Classifier to Predict Intensified Locoregional Approach Need in Stage III Non-Small Cell Lung Cancer
Chenchen Zhang, China

EP06.01

Track: Management of Lung Cancer in the Era of COVID-19

EP06.01-001 The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review
Angelo Rizzolo, Canada

EP06.01-002 Cancer Care in a Time of COVID: Lung Cancer Patient's Experience of Telehealth and Connectedness.
Anne Fraser, New Zealand

EP06.01-003 Impact of COVID-19 on Lung Cancer Patients; The Patients' Perspective
Desiree Hao, Canada

EP06.01-004 Lung Cancer Resection During the Covid-19 Pandemic: A Single Centre Study
Tunde Oyebanji, United Kingdom

EP06.01-005 COVID-19 and Post-COVID Outcomes in Lung Cancer Patients: Experience from an Indian Cancer Center
Debapriya Mondal, India

EP06.01-006 Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis.
Enrica Capelletto, Italy

EP06.01-007 Fate of Pneumonectomy Patients During Covid-19 Pandemic
Gökberk Güler, Turkey

EP06.01-008 COVID-Protected Pathways for Image Guided Lunc Cancer Intervention During the COVID-19 Pandemic: A Cohort Study
Alexander Sheeka, United Kingdom

EP06.01-009 Maintaining Thoracic Services During COVID-19 - A Single Centre Experience
Hasanali Walji, United Kingdom

EP06.01-010 Clinical Outcomes after Hypo Fractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer During The Covid-19 Pandemic In Morocco
Meriem Cherkaoui, Morocco

EP06.01-011 COVID-19 Impact in Thoracic Surgery: a Comparison Between Public and Private Care in a Single-Center Facility
Maria Teresa Tsukazan, Brazil

EP06.01-012 Impact of COVID-19 on the Stage of Lung Cancer Diagnosis at the Mohamed VI Center for Cancer Treatment in Morocco
Souleymane Panandtigri, Morocco

EP06.01-013 Differences of Oncology Treatment for Lung Cancer Patients in Pandemic COVID-19 Year- Our Clinical Experience
Simonida Crvenkova, North Macedonia

EP06.01-014 Lung Resections After COVID: Short-term Outcomes
Srinivas Kodaganur Gopinath, India

EP06.01-015 Will Virtual Care Stand the Test of Time; One Site's Perspective on the Continuity of Virtual Care Post-Pandemic
Suheon Lee, Canada

EP06.01-016 Nationwide Activity of Lung Cancer Surgery Before and During the COVID-19 Pandemic
Tanel Laisaar, Estonia

EP06.01-017 Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours
Yago Garitaonaindía Díaz, Spain

EP07.01

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Clinical

EP07.01-001 Molecular Profiling Predicts Outcomes in Patients With Resected Malignant Pleural Mesothelioma
Christian Rolfo, United States

EP07.01-002 Surgery in Stage I-III Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER)- Medicare Analysis 1995-2015
Qian Wang, United States

EP07.01-003 Metadata-Oriented Data Engineering Approach for Integration of Medical Data: A Pilot Study
Yusuf Kahya, Turkey

EP07.01-004 Long Survivor Epithelioid Pleural Mesotheliomas Are Characterized by Tertiary Lymphoid Structures: An Update to the MATCH Study
Federica Grosso, Italy

EP07.01-005 Second Primary Cancers in a Population-Based Mesothelioma Registry
Giovanni Ceresoli, Italy

EP07.01-006 Clinicopathologic Determinants of Survival in Thoracic NUT Carcinoma (TNUT): Analysis of a Pooled Database
Philip Haddad, United States

EP07.01-007 Is Extended Resection for Tracheo Bronchial Adenoid Cystic Carcinoma Warranted ?
Jérôme Estephan, France

EP07.01-008 Perturbation of Warburg Effect by Dichloroacetate and Niclosamide in Malignant Pleural Mesothelioma in Vitro and in Vivo
James Chung-Man Ho, China

EP07.01-009 Solitary Fibrous Tumours of the Pleura, Clinical and Surgical Dilemma. Single-Center Experience
Krzysztof Kurowski, Spain

EP07.01-010 Results of Multimodal Treatment in Patients with Malignant Pleural Mesothelioma Undergoing Pleurectomy/Decortication
Kubra Alphan Kavak, Turkey

EP07.01-011 Integrating PD-L1 Expression to the CALGB Prognostic Scoring System in Malignant Pleural Mesothelioma
Luis Cabrera, Mexico

EP07.01-012 Ipilimumab and Nivolumab in Pretreated Patients with Malignant Pleural Mesothelioma
Marko Jakopovic, Croatia

EP07.01-013 Physical Function, Symptom Burden, and Quality of Life in Patients with Malignant Pleural Mesothelioma
Meng Wu, United States

EP07.01-014 Mesothelioma-Associated Fibroblasts Enhance Mesothelioma Aggressiveness and Modulate Drug Response
Michael Grusch, Austria

EP07.01-015 Multimodality Imaging for Characterization, Classification, and Staging of Malignant Pleural Mesothelioma, Focusing on MR Imaging
Mi Young Kim, South Korea

EP07.01-016 Role of Neoadjuvant Chemotherapy in Thymic Tumours
Riad Abdeljalil, Jordan

EP07.01-017 Malignant Fibrous Solitary Tumour of the Pleura Is Not All the Same: Evaluation of Risk Stratification Models in a Large Single Centre Series
Sara Ricciardi, Italy

EP07.01-018 Phase III Randomized Trial on Surgery, Chemo and Pleural Radiation (IMPRINT) for Resectable Pleural Mesothelioma (NRG LU-006)
Andreas Rimner, United States

EP07.01-019 Multiinstitutional Patterns of Use and Compliance with Tumour Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma
Rupesh Kotecha, United States

EP07.01-020 Pulmonary MALT Lymphoma: Detailed CT Findings
Kyongmin Beck, South Korea

EP07.01-021 Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
Sara Manglaviti, Italy

EP07.01-022 Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)
Susana Cedres, Spain

EP07.01-023 Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)
Susana Cedres, Spain

EP07.01-024 Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma
Sophie Rovers, Belgium

EP07.01-025 Survival Advantage of Pulmonary Metastasectomy in Advanced Melanoma Patients: A Population-Based Study
Sebawe Syaj, Jordan

EP07.01-026 Primary Pulmonary Ewing´S Sarcoma: Post Hoc Analysis From Two International Multicenter Prospective Randomized Trials
Theresa Stork, Germany

EP07.02

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Preclinical

EP07.02-001 Evaluation of FGF18 as a Contributing Factor in Malignant Pleural Mesothelioma Growth and Its Role as a Potential Biomarker
Berta Mosleh, Austria

EP07.02-002 Investigating the Role of MicroRNAs in Cell Growth and Cisplatin-Sensitivity of Malignant Pleural Mesothelioma
Michaela Kirschner, Switzerland

EP07.02-003 Characterization of the Extracellular Vesicle-Derived Transcriptome in Malignant Pleural Mesothelioma
Michaela B Kirschner, Switzerland

EP07.02-004 Endogenous Retrovirus Expression and Type I Interferon Signaling in Human Mesothelioma
Suna Sun, Switzerland

EP07.02-005 Multicenter Clinical Analysis, Gene Expression Profiling and Correlation Analysis of Immune Cell Infiltration in Pleural Mesothelioma
Xiaoling Xu, China

EP07.02-006 Tumour Immune Microenvironment Related Makers are Overexpressed and Served as Favourable Prognostic Factors in Resectable ESCC
Xiaoling Xu, China

EP07.03

Track: Mesothelioma, Thymoma, and Other Thoracic Malignancies - Thymoma

EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma
Hyeon Seok Choi, South Korea

EP07.03-002 Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience
Camille Gauvin, Canada

EP07.03-003 First Line Combination of Toripalimab and Chemotherapy in Advanced Thymic Carcinoma: A Single-Center, Prospective, Single-Arm, Phase II Trial
Xingsheng Hu, China

EP07.03-004 Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma
Mao Uematsu, Japan

EP07.03-005 MesoGraph: Graph Neural Networks for Weakly Supervised Cellular Profiling in the Subtyping of Malignant Mesothelioma Images
Mark Eastwood, United Kingdom

EP07.03-006 Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data
Rupesh Kotecha, United States

EP07.03-007 Clinicopathological Analyses for Predicting Recurrence After Complete Resection of Thymoma
Takahiro Suzuki, Japan

EP08.01

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

EP08.01-001 Update Analysis of Sintilimab With Two Cycles Chemotherapy for Untreated Advanced Squamous Non-small-Cell Lung Cancer
Huijuan Wang, China

EP08.01-002 Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy
Junipearl Cheng, Australia

EP08.01-003 Efficacy of Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma, A Multicenter Retrospective Study
Zhimin Zeng, China

EP08.01-004 Pattern of Subsequent Treatment and Outcomes in Relapsed PD-L1 high NSCLC Pre-treated with Pembrolizumab
Anifat Elegbede, Canada

EP08.01-005 A Multicenter Prospective Observational Study of Atezolizumab in Unresectable Advanced or Metastatic NSCLC in Japan: J-TAIL
Akito Hata, Japan

EP08.01-006 Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy
Alessandro de Toma, Italy

EP08.01-007 Real-World Outcomes of Patients with Advanced Lung Adenocarcinoma Treated with First-Line Chemo-Immunotherapy in Italy
Alessandro Leonetti, Italy

EP08.01-008 Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
Ana Fonseca, Portugal

EP08.01-009 TRBV Haplotype Profile Was Related to Immune-Induced Adverse Events in Chinese Patients With Advanced NSCLC
Xiaomin Niu, China

EP08.01-010 Troponin Elevation and the Risk of Myocarditis among NSCLC Patients Treated with Immune Checkpoint Inhibitors
Barliz Waissengrin, Israel

EP08.01-011 Diabetes Mellitus (DM) is Associated with Poor Outcome in Pembrolizumab-treated Non-Small Cell Lung Cancer (NSCLC) Patients
Barliz Waissengrin, Israel

EP08.01-012 First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
Beatrice Benetti, Italy

EP08.01-013 Ramucirumab plus Atezolizumab in Patients with Stage IV NSCLC Previously Treated with Immune Checkpoint Blockade
Brett Herzog, United States

EP08.01-014 Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303
Caicun Zhou, China

EP08.01-015 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Anti-oxMIF Antibody ON203 in Malignant Solid Tumours
Christine Landlinger-Schubert, Austria

EP08.01-016 A Review Of Real-World Treatment Outcomes Of mNSCLC Patients Following Progression On Or After Platinum-Based Chemotherapy
Cloe Koh, United States

EP08.01-017 Evaluation of Blood Tumour Mutation Burden for Efficacy of Second- Line Atezolizumab Treatment in Non-small Cell Lung Cancer
Cheol-Kyu Park, South Korea

EP08.01-018 Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression
Cole Friedes, United States

EP08.01-019 Modifiable biomarkers of response to immune checkpoint inhibitor treatment in non-small cell lung cancer
Daniel Spakowicz, United States

EP08.01-020 Phase 2 Platform Trial of Anti-TIGIT GSK'859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)
David Spigel, United States

EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy
Shouryadeep Srivastava, United States

EP08.01-022 Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events
Yasar Ahmed, Ireland

EP08.01-023 Factors Associated with Survival and Refusal of Physician Recommended Immunotherapy in Metastatic Non Small Cell Lung Cancer
Iktej Jabbal, United States

EP08.01-024 Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey
Ozan Yazici, Turkey

EP08.01-025 PD-L1 Tumour Tissue Expression and Its Relation with Clinico-pathological Profile in Advanced NSCLC
Sindhu Kilaru, India

EP08.01-026 Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients
Esther Swart, Netherlands

EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
Edward Garon, United States

EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
Emily Lin, Taiwan

EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Ernest Nadal, Spain

EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
Federico Cappuzzo, Italy

EP08.01-031 Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response
Fabienne Lusky, Germany

EP08.01-032 Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
Yun Fan, China

EP08.01-033 ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC
Yun Fan, China

EP08.01-034 Association of Sarcopenia with Survival in Advanced NSCLC Patients Receiving Concurrent Immunotherapy and Chemotherapy
Fabian Bolte, United States

EP08.01-035 Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC
Guanghui Gao, China

EP08.01-036 Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner
Hiroyuki Inoue, Japan

EP08.01-037 Association of Baseline NLR and BMI with Clinical Outcomes in NSCLC Patients Treated with Immunotherapy Alone Versus Chemo-Immunotherapy
Hita Moudgalya, United States

EP08.01-038 Clinical Predictors of Treatment Efficacy in Patients with Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors
Fang Hu, China

EP08.01-039 Impact of Pulmonary Function Indexes on Immunotherapy Efficacy in Lung Adenocarcinoma Patients and the Potential Prognostic Factors
Fang Hu, China

EP08.01-040 Peripheral Blood Cells as Predictors for Efficacy of Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer
Jacobo Rogado, Spain

EP08.01-041 Impact of Gender on Response to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer
Jae Cheol Lee, South Korea

EP08.01-042 NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
Ying Cheng, China

EP08.01-043 Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
Joao Alessi, United States

EP08.01-044 A Phase 2 Multi-Cohort Study of Tiragolumab, Atezolizumab and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer
Joshua Reuss, United States

EP08.01-045 The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumour Mutation Burden and Survival
Julie Wu, United States

EP08.01-046 Examination of Long-Term Administration of Pembrolizumab in Patients with Non-small Cell Lung Cancer at Our Institution
Kazuhito Nii, Japan

EP08.01-047 Chemo-immunotherapy is Associated With Better Survival Than Chemotherapy Alone In Stage IV Non-small Cell Lung Cancer
Krishna Patel, United States

EP08.01-048 Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort
Laura Gutiérrez Sainz, Spain

EP08.01-049 Unscheduled Hospitalizations in Patients With Thoracic Tumours in the Era of Immunotherapy
Laura Gutiérrez-Sainz, Spain

EP08.01-050 Survival Outcome of Metastatic Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An Analysis of National Cancer Database (NCDB)
Lei Deng, United States

EP08.01-051 Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy
Shenduo Li, United States

EP08.01-052 Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
Xuxinyi Ling, China

EP08.01-053 PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs
Yutao Liu, China

EP08.01-054 ICIs combined with Single-agent Chemotherapy in Two or More Lines Treatment for Advanced Non-Small Cell Lung Cancer
Yutao Liu, China

EP08.01-055 Utilization of Tumour Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer
Wenbin Li, China

EP08.01-056 Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting
Xin Li, China

EP08.01-057 Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS
Martin Reck, Germany

EP08.01-058 Access to Immunotherapy in Control Arms of Pivotal First Line Immunotherapy Trials in Metastatic Non-Small Cell Lung Cancer
Maham Bakhtyar, Pakistan

EP08.01-059 Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer
Mehmet Altan, United States

EP08.01-060 Long term Survival Outcomes in NSCLC Patients with Targeted Therapy and Immunotherapy: An IASLC Analysis of ASCO CancerLinQ Discovery Data
Madhusmita Behera, United States

EP08.01-061 A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor
Megan Daly, United States

EP08.01-062 Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy
Mingjia Li, United States

EP08.01-063 Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%
Mohsin Shah, United States

EP08.01-064 Serum NY-ESO-1 and XAGE1 Antibodies Predict and Monitor Clinical Responses to Immune Checkpoint Therapy for NSCLC
Mikio Oka, Japan

EP08.01-065 Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer
Mariano Provencio, Spain

EP08.01-066 Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?
Mariano Provencio, Spain

EP08.01-067 Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
Tuan Hoang, Canada

EP08.01-068 Going for the Ligand After a Stint With the Receptor: Can Switching Target From PD-1 to PD-L1 (Or Vice-Versa) Be Beneficial?
Nida Khan, United States

EP08.01-069 A Retrospective Study of Immune Checkpoints Rechallenge/ Retreatment in Metastatic NSCLC Progressing after Previous ICIs
Nuria Mederos Alfonso, Switzerland

EP08.01-070 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
Jun Zhao, China

EP08.01-071 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
Jun Zhao, China

EP08.01-072 Clinical Value of Patras Immunotherapy Score (PIOS) Formula in Patients With Advanced NSCLC Treated With Immunotherapy/Chemotherapy
Petros Christopoulos, Germany

EP08.01-073 AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
Rajiv Kumar, New Zealand

EP08.01-074 'Long Responders' Compared to 'Non-Responders' to a First Line Immune Checkpoint Inhibitor in Incurable Non-Small Cell Lung Cancer
Rebekah Rittberg, Canada

EP08.01-075 Combination of Baseline Disease and Smoking Pack-Years Can Guide The 1st-line Treatment Decision in Advanced NSCLC with High PD-L1 Expression
Ren Yuan, Canada

EP08.01-076 KEYNOTE B36: A Pilot Study of First-line Tumour Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer
Rupesh Kotecha, United States

EP08.01-077 Predicting Response to Checkpoint Inhibitors Using Complex Molecular Characteristics and Immunoprofiling in Patients With NSCLC
Simona Borilova, Czech Republic

EP08.01-078 Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors
Susana Cedres, Spain

EP08.01-079 Long Term Use of Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer (NSCLC) and Abnormal Marrow Pathology: A Case Series
Shane Wing, United States

EP08.01-080 Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
Bo Shen, China

EP08.01-081 A Phase I Dose-Escalation Study of HBM4003, an anti-CTLA-4 Heavy Chain Only Monoclonal Antibody, in Combination with Pembrolizumab
Shun Lu, China

EP08.01-082 Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients: A Prospective Study
Shun Lu, China

EP08.01-083 Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden
Simon Ekman, Sweden

EP08.01-084 Non-Invasive Detection of Predictive Biomarkers for PD-1 Inhibitor Treated Non-Small Cell Lung Cancer Patients
Simone Stensgaard, Denmark

EP08.01-085 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
Si-Yang Liu, China

EP08.01-086 Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer
Samuel Rosner, United States

EP08.01-087 First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices
Stephen Liu, United States

EP08.01-088 Direct Acting Antivirals (DAA) and Immune Checkpoint Inhibitors (ICIs) Therapy in Patients with Lung Cancer and Hepatitis C
Marco Tagliamento, Italy

EP08.01-089 Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Brain Metastases in Patients With Non-small Cell Lung Cancer
Fei Teng, China

EP08.01-090 Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront.
Teresa Gorria, Spain

EP08.01-091 Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone +/- Chemotherapy Upfront
Teresa Gorria, Spain

EP08.01-093 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer
Lin Wu, China

EP08.01-094 A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)
Lin Wu, China

EP08.01-095 Efficacy and Safety of Combining Endostar with Camrelizumab plus Chemotherapy in Advanced NSCLC Patients: A Multi-Center Retrospective Study
Lin Wu, China

EP08.01-096 Lung Immune Prognostic Index is Prognostic in Patients Treated with PD-1 Inhibitor Combined with Chemotherapy for Non-small Cell Lung Cancer
Anning Xiong, China

EP08.01-097 Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy
Xiangling Chu, China

EP08.01-098 Evaluating Risk Factors for Pneumonitis in Stage III NSCLC Patients Receiving Durvalumab after Definitive Chemoradiation
Xiaokui Mo, United States

EP08.01-099 Activity of aPD1-MSLN-CART Cells against Metastatic Lung Cancer in a Phase 1 Trial
Xiaorong Dong, China

EP08.01-100 Unlocking Primary Resistance to Checkpoint Inhibitors in Non-small Cell Lung Cancer by Metagenomic and Metabolomic
Xiaorong Dong, China

EP08.01-101 Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC
Yiqing Huang, Singapore

EP08.01-102 Anlotinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy
Lian Yu, China

EP08.01-103 Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
Lian Yu, China

EP08.01-104 Baseline Tumour Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy
Yuji Uehara, Japan

EP08.01-105 Efficacy of First-Line Immune Checkpoint Inhibitors in Patients with Advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 Alterations
Yuji Uehara, Japan

EP08.01-106 PD-1/PD-L1 Inhibitors Increase Myocardial Infarction in Osimertinib-Treated Patients with Non-Small Cell Lung Cancer
Lucheng Zhu, China

EP08.01-107 The Increase of Blood Intratumour Heterogeneity Is Associated with Unfavorable Outcomes of ICIs Plus Chemotherapy in NSCLC
Juan Zhou, China

EP08.01-108 Real-Life Costs and Benefit of First-Line Pembrolizumab for Advanced NSCLC - A Propensity-Score Matched Case-Control Study
Vanessa Rambousek, Austria

EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC
Martin Forster, United Kingdom

EP08.01-110 Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumour-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC
Jason Chesney, United States

EP08.02

Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

EP08.02-001 Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Ying Wang, China

EP08.02-002 Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia
Jie Tan, China

EP08.02-003 Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation andctDNA Cleared Analysis
Yanwei Li, China

EP08.02-004 Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY
Huijuan Wang, China

EP08.02-005 A Prospective Non-randomized Observational Study on Efficacy and Its Relative Factors of Pemetrexed Combined With EGFR-TKIs in NSCLC
Huijuan Wang, China

EP08.02-006 Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients
Huijuan Wang, China

EP08.02-007 Disease Burden and Clinical Outcomes of Advanced ROS1 Positive NSCLC with Different Fusion Partners
Zihua Zou, China

EP08.02-008 Tumour Invasiveness and Clinical Outcomes between Metastatic ROS-1 and ALK Positive NSCLC
Zihua Zou, China

EP08.02-009 Progression Pattern, Resistance Mechanism and Subsequent Therapy for ALK Positive NSCLC in the Era of Second—Generation ALK—TKIs
Zihua Zou, China

EP08.02-010 Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China
Liang Gong, China

EP08.02-011 Design of a Phase I Trial (TOTEM) to Test Repotrectinib in Combination with Osimertinib in Advanced, Metastatic EGFR-Mutant NSCLC
Andrés Aguilar, Spain

EP08.02-012 Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea
Beung-Chul Ahn, South Korea

EP08.02-013 Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC
Amanda Gibson, Canada

EP08.02-014 Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort
Amanda Gibson, Canada

EP08.02-015 The Utility of Liquid Biopsies for Management of Stage IV Non-small Cell Lung Cancer (NSCLC) in an Academic Community Medical Center
Alisha Maity, United States

EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
Benjamin Besse, France

EP08.02-017 Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data
Lior Apter, Israel

EP08.02-018 Phase 1/2 Study of BLU-451, a Small Molecule Inhibitor of EGFR, in EGFR Exon 20 Insertion-Mutant Incurable Advanced Cancers
Alexander Spira, United States

EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Alexander Spira, United States

EP08.02-020 Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation
Anupong Tangpeerachaikul, Thailand

EP08.02-021 A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain Metastases
Yi Tang, China

EP08.02-022 Investigating Partners in Crime: Osimertinib Resistance Mechanisms in Non-small Cell Lung Cancer Using Focused CRISPR Screen
Bengisu Uluata Dayanc, Turkey

EP08.02-023 Differentiation Syndrome in a Patient with Non-Small-Cell Lung Cancer Harboring IDH2 Mutation Treated with Enasidenib.
Bhoomika Sukhadia, United States

EP08.02-024 Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis
Bindu Venugopal, Canada

EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial
Byoung Chul Cho, South Korea

EP08.02-026 Real-world Efficacy of EGFR-TKI in Advanced NSCLC and Clinical Predictors of Outcome in Maharaj Nakorn Chiangmai Hospital in Thailand.
Chaiyut Charoentum, Thailand

EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC
Chao-Chi Ho, Taiwan

EP08.02-028 Germline HRR Mutations in Metastatic NSCLC and Impact on Progression-Free Survival: A Single-Center Retrospective Study
Chetan Vakkalagadda, United States

EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
James Chih-Hsin Yang, Taiwan

EP08.02-030 Tusamitamab Ravtansine in Patients with NSQ NSCLC and Negative or Moderate CEACAM5 Expression Tumours and High Circulating CEA
Christine Soufflet, France

EP08.02-031 NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC
Christoph Arolt, Germany

EP08.02-032 High Efficiency Multiplex Detection of Molecular Alterations in Supernatants of Pleural Effusion and Cerebrospinal Fluid
Clara de las Casas, Spain

EP08.02-033 Anlotinib in Elderly Patients With Advanced Non-squamous NSCLC Who Had Not Received Systemic Chemotherapy: A Single-Arm, Phase II Study
Da Zhao, China

EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L
Daniel Breadner, Canada

EP08.02-035 Clinical Utility of Liquid Biopsy After Progression to First and Second-Generation TKIs in Advanced EGFR Mutant NSCLC Patients
David Heredia, Mexico

EP08.02-036 Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer
Diana Sousa, Portugal

EP08.02-037 Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
Anastasios Dimou, United States

EP08.02-038 Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
Shuai Fu, China

EP08.02-039 An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
Xinyong Zhang, China

EP08.02-040 Dacomitinib Induced Febrile Neutropenia: a Rare Serious Adverse Event
Debapriya Mondal, India

EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumours: The Phase 1/2 ARROS-1 Study
Alexander Drilon, United States

EP08.02-042 EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC
Laercio Da Silva, United States

EP08.02-043 The Current State of Biomarker Testing in Lung Cancer as Seen by Health Care Providers
Daniel Saez, United States

EP08.02-044 Adding Alectinib Rescues Progression on Osimertinib Due to Acquired ALK p.R1275Q Variant in EGFR p.L858R-mutated NSCLC
Edyta Urbanska, Denmark

EP08.02-045 Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer
Elaine Shum, United States

EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
Elio Gregory Pizzutilo, Italy

EP08.02-047 The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs
Elizabeth Dudnik, Israel

EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
Federico Cappuzzo, Italy

EP08.02-049 A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumours With HER2 Aberrations
Frans Opdam, Netherlands

EP08.02-050 A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
Shencun Fang, China

EP08.02-051 High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
Yun Fan, China

EP08.02-052 Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E-Mutation Positive Metastatic NSCLC
Yun Fan, China

EP08.02-053 Non-small Cell Lung Cancer withMETExon14 Skipping Mutation: Literature Review of Real-World Evidence Data
Fernanda Estevinho, Portugal

EP08.02-054 Efficacy and Safety of TKI Dose Reduction - Can Less Mean More?
Fernando Pereira Da Silva, Portugal

EP08.02-055 Targeting Lung Adenocarcinoma Cells with a Novel Disulfide Reductase Inhibitor
Fraser Johnson, Canada

EP08.02-056 Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors
Flávia Duarte, Brazil

EP08.02-057 Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance
Lingxin Feng, China

EP08.02-058 A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience
Fran Seiwerth, Slovenia

EP08.02-059 EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis
Gilberto de Castro, Brazil

EP08.02-060 How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry
Giannis Mountzios, Greece

EP08.02-061 Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?
Grace Chazan, Australia

EP08.02-062 Evaluation of In Silico Tools to Determine Potential Actionability of Missense Variants with Experimental Therapies for NSCLC
Lena Chae, United States

EP08.02-063 SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
Qing Zhou, China

EP08.02-064 ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Qing Zhou, China

EP08.02-065 Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations
Hazel O'Sullivan, United Kingdom

EP08.02-066 Real-World Data on the Side Effects of Alectinib, Brigatinib and Lorlatinib
Debra Montague, United Kingdom

EP08.02-067 Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Meijuan Huang, China

EP08.02-068 ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)
Jie Huang, China

EP08.02-069 A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases
Siyuan Huang, China

EP08.02-070 High Incidence of Peridiagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer
Inmaculada Aparicio Salcedo, Spain

EP08.02-071 Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort
Ishjot Litt, Canada

EP08.02-072 The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs
Joanna Chorostowska-Wynimko, Poland

EP08.02-073 Clinical and Genomic Analysis of Primary and Secondary MET Fusions with Intact Kinase Domain in Lung Cancer
Bo Jin, China

EP08.02-074 Impact of Germline BRCA1/2 Alterations on EGFR Mutant Advanced Non-small Cell Lung Cancer Outcomes
Jyoti Patel, United States

EP08.02-075 Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion
Jens Sørensen, Denmark

EP08.02-076 Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab
Fenge Jiang, China

EP08.02-077 Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumour Suppressor Genes
Jie Wang, China

EP08.02-078 Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)
Ying Cheng, China

EP08.02-079 The Use of Lung Adenocarcinoma Patient-Derived Xenografts and Organoids to Study GDP-KRAS G12C Inhibitor Resistance
Joshua Rosen, Canada

EP08.02-080 EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting
Janakiraman Subramanian, United States

EP08.02-081 Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
Joel Neal, United States

EP08.02-082 Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
Jae Yun Lee, Canada

EP08.02-083 Real World Treatment and Outcomes in EGFR-mutated Advanced Non-small Cell Lung Cancer Patients: A Nationwide Cohort for 1,932 Thai Patients
Kakanan Tienchai, Thailand

EP08.02-084 Evaluation of Tumour Heterogeneity (TH) as a Prognostic Biomarker in Osimertinib treated Non-Small Cell Lung Cancer Patients
Karthikeyan Murugesan, United States

EP08.02-085 In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI
Kenichi Suda, Japan

EP08.02-086 Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma
Young-Chul Kim, South Korea

EP08.02-087 A 28-Years Old Pregnant Woman Diagnosed as ALK-Rearrangement Lung Adenocarcinoma With Multiple Brain Metastasis - Case Report
Simona Laštíkova, Slovakia

EP08.02-088 Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients
Laura Gutiérrez Sainz, Spain

EP08.02-089 Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
Lauren Jones, Canada

EP08.02-090 Sotorasib Drug-Drug Interactions: Essential Guidance Requested by Physicians Worldwide
Leila-Sophie Otten, Netherlands

EP08.02-091 Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
Yan Li, China

EP08.02-092 Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib
Na Li, China

EP08.02-093 Loss of Tumour Endothelial QKI Expression Results in Pronounced Reductions in Metastasis and Remodeling of the Tumour Microenvironment
Lincy Edatt, United States

EP08.02-094 Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial
Gen Lin, China

EP08.02-095 Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib
Chunling Liu, China

EP08.02-096 Different Epidermal Growth Factor Receptor Inhibitor Generations Plus Antiangiogenic for EGFR-Mutated NSCLC: A Meta-Analysis
Leen Al-Kraimeen, Jordan

EP08.02-097 Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina
Luis Basbus, Argentina

EP08.02-098 Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab±Platinum in First-Line Metastatic NSCLC
Martin Reck, Germany

EP08.02-099 Liquid Biopsies as a Tool for Monitoring Patients with Metastatic ALK-positive NSCLC
Maiken Ulhøi, Denmark

EP08.02-100 Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression
Ziyi Xu, China

EP08.02-101 Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study
Maristella Bungaro, Italy

EP08.02-102 Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer
Marta Garcia de Herreros, Spain

EP08.02-103 Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience
Martin Rupp, Canada

EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World
Martina Lorenzi, Italy

EP08.02-105 KRAS p.G12 Mutated Advanced Non-Small Cell Lung Cancer. Characteristics and Outcomes from a Danish Nationwide Observational Study
Matilde Frost, Denmark

EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
Matthias Scheffler, Germany

EP08.02-107 Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer
Matthew Villanueva, Pharmd, United States

EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
Marina Garassino, United States

EP08.02-109 A Drug-Drug Interaction Study of Mobocertinib and Midazolam in Patients With Advanced Non-Small Cell Lung Cancer
Michael Hanley, United States

EP08.02-110 Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy
Miguel Garcia, Canada

EP08.02-111 RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
Melissa Johnson, United States

EP08.02-112 Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province
Michelle Dean, Canada

EP08.02-113 Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Masanobu Okahisa, Japan

EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
Moritz Glaser, Germany

EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan
Motohiro Tamiya, Japan

EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumours
Miguel Villalona Calero, United States

EP08.02-117 Online CME Improves Clinicians' Ability to Identify and Manage Patients with NSCLC and EGFR Exon 20 Insertion Mutations
Michelle Worst, United States

EP08.02-118 TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumours
Nagasaka Misako, United States

EP08.02-119 RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer
Nicole Yun, United States

EP08.02-120 MET Alterations at Presentation in NSCLC Patients Harboring EGFR Mutations and ALK, RET and ROS1 fusions
Núria Jordana, Spain

EP08.02-121 The Landscape of Anti-neoplastic Drugs for Malignant Pleural Effusion in Non-small Cell Lung Cancer: A Systematic Review of Clinical Trials
Obada Ababneh, Jordan

EP08.02-122 Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)
Oliver Illini, Austria

EP08.02-123 First Line Osimertinib in Lung Cancer Patients with Postoperative Recurrence
Atsushi Osoegawa, Japan

EP08.02-124 Lorlatinib Treatment Related Adverse Events: Single Centre Real-World Experience in ALK and ROS1-driven NSCLC
Parvin Begum, United Kingdom

EP08.02-125 Tumour Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer
Paul Stockhammer, United States

EP08.02-126 The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Petros Christopoulos, Germany

EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
Bin-Chi Liao, Taiwan

EP08.02-128 Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial
Hyungjun Park, South Korea

EP08.02-129 Closing the Gaps with Blood-Based Next Generation Sequencing
Pratik Shah, United States

EP08.02-130 Tegavivint Exhibits Antitumour Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumour Microenvironment
Raghav Chandra, United States

EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program
Reyes Bernabé-Caro, Spain

EP08.02-132 Fatal Interstitial lung disease induced by Osimertinib: a case report
Ricardo Cordeiro, Portugal

EP08.02-133 Sequential Afatinib to Osimertinib in EGFR-mutant NSCLC: A Prospective Observational Study, Gio-Tag Japan Interim Report
Ryo Morita, Japan

EP08.02-134 Real-world Efficacy of Dacomitinib in Patients with Previously EGFR-TKI Treated Non-small Cell Lung Cancer
Chien-Yeh Chi, Taiwan

EP08.02-135 Anti-EGF Antibodies Significantly Improve the Activity of MET and KRAS Inhibitors in Preclinical Models of Non-small Cell Lung Cancer (NSCLC)
Silvia Garcia-Roman, Spain

EP08.02-136 Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Juan Shen, China

EP08.02-137 Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment
Shun Lu, China

EP08.02-138 SAFFRON: Ph3 Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
Shun Lu, China

EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
Shun Lu, China

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+ osimertinib in EGFRm NSCLC Post-Osimertinib
Myung-Ju Ahn, South Korea

EP08.02-141 'Our' EGFR population - experience in a secondary center
Sofia Silva, Portugal

EP08.02-142 Effects of Afatinib on the Treatment and Prognosis of Brain Metastasis in Advanced EGFR Mutation (+) NSCLC
Sung Yong Lee, South Korea

EP08.02-143 Shortening of the Turn around time (TAT) in the Examination of Rapid On-Site cytologic Evaluation (ROSE) at transbronchial biopsy.
Yoshihiro Taguchi, Japan

EP08.02-144 The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer
Tatsuro Okamoto, Japan

EP08.02-145 An Efficacy Analysis of Advanced Non Small Cell Lung Cancer With MET Exon 14 Skipping in the Real World
Fei Teng, China

EP08.02-146 Proposal of Foretinib as Second-Line TKI after Capmatinib/Tepotinib Treatment Failure in NSCLC with MET Exon 14 Mutation
Toshio Fujino, Japan

EP08.02-147 Clinical Outcomes in Patients with or without Cell Cycle Gene Alterations in EGFR mutated Non-Small Cell Lung Cancer
Turja Chakrabarti, United States

EP08.02-148 Extended Follow-up of Efficacy and Safety of Larotrectinib in Patients With TRK Fusion Lung Cancer
Victor Moreno, Spain

EP08.02-149 Spanish Multicenter Retrospective Study of Real-Life Experience of Advanced NSCLC with EGFR Exon 20 Insertions Treated With Amivantamab
Víctor Albarrán-Artahona, Spain

EP08.02-150 Molecular Heterogeneity of Compound Epidermal Growth Factor Receptor (EGFR) Mutations in Lung Adenocarcinoma (LAC)
Ramesh Bulusu, United Kingdom

EP08.02-151 A Real World Evidence of Lorlatinib for Taiwanese with advanced ALK Positive Non-Small Cell Lung Cancer
Wade Fang, Taiwan

EP08.02-152 Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis
Zhaoxia Wang, China

EP08.02-153 The Efficacy and Safety of EGFR-TKIs plus Anlotinib in Maintenance Therapy for Oligoprogressive Advanced or Metastatic EGFR Mutant NSCLC
Zhaoxia Wang, China

EP08.02-154 Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial
Hualin Chen, China

EP08.02-155 The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
Yen Hsiang Huang, Taiwan

EP08.02-156 Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US
Yin Wan, United States

EP08.02-157 Acquired EGFR Exon 19 Deletion Is a Resistance Mechanism to BRAF/MRK Inhibition in BRAF V600Emutant NSCLC
Fang Wu, China

EP08.02-158 Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC
Lin Wu, China

EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study
Lin Wu, China

EP08.02-160 A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy
Lin Wu, China

EP08.02-161 An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer
Lin Wu, China

EP08.02-162 Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
Xiuning Le, United States

EP08.02-163 Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer
Xiuning Le, United States

EP08.02-164 The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand
Siriwimon Saichaemchan, Thailand

EP08.02-165 Small Cell Transformation After Lorlatinib ALK Resistance - A Case Report with Clonal Evolution
Xiaoling Xu, China

EP08.02-166 Brain Metastases in Patients with ALKrearranged or ROS1-fusion Non-small-Cell Lung Cancers in China
Shaoyu Yang, China

EP08.02-167 Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters
Yasi Xu, China

EP08.02-168 Efficacy, Safety and Treatment Courses for Patients with ALK Oncogene Positive NSCLC; Retrospective Data in Single Institute
Yuki Akazawa, Japan

EP08.02-169 Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation
Dian Sheng Zhong, China

EP08.02-171 PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Maria García Campelo, Spain

EP08.02-172 Effect of EGFR Inhibition on Bone Health in NSCLC Patients without Skeletal Metastasis
Marcella Mandruzzato, Italy

EP08.03

Track: Metastatic Non-small Cell Lung Cancer - Oligometastatic Disease

EP08.03-001 A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases
Chunyu He, China

EP08.03-002 Local Ablative Therapy in Oligoprogressive NSCLC - Results from a Tertiary Cancer Center of India
Anil Tibdewal, India

EP08.03-003 Surgery for Primary Tumour is Associated with Prolonged Overall Survival in Patients with Oligometastatic NSCLC
Jose Corona-Cruz, Mexico

EP08.03-004 Outcomes of Oligometastatic Non-Small Cell Lung Cancer Patients Undergoing Surgical Resection: A Single Center Experience
Fulden Gorguner, Turkey

EP08.03-005 HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours
Fiona Mcdonald, United Kingdom

EP08.03-006 Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis
Isabelle Opitz, Switzerland

EP08.03-007 Spontaneous Regression in Metastatic Non-small Cell Lung Cancer: A Case Report
Maria La Mantia, Italy

EP08.03-008 Whether Immunotherapy Should Be Maintained or Not After Acquired Resistance in Advanced Nsclc
Shun Lu, China

EP08.04

Track: Metastatic Non-small Cell Lung Cancer - Palliative Chemotherapy

EP08.04-001 Weekly versus 3-Weekly Regimens of Carboplatin and Paclitaxel in Metastatic NSCLC: A Real-World Data
Barliz Waissengrin, Israel

EP08.04-002 Australian Vinorelbine Use in Advanced Lung cancer (The AVAL Study)
Ben Markman, Australia

EP08.04-003 A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
Chawalit Chayangsu, Thailand

EP08.04-004 Impact of Comorbidity Scores on Overall Survival in Advanced Non-Small Cell Lung Cancer Patients -A Real-World Experience from Eastern India
Srikanth Mamidi, India

EP08.04-005 Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion
Shinnosuke Takemoto, Japan

EP08.04-006 Risk Factors of Chemotherapy-Induced Severe Neutropenia in Elderly Lung Cancer: Data From a Regional Hospital in Thailand
Sunee Neesanun, Thailand

EP08.05

Track: Metastatic Non-small Cell Lung Cancer - Palliative Radiotherapy

EP08.05-001 Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
David Mak, Canada

EP08.05-002 Sequencing of T cell Receptor Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis
Xiaorong Dong, China

EP08.05-003 Evaluation of Dose Changes in Different Periods after 125I Seed Implantation in Lung Cancer
Haihua Yang, China

EP08.05-004 The Optimal Intervention Timing of Hypofractionated Stereotactic Radiotherapy for EGFR Mutated NSCLC Patients With Limited Brain Metastases
Lin Zhou, China

EP09.01

Track: Nursing and Allied Health Professionals

EP09.01-001 International Collaboration for Thoracic Oncology Education
Beth Sandy, United States

EP09.01-002 Patient with Immune-associated Dermatomyositis Caused byAdvanced NSCLC Treated with ICIs
Yuanyong Wang, China

EP10.01

Track: Palliative and Supportive Care

EP10.01-001 Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Lung Cancer: Dose-Response Effect and Toxicity
Kaicheng Pan, China

EP10.01-002 The Effect of Group Rehabilitation Training in the Ward on the Psychological Status and Quality of Life of Lung Cancer Patients
Li Li, China

EP10.01-003 Non-Small Cell Lung Cancer Treatment Preferences Among EGFR Mutation Patients and Physicians in Japan
Akira Inoue, Japan

EP10.01-004 Perspectives of Patients with Metastatic Lung Cancer on Symptom Screening and Patient-Reported Symptom Trajectory Data
Amir H. Safavi, Canada

EP10.01-005 Australian Lung Cancer Survivors Experiences of Novel Treatments, Healthcare, and Ongoing Physical and Psychological Needs
Bea Brown, Australia

EP10.01-006 Differences In Toxicity Among Platinum-Based Combinations As Reported By Non-Small Cell Lung Cancer (NSCLC) Patients
Christie Lagogianni, United Kingdom

EP10.01-007 Real World Data Comparing Lung Cancer Side-Effects Between Past/Current Smokers And Never Smokers
Christie Lagogianni, United Kingdom

EP10.01-008 Examining Social Determinants of Health Among Newly Diagnosed Lung Cancer Patients Contacted for Early Specialist Palliative Care Consultation
Desiree Hao, Canada

EP10.01-009 The Impact of the COVID-19 Pandemic on Palliative Care for Cancer: A Preliminary Cross-Country Survey of Clinical Oncologists
Yu Wang, China

EP10.01-010 Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)
Zhen Wang, China

EP10.01-011 Prognostic Impact of Body Composition Phenotypes in Non-small Cell Lung Cancer Patients Receiving First-Line Pembrolizumab
Ilaria Trestini, Italy

EP10.01-012 Geriatric Assessment in Patients Undergoing Lung Cancer Surgery and Their Family Caregivers
Jae Kim, United States

EP10.01-013 Erector Spinae Plane Block for Post-thoracotomy Analgesia; Comparison with Intercostal Block; Preliminary Results
Kubra Alphan Kavak, Turkey

EP10.01-014 A Multidisciplinary Team to Manage Patients with Lung Cancer and Opioid Use Disorder
Lawrence Feldman, Md, United States

EP10.01-015 The Role of CT-Scan as a Body Composition Tool in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
Maristella Bungaro, Italy

EP10.01-016 Cachexia's Impact on Immunotherapy Dose Reduction, Treatment Discontinuation, and Survival: a Systematic Review
Richard Skipworth, United Kingdom

EP10.01-017 Use of Lalaby in Lung Cancer Patients to Trace Performance from Phone Sensors and Reported Outcomes Involving Quality of Life
Teresa Soria-Comes, Spain

EP10.01-018 Thromboprophylaxis for Lung Cancer Patients: Results From ACT4CAT Trial
Nikolaos Tsoukalas, Greece

EP10.01-019 Rowing Against Cancer: From a Support Project to a Research Program. Perspectives and Challenges of Rowing in Metastatic Lung Cancer Patients
Veronica Franchina, Italy

EP10.01-020 Nutritionassessment for With Common Cancer Patients in a Cancer Hospital of China
Mengting Chen, China

EP11.01

Track: Pathology - Genomics & Analytics

EP11.01-001 Training Increases Concordance in Classifying Pulmonary Adenocarcinomas According to the Novel IASLC Grading System
Jiani Gao, China

EP11.01-002 Malignant Pleural Effusion Cell Blocks Are Reliable Resources for PD-L1 Analysis in Advanced Lung Adenocarcinomas
Aruna Nambirajan, India

EP11.01-003 Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation
Nguyen Lam, Viet Nam

EP11.01-004 An Effective Two-step Reflex Test for 10 Biomarkers Analysis in Non-small Cell Lung Cancer
Giacomo Pelizzari, Italy

EP11.01-005 Ultra-Fast Gene Fusion Assessment as a Reflex Testing in Daily Clinical Practice for Advanced Non-small Cell Lung Cancer Patients
Paul Hofman, France

EP11.01-006 Setting Up an Ultra-Fast Next-Generation Sequencing Approach as a Reflex Testing at Diagnosis in Non-squamous Non-small Cell Lung Cancer
Paul Hofman, France

EP11.01-007 Tracking ROS1 Fusions in NSCLC - Mirage or Truth When Screening the Desert
Johanna Mattsson, Sweden

EP11.01-008 Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System
Kanako Shinada, Japan

EP11.01-009 Amplicon-Based Next-Generation Sequencing Rescues "Quantity Not Sufficient" NSCLC Samples and Provides Clinical Information
Matthew Beer, United States

EP11.01-010 A Prospective Validation Study of Lung Cancer Gene Panel Testing Using Cytological Specimens
Kei Morikawa, Japan

EP11.01-011 Clinical Application of Liquid Biopsy for Assessing Early EGFR Mutation Detection in Non-Small Cell Lung Carcinoma
Amber Rathor, India

EP11.01-012 Genomic Landscape of Liquid Biopsy in Advanced Lung Cancer Patients, an Indian Experience
Shivani Sharma, India

EP11.01-013 Genomic Landscape of Pulmonary Sarcomatoid Carcinoma
Hyun Jung Kwon, South Korea

EP11.01-014 Optimizing Targetable Gene Screening by Sequential Multi-platform Detection Applied to Driver-negative mNSCLC Patients Detected by DNA-NGS
Yaxi Wang, China

EP11.02

Track: Pathology - New Technology

EP11.02-001 Natural Language Processing to Abstract Preneoplastic and Incidental Pulmonary Lesions from Pathology Reports
Jessica Petricca, Canada

EP11.02-002 A Comparative Study of PD-L1 Scoring: Humans versus AI
Luka Brcic, Austria

EP11.03

Track: Pathology - Tumour Biology

EP11.03-001 Loss of SUSD2 Expression in Lung Adenocarcinoma Correlates with Solid Pattern, Higher Histological Grading and Higher Ki-67 Cycling Index
Hangjun Wang, Canada

EP11.03-002 Prognostic Significance of YAP1 and Its Association with Neuro-endocrine Markers in Pulmonary Large Cell Neuro-endocrine Carcinoma (LCNEC)
Xujie Sun, China

EP11.03-003 Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases
Yu Zhi Zhang, United Kingdom

EP11.03-004 Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma
Shengnan Zhao, China

EP11.04

Track: Pathology - Tumour Diagnostics

EP11.04-001 Cytokeratin 5-Positive Pulmonary Adenocarcinoma: A Study with Resected Specimens
Akihiko Yoshizawa, Japan

EP11.04-002 The Histopathological Reasons for Better Survival of Patients with Lepidic Pattern Dominant Adenocarcinoma
Ismail Sarbay, Turkey

EP12.01

Track: Patient Advocacy

EP12.01-001 What Do Patients Want - a European Study Into ALK-Positive Patients Perspectives
Jamie Gibbard, United Kingdom

EP13.01

Track: Pulmonology, Radiology, and Staging

EP13.01-001 The Burden of Incidental Extra-thoracic Positron Emission Tomography-CT (PET-CT) Findings in Thoracic Malignancies
Dana Li, United Kingdom

EP13.01-002 Radiomic Signature on CT Images: A Noninvasive Biomarker for Pretreatment Discrimination of EGFR Mutations in NSCLC Patients
Yusuf Kahya, Turkey

EP13.01-003 Diagnostic Yield of Radial Probe Endobronchial Ultrasonography without Fluoroscopic guidance in Peripheral Pulmonary Lesions
Joonhee Han, South Korea

EP13.01-004 Accuracy of Clinical Stage in Resectable Non-small Cell Lung Cancer (NSCLC)
Hye Ran Gwon, South Korea

EP13.01-005 Role of Artificial Intelligence on Chest Radiographs for Detecting Resectable Early Lung Cancer
Eunhye Lee, South Korea

EP13.01-006 Safety of Image Guided Research Biopsies in Patients with Thoracic Malignancies
Jia Luo, United States

EP13.01-007 Differentiation between heterogeneous GGNs and part solid nodules using histogram on thin-section CT.
Hirofumi Koike, Japan

EP13.01-008 Needle Aspiration versus Forceps Biopsy Using Electromagnetic Navigation Bronchoscopy: CONFIDENT-ENB Trial Design
Yeon Wook Kim, South Korea

EP13.01-009 A Modified T Categorization for Pathological Stage I Lung Adenocarcinoma with Lepidic Component in Chinese Population
Shenghui Li, China

EP13.01-010 Effect of Perioperative Respiratory Muscle Training with Gamification for Lung Cancer
Masao Saito, Japan

EP13.01-011 Combining Automated Malignancy Risk Estimation with Lung Nodule Detection May Reduce Physician Effort and Increase Diagnostic Accuracy
Michael Calhoun, United States

EP13.01-012 Exploring Factors Affecting Variability in Lung Cancer Outcomes Across Southeastern Ontario, Canada
Shahad Alghamdi, Canada

EP13.01-013 Determination of the Timing of Bevacizumab Administration in Osimertinib and Bevacizumab Combination Therapy
Fei Teng, China

EP13.01-014 Evaluation of Malignancy and Survival in Patients Operated With a Preliminary Diagnosis of Interstitial Lung Disease
Tiffany Ergin, Turkey

EP13.01-015 Correlation Between CT Signs and Ki67 Expression in Non-small Cell Lung Cancer
Yuanyong Wang, China

EP13.01-016 Are Follow-up Tests Useful in NSCLC? Experience of a Tertiary Hospital
Yago Garitaonaindía Díaz, Spain

EP13.01-017 Assessing Variance Between Radiology versus Multidisciplinary Clinic Recommendations in the Pulmonary Nodule and Lung Screening Clinic
Inga Lennes, United States

EP14.01

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - Informing ES-SCLC

EP14.01-001 SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
Guohao Xia, China

EP14.01-002 Efficacy and Safety of Tiselizumab Combined with Anlotinib and 2-cycle Irinotecan as Second-line Treatment of Small Cell Lung Cancer
Xian Chen, China

EP14.01-003 Parotid Metastases from Primary Lung Cancer: Case Series and Systematic Review on the Clinical Features
Rulan Wang, China

EP14.01-005 Weekly Sequential ACOCEV Chemotherapy (ADR, CTX, CBDCA, VP16, VCR) for Elderly - Poor PS SCLC Patients: An Observational Study
Antonio Santo, Italy

EP14.01-006 CeLEBrATE: Phase II trial of CarbopLatin, Etoposide, Bevacizumab and Atezolizumab in Patients with exTEnsive-Stage SCLC-GOIRC-01-2019
Giuseppe Lamberti, Italy

EP14.01-007 Next-Generation Sequencing to Dynamically Detect Mechanisms of Resistance to ALK Inhibitors in ALK-positive SCLC Patient: A Case Report
Renhong Guo, China

EP14.01-008 Checkpoint Inhibitors Prevent New Onset of Brain Metastases in Relapsed Extensive Disease Small-Cell Lung Cancer
Jan Stratmann, Germany

EP14.01-009 A Comparative Study of Histological Predictors of Outcome in Patients with Lung Typical and Atypical Carcinoids
Joana Rei, Portugal

EP14.01-010 CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer
Ying Cheng, China

EP14.01-011 Carcinoid Tumour of the Lung with Osteomimicry. Case Report
Lovorka Batelja Vuletic, Croatia

EP14.01-012 A Case Report of Lung Large Cell Neuro-endocrine Carcinoma with Carcinoid Morphology
Lovorka Batelja Vuletic, Croatia

EP14.01-013 First-Line Chemotherapy vs Chemoimmunotherapy in Stage IV Large Cell Neuro-endocrine Carcinoma of the Lung, a Retrospective Study
Lingbin Meng, United States

EP14.01-014 Risk Factors for Brain Metastasis in Patients with Small Cell Lung Cancer: A Systematic Review and Meta-analysis
Lizza Hendriks, Netherlands

EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC
Luis Paz-Ares, Spain

EP14.01-016 Anlotinib Plus Toripalimab as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer: a Single-Arm Phase II Study
Dongqing Lv, China

EP14.01-018 Small Cell Lung Carcinoma in Morocco
Ouassima Erefai, Morocco

EP14.01-019 Identifying Circulating DNA Methylation Patterns in Small Cell Lung Cancer Patients
Sami Ul Haq, Canada

EP14.01-020 Trial in Progress: [177Lu]Lu-DOTA-TATE Combination Therapy in Treatment-Naïve Extensive Stage Small Cell Lung Cancer
Stephen Liu, United States

EP14.01-021 Anlotinib Plus Irinotecan or Docetaxel in Small-Cell Lung Cancer (SCLC) Relapsed within Six Months: a Single-Arm Phase II Study
Bing Xia, China

EP14.01-022 Immune Thrombocytopenia in a Patient with Large Cell Neuro-endocrine Carcinoma Under Dual Immune Checkpoint Inhibition
Ioannis Gkiozos, Greece

EP14.01-023 A Randomized Phase II Study of Irinotecan Plus Cisplatin With or Without Simvastatin in Ever-Smoking Small Cell Lung Cancer
Youngjoo Lee, South Korea

EP14.01-024 Transformation of SCLC to Lung Squamous Cell Carcinoma after First-Line Chemotherapy and Response to Sintilimab: A Case Report
Zhisheng Liu, China

EP14.01-025 Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients
Wei Zhang, China

EP14.02

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - Preclinical/Translational

EP14.02-001 Could the Oxidative Stress Be Used as a Marker for Neuro-endocrine Lung Tumours?
Luigi Andriolo, Italy

EP14.02-002 Cisplatin in Combination with Entinostat exerts Synergistic Antineoplastic Activity in Small Cell Lung Cancer
Anna Schwendenwein, Austria

EP14.02-003 Clinical Significance of MYC Family Members in Surgically Resected Limited-Stage Small Cell Lung Cancer: A Multicenter Study
Christian Lang, Austria

EP14.02-004 Barasertib Inhibits the Growth of SCLC Cell Lines and Transformed SCLC Patient Derived Model In Vitro and In Viv
Jin Soo Kim, South Korea

EP14.02-005 Therapeutic targeting Mevalonate-Geranylgeranyl Diphosphate Pathway with Statins Overcomes Chemotherapy-resistance in SCLC
Chenchen Guo, China

EP14.02-006 Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer
Kristiina Boettiger, Austria

EP14.02-007 Hes1 Protein Expression and Its Significance in Resected Small Cell Lung Cancers
Xujie Sun, China

EP14.03

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - RT

EP14.03-001 DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive Stage Small Cell Lung Cancer
Aditya Juloori, United States

EP14.03-002 Low-Dose Radiotherapy Plus Sugemalimab in Second-Line Treatment for Advanced-Stage Small-Cell Lung Cancer: Initial Results of a Phase I Study
Youling Gong, China

EP14.03-003 Phase I Study of Palliative Radiotherapy with Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Neal Mccall, United States

EP14.03-004 Neuro-cognitive Effect of HS-PCI in LS-SCLC
Suryakanta Acharya, India

EP14.03-005 Role of Radiotherapy Fraction in Limited-Stage SCLC: a Meta-Analysis of 8585 Reconstructed Individual Patient Data
Jingjing Zhao, China

EP14.04

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours – RW

EP14.04-001 Treatment and Outcomes of Patients with Limited-Stage Small-cell Lung Cancer in the Canadian SCLC Database (CASCADE)
Sara Moore, Canada

EP14.04-002 The Impact of Response on Survival in Extensive-Stage Small-Cell Lung Cancer in the CASPIAN Study
Sukhvinder Johal, United Kingdom

EP14.05

Track: Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

EP14.05-001 Chemoimmunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer and ECOG Performance Status of 2 or 3
Muskan Agarwal, United States

EP14.05-002 Impact of Body Mass Index on Survival in Patients with Small Cell Lung Cancer
Alejandro Rios-Hoyo, Spain

EP14.05-003 Recent Stage Shifts and Changes in the Treatment of Stage I Small Cell Lung Cancer in the United States
Chinmay Haridas, India

EP14.05-004 Temozolomide and Atezolizumab as Second Line Treatment for Extensive Stage Small Cell Lung Cancer: A Randomized, Multi-Cohort Phase 2 Trial
Dwight Owen, United States

EP14.05-005 Survival of Small Cell Lung Cancer in Relation to Chemotherapy Dose Intensity
Elisa Fernández Pérez, Spain

EP14.05-006 The Impact of Adjuvant Chemotherapy on Survival of Stage I Lung Large Cell Neuro-endocrine Carcinoma: A Meta-Analysis of Comparative Studies
Philip Haddad, United States

EP14.05-007 A Study of the Best Reduction in Target Lesion Size and Treatment Duration in the Durvalumab plus Platinum-Etoposide Regimen for ES-SCLC
Kageaki Watanabe, Japan

EP14.05-008 Development of a Prognostic Model for High-Grade Neuro-endocrine Carcinoma of the Lung Using Next-Generation Sequencing
Hye Sook Kim, South Korea

EP14.05-009 LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
Niels Reinmuth, Germany

EP14.05-010 Real-World Eligibility for Clinical Trials in Extensive Stage Small Cell Lung Cancer Patients
Navdeep Dehar, Canada

EP14.05-011 Real-World Impact of Platinum Sensitivity and Disease Stage on Survival Among Medicare Patients with Small Cell Lung Cancer
Paul Cockrum, United States

EP14.05-012 Comparing Costs for Medicare FFS Patients Treated with Etoposide or Irinotecan for Extensive Stage Small Cell Lung Cancer
Paul Cockrum, United States

EP14.05-013 Real-World Resource Use and Costs by Stage and Platinum Sensitivity among Medicare Patients with Small Cell Lung Cancer
Paul Cockrum, United States

EP14.05-014 Trends in Population Survival Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021
Paul Cockrum, United States

EP14.05-015 Quantifying Recent Trends in Real-World Treatment Patterns Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021
Paul Cockrum, United States

EP14.05-016 Patterns of Care for Small Cell Lung Cancer in Victoria Australia. A Prospective Population-Based Observational Study.
Rob Stirling, Australia

EP14.05-017 Real World Eligibility of Immune Checkpoint Inhibitors with Platinum-Doublet in Extensive Stage Small Cell Lung Cancer
Rebekah Rittberg, Canada

EP14.05-018 Major Lung Resection for Carcinoid Tumour; Does It Affect Quality of Life?
Riad Abdeljalil, Jordan

EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021
Robert Ramirez, United States

EP14.05-020 Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE)
Sara Moore, Canada

EP14.05-021 Promising Long-Term Survival after Surgical Resection of Early Stage Small Cell Lung Cancer in a Modern Single-Center Cohort
Sora Ely, United States

EP14.05-022 The Drug Induced Interstitial Lung Disease in Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer
Rei Takamiya, Japan

EP14.05-023 Characterization of Real-World Use of Lurbinectedin in Adult Small Cell Lung Cancer Patients in the United States
Xue Wang, United States

EP15.01

Track: Tobacco Control and Risk Reduction

EP15.01-001 Ask, Advise, Help (AAH) Smoking Cessation Brief Advice Delivery in Patients with Diagnosed Lung Cancer: A Retrospective Audit
John Lau, Australia

EP15.01-002 Lowering Rates of Smoking after Cancer Diagnosis: Use Social Networks
Melissa Neumann, United States

EP16.01

Track: Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

EP16.01-001 Transforming Growth Factor-inhibits Interferon-mediated Immune Resistance in Lung Cancer
Ye Fan, China

EP16.01-002 T Cell Receptor Diversity among Non-Small Cell Lung Cancer Patients Treated with Pembrolizumab Alone or in Combination with Chemotherapy.
Afaf Abed, Australia

EP16.01-003 The Dynamic Immune Signature of Patients with Advanced Non-small Cell Lung Cancer in Prediction of Infection After Receiving Immunotherapy
Chia-I Shen, Taiwan

EP16.01-004 Pleural Mesotheliomas Related with Geographical Asbestos Exposure Show Higher PD-L1 Expression
Yusuf Kahya, Turkey

EP16.01-005 Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma
Guanghui Gao, China

EP16.01-006 CD47 Inhibition Impairs the Growth of Orthotopic, Immune Competent Lung Tumour Models
Kelsie Thu, Canada

EP16.01-007 Molecular Characterization by Next-Generation Sequencing (NGS) of Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
Laura Gutiérrez Sainz, Spain

EP16.01-008 The Effect of Cytochrome P450 Family 4 Subfamily B Member 1 (CYP4B1) on Lung Adenocarcinoma (LUAD) Immune Microenvironment
Leen Al-Kraimeen, Jordan

EP16.01-010 A Machine-Learning Based Survival Prediction for Lung Adenocarcinma by Analyzing Infiltrated Lymphocytes Profiles with CIBERSORT
Tong Lu, China

EP16.01-011 PD-L1 Expression on Cytological Imprints and Circulating Tumour Cells versus Standardized Immunohistochemistry in NSCLC
Martin Reck, Germany

EP16.01-012 Immunophenotyping of Lung Adenocarcinoma in situ Based on CD8-positive T Cell Infiltration
Yu Ma, China

EP16.01-013 The Diagnostic Accuracy of Tumour Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis
Maria La Mantia, Italy

EP16.01-014 Characterisation of Circulating Immune Cells in a Cohort of Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Marta Gascón- Ruiz, Spain

EP16.01-015 Introducing "BiomeOne" a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients
Maximilian Hochmair, Austria

EP16.01-016 Tumour Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages
Moshe Giladi, Israel

EP16.01-017 T-cell Repertoire Heterogeneity and Homogeneity in Synonymous Multiple Primary Lung Cancers
Naixin Liang, China

EP16.01-018 SAKK 16/14 -Peripheral Immune Cell Populations Inresponse to Neoadjuvant Durvalumab in Patients with Stage IIIA(N2) NSCLC
Sacha Rothschild, Switzerland

EP16.01-019 The Role of the Pregnancy Associated Protein Glycodelin and Its Influence on the Immune System in Non-small-Cell Lung Cancer
Sarah Richtmann, Germany

EP16.01-020 Predictive Effect of Spatial Protein Signature in Advanced NSCLC Receiving Immunotherapy with a Bispecific Antibody
Xinyu Song, China

EP16.01-021 Less Immune Cell Infiltration and Worse Prognosis for NSCLC Patients with XPO1 Copy Number Alterations
Xuanzong Li, China

EP16.01-022 A Signature of B Cells-Related Gene Pairs Predicts Oncologic Outcomes and Response to Immunotherapy in NSCLC Patients
Xuanzong Li, China

EP16.01-023 Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
Yuan Li, China

EP16.01-024 Differential Efficacy of Combined GITR Co-stimulation with PD-1 Blockade in Preclinical Non-small Cell Lung Cancer Models
Sheng Yan, Hong Kong

EP16.01-025 Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
Wen-Fang Tang, China

EP16.01-027 MIF ImprovesImmune Microenvironmentof Lewis Lung Cancer Brain Metastases after Radiotherapy ViaReducing M2 Macrophages
Xiaorong Dong, China

EP16.01-028 Immunomodulatory Effects of Cryoablation Combined With Immune Checkpoint Inhibitors in a Murine Lung Cancer Model
Yoshikane Yamauchi, Japan

EP16.01-029 Inter-tumour Heterogeneity of PD-L1 Expression in Non-small Cell Lung Cancer
Yuichi Saito, Japan

EP16.01-030 Peripheral T-Cell Receptor Repertoire Profiling in Non-small Cell Lung Cancer Using an Amplicon-Based Sequencing Assay
Zi Yi Wan, Singapore

EP16.01-031 Association Between Programmed Death Ligand-1 (PD-L1) Expression and Clinicopathological Features in Non-small Cell Lung Cancer (NSCLC)
Sena Valcárcel González, Spain

EP16.01-032 Guiding Monotherapy with Docetaxel or Atezolizumab via the Tumour Mutation Index in Non-small Cell Lung Cancer Patients
Baohui Han, China

EP16.01-033 Characterisation of T Cell Receptor Repertoire in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Andrea Goñi, Spain

EP16.02

Track: Tumour Biology and Biomarkers - Minimally Invasive Biomarkers

EP16.02-001 Integration of Primer Exchange Reaction and DNAzyme for Electrochemical Detection of PD-L1-Expressing Exosomes in Lung Cancer
Bing Bo, China

EP16.02-002 Circulating Tumour DNA (ctDNA) Changes in Patients With Lung Cancer from a Real-World Prospective Clinico-Genomic (PCG) Study
Anne Chiang, United States

EP16.02-003 Real World Experience and Feasibility of Tissue Informed CGP and ctDNA Testing in a Cohort of NSCLC Patients
Georges Azzi, United States

EP16.02-004 Clinical Significance and Genomic Characteristics of CD56+ Circulating Tumour Cells in Small Cell Lung Carcinoma
Charles Ricordel, France

EP16.02-005 Liquid Biopsy Detects Genomic Drivers in Non-small Cell Lung Cancer without EGFR Mutations by Single-plex Testing: WJOG13620L
Daisuke Hazama, Japan

EP16.02-006 Evaluation of Carcinoembryonic Antigen (CEA) as Predictive Marker in Patients with Metastatic Non-small Cell Lung Cancer
Debapriya Mondal, India

EP16.02-007 Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies
Estela Sánchez-Herrero, Spain

EP16.02-008 Cerebrospinal Fluid as a Liquid Biopsy for Molecular Characterization of Brain Metastases in Patients With Non-small Cell Lung Cancer
Georgios Tsakonas, Sweden

EP16.02-009 Psychobiological Stress Responses to a Lung Cancer Diagnosis.
Hronn Hardardottir, Iceland

EP16.02-010 Predictive Value of Serum Reactive Oxygen Species Modulator 1 for Surgically Resected Lung Adenocarcinoma
Seung Hyeun Lee, South Korea

EP16.02-011 Liquid Biopsies in the Setting of Early-Stage Lung Cancer for the Detection of Actionable Mutations
Joana Espiga de Macedo, Portugal

EP16.02-012 cfDNA Analysis Implementation in Early Stage Lung Cancer
Joana Espiga de Macedo, Portugal

EP16.02-013 Retrospective Analysis of BRCA1/2 Alterations in Advanced NSCLC Using An Amplicon-based NGS Liquid Biopsy Assay
Jonathan Poh, Singapore

EP16.02-014 A Comparative Analysis of Gene Alteration Detected With NGS in Tumour Tissue and Peripheral Blood in Lung Cancer
Laura Gutiérrez-Sainz, Spain

EP16.02-015 Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC
Loukia Karacosta, United States

EP16.02-016 Exploration of Factors Affecting the Performance of MRD Tumour-Informed Assay in Chinese Lung Cancer Patients
Guomin Lin, China

EP16.02-017 Predictive Value of Peripheral Blood Immune Cell Profiling in EGFR-T790M Mutant Lung Adenocarcinoma
Yutao Liu, China

EP16.02-018 Liquid Biopsies First to Make Treatment Decisions in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC)
Luis Raez, United States

EP16.02-019 Metabolic Changes in Sputum and Exhaled Breath Condensate of Non-small Cell Lung Cancer Patients after Surgical Resection
Naseer Ahmed, Canada

EP16.02-020 Lung Cancer Cell Dynamics Significantly Depended on Blood Cell Circuit, Biochemical Factors, Hemostasis System, Cancer Characteristics
Oleg Kshivets, Russian Federation

EP16.02-021 The Expression of CEACAMs and Serum CEA Levels as Biomarkers of Postoperative Cancer Recurrence in Non-small Cell Lung Cancer
Bubse Na, South Korea

EP16.02-022 Circulating Tumour DNA Minimal Residual Disease Assay Predicts Outcome in Lung Cancer Patients Who Had Curative Treatments
Youjin Oh, United States

EP16.02-023 Extracellular Vesicles Long RNA Sequencing as Diagnostic Biomarkers for Lung Adenocarcinoma Patients with Tumour Size Smaller than 2cm
Fangfei Qian, China

EP16.02-024 Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer
Rui Fu, China

EP16.02-025 SerumTumour Markers as a Surrogate forRadiographicAssessment of Non-Small Cell Lung Cancer
Scott Strum, Canada

EP16.02-026 Dynamic Change of Indoleamine 2,3-dioxygenase Activity Predicts Survival in Radiotherapy- Received Unresectable Stage III NSCLC
Linfang Wu, China

EP16.02-027 Targeted Methylation Analysis of Circulating Cell-Free DNA to Predict Outcomes in Clinical Stage I NSCLC Patients
Yohan Bossé, Canada

EP16.02-028 Schwann Cell Exosomes Promote Lung Cancer Progression via miRNA-21-5P Cargo
Yan Zhou, China

EP16.02-029 Plasma-Based Next Generation Sequencing for Molecular Characterization of Lung Adenocarcinoma: A Multicentric Cohort From Argentina
Martina Spotti, Argentina

EP16.03

Track: Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapeutics

EP16.03-001 High Frequency of KRAS Mutation, Uncommon EGFR Mutation and TMB-H in Xuanwei Female Patients With Lung Adenocarcinoma
Heng Li, China

EP16.03-002 Mechanisms of Resistance to First-line Osimertinib in Hispanic Patients with EGFR mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP∫)
Andres Cardona, Colombia

EP16.03-003 Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC)
Andres Cardona, Colombia

EP16.03-004 Targeting SHP2 Reverts Oncogenic Mediated Resistance to KRAS-G12C Inhibition
Alicia Tüns, Germany

EP16.03-005 Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists
Ben Markman, Australia

EP16.03-006 Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients
Hui Chen, China

EP16.03-007 Comprehensive Analysis of m6A-Related Gene Mutation Characteristics and Prognosis in Lung Adenocarcinoma
Jinghua Chen, China

EP16.03-008 The Landscape of NFE2L2 Alteration in Chinese Lung Cancer Patients
Xuejun Dou, China

EP16.03-009 Patterns of KEAP1 Genomic Co-alterations in Advanced Non-small Cell Lung Cancer Identified by Plasma-Based Genyotyping
Dwight Owen, United States

EP16.03-010 Molecular and Clinical Characterization of Lung Adenocarcinoma With Respect to Patient Age at Diagnosis
Elsa Arbajian, Sweden

EP16.03-011 The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity
Francesco Passiglia, Italy

EP16.03-012 Novel Human-derived EML4-ALK Fusion cell lines identify ribonucleotide reductase RRM2 as a Target of Activated ALK in NSCLC
Ganesh Umapathy, Sweden

EP16.03-013 Psychological Distress and Beta-2 Adrenergic Receptor Expression in Non-small Cell Lung Cancer Cells
Hronn Hardardottir, Iceland

EP16.03-014 Simultaneous Detection of FGFR Gene Aberrations in Squamous Non-small Cell Lung Cancer Using Targeted DNA- and RNA-based NGS
Joanna Chorostowska-Wynimko, Poland

EP16.03-015 Centrosome Amplification Is a Prognostic Indicator and Potential Therapeutic Vulnerability in Non-small Cell Lung Cancer
Kelsie Thu, Canada

EP16.03-016 Targetable Alterations in Non-Small Cell Lung Cancer According to Age and Sex
Erin Kimbrough, United States

EP16.03-017 Spatial Heterogeneity of Tumour Microenvironment of Lung Adenocarcinoma Associated With Genomic Alterations
Kwon Joong Na, South Korea

EP16.03-018 Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma
Guomin Lin, China

EP16.03-019 Landscape of EGFR Extracellular Domain Mutations in Advanced Non Small Cell Lung Carcinoma
Lesli Kiedrowski, United States

EP16.03-020 High Tumour Mutational Burden by Whole-Genome Sequencing in Resected NSCLC in Never Smokers is Associated with Worse Prognosis
Louis-Jacques Ruel, Canada

EP16.03-021 Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
Luis Raez, United States

EP16.03-022 Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Sampling Is Sufficient for Lung Cancer Molecular Profiling
Luis Raez, United States

EP16.03-023 KRAS Alterations, Clinicopathological Features and Co-occurring Drivers Associated with Prognosis in Advanced NSCLC Patients
Maritza Ramos-Ramirez, Mexico

EP16.03-024 Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A
Mark Klein, United States

EP16.03-025 Immunogenomics of Clinical Resistance to KRAS G12C Inhibition
Mark Woodcock, United States

EP16.03-026 Metastasis Sites and Genomic Alterations in Advanced Non Small Cell Lung Cancer: A Retrospective Study
Juan Martínez-Valenciano, Mexico

EP16.03-027 Routine Molecular Testing Using the TSO500+ NGS Panel in a Cohort of Patients with NSCLC
Miguel Mosteiro Lamas, Spain

EP16.03-028 Cancer Cells May be Re-sensitized to Tumour Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway
Moshe Giladi, Israel

EP16.03-029 SLIT2 Expression in NSCLC With Long-Term Response to Pemetrexed
Eiji Nakajima, Japan

EP16.03-030 AKT Inhibition as a Therapeutic Strategy to Constrain Histological Transdifferentiation in EGFR-mutant Lung Adenocarcinoma.
Alvaro Quintanal-Villalonga, United States

EP16.03-031 Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer Harboring Different EGFR Exon 19 Del/Delins Variants
Shun Lu, China

EP16.03-032 Structure-Based Classification of Chinese Patients with Non-Canonical EGFR-Mutant Non-Small Cell Lung Cancer
Shun Lu, China

EP16.03-033 Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
Shun Lu, China

EP16.03-034 Differential Prognostic Effect of EGFR Mutation According to Smoking Status and Pathologic Stage in Non-mucinous Lung Adenocarcinoma
Sukki Cho, South Korea

EP16.03-035 Driver Mutations on Metastatic NSCLC - Experience in a Secondary Center
Sofia Silva, Portugal

EP16.03-036 Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC
Stephanie Saw, Singapore

EP16.03-037 Poor Prognosis of Patients with EGFR Mutations Left behind by Selective Detection in NSCLC
Taisuke Matsubara, Japan

EP16.03-038 Single-cell Analyses Reveal Tumour Microenvironment Differences between EGFR 19del and L858R mutations in Lung Adenocarcinoma
Tao Wang, China

EP16.03-039 Characterizing SHPRH as a Novel Tumour Suppressor Gene in Lung Adenocarcinoma
Tianna Sihota, Canada

EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base
Umberto Malapelle, Italy

EP16.03-041 Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers
Venessa Chin, Australia

EP16.03-042 BET Inhibitors Stimulate NK Cytotoxic Activity in NSCLC through Attenuation of YAP/TAZ and SMAD3 Transcriptional Programs
Valentina Sancisi, Italy

EP16.03-043 Comprehensive Genomic Profiling of Tumour Mutational Burden-high in Chinese Lung Cancer Patients
Wei Li, China

EP16.03-044 Genomic Evidence Depicting Clonal Evolution of Lung Adenosquamous Carcinoma
Yuchen Han, China

EP16.03-045 The Effect of Vascular Endothelial Growth Factor Gene Polymorphisms in the Clinical Outcome of Patients with Lung Cancer
Younes El Founini, Morocco

EP16.03-046 Tumour Grade Associated Genomic Mutations in Chinese Patients with Lung Cancer
Min Zheng, China

EP16.03-047 Genomic Landscape of Squamous Cell Carcinoma Lung in an Indian Cohort
Ullas Batra, India

EP16.04

Track: Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

EP16.04-001 The Role of Stromal PDGFR-activation in NSCLC
Amanda Lindberg, Sweden

EP16.04-002 Combining Patient-Derived Xenografts and Barcoding Technology to Evaluate Response to Targeted Therapies in ALK+NSCLC
Anne Petzold, Germany

EP16.04-003 High Dimensional Spatial Profiling of the NSCLC Tumour Microenvironment
Arutha Kulasinghe, Australia

EP16.04-004 Impact of Gender on Cellular Response to Cigarette Smoke Extract
Anne-Marie Baird, Ireland

EP16.04-005 Investigating the Side Effects of Docetaxel on Rat Lung and Heart
Berna Komurcuoglu, Turkey

EP16.04-006 A Novel Orthotopic Xenograft Mouse Model to Study Lung Cancer-Associated Fibroblasts and Lymphangiogenesis
Caoyang Chen, China

EP16.04-007 ALDH2 Downregulation, Aberrant DNA Methylation, and Loss of Stemness Pathways as an Enhanced Biomarker in Lung Adenocarcinoma
Thi-Oanh Tran, Taiwan

EP16.04-008 Cytotoxic Effects of Carnosic Acid Are Mediated by Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling in H1299 NSCLC Cells
Eric O'Neill, Canada

EP16.04-009 The Proliferative Effect of 27-Hydroxycholesterol as a Selective Estrogen Receptor Modulator on Pathology of NSCLC
Ikki Takada, Japan

EP16.04-010 Histological and Genetic Parental Tumour Characteristics are Conserved in Patient-derived Non-small Cell Lung Cancer Organoids
Isabelle Opitz, Switzerland

EP16.04-011 Sex Hormone Signalling in Lung Adenocarcinoma Limits Tumour Virulence
John Le Quesne, United Kingdom

EP16.04-012 Retrospective Analysis of Non-Small Cell Lung Cancer with Mucinous Histology Subtype
Katherine Garcia, United States

EP16.04-013 Spatial Multi-Omics Landscape of Radiologically Preinvasive/Invasive Lesion in Part-Solid Lung Adenocarcinoma
Kwon Joong Na, South Korea

EP16.04-014 NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma
Mariola Blanco Clemente, Spain

EP16.04-015 Chemotherapy Upregulates Programmed Cell Death Ligand 1 Expression in Non-Small Cell Lung Cancer Cell Lines and Patient-Derived Organoid Models
Maryam Khalil, Canada

EP16.04-016 Overexpression of CEACAM6 Activates Src-FAK Signaling and Inhibits Anoikis, through Homophilic Interactions in Lung Adenocarcinomas
Eun Young Kim, South Korea

EP16.04-017 Lineage Switching and Tumour Microenvironment Roles of Tumour Suppressors in Autochthonous Lung Cancer Models
Nisitha Sengottuvel, United States

EP16.04-018 DNA Mismach Repair in Lung Adenocarcinoma in Morocco
Ouassima Erefai, Morocco

EP16.04-019 Impact of Chemotherapy on Tridimensional Multicellular Non-small Cell Lung Cancer Spheroids With Microenvironment Cells
Pauline Hulo, France

EP16.04-020 Dysregulation of 14-3-3 Signaling Adapters in Lung Adenocarcinoma, New Insights Into the Impact on Cancer Cell Biology
Rhys Hamon, Australia

EP16.04-021 Chromatin Remodeling Drives Lung Pre-malignancy and is a Target for Prevention
Steven Belinsky, United States

EP16.04-022 Prognosis of Epithelial-Mesenchymal Transition-Related lncRNA Profile in LUSC Patients
Shanshan Xiao, China

EP16.04-023 Development and Validation of a Necroptosis-related Prognostic Model for Lung Adenocarcinoma
Tao Wang, China

EP16.04-024 HMGB1-mediated Autophagy Promotes Gefitinib Resistance in Human Non-small Cell Lung Cancer
Zhaoxia Wang, China

EP16.04-025 Statins Suppress SOAT1 Expression & Reduce Cholesterol Esterification in Statin-sensitive Lung Cancer Cells
Katsuhiko Warita, Japan

EP16.04-026 Effectiveness of Atorvastatin and SR-12813 Combination in Statin-resistant and Statin-sensitive Lung Cancer Cell Lines
Tomoko Warita, Japan

EP16.04-027 Identification of Optimal Internal Reference Gene to Analyze the Anticancer Effects of Statins in Lung Cancer Cells
Tomoko Warita, Japan

EP16.04-028 PHLPP2 Regulates Ferroptosis Through Nrf2 Pathway to Affected Cell Cycle and Apoptosisin Lung Squamous Cell Carcinoma
Haihua Yang, China

EP16.04-029 Downregulation of PHLPP2 Induced by Radiation Promotes GPX4-mediated Ferroptosis Defense and Radioresistance in Lung Cancer
Haihua Yang, China

EP16.04-030 Cancer-Associated Fibroblasts Attenuate DNA Damage Repair by Promoting Glycolysis in Non-small Cell Lung Cancer
Hongfang Zhang, China

EP16.04-031 Connexin 43 Overexpression Induces Angiogenesis in Vitro Following Phosphorylation at Ser279 in its C Terminus
Zizi Zhou, China

EP16.04-032 Indoleamine 2,3-dioxygenase 1 (IDO1) Blood Metabolites May Improve Predictive Accuracy for Radiation Pneumonitis
Fengming Kong, Hong Kong

Journal of Thoracic Oncology

Official Journal of the International Association for the Study of Lung Center

Editor-in-Chief:
Alex A. Adjei, MD, PhD, FACP
Chairman, Taussig Cancer Institute – Cleveland Clinic, Cleveland, OH USA

The ***Journal of Thoracic Oncology (JTO)*** the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. ***JTO*** emphasizes a multidisciplinary approach, and includes original research (clinical trials, and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.



IASLC | INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

2021 Journal Impact Factor*

20.121

*Journal Citation Reports®
(Clarivate Analytics, 2022)

visit jto.org

*A subscription to **JTO** is a benefit of membership in the IASLC.* **To join, visit www.IASLC.org**

Learn more at JTO.org

ELSEVIER

10 AUTHOR INDEX

AUTHOR INDEX

A

Aabed, Wesam A. EP01.02-002
Aarntzen, Erik H. MA04.08
Aarts, Mieke J. EP08.01-026
Ababneh, Obada EP02.04-008, EP08.02-096, EP08.02-121, EP16.01-008
Abadier, Michael EP16.02-027
Abazeed, Mohamed E. EP14.03-001
Abbosh, Chris EP16.02-027
Abbruzzese, James EP08.02-116
Abdalla, Georgia L. OA08.03
Abdallah, Farah EP14.05-018
Abdel-Aziz Kamal, Khaled EP09.01-001
Abdeljalil, riad EP07.01-016, EP14.05-018
Abdel Karim, Nagla ES17.07
Abdo, Mustafa EP16.01-011
Abdulkader, Ihab P2.07-02
Abdulkarim, Bassam EP05.02-019, OA06.07
Abe, Jiro MA03.05
Abe, Miyuki EP08.02-123
Abed, Afaf EP16.01-002
Abel, John P2.15-01
Abhi, Dhruv MA09.07
Abo Atta, Bian EP08.01-010
Abouabdou, Somaya E. P2.04-04
Aboubakar, Frank OA07.06
Aboubakar Nana, Frank EP08.01-090, EP08.01-091
Aboukheir, Aihab EP02.03-012
Abraham, Rohan EP01.05-007
Abrams, David OA10.03
Abrão, Fernando C. EP02.03-029
Abravan, Azadeh EP05.01-010
Absenger, Gudrun EP02.01-008, EP16.01-015
Abu-El-Noor, Nasser EP01.02-002, P2.11-01
Abukmail, Hanan EP01.02-002, P2.11-01
Abuladze, Mariam EP01.03-013
Abu-shanab, Ahmad EP07.01-016, EP14.05-018
Acar, Ramazan EP08.01-024
Acharya, Rashmi MA14.04, OA06.03
Acharya, Suryakanta EP14.03-004
Acharyulu, V. Raja Manohar EP08.04-004
Acker, Fabian EP14.01-008
Ackerson, Bradley EP02.02-006
Adamo, Bárbara EP03.01-012, P1.07-02
Adamo, Vincenzo EP05.01-024, EP08.01-007, EP10.01-019
Adamson, Justus EP02.02-006
Addeo, Alfredo EP08.02-116, EP08.02-122
Addison, Daniel EP05.01-021
Adewole, Olanisun O. EP04.01-001
Adjei, Alex EP08.01-028, MA13.09, MTE01.01, WS01.01, WS01.02, WS03.09
Adjei, Alex A. EP05.01-011
Adler, Brendan EP01.03-003
Adusumilli, Prasad ES35.02
Aerts, Joachim G. P1.02-03, ES26.01, MA10.06, OA04.01
Afonso, Margarida EP08.02-036
Afsana, Afroz P2.08-02
Agarwal, Jai P. MA09.03
Agarwal, Jai Prakash EP08.03002
Agarwal, Muskan EP14.05-001
Agbarya, Abed EP08.02-047, EP08.02-060
Aggarwal, Aditi EP11.01-012
Aggarwal, Charu EP08.01-018, ES24.01, P1.10-01, P1.15-07
Aggarwal, Ishita EP14.05-010
Aghlara-Fotovat, Samira P1.14-02
Agostara, Alberto Giuseppe EP08.02-046
Agrawal, Amiya MA09.03
Agrawal, Nishant P2.15-01
Agrawal, Sanjay EP13.01-001
Aguado, Cristina EP08.02-120
Aguado, Ramon EP06.01-017, EP13.01-016
Aguado de la Rosa, Carlos MA06.03, PL03.12
Aguado Esteban, Cristina EP08.02-032
Aguado Noya, Ramon EP08.01-066
Aguado Noya, Ramón EP16.04-014
Aguarón, Alfonso MA08.08
Aguiar Jr, Pedro EP04.01-022, EP08.02-042, WS07.06
Aguilar, Andrés EP08.02-011, EP08.02-032, EP08.02-120 MA06.03, PL03.12
Aguilar-Company, Juan P1.12-04
Aguinate, Lukas EP14.01-008
Agulnik, Jason EP03.01-016, EP04.02-004, EP05.02-019, EP06.01-001,EP11.03-001, EP14.04-001,EP14.05-020
Ahlborn, Lise B. EP01.07-001
Ahmad, Azura EP08.02-162
Ahmed, Mohamed EP03.01-010
Ahmed, Naseer EP16.02-019
Ahmed, Sadia EP10.01-008
Ahmed, Sara EP08.01-045
Ahmed, Yaman EP08.02-121
Ahmed, Yasar EP08.01-022
Ahn, Beung-chul EP08.02-012
Ahn, Jaeil EP08.01-044
Ahn, Jin Seok MA07.09
Ahn, Myung-Ju EP08.02-025, EP08.02-108, EP08.02-140, MA13.03,MA13.04, OA03.05, P1.15-11
Ahn, Yong Chan EP02.02-004, EP02.02-005, ES16.04
Ahnert, Jordi EP08.02-116
Ai, Xinghao EP08.01-082
Aieta, Michele EP05.01-024, EP06.01-006
Aigner, Clemens EP02.01-010, EP04.01-016, EP04.02-005, EP07.01-026, IBS05.02, MA06.08, P1.14-05
Ainhoa, Ainhoa OA06.04
Aix, Santiago Ponce EP08.02-081
Ajaj, Rami EP11.02-001
Šajnić, Andreja EP08.02-058
Akagi, Kazumasa EP08.04-005
Akamatsu, Hiroaki EP08.01-005, MA08.10
Akazawa, Yuki EP08.02-168
Akcam, Tevfik &. EP13.01-014
Akcam, Tevfik I. EP02.03-026, EP02.03-027
Akgül, Seçkin EP05.01-026
Akhdar, Marah EP02.04-008, EP05.02-012, EP05.03-010, EP07.01-025, EP08.02-121
Akhurst, Tim MA09.05, P2.03-01
Akinbobola, Olawale EP02.03-022
Akinbobola, Wale MA03.08
Akopov, Andrey EP08.01-014, PL03.09
Akyürek, Nalan EP08.01-024
Akyurek, Serap EP13.01-002
Alahmadi, Asrar EP08.01-062, EP08.01-098, EP14.05-004,OA12.04
Alam, Aftab EP16.03-024
Alama, Angela EP08.01-088
Alamgeer, Muhammad P2.08-02
Alatorre-Alexander, Jorge EP08.01-027, OA15.04
Al-Awadhi, Aydah EP03.01-010
Alay, Ania EP16.03-027, P2.14-04
Al Baloushi, Mouz EP03.01-010
Albarran, Victor EP08.02-060, OA07.06, P1.16-02
Albarrán-Artahona, Víctor EP03.01-012, EP08.01-090, EP08.01-091
Albarran-Artahona, Victor EP08.02-102
Albarrán-Artahona, Víctor EP08.02-149
Albarran-Artahona, Victor MA07.07, OA13.04
Albarrán-Artahona, Víctor P1.07-02
Albayaty, Muna EP08.02-108
Albayya, Faris EP08.02-018, EP08.02-019, EP08.02-045
Alber, Markus EP05.01-017
Alberti, Martina EP11.01-004
Alborelli, Ilaria EP16.01-018, MA12.04
Albrecht, Federico EP05.01-025, EP07.03-006
Alcala, Karine MA11.05, P1.01-01
Alcala, Nicolas MA01.07, MA01.09, MA02.03, OA04.05
Alcantar, Juan OA12.03
Al-Dadah, Mohammed EP01.02-002, P2.11-01

Aldea, Mihaela P1.16-02
Alden, Stephanie P1.15-03
Aldige, Carolyn ES27.01
Aleshin, Alexey EP16.02-003, P2.13-02
Alessi, Joao V. EP08.01-043, P1.15-03, MA02.09
Alexander, Marliese EP08.02-061 EP14.05-016, ES24.06
Alexandris, Panos PL03.03
Alexandrov, Ludmil B. OA04.05
Alexeyenko, Andrey P2.13-03
Alfranca, Arantzazu EP08.01-040
AlGhamdi, Shahad EP04.01-024, EP13.01-012
Al-Hashami, Zamzam EP08.01-074 EP08.02-089, EP14.05-017
Aliani, Michel Aliani EP16.02-019
Alimohamed, Nimira EP06.01-003
Aljbour, Jomana EP01.02-002 P2.11-01
Alkapalan, Deema EP01.04-004
Al-Kraimeen, Leen EP08.02-096, EP16.01-008
Al-Kraimeen, Leen M. EP05.03-010
Allara, Isabella G. EP08.02-093
Allavena, Paola EP07.01-004
Allegra, Maryline EP11.01-006
Allen, Coy EP02.04-002
Allen, Shanna EP01.01-003
Alley, Evan EP08.01-023
Almeida, Élin EP08.02-054
Almodôvar, Teresa EP03.01-009
Almodovar, Teresa EP04.01-011
Almquist, Daniel EP14.05-001
Almre, Ingemar EP06.01-016
Alonso, Alberto EP01.05-002, P1.04-01
Alonso, Diana EP05.02-002, EP05.02-003
Alonso, Marta P2.07-02
Alpert, Naomi EP07.01-002, EP08.01-047
Al Qawasmeh, Khaled EP03.01-010
Alquicira Hernandez, Jose EP16.03-041
Alruzaygat, Malik EP01.02-002, P2.11-01
Alsafar, Noura EP06.01-003
Alsaid Ahmad, Mohammad EP08.02-121
Al-Saleem, Fetweh EP08.02-015
Al-Ser, Mohammed P2.11-01
Al-Ser, Osaid EP07.01-025
Alser, Mohammed EP01.02-002
Alser, Osaid EP05.02-012
Al-shadiafat, Raghad EP08.02-121
AlShammari, Abdullah EP01.07-006, EP02.03-002
Al-Sharour, Fatima EP08.01-040
Al-Slaibi, Ibrahim EP01.02-002, P2.11-01
Alt, Jürgen EP14.01-008
Altan, Mehmet EP08.01-059
Althoff, Friederike C. EP14.01-008
Althouse, Sandra MA06.05
Altmüller, Janine MA01.09
Altorki, Nasser EP02.04-004, OA09.05, PL03.09
Altorki, Nasser Khaled ES08.05, PL03.06
Aluffi, Gregorio EP10.01-011
Alunni Fegatelli, Danilo EP14.02-001
Álvarez, Rosa EP08.01-048
Alvarez, Rosa EP08.02-110
Alvarez, Sophie P2.14-03
Álvarez Álvarez, Rosa EP08.02-070
Álvarez Fernández, Carlos EP16.01-031
Alves, Paula EP08.02-132
Amann, Joseph EP08.01-019
Amat, Ramon EP07.01-022, EP07.01-023, EP08.01-078
Amatu, Alessio EP08.02-046
Ambrosi, Francesca EP02.03-019
Ambrosini, Valentina MA01.08
Amin, Harshad EP08.02-111
Aminkeng, Folefac EP08.01-101
Amino, Yoshiaki EP02.01-006
Ampollini, Luca EP02.04-001
Amundson, Adam C. EP05.01-011
An, Jisong EP16.04-013
An, Kevin EP16.03-039
Anagnostou, Valsamo EP02.04-007, EP08.01-086
Anand, Sidharth OA12.03
Anastasiadis, Panos P2.14-03
Andersén, Heidi EP04.01-012
Andersen, Jon L. EP08.02-105
Andersen, Jon Alexander Lykkegaard EP08.02-099
Andersen, Sigve EP01.01-005
Andersen, Kristin EP10.01-014
Anderson, Eric OA10.03
Anderson, Eric D. EP02.03-008
Ando, Emiko EP10.01-003
Andratschke, Nicolaus EP08.03-005
Andreadis, Charalampos EP10.01-018
Andreetti, Claudio EP01.06-001, EP05.03-002
Andres-Pons, Amparo EP05.01-030
Andrianova, Lana EP08.02-081
Andric, Zoran OA15.03
Andrikou, Kalliopi EP08.01-030
Andrini, Elisa EP14.01-006, MA01.08
Andriolo, Luigi G. EP14.02-001
Ang, Mei-Kim EP16.03-036, P2.13-02
Ang, Yvonne EP08.01-101
Angeles, Arlou EP08.01-031
Angerilli, Valentina P1.15-06
Anikin, Vladimir EP11.03-003, P1.12-05
Anjum, Rana P1.11-01
Ansari, Jawaher EP03.01-010
Ansmann, Lena EP04.01-014
Antic, Vladan EP16.02-002
Antivero, Ana L. EP08.02-097
Antoni, Delphine PL02.06
Antoniou, Georgios EP11.03-003
Antonoff, Mara B. PL02.07
Antunes, Carolina EP03.01-009, EP05.03-006
Aokage, Keiju EP02.01-005, ES08.04
Aparicio, Cristina-Mihaela S. EP01.01-010
Aparicio, Inmaculada EP08.02-110
Aparicio Salcedo, Inmaculada EP08.02-070
Aparisi Aparisi, Francisco EP08.02-070
Aparnathi, Mansi K. EP14.01-019
Appel, Haley EP07.03-006
Appelt, Ane EP05.01-017
Aprile, Giuseppe EP08.01-012
Aprile, Vittorio EP02.03-019
Apte, Aditya P1.10-03
Apter, Lior EP08.02-017
Aqel, Wafa EP01.02-002, P2.11-01
Ara, Jordi EP01.03-002
Araki, Osamu EP05.02-017
Arana, R MA10.08
Aranda, Ignacio P2.07-02
Arasanz, Hugo EP08.01-090, EP08.01-091, OA07.06
Aratari, Maria Teresa EP07.01-017
Araújo, António EP03.01-009, EP04.01-011, EP05.03-006
Araujo, Antonio EP16.03-011
Araújo, António OA15.02
Araújo, Luiz H. EP03.01-003
Araujo, Luiz Henrique EP08.01-027, OA15.04
Araz, Murat EP08.01-024
Arbajian, Elsa EP16.03-010
Arbour, Kathryn OA03.04
Archer, Sally OA08.04
Archila, Pilar EP16.03-002, EP16.03-003
Arcocha, Ainara EP03.01-012, EP08.02-102 MA07.07, OA13.04,P1.07-02, P1.16-02
Ardavanis, Alexandros EP10.01-018
Ardizzoni, Andrea EP14.01-006, ES38.05, MA01.08
Areses, María EP08.02-149
Argalia, Giulia MA01.08
Ariyasu, Ryo EP02.01-006
Arizio, Francesca EP16.03-011
Ariznabarreta, Oneka P. EP16.04-004
Arkenau, Tobias EP08.02-116
Arline, Candice EP16.03-022
Armero, Victoria S. EP16.03-020
Arnold, Anthony EP04.01-025
Arnold, Belinda EP04.01-025
Arolt, Christoph EP08.02-031, EP08.02-106
Aronson, Boaz OA15.05
Arora, Himanshi EP16.03-041
Arrabal, Natalia EP04.01-002, EP04.01-002
Arregui, Marta EP08.02-110
Arrieta, Oscar EP03.01-003, EP05.01-001, EP07.01-011, EP08.02-035, EP08.03-003, EP16.03-002, EP16.03-003, EP16.03-023, MA09.09, MA14.03, OA01.02, WS07.03, WS07.04
Arriola, Edurne EP14.05-002, P2.07-02
Arroyo-Hernandez, Marisol EP08.03-003
Artal, Ángel EP08.02-131
Artal Cortés, Ángel EP08.02-070
Arteta-Bulos, Rafael EP08.01-023
Aruga, Takehito EP05.02-017
Arunachalam, Ashwini EP05.01-002
Arzoo, Karo MA07.05
Asadi, Nizar EP11.03-003, P1.12-05
Asakura, Keisuke EP07.03-007
Asamura, Hisao EP07.03-007, ES08.03, MA04.05, MA10.04, PL02.02
Asato, Takayuki MA13.03
Asensio–Cuesta, Sabina EP10.01-017
Asfora, Fernanda EP03.01-007
Ashizawa, Kazuto EP01.04-005, EP13.01-007, MA11.07
Ashouri, Shahryar MA07.05
Ashraf, Muhammad A. EP01.07-006

Ashrafi, Ahmad S PL03.06
Ashrafian, Leanne ES02.04
Ashrafinia, Saeed MA03.04
Asmundsson, Jurate EP16.03-013
Aspelund, Thor EP16.02-009, EP16.03-013
Aspria, Patrizia EP10.01-019
Assaf, Juan David EP07.01-022, EP07.01-023, EP08.01-078
Assaf, Zoe J. EP16.02-002
Astuti, Triwahju EP01.01-004
Atarashi, Yusuke EP08.01-064
Athanasiadis, Athanasios EP10.01-018
Athanasiadis, Ilias EP10.01-018
Ativitavas, Touch EP02.01-016
Atkar-Khattra, Sukhinder EP01.07-004, MA11.08, OA13.03, P1.04-02
Atmaca, Akin EP14.01-008
Attaleb, Mohammed EP16.03-045
Attili, Ilaria EP08.01-030
Au, Kwok Hung OA07.05
Aubry, Marc EP16.02-004
Auchincloss, Hugh OA05.06
Auclin, Edouard EP03.01-012, EP08.01-090, EP08.01-091, EP08.02-149, MA07.07, OA07.06, OA13.04, P1.07-02, P1.12-04, P1.16-02
Aun, NingYee EP06.01-004
Aung, Pyi Phyo P1.16-03
Avancini, Alice EP10.01-011
Avedano, Maria Carolina EP07.03-006
Avery, Sandra EP04.01-025
Avila, Kimberly EP08.02-130
Avila, Ricardo S. EP01.01-002, EP01.04-005, MA11.07
Aviles-Salas, Alejandro EP07.01-011
Aw, Wen Y. EP08.02-093
Awad, Mark M. EP08.01-043, MA02.09, OA15.05, P1.15-03
Awad, Mark M. OA12.06
Ay, Leyla P16.01-015
Ayala de Miguel, Carlos EP14.05-005
Aydın, Sercan EP02.03-026
Ayers-Ringler, Jennifer P2.14-03
Azam, Salma H. EP16.03-025
Azari, Feredun OA14.05
Azkárate, Aitor EP08.02-011
Azribi, Fathi EP03.01-010
Azuara, Dani EP16.03-027
Azuma, Koichi EP16.02-005, MA06.04
Azzi, Georges EP16.02-003
Baas, Paul IBS06.01,

B

OA04.06, WS04.12
Babu, Sunil OA12.03
Baca, Yasmine EP16.03-021
Bacchin, Diana EP02.03-019
Bacelic Gabelica, Ana EP05.01-018
Bach, Peter B. EP01.01-003
Bachurin, Leonid EP14.05-005
Backhus, Leah ES13.02,MA04.09
Backman, Max MA05.04
Badalamenti, Giuseppe EP16.01-013
Badin, Firas P2.10-02
Bae, Bong Kyung EP02.02-004, EP02.02-005
Bae, Chihoon EP02.03-013
Bae, Suk-Chul EP08.02-086
Baeza, Sonia EP01.03-002, EP01.05-001
Bai, Chunxue WS02.01, WS02.33, WS08.02
Bai, Jun EP08.02-063
Bai, Na EP08.02-073
Baik, Christina EP08.02-163
Bains, Manpreet EP01.02-005
Bains, Puneet EP08.02-034
Baird, Anne-Marie EP16.04-004, MA08.08, OA01.06, WS01.03
Baisamut, Thanyanan ES24.04, IBS03.02
Baixeras, Núria EP16.03-027
Baixeras, Nuria P2.07-02
Bajaj, Pawan EP08.01-109
Baka, Sofia ES15.05
Bakhtyar, Maham EP08.01-058
Bakogeorgos, Marios EP14.01-022
Bakouny, Ziad OA06.06
Bal, Matthieu EP05.01-019
Bal, Shakti K. EP08.04-004
Bala, Silvana EP03.01-004
Balantaram, Karmugi EP04.01-001
Balar, Aneri EP01.05-008
Balaraj, Khalid EP03.01-010
Balaratnam, Karmugi EP02.04-009, EP03.01-002, EP08.02-082
Balata, Haval EP01.05-002, P1.02-02, P1.04-01
Balbi, Maurizio P1.15-04
Baldi, Federico EP08.01-088
Baldini, Gabriele EP05.02-015
Baldonado, Jobelle J. EP02.03-005
Baldonado, J Jobelle Joyce Anne EP02.03-012
Baldwin, David EP01.02-005, EP01.06-002, EP04.02-002, ES27.03, PL03.03, WS02.02, WS02.15, WS02.36
Baldwin, David R. P1.02-03
Ball, David EP05.01-023, MA09.02
Ball, Grace EP05.01-008
Ballas, Marc EP08.01-020
Ballatore, Zelmira MA10.07
Ballestrero, Alberto EP04.01-005
Ballinari, Gianluca EP10.01-016
Ballo, Matthew T. EP07.01-019
Balmaña, Judith EP07.01-023
Baloglu, Samed EP13.01-002
Bamgboje-Ayodele, Adeola EP04.01-025
Banerjee, Smita P2.08-09
Banfill, Kathryn EP05.01-012
Bang, Andrew ES11.05
Bangar, Lovedeep P2.09-02
Bánkfalvi, Ágnes P1.14-05
Banks, Emily EP10.01-005
Banks, LaKedia C. EP04.02-003
Banna, Giuseppe EP08.02-060
Bansal, Radhika MA13.09
Bao, Hairong EP16.03-044
Bao, Hua EP01.01-011, EP16.01-025, EP16.02-024, WS08.21
Bao, Minwei EP08.01-107, WS08.16
Başoğlu Tüylü, Tuğba EP08.01-024
Bar, Jair EP08.02-047, EP08.02-122
Bara, Ilze EP02.04-005
Baramia, Micheil EP01.03-013
Baranauskas, Marcus V. EP02.03-010
Baranowski, Ralitsa P1.13-01
Barany, Nandor EP14.02-002, MA01.04
Barata, Fernando EP03.01-009, EP04.01-011
Barata, Juliana EP08.02-036
Baratta, Cristina EP14.05-023
Barba, Andrés EP08.01-029
Barba Joaquín, Andrés EP08.01-109
Barbera, Lisa EP10.01-008
Barberio, Brigida P1.15-06
Barbie, David A. P2.10-04
Barbieri, Fausto EP08.01-007
Barbieri, Vito EP16.03-011
Barbounis, Vasileios EP10.01-018
Barcelos, Isabella F. EP08.02-042
Barile, Rosalba EP07.01-005
Barinow-Wojewodzki, Aleksander EP08.02-072
Barisione, Emanuela EP04.01-005
Barlesi, Fabrice OA15.03, P1.10-01, P1.16-02
Barletta, Giulia EP08.01-088, EP08.02-046
Barnes, Amanda EP08.01-086
Barneto, Isidoro MA06.03, PL03.12
Baron, Anna EP01.05-008, EP01.05-009
Barr, Martin P. EP02.01-002
Barraco, Nadia EP08.03-007, EP16.01-013
Barradas, Lourdes EP03.01-009 EP04.01-011, EP05.03-006
Barragan, Pablo MA14.03, WS07.03
Barrett, J. Carl OA15.05
Barrichello, Adriana EP08.01-043
Barrichello, Adriana P. MA02.09
Barrichiello, Adriana P1.15-03
Barrios, Carlos H. EP03.01-003
Barritault, Marc EP11.01-005
Barroso, Ana EP03.01-009, EP04.01-003, EP04.01-011, EP05.03-006, EP08.01-008
Barry, Simon T. OA15.05
Barry, Teresa EP07.01-013
Barsheshet, Yiftah EP16.01-016, EP16.03-028
Bartholomew, Karen EP01.03-001, EP01.03-009
Bartlett, Emily EP06.01-008
Barton, Jürgen EP04.01-015
Barutca, Sabri EP16.04-005
Barve, Minal EP08.02-049
Bar Ziv, MD, Ortal P1.09-01
Basak, Priyanka MA13.07
Basbus, Luis EP08.02-097
Baschnagel, Andrew M. EP14.03-001
Bashir, Bashir EP08.02-024
Bassett, Julie P1.01-01
Bassetti, Michael EP14.03-001
Baste, Jean-Marc OA14.03
Basu, Sanjib EP08.01-037
Basu Roy, Upal EP04.01-004, ES22.06, MA08.04, OA01.06
Batelja Vuletic, Lovorka EP14.01-011, EP14.01-012
Bates, Andrew OA08.05
Batiashvili, Nino EP01.03-013
Batra, Nishtha EP06.01-014
Batra, Ullas EP16.03-047

Battafarano, Richard MA03.04
Battiston, Monica EP11.01-004
Bauer, Thomas PL03.06
Bauman, Jessica EP08.02-041
Bauml, Joshua M. MA07.04, P1.15-07, P1.16-01
Bautista Blaquier, Juan P1.12-04
Bayarri Lara, Clara I. P2.13-01
Bayman, Neil EP05.01-012
Bayona, Cristina EP08.02-131
Baz, David Vicente EP14.01-004
Bazan, Jose EP05.01-021
Bazan, Viviana EP08.03-007, EP16.01-013
Bazan Russo, Tancredi Didier EP08.03-007, EP16.01-013
Bazhenova, Lyudmila MA05.08
Lyudmila Bazhenova EP08.02-029
Bearz, Alessandra EP02.04-001
Beasley, Mary Beth P2.12-05
Beasly, Aaron EP16.01-002
Beasly, Mary Beth MA12.07
Beattie, Rory EP06.01-004
Beauchamp, Marla K. MA08.03
Bebb, Dafydd G. EP08.02-112
Bebb, Gwyn EP02.04-003, EP05.02-001, EP08.01-004, EP08.02-014, EP08.02-071
Bebb, Gwyn D. EP04.02-001
Bebb, Gwyn J. EP08.02-013
Bechini, Jordi EP01.03-002
Beck, Andrew H. P2.15-01
Beck, Kyongmin S. EP07.01-020
Becker, Katja EP08.02-055
Becker von Rose, Aaron EP14.01-008
Beddow, Emma EP11.03-003, P1.12-05
Bedmar Martinez, Alex OA13.04
Beeken, Rebecca PL03.03
Beer, Matthew EP11.01-009
Begueret, Hugues EP11.01-005
Begum, Parvin EP08.02-124
Begum, Sofina EP11.03-003, P1.12-05
Behar Harpaz, Silvia MA11.03
Behera, Digambar OA11.07
Behera, Madhusmita EP08.01-060
Behl, Deepti EP07.01-019
Behr, Carina M. EP01.02-001
Behr, Jürgen EP04.01-015
Bekaii-Saab, Tanios S. P1.15-08
Belabed, Meriem P2.12-05
Belani, Chandra EP08.01-060
Belderbos, Jose EP05.01-009, ES23.02
Belderbos, Jose S. EP05.01-010
Belderbos, José S. MA03.09
Belderbos, Jose S. OA06.05
Belina, Ivica P2.04-01
Belinsky, Steven EP16.04-021
Belka, Claus MA06.08
Bell, Korina MA08.08
Bellodi, Andrea EP04.01-005
Belloum, Yassine EP16.01-011
Belluomini, Lorenzo EP10.01-011
Bell-Williams, Rebecca EP01.02-005
Beltrán Guerra, Isabel EP14.05-005
Benato, Cristiano EP14.01-005
Bencina, Goran EP08.01-083
Bendall, Sean C. EP16.02-015
Benedict, Stanley EP05.01-019
Benegas, Mariana EP02.02-007
Benetti, Beatrice EP08.01-012, P1.15-06
Benider, Abdellatif EP06.01-012
Beninato, Teresa EP07.01-021, EP08.01-006, EP08.02-046, MA10.07, P1.15-02
Benítez, Jose C. MA10.08
Benítez-López, Gretel EP08.02-149
Benitez Martin, Marta OA06.04
Benitez-Montanez, Jose OA07.06
Benito, Amparo P2.07-02
Ben-Joseph, Rami EP14.05-023
Benner, Brooke EP14.05-004, OA12.04
Bennett, Elizabeth PL03.09
Bennett, Jonathan EP13.01-001
Bennett, Kirsten EP01.03-003, OA13.06
Bennicelli, Elisa EP08.01-088
Bennini, Nouri EP03.01-010
Bennouna, Jaafar EP16.04-019
Benny, Kevin P2.08-03, P2.08-04
Benzaquen, Jonathan EP11.01-005, EP11.01-006
Benzerdjeb, Nazim EP11.01-005
Berardi, Rossana EP05.01-024 EP06.01-006, EP08.02-046, MA10.07
Berezowska, Sabina ES10.04
Berg, Christine ES32.01
Berg, Stephanie OA06.06
Berger, Michael F. EP05.01-014
Berger, Walter EP07.01-014
Berghoff, Karin EP08.02-162, OA03.05
Berglund, Anders EP08.01-083
Berktas, Mehmet EP08.02-080
Bermudez, Maritza EP16.03-002 EP16.03-003
Bernabé, Reyes MA06.03 OA02.03, PL03.12
Bernabé Caro, Reyes EP08.02-016
Bernabé-Caro, Reyes EP08.02-131
Bernardo, Filipa EP03.01-009, EP05.03-006
Bernardo, Manuela EP03.01-009, EP05.03-006
Bernhardt, Christiane EP05.01-030
Bernitzky, Dominik EP02.01-009
Bernoussi, Zakia EP16.04-018
Berrocal, Laura EP08.02-032
Berry, Lynne EP08.01-028
Berry, Robyn EP04.01-013
Bertaglia, Valentina EP10.01-015
Bertani, Alessandro EP08.03-007
Bertino, Erin EP08.01-062, EP08.01-098, P2.02-02
Bertino, Erin M. EP14.05-004, OA12.04
Bertoglio, Pietro EP02.03-019, MA04.05
Bertolini, Alessandro EP05.01-024, EP06.01-006
Bertolini, Francesco EP16.03-042
Bertolotti, Raffaella P1.04-03
Bertran-Alamillo, Jordi EP08.02-135
Bertrand, Miriam P2.14-02
Besse, Benjamin EP08.01-090, EP08.01-091, EP08.02-016, EP08.02-041, ES07.01, MA07.07, MA10.08, OA07.06, OA13.04, OA15.05, P1.16-02, PL03.10
Bestvina, Christine EP14.03-001
Bestvina, Christine M. OA03.03, OA03.06
Bezjak, Andrea ES09.04, ES20.01, PL04.01
Bhagwakar, Jan EP04.01-017
Bharat, Ankit EP05.03-011
Bhardwaj, Tina N. EP11.01-012
Bhatnagar, Adityanarayan OA08.05
Bhatnagar, Vishal EP04.01-004
Bhatt, Kamalnayan EP14.01-015
Bhatti, Parveen P1.02-04
Bhatti, Sajjad A. EP08.01-058
Bhosle, Jaishree EP08.02-065, EP08.02-124, MA12.09
Bhuniya, Sourin EP08.04-004
Bi, Jiwang EP05.02-014, WS08.22
Bi, Minghong MA14.05
Bi, Nan EP05.01-004, EP05.01-016, EP14.03-005, EP16.02-026
Bianco, Valentina P2.04-03
Bibault, Jean-Emmanuel PL04.05
Biber, Joshua EP08.02-171
Bibi, Amna EP03.01-014, EP08.01-019
Biddle-Snead, Charles P2.15-01
Bie, Fenglong EP16.01-023, WS08.20
Bielak, Dominika OA06.03
Bigot, Ludovic EP08.02-020
Bilaceroglu, Semra ES06.04
Billah, Baki OA01.03
Bille, Andrea MA06.06
Bin, Yawen EP08.01-100
Bing, Zhongxing EP16.01-017
Biondo, Patricia EP10.01-008
Birajdar, Shivgonda EP16.03-024
Bironzo, Paolo EP05.01-024, EP16.03-011, ES13.01, MA13.10, P2.04-03
Biswas, Bivas EP06.01-005, EP08.02-040, EP16.02-006
Bitar, Lela EP05.01-018, EP07.01-012, EP08.02-058
Bitter, Elisabeth EP08.02-114
Bitto, Alessandra EP10.01-019
BIttoni, Marisa EP03.01-014
Bivona, Trever EP08.02-147, ES07.03
Blaauwgeers, Hans MA12.08
Black, Edward EP03.01-010
Blackhall, Fiona OA12.05
Blackmon, Shanda ES33.01
Blais, Normand EP04.01-020, EP07.03-002
Blakely, Collin M. EP08.02-147
Blanc-Durand, Felix EP08.01-090, EP08.01-091
Blanc-Durand, Félix OA07.06
Blanchette, Phillip EP02.01-013
Blanco, Remei P1.15-09
Blanco Clemente, Mariola EP04.01-019, EP06.01-017, EP08.01-066, EP13.01-016, EP16.04-014
Blanksma, Alice EP04.01-014
Blanquart, Christophe EP16.04-019
Blaquier, Juan B. EP16.02-029, EP16.03-002
Blasco, Ana EP08.01-029
Blasco, Paula EP03.01-012

Bliss, Judith EP08.03-005
Block, Mark EP16.03-022
Blum, Torsten ES04.01, HOD01.03
Blume, Jeffrey D. EP01.05-010
Blumenfeld, Philip P2.01-02
Blumenschein, George R. EP08.01-059
Bluthgen, María V. EP16.02-029
Bluthgen, Maria Virginia P1.12-04
Bluthgen, Virginia EP08.02-097
Bo, Bing EP16.02-001
Boccuti, Anne EP14.05-023, P2.10-02
Bødtger, Uffe EP01.07-001
Boerckel, Winfield MA08.07, P2.08-05, P2.08-06
Boeri, Mattia P1.15-02
Boettiger, Kristiina EP14.02-002, EP14.02-003, EP14.02-006
Boeva, Valentina EP07.02-003
Boffa, Daniel J. OA11.03
Boffetta, Paolo ES32.02, ES32.04
Boghean, Lidia P2.14-03
Bogos, Krisztina IBS14.01, MA01.04
Boigues, Marc OA06.04
Bokan, Darijo EP03.01-017, EP04.02-006
Bokas, Alexandros EP10.01-018
Bokhari, Abdulmalik EP16.03-012
Boland, Anne MA01.09
Bolaño-Guerra, Laura EP08.02-035, MA09.09
Bolte, Fabian J. EP08.01-034
Bonanno, Laura EP08.01-012, EP08.01-030, EP08.02-048, EP08.02-104, EP08.02-140, P1.15-06
Bondarenko, Igor P1.15-11, P1.15-12, PL03.09
Bonetti, Andrea EP14.01-006
Bonfanti, Barbara EP02.03-019
Boni, Luca EP02.04-001
Bonifacio, Annalisa MA13.05
Bonomi, Philip EP08.01-037
Bonomi, Philip D. EP10.01-016
Bontempi, Dennis P1.15-01
Bontoux, Christophe EP11.01-005, EP11.01-006
Booth, Sarah EP01.07-006
Booth, Sarah A EP02.03-002
Booton, Richard EP01.05-002, EP04.01-009, P1.04-01
Bootsma, Matthew P2.02-02
Borad, Mitesh P2.14-03
Borchardt, Imanuely Borchardt OA08.03
Borczuk, Alain MA12.07
Bordi, Paola EP02.04-001, EP08.01-007, P1.15-04
Bordone, Olivier EP11.01-006
Borges, Giuliano EP03.01-003
Borges, Graziela OA08.03
Borghaei, Hossein EP14.01-015, EP16.03-021, OA12.05
Borghetti, Paolo EP05.01-024, EP06.01-006
Borgia, Jeffrey EP11.01-009
Borgia, Jeffrey A. EP08.01-037, EP08.02-119
Borgovan, Theo P1.11-01
Borilova, Simona EP08.01-077
Borissova, Svetlana EP01.07-001
Borondy-Kitts, Andrea P2.08-09
Borra, Gloria EP05.01-024, EP06.01-006, EP08.02-048
Borrione, Patricia EP03.01-007
Bortolami, Alberto EP08.02-104
Bortolot, Martina EP11.01-004
Bortolus, Giorgia EP11.01-004
Bosch-Barrera, Joaquim EP08.02-070, MA06.03, PL03.12
Bosetti, Cristina EP07.01-004
Bossé, Yohan EP16.02-027, EP16.03-020
Bossmann, Stefan H. EP01.01-010
Bote de Cabo, Helena EP08.02-070
Botling, Johan EP11.01-007, EP16.04-001, MA05.04, MA12.07
Bottcher, Bettina EP01.02-002, P2.11-01
Bottiglieri, Achille EP08.01-006
Bottini, Annarita EP04.01-005
Boubia, Souheil EP16.03-045
Bouchbika, Zineb EP06.01-010, EP06.01-012
Boudreau, Dominique K. EP16.03-020
Boukovinas, Ioannis EP08.02-060, EP10.01-018
Boumber, Yanis EP04.01-007, EP04.01-008, EP08.02-028
Bourhafour, Mouna EP06.01-010, EP06.01-012
Bourla, Ariel B. EP16.02-002
Bowker, Riley EP02.03-020
Bowles, Daniel W. MA13.04
Bowyer, Samantha OA03.04
Box, Adrian EP08.01-004, EP08.02-112
Boyault, Sandrine OA04.05
Boyer, Michael EP16.03041, MA01.10, OA12.05, OA15.06, P1.12-02
Boyer, Michael J. P1.15-08
Boyeras Navarro, Iris ES04.05
Bozorgmehr, Farastuk EP08.01-031
Bozzano, Federica EP08.01-088
Bradbury, Penelope EP02.04-009, EP03.01-002, EP08.01-067, EP08.02-082
Bradbury, Penelope A. EP04.01-001, MA14.08
Bradley, Jeffrey P2.04-05
Bradley, Jeffrey D. EP07.01-018, EP14.03-003, ES03.03, P1.10-04
Bradley, MaryAnn MA08.09
Bradley, Patrick EP01.05-002, EP04.01-009, P1.04-01
Braga, Sara EP08.02-054
Brägelmann, Johannes EP08.02-031, EP08.02-106
Brahmer, Julie EP02.04-007, EP08.01-086, PL01.04
Brahmer, Julie R. OA15.06
Brain, Kate PL03.03
Brambilla, Cecilia EP11.03-003, P1.12-05
Brambilla, Marta EP07.01-021, EP08.01-006, EP08.02-046, MA10.07, P1.15-02
Bramer, Andrew EP01.04-004
Bramson, Joshua P. EP08.02-015
Brand, Maragret EP14.05-016
Brand, Margaret EP04.01-023, OA01.03, OA01.04
Brandão, Evelise EP02.04-005
Brandao, Mariana OA11.02
Brandolini, Jury EP02.03-019
Brandstädter, Christina EP08.02-055
Brannman, Lance EP05.02-013, EP14.04-002
Brant, Boris EP16.01-016, EP16.03-028
Bratman, Scott V. EP14.01-019
Braubach, Oliver EP16.04-003
Brauer, Michael OA13.03
Bravo, Caroline OA10.05
Bray, Victoria EP04.01-025
Bray, Victoria J. EP08.01-002
Brcic, Luka E P02.01-008, EP11.02-002, MA01.04
Breadner, Daniel EP02.01-013, EP08.02-034, EP16.02-025
Breen, William G. EP05.01-011
Brekken, Rolf A. EP08.02-130
Brenes, Jesús P2.14-04
Brennan, Paul P1.01-01
Brenner, Darren EP04.02-001
Bressel, Mathias EP05.01-023
Bria, Emilio EP02.04-001, EP05.01-024, EP05.03-008, EP06.01-006, EP08.02-048, EP10.01-011, ES06.03
Brice, Kayla EP16.02-018, EP16.03-022
Brice, Kayla EP08.02-107
Briggs, Lisa EP04.01-023, EP14.05-016
Brighenti, Matteo EP05.01-024,EP06.01-006, EP14.01-006
Brims, Fraser EP01.03-003, EP04.01-023, OA13.06
Bringas Beranek, Marianela EP08.02-070
Bringuier, Pierre Paul EP11.01-005
Brito, Ulisses EP03.01-009, EP04.01-011, EP05.03-006
Britton, John PL03.03
Brock, Malcolm V. MA03.04
Brockelsby, Christopher EP01.06-005
Brody, Rachel OA06.03
Brooke, Mark EP04.01-023
Brooks, Rebecca EP08.02-150
Brophy, Mary EP08.01-045
Brouchet, Laurent EP02.03-021
Brousset, Pierre EP11.01-005
Brower, Ashton OA08.04
Brown, Bea E P10.01-005, EP16.03-041, P1.12-02
Brown, Catherine EP04.01-001
Brown, Chris P1.12-02
Brown, M C. EP03.01-002
Brown, M. Catherine EP02.04-009 EP08.02-082
Brown, Sarah EP05.01-007
Brownstein, Jeremy EP05.01-021
Brucci, Giorgia EP08.01-088
Brugger, Jonas EP02.01-009
Bruna, Jordi EP08.01-029
Brundage, Michael EP04.01-024, EP13.01-012
Brunelli, Vanessa EP04.01-023
Brungs, Daniel EP08.02-029

Brunnström, Hans EP08.01-083, EP11.01-007, EP16.04-001, MA05.04
Bruns, Rolf OA03.05
Brustugun, Odd Terje ES05.04, P2.13-03
Bryl, Maciej EP08.02-072
Bryson, Emily EP10.01-004
Bubendorf, Lukas LA03.03, MA12.07
Bucheit, Leslie EP08.02-028, EP08.02-074, EP16.03-009, MA07.07
Bucknell, Nicholas W. EP05.01-023
Budach, Wilfried MA06.08
Buderi, Silviu EP11.03-003, P1.12-05
Budhani, Irfan A. EP01.04-004
Buduhan, Gordon EP16.02-019
Bueno, Raphael P1.13-02
Buffoni, Lucio EP16.03-011
Buglioni, Simonetta EP08.01-030
Bulusu, Ramesh EP08.02-150
Bulut, Halil I. EP05.03-001
Bulutay, Pinar EP05.02-004, EP05.02-005
Bungaro, Maristella EP08.02-048, EP08.02-101, EP10.01-015, P2.04-03
Bunn, Becky EP08.01-060
Bunn, Paul EP08.01-028, LA01.02, OA14.06
Bunn Jr, Paul A. OA06.03
Buño, Antonio EP08.01-048
Burger, David EP08.02-090
Burgers, Jacobus A. OA04.06
Buriolla, Silvia EP11.01-004
Burn, Kenly P2.08-07
Burns, Timothy F. OA03.06
Burotto, Mauricio EP16.03-002
Burt, Bryan P1.14-02
Burtness, Barbara MA02.07
Bush, Aaron EP05.01-011
Bushong, Judith EP05.02-018,
Bushunow, Peter P2.10-02
Bustamante Alvarez, Jean EP07.01-019
Busuito, Giulia EP16.01-013
But-Hadžić, Jasna EP05.01-013
Buti, Sebastiano P1.15-04
Butler, John EP04.02-002
Butow, Phyllis EP10.01-005
Butterworth, Karl EP05.01-007
Butterworth, Karl T. P1.10-03
Buttiglieri, Alessandro EP02.03-007
Büttner, Reinhard EP08.02-031, EP08.02-106, EP08.02-114
Butts, Emily EP05.01-011
Buyukceran, Emre Utkan EP13.01-002
Byers, Lauren EP08.02-163, ES05.06
Byers, Lauren A. MA01.03, P2.10-01
Byers, Stephen EP08.01-044
Bylund, Carma P2.08-09
Byrne, Keelan EP05.01-023

C

Cabanero, Michael EP11.02-001
Cabrera, Carlos EP08.02-032
Cabrera, Luis A. EP07.01-011, EP16.03-023, WS07.04
Cabrera-Miranda, Luis EP08.02-035, MA09.09
Cabrera-Miranda, Luis A. EP08.03-003
Caccialanza, Riccardo EP10.01-015
Cacciola, Francesca EP10.01-019
Cafaro, Iacopo EP04.01-005
Caggiari, Laura EP11.01-004
Cagirici, Ufuk EP02.03-026, EP13.01-014
Cagırıcı, Ufuk EP02.03-027
Cai, Danyang EP16.04-028, EP16.04-029
Cai, Junliang EP05.02-018, WS08.11
Cai, Qiang EP01.05-011
Cai, Yiran EP08.01-107, WS08.16
Cailler, Françoise OA14.05
Cakan, Alpaslan EP02.03-026, EP02.03-027, EP13.01-014
Cakiroglu, Ece EP08.02-022
Calabrese, Fiorella EP07.01-004
Calandri, Marco EP02.03-007
Calapre, Leslie EP16.01-002
Caldart, Alberto EP10.01-011
Caldas Montella, Tatiane EP04.01-022, WS07.06
Calhoun, Michael E. EP13.01-011
Calhoun, Royce F. EP01.04-004
Califano, Raffaele ES30.02
Caliman, Enrico EP08.01-007
Callahan, Jason EP05.01-023, MA09.05, P1.10-02, P2.03-01
Callari, Maurizio EP07.01-004
Callejo, Ana EP07.01-022, EP07.01-023, EP08.01-078
Calles, Antonio EP08.02-011, EP08.02-041, EP08.02-110, P2.07-02
Calles Blanco, Antonio EP08.01-048, EP08.02-070
Callister, Matthew PL03.03
Calò, Valentina EP16.01-013
Calvert, Paula EP08.01-022
Calvetti, Lorenzo EP08.01-012
Calvinho, Paulo EP05.03-003
Calvo, Alejandro EP02.01-004
Calvo, Alfonso EP16.01-009, MA02.08
Calvo, Virginia EP06.01-017, EP13.01-016, EP16.02-007, MA06.03, OA02.03, PL03.12
Calvo de Juan, Virginia EP04.01-019, EP08.01-066, EP16.04-014
Camacho, Carolina EP05.03-006
Camacho, Elvira EP04.01-011
Câmara, Gabriela EP04.01-011
Camerini, Andrea EP02.04-001, EP08.01-007
Cameron, Erin OA10.05
Cameron, Robert B. EP07.01-019
Camidge, D. Ross EP08.02-041, EP08.02-117
Camidge, Ross EP08.02-019, EP08.02-029
Camilleri-Broët, Sophie EP05.02-019
Caminoa, Alejandra P2.07-02
Cammisotto, Vittoria EP14.02-001
Campaign to End Lung Cancer Stigma, ACS. P2.08-07
Campainha, Sérgio EP04.01-003, EP08.01-008
Campana, Davide MA01.08
Campisi, Marco P2.10-04
Campo Cañaveral, Jose Luis EP06.01-017
Campos, Clodoaldo EP03.01-003
Campos, Igor EP03.01-007
Campos Balea, Begoña EP08.01-065
Campos-Gomez, Juan A. EP04.01-029
Campos-Gomez, Saul EP04.01-029
Camps, Abigail OA08.04
Camps, Carlos MA06.03, P1.09-03, PL03.12
Camps Herrero, Carlos EP08.02-070
Canário, Dolores EP04.01-011
Canavan, Maureen E. OA11.03
Cancellieri, Alessandra EP05.03-008
Canfell, Karen MA11.03, P1.08.01
Cang, Shundong EP08.02-139, OA03.07
Cannon, Megan EP08.02-117
Cano, Fernando EP13.01-016
Canova, Stefania EP06.01-006
Cantero, Alexandra EP08.01-029
Cantos Sanchez de Ibargüen, Blanca EP04.01-019, EP08.01-066, EP16.04-014
Cao, Biwei EP14.01-013
Cao, Lei EP16.01-017
Cao, Lejie EP08.02-139
Cao, Peiguo EP08.02-139, EP08.02-158, WS08.14
Cao, Pianpian OA10.03
Cao, Yanyan EP14.05-023
Cao, Yi EP16.02-002
Cao, Yongqing EP08.02-158, WS08.14
Cao, Zhili EP16.01-017
Capelletto, Enrica EP06.01-006, EP10.01-015, ES15.07, OA10.01
Capizzi, Irene EP10.01-015
Cappuzzo, Federico EP08.01-030, EP08.02-048, EP16.03-040, ES28.05, P2.14-02
Caravaca, Gerard OA13.04
Carbone, David EP03.01-014, EP08.01-062, ES34.06, LA03.02, P1.03-01
Carbone, David P. EP08.01-019, EP08.01-098, EP14.05-004, EP16.03-009, OA12.04, OA14.06, P1.15-08
Carbone, Luigi EP07.01-017
Carbone, Michele WS04.18
Carbonell, Caterina EP07.01-022, EP07.01-023, EP08.01-078
Carcedo, David EP04.01-002
Carcereny, Enric EP08.01-021, OA06.04, P1.09-03, P1.15-09
Card, Cynthia EP06.01-003
Cárdenas, Nuria EP08.02-149
Cárdenas-Fernández, Daniela EP08.02-035, MA14.03, WS07.03
Cardillo, Giuseppe EP05.03-008, EP07.01-017
Cardona, Andres F. EP03.01-003, EP05.01-001, EP07.01-011, EP16.03-002, EP16.03-003
Cardona, Andrés F. MA09.09, MA14.03, P2.13-01, WS07.03, WS07.07
Cardoso, Teresa EP04.01-011

Carleo, Francesco EP07.01-017
Carley, Christopher EP02.03-009
Carli, Francesco EP05.02-015
Carlisle, Jennifer W. EP14.03-003, P1.10-04
Carmelo, Alessandro EP02.03-007
Carp, Ned EP02.03-023
Carpana, Camilla EP08.01-007
Carpeño, Javier de Castro EP04.01-002, EP14.01-004
Carracedo, Carlos EP16.03-021
Carracedo Uribe, MD, Carlos R. EP08.02-107
Carranza, Hernán EP16.03-002, EP16.03-003
Carreño, Juan Manuel OA06.03
Carrera, Vinicius EP03.01-007
Carson, William E. EP14.05-004, OA12.04
Carta, Anna Maria EP05.01-024, EP06.01-006
Carta, Annamaria EP08.01-007, EP08.02-046
Carter, Lisa P2.08-07
Carter-Harris, Lisa P2.08-09
Caruana, Michael MA11.03
Carver, Jennifer P1.11-01
Casadevall, David P1.12-04
Casanova Schulze, Paulo A. EP06.01-011
Casarrubios, Marta OA02.03
Casas Duran, Francesc EP02.02-007
Cascone, Tina EP08.02-163, ES28.01, MA05.02
Caserta, Chase EP14.05-003
Cases Copestake, Carla EP02.02-007
Casiraghi, Monica ES08.02, P1.04-03
Castagneris, Nicolas EP08.02-097, EP16.02-029
Castañares, Diana MA14.03, WS07.03
Castañon, Carmen EP05.02-002, EP05.02-003
Castellana, Luisa EP16.01-013
Castellano, Giancarlo OA13.04
Castillo, Bertha P1.14-02
Castillo, Dan R. OA06.06
Castillo, Oleguer EP08.02-102, P1.07-02
Castillo, Rebeca EP16.02-014
Castine, Michael EP08.02-111
Castro, Elena MA07.07
Castro, Michael EP16.03-024
Castro, Natalia EP08.01-090, EP08.01-091, OA07.06
Castro, Patrícia EP14.01-009
Catanzariti, Luigi EP08.02-031, EP08.02-106
Catino, Annamaria P2.10-05
Catley, Delwyn OA10.04
Caumont, Charline EP11.01-005
Caushi, Fatmir EP03.01-004
Caux, Christophe O A04.05
Cavic, Milena ES20.02, P1.02-02
Cawston, Hélène EP14.04-002
Cay Senler, Filiz EP08.01-024
Cazaux, Mathilde EP02.03-021
Cebollero, Maria P2.07-02
Cecchi, Cristina P2.04-03
Cecchini, Matthew J. OA06.07
Cecere, Fabiana EP02.04-001, EP05.01-024, EP06.01-006, EP08.01-007
Cederholm, Axel EP16.04-001
Cedres, Susana EP07.01-022, EP07.01-023, EP08.01-078
Cedzynska, Magdalena ES29.07, ES37.02
Cella, Eugenia EP08.01-088
Cengel, Keith EP08.01-018
Centonze, Giovanni MA01.07
Cerchiaro, Eleonora EP07.01-005
Cerea, Giulio EP08.01-007, EP08.02-046
Ceresoli, Giovanni EP05.01-024, EP06.01-006
Ceresoli, Giovanni L. EP07.01-005, OA04.07
Cervera, Ester EP01.03-002
Cesur, Ezgi EP05.02-004, EP05.02-005, EP05.03-007
Cha, Steven P1.15-08
Cha, Yoon Jin EP16.04-016
Chachoua, Abraham EP01.06-003
Chaddha, Udit P2.12-05
Chae, Lena EP08.02-062
Chae, Young K. EP08.02-028
Chae, Young Kwang EP04.01-007, EP04.01-008, EP05.03-011, EP08.02-023, EP16.02-022, P2.12-04
Chaft, Jamie EP02.04-005, OA14.06, EP05.01-025
Chaillot, Laura EP16.02-004
Chakrabarti, Debasis EP14.01-015
Chakrabarti, Turja EP08.02-147
Chakrabortty, Sudipto EP16.02-008
Chakravarthy, Karthik EP08.01-062
Chalabreysse, Lara EP11.01-005
Chalitsios, Christos PL03.03
Chalmers, Anthony EP05.01-007
Chamarthi, Rajesh EP01.06-004
Chambers, Carole R. EP08.02-112
Chamorro, Diego F. EP05.01-001, EP16.03-002, EP16.03-003
Champiat, Stephane OA12.05
Chan, Bryan A. EP05.01-026
Chan, Chang-Chuan OA13.07
Chan, Clara EP05.01-012
Chan, Dalin EP16.02-008
Chan, Johan EP16.03-036
Chan, Sze Wah Samuel S. P1.15-10
Chan, Wing C. EP04.01-027
Chan, Wing Yan Joyce EP02.02-008
Chandra, Raghav EP08.02-130
Chang, Aliss TC EP02.02-008
Chang, Ashley OA14.05
Chang, Gee-Chen EP05.01-003, EP08.01-073, EP08.02-151, EP08.02-155
Chang, Huang Chih EP08.02-027
Chang, Jee Suk EP05.01-034
Chang, Jiahua OA02.05
Chang, Jianhua EP08.01-033, EP08.01-042
Chang, Joe ES09.01
Chang, John W. EP08.02-151
Chang, Qing MA13.05
Chang, Yeun-Chung ES18.05
Chang, Yoon Soo EP08.02-142, EP16.04-016
Chantharakhit, Chaichana P2.02-01
Chaoui, Imane EP16.03-045
Charalambous, Andreas ES14.02
Charoentum, Chaiyut EP08.02-026, EP08.04-003
Charpidou, Andriani EP14.01-022
Chate, Rodrigo C. MA11.09, WS07.05
Chatterjee, Debopam EP08.04-004
Chatterji, Soumyadip EP06.01-005
Chatziioannou, Aristotelis EP16.02-004
Chaudhuri, Aadel A. WS08.06
Chauv, James MA07.05, OA12.03
Chaves, Andreia EP04.01-011
Chaves Conde, Manuel EP14.05-005
Chavez, Gordon EP08.01-016
Chawla, Sheema EP07.01-019
Chayangsu, Chawalit EP08.04-003
Chazan, Grace EP08.02-061
Cheema, Parneet EP08.01-020, EP08.02-034, MA12.05
Cheema, Parneet K. EP08.01-021, OA12.06
Cheick, Diarra MA13.04
Chekrine, Tarik EP06.01-010, EP06.01-012
Chella, Antonio EP08.02-048, MA10.07, PL03.09
Chellappan, Srikumar ES37.03
Chen, Allen P1.06-01
Chen, Bolin EP08.01-093, EP08.01-094, EP08.02-161
Chen, Caiping EP16.03-006
Chen, Caoyang EP16.04-006
Chen, Chang EP02.01-003, EP02.01-007, EP13.01-009, MA04.03, MA06.09, P1.14-03
Chen, Chengshui EP08.02-139
Chen, Chung-Yu EP08.02-027
Chen, David MA11.08
Chen, Dongna EP08.01-054
Chen, Fangjun EP01.01-011
Chen, Gong-Yan EP08.02-064
Chen, Gongyan EP08.02-139, OA02.05
Chen, Haizhu EP16.02-017
Chen, Hao EP01.01-006
Chen, Heidi EP01.05-008, EP01.05-009
Chen, Hongbin EP02.04-006, EP08.01-050, EP08.02-118
Chen, Hua Lin EP08.02-078
Chen, Hualin EP08.02-154
Chen, Hui EP16.03-006
Chen, Huoguang EP08.02-154
Chen, Jianbin EP16.03-036
Chen, Jianhua EP08.02-063
Chen, Jianing EP08.01-097
Chen, Jin-Feng EP05.02-008
Chen, Jinfeng EP05.02-014, WS08.22
Chen, Jinghua EP16.03-007
Chen, Jun EP08.02-139
Chen, Jun z. EP08.02-010
Chen, Kaiyan EP08.01-032
Chen, Ke-Neng EP05.02-018, WS08.11
Chen, Kuan-Yu EP08.02-127
Chen, Kuifei MA09.08
Chen, Kun-Chieh EP08.02-155
Chen, Liangan EP08.02-139
Chen, Lijuan EP16.03-006
Chen, Liming MA01.07
Chen, Lin B. EP08.01-095
Chen, Lingjuan EP08.01-099, MA09.04, WS08.13
Chen, Meng EP16.04-028, EP16.04-029, MA09.08
Chen, Mengting EP10.01-020
Chen, Ming EP08.01-073, OA02.05
Chen, Minyue P2.10-04
Chen, Qian EP14.01-016
Chen, Qixun EP05.02-018
Chen, Qun EP08.02-139

Chen, Rongrong EP08.01-082, EP16.01-017
Chen, Shanhao EP08.01-097
Chen, Shanni EP08.04-002
Chen, Sheau-Chiann EP01.05-008
Chen, Shengnan EP16.03-044, MA05.07
Chen, Simon MA10.05
Chen, Tao EP13.01-009
Chen, Weiwei EP16.04-032
Chen, Xian EP14.01-002
Chen, Xiaohui EP05.02-009
Chen, Xiaoxia EP16.01-005
Chen, Xiaoxiang EP08.01-081
Chen, Xueqin EP05.01-031, EP08.01-056, EP08.02-136, EP08.02-166, EP14.01-021
Chen, Ya-Chi EP08.02-111
Chen, Yan WS02.19
Chen, Yanhua EP08.02-158, EP16.02-026, WS08.14
Chen, Yankuan T. EP16.03-039
Chen, Yedan EP16.03-044
Chen, Ying EP08.02-064
Chen, You-Hao EP05.02-011, WS08.19
Chen, Yuan EP08.01-042, EP08.02-064
Chen, Yufan EP05.02-010
Chen, Yuh-Min EP08.02-134, EP16.01-003, PL03.09
Chen, Yun MA03.04
Chen, Zhange MA02.05
Chen, Zhendong MA14.05
Cheng, Chao EP05.02-009
Cheng, Dangxiao EP14.01-019
Cheng, Grace EP08.02-055
Cheng, Junipearl EP08.01-002
Cheng, Lei EP08.01-035
Cheng, Michael OA03.04
Cheng, Shishi MA09.04
Cheng, Sierra EP02.04-009, EP03.01-002, EP03.01-016, EP04.01-001, EP08.02-082, EP14.04-001, EP14.05-020
Cheng, Sierra C. MA14.08
Cheng, Susanna EP08.02-034, EP08.02-140
Cheng, Xiangyang EP02.04-010
Cheng, Ying EP08.01-014, EP08.01-042, EP08.01-073, EP08.02-029, EP08.02-078, EP08.02-139, EP08.02-159, EP14.01-010, OA15.06
Cheng, Yufeng OA02.05
Chen-Yoshikawa, Toyofumi Fengshi EP02.01-015
cherkaoui, Meriem EP06.01-010
Chesney, Jason MA06.05
Cheung, Gavin T. OA07.05
Cheung, Ka Man OA07.05
Cheung, Patrick EP08.05-001
cheung, patrick C. EP05.01-020
Cheung, Winson EP02.04-003, EP04.02-001, EP05.02-001, EP08.02-071
Cheung, Winson J. EP08.02-014
Cheung, Winson Y. EP03.01-016, EP08.01-004, EP08.02-013, EP08.02-112, EP14.04-001, EP14.05-020
Cheville, John P2.14-03
Chewaskulyong, Busyamas EP08.02-026
Chi, Chien-Yeh EP08.02-134
Chia, Brendan P2.13-02
Chia, Collin EP04.01-023
Chia, Puey Ling OA15.07
Chiabudini, Marco EP05.01-030
Chiang, Anne EP16.02-002
Chiang, Chi-Lu EP05.01-003, EP08.02-027, EP08.02-134, EP16.01-003
Chiappetta, Marco EP05.03-008
Chiappori, Alberto ES06.01
Chiappori, Alberto A. EP08.01-021, OA03.06
Chiari, Rita EP08.02-048, P2.14-02
Chiaruttini, Maria Vittoria P1.15-02
Chiba, Masato EP08.02-146
Chicone, Michele EP14.02-001
Chida, Masayuki EP05.02-017
Chik, Yin Kwan Jeannie EP08.02-162
Chiles, Caroline EP01.07-002
Chin, Alexander OA14.04
Chin, Venessa EP10.01-005, EP16.03-041, P1.12-02
Chiong, Justin EP08.02-090
Chiou, Jeng-Fong EP08.01-028
Chirovsky, Diana EP02.03-009, EP08.01-083, OA07.04, OA15.06
Chisamore, Michael MA13.07
Chitikela, Sindhura Durga EP03.01-006
Chiu, Chao-hua EP08.02-029, MA13.04
Chmielewska, Izabela EP01.01-008
Chmura, Steven EP14.03-001
Cho, Byoung Chul EP08.01-027, EP08.02-012, EP08.02-025, EP08.02-108, EP08.02-140, MA07.04, MA07.08, OA15.04, OA15.06, P1.15-11, P1.16-01
Cho, Eun Kyung EP08.02-025, P1.16-01
Cho, EunKyung EP08.01-073
Cho, Hyun-Ju EP08.01-017
Cho, Jong Ho MA03.03
Cho, May Myat ES37.01
Cho, Sukki EP16.03-034
Cho, Young-Jae EP13.01-008
Chodick, Gabriel EP08.02-017
Choi, Chang Min EP08.01-017
Choi, Chang-Min EP08.02-118, EP08.02-128, EP08.02-142
Choi, Hongyoon EP16.03-017, EP16.04-013
Choi, Hyeon Seok EP07.03-001
Choi, James J. EP02.01-001
Choi, Juwhan EP08.02-142
Choi, Myeong Geun EP08.01-041
Choi, Sehoon EP05.03-004
Choi, Yong Soo MA03.03
Choi, Yoo-Kyung EP05.01-032
Choi, Yoonha OA03.04
Chong, Leslie M. P1.15-08
Chopade, Sunil EP08.03-002
Cho-Phan, Cheryl P2.14-01
Chorostowska-Wynimko, Joanna EP08.02-072, EP16.03-014, HOD02.03
Choudhury, Sayantani R. EP16.03-024
Choudhury, Yukti EP01.01-006, EP16.01-030, EP16.02-013
Chow, James C. OA07.05
Chow, Justine L. EP16.03-039
Chow, Oliver EP02.04-004
Chowdhury, Deepro EP03.01-016, EP14.04-001, EP14.05-020
Chowdhury, Maisha T. EP02.04-009, EP03.01-002, EP04.01-001
Christenson, Gwen OA12.04
Christie, James EP16.03-024
Christoph, Daniel C. EP05.01-030
Christophersen, Malene S. EP01.07-001
Christopoulos, Petros EP05.01-030, EP08.01-031, EP08.01-072, EP08.02-060, EP08.02-126, EP16.01-019
Christopoulou, Athina EP10.01-018
Chu, CM EP02.02-008
Chu, Li P2.10-03
Chu, Qian EP08.01-070, EP08.02-094, WS08.15
Chu, Tianqing EP08.01-096, EP16.01-032
Chu, Timothy Shun Man EP05.01-029
Chu, Xiang-Peng EP16.03-007
Chu, Xiangling EP08.01-097
Chu, Xiao P2.10-03
Chua, Kevin L. ES16.06, P2.13-02
Chuang, Tzu-Po EP16.03-012
Chudgar, Neel EP01.04-001
Chun, Sung-Min E P08.01-017
Chung, Jae Ho EP02.03-028
Chung, Jin Haeng MA12.07
Chung, Jin-Haeng EP11.01-013, ES21.01
Chung, Sangyun EP08.02-125
Ciarrocchi, Alessia EP16.03-042
Ciccone, Anna M. EP01.06-001, EP05.03-002
Cicenas, Saulius MA06.01
Cinieri, Saverio EP14.01-006
Cintoni, Marco EP10.01-011
Ciocca, Vincent EP08.02-015
Citarella, Fabrizio EP08.01-007
Ciuffreda, Libero EP05.01-024, EP06.01-006
Ciunci, Christine EP08.01-018, P1.15-07
Ciupek, Andrew OA03.01, P1.12-01, P2.08-01
Ciupek, PhD, Andrew P1.09-01
Claesson-Welsh, Lena OA09.06
Clave, Sergi P2.07-02
Clay, Tim EP08.01-073, EP08.01-109
Clevers, Hans MA02.03
Clevers, Saar EP05.01-009
Clinton, Steven EP03.01-014
Clode, Lynsey OA08.05
Cloonan, Suzanne EP16.04-004
Cloyes, Rebecca P1.03-01
Cobo, Mabuel P1.15-09
Cobo, Manuel EP08.02-011, MA06.03, OA02.03, P1.09-03, PL03.12
Cobo Dols, Manuel EP08.01-065, OA15.03
Coburn, Natalie EP10.01-004
Coburn, Natalie G. EP04.01-027
Coca, Margarita EP08.02-131
Cockrum, Paul EP14.05-011, EP14.05-012, EP14.05-013, EP14.05-014, EP14.05-015, EP14.05-019
Coco, Simona EP08.01-088
Coelho, Juliano C. EP03.01-003
Cohen, Aharon EP08.02-047
Cohen, Emil EP08.01-044
Cohen, Roger EP08.01-018
Cohen, Roger B. P1.15-07

Cohen, Victor EP03.01-016, EP06.01-001, EP11.03-001, EP14.04-001, EP14.05-020
Colantonio, Ida EP14.01-006
Cole, Aidan J. P1.10-03
Collado, Roberto EP04.01-002
Collaud, Stéphane EP07.01-026
Collazo-Lorduy, Ana EP06.01-017, EP13.01-016
Collazo Lourdy, Ana EP16.04-014
Collinson, Fiona EP05.01-007
Colomer, Ramon EP08.01-040
Comanescu, Alina EP16.03-011, ES17.06
Comel, Andrea EP14.01-005
Compañ, Desamparados P2.07-02
COMPTE, MARINA EP01.03-002
Concannon, Kyle MA01.03
Conde, Esther P2.07-02
Conde-Flores, Emilio EP16.03-023, WS07.04
Conejero, J. Alberto EP10.01-017
Connolly, Casey EP01.04-005, MA11.07
Conron, Matthew EP14.05-016
Consonni, Dario EP07.01-005
Conti, Massimo PL03.06
Contreras Toledo, Debora Corina EP16.01-031
Conway, Jake R. P2.15-01
Conway, James OA15.05
Cookson, William EP07.03-005
Cookson, William O. EP11.03-003, P1.12-05
Coolen, Carl EP16.04-020
Cools-Lartigue, Jonathan EP05.02-015, EP05.02-019
Cooper, Wendy EP16.03-005, ES10.02, MA12.07
Coote, Joanne EP05.01-012
Copeland, Harriet PL03.03
Corcoles Padilla, Juan Manuel EP07.01-009
Cordeiro, Ricardo J. EP08.02-132
Cordeiro de Lima, Vladimir EP16.03-002, EP16.03-003
Cordero, David EP16.03-027, P2.14-04
Cordes, Sebastian MA06.08
Coremans, Ida E. MA03.09
Corke, Lucy EP02.04-009, EP03.01-002, EP04.02-004, EP08.01-067, EP08.02-082
Corona-Cruz, Jose F. EP01.05-004, EP08.03-003
Corral, Jesús EP08.02-159
Corrales, Luis EP05.01-001, EP07.01-011, EP16.03-002, EP16.03-003, MA09.09
Corral Jaime, Jesús EP08.02-070
Corre, Romain P1.11-01
Cortellini, Alessio EP08.01-043
Cortinovis, Diego EP02.04-001, EP05.01-024, EP16.03-040
Cortinovis, Diego L. EP08.02-048
Cortinovis, Diego Luigi P2.14-02
Cortiula, Francesco EP11.01-004
Cortot, Alexis OA03.05
Cosaert, Jan OA15.05
Coskun, Ozlem Silan EP08.02-022
Costa, João EP08.02-054
Cotarla, Ion EP05.02-013
Cousin, Sophie EP08.01-020, EP08.02-030
Coutinho, Daniel EP04.01-003, EP08.01-008
Couture, Christian EP16.03-020
Covarrubias-Zambrano, Obdulia EP01.01-010
Coves, Juan P1.15-09
Crama, Leonardo EP04.01-002
Craveiro, Ana EP08.02-036
Crawford, Jeanette EP08.01-044
Crengle, Sue EP01.03-009
Cressman, Sonya MA11.03
Creswell, Karen EP08.01-044
Crichard, Emily MA09.07
Crinò, Lucio P2.14-02
Cristofori, Riccardo Carlo EP02.03-006
Criswell, Angela P1.12-01
Croft, Brandon EP14.01-004
Cronemberg, Eduardo EP03.01-003
Cronin, Dianna P2.08-03, P2.08-04
Crosbie, Philip EP01.05-002, PL03.03
Crosbie, Philip A. P1.04-01
Cross, Sarah EP08.02-108
Cruellas, Mara EP07.01-023, EP16.01-014
C. Ruffinelli, Jose EP08.01-090
Crulhas, Bruno P. EP02.01-002
Cruz, Alberto MA06.03
Cruz, Casey EP01.04-001
Cruz, Felipe S. EP03.01-003
Cruz, Zenito EP05.03-003
Cruz-Bermúdez, Alberto OA02.03
Cruz Castellanos, Patricia EP08.01-048, EP08.02-088, EP16.01-007
Cruz-Castellanos, Patricia EP08.01-049, EP16.02-014
Cruz-Gomez, Sebastian MA02.07
Cruz-Rico, Graciela EP08.02-035, EP16.03-023, WS07.04
Crvenkova, Labina EP06.01-013
Crvenkova, Simonida EP06.01-013
Csőszi, Tibor OA12.06
Cuchelkar, Vaikunth EP14.01-015
Cucinella, Alessandra EP14.01-005
Cucurull, Marc OA06.04
Cucurull Salamero, Marc EP08.02-070
Cuello, Mauricio EP05.01-001, EP16.03-002, EP16.03-003
Cuenin, Cyrille MA01.09, OA04.05
Cuesta, Emilio EP08.01-048
Cufer, Tanja E P08.02-122
Cui, Jiuwei EP08.01-070, EP08.01-071, EP08.02-139, OA02.05, WS08.15
Cui, Wanda EP08.02-124, ES13.04
Cui, Wanyuan EP08.02-065, MA12.09
Cui, Yunfeng EP02.02-006
Cui, Zhanfei EP16.03-006
Culligan, Melissa EP07.01-001
Cummings, Amy MA07.05, OA12.03
Cunningham, Niamh EP08.02-065, EP08.02-124
Curioni-Fontecedro, Alessandra EP08.03-006, MA10.10, OA12.01, P1.14-01
Curran, Walter OA08.01
Currow, David C. EP10.01-016
Curtin, Joshua C. P1.16-01
Cusenza, Stefania EP16.01-013
Cutaia, Sofia EP16.01-013
Czyżewicz, Grzegorz OA12.06
Czyzewicz, Grzegorz EP08.02-072

D

Daba, Hiba EP16.02-018
Dacic, Sanja EP11.02-002, IBS10.01, MA12.07, P1.06-01
Da costa, Felipe EP01.05-004
Dada, Hiba EP16.03-016
Dada, Hiba I. EP16.03-019
Daga, Haruko MA06.04
Dagogo-Jack, Ibiayi EP08.02-116
D`Agostino Jr, Ralph EP14.05-023
Daher, Sameh EP08.02-122
Dai, Ming-Shen EP08.02-148
Dai, Tian OA03.03, OA03.06
Dai, Yuwen EP14.01-007
Dakhil, Shaker OA12.03, P2.10-02
Dal Bello, Maria Giovanna EP08.01-088
Dale, William EP10.01-012
Dallari, Barbara EP07.01-005
Dallas, Lorraine S. MA08.06
Dall'ollio, Filippo OA07.06
Dal Maso, Alessandro EP08.01-012, EP08.01-030, EP08.02-104, MA10.07, P1.15-06
Dal Pra, Alan EP07.01-019
Daly, Alison EP16.04-012
Daly, Megan EP05.01-019
Daly, Megan E. EP08.01-061, HOD01.02
D'Amelio Jr., Anthony EP14.01-020
Damhuis, Ronald A. EP08.01-026, MA03.09, OA06.05
Damiano, Carmela P2.04-03
D'Amico, Thomas ES28.03
Damiola, Francesca MA01.07, MA01.09, MA02.03, OA04.05
D'Andrilli, Antonio EP01.06-001, EP05.03-002
Dang, Manpreet EP02.01-013
Daniel, Davey EP08.02-111
Daniello, Lea EP08.01-031, EP08.01-072
Daniels, Micaela MA08.07, P2.08-05, P2.08-06
Daraghmeh, Motaz EP01.02-002, P2.11-01
d'Arienzo, Paolo D EP08.02-065
D'Arienzo, Paolo EP08.02-124
Darling, Gail EP04.01-027, OA10.05, P1.02-01
Da Ros, Valentina EP08.02-104
Darvishian, Maryam P1.02-04
Darwiche, Kaid EP02.01-010, EP04.01-016, EP04.02-005, MA06.08
Das, Amit EP08.02-130
Das, Ankit EP01.01-006
Das, Millie EP04.01-017, EP04.02-003, EP08.01-045
Das, Parthib EP08.01-062
Das Gupta, Abhijit EP16.02-027
da Silva, Laercio L. EP08.02-042
Date, Hiroshi MA10.04
Datta, Ananda EP08.04-004
Datta, Paromita EP05.02-013
D'Avella, Chris P1.15-07

D'Avella, Christopher EP08.01-018
D'Aveni, Alessandro EP07.01-005
Davey, Kieran EP14.05-009
Davidson, Michael EP08.02-065, EP08.02-124, MA12.09
Davies, Marianne EP09.01-001, ES14.04
Davies, Melissa ES35.05
Davies, Michael P. EP01.06-006
Davila, Elena EP05.02-002, EP05.02-003
Davis, Christiana EP08.01-018, P1.15-07
Davis, Kimberly OA10.03
Davis, Laura E. EP04.01-027
Dawe, David EP03.01-016, EP14.04-001, EP14.05-020
Dawkins, Paul EP01.02-003, EP04.01-021, EP04.01-023, EP04.02-002
Dawoud, Emad EP03.01-010
Day, Courtney N. EP05.01-011
Dayton, Talya MA01.09, MA02.03
Ddamba, Jimmy EP02.03-020
de Abreu, Igor Renato L. EP02.03-029
De Abreu Lourenco, Richard EP01.02-004
de Almeida, Patricia OA14.06
Dean, Emma OA15.05
Dean, Michelle EP02.04-003, EP04.02-001, EP05.02-001, EP08.02-013, EP08.02-014, EP08.02-071
Dean, Michelle L. EP08.02-112
De Andrade, Helena EP03.01-003
De Araújo Neto, César Augusto MA11.09, WS07.05
Deasy, Joe O. P1.10-03
De Bock, Geertruida H. EP01.05-006
De Bondt, Charlotte EP08.02-162
De Braud, Filippo MA10.07, P1.15-02
De Braud, Filippo M. EP07.01-021
De Braud, Filippo Maria Guglielmo EP08.01-006
DeBrito, Pedro A. EP02.03-008
De Castro, Gilberto EP08.01-042, EP08.02-059
De Castro, Javier EP08.01-049, EP08.02-131, MA06.03, P2.07-02, PL03.12
De Castro Carpeño, Javier EP08.01-048, EP08.02-088, EP16.01-007, EP16.02-014, OA02.03
De Castro Jr, Gilberto OA15.06
Degen, Kathleen P. EP08.02-015
Dégi, Csaba L. P2.04-02
De Gooijer, Cornedine J. OA04.06
De Gruijl, Tanja D. MA12.03
De Guzman, Roselle ES32.06
Dehame, Virginie EP16.04-019
Dehar, Navdeep EP14.05-010
Dehbi, Hind EP16.03-045
De Jaeger, Katrien E. MA03.09
Dejima, Hitoshi EP16.01-028
De Jong, Monique EP05.01-009
De Jong, Renske EP05.01-009
Dekker, Andre P1.15-01
Dekker, Andre L. MA03.09
DeKlerk, Nick EP01.03-003
De Koning, Harry J. OA05.04, WS02.06, WS02.24, WS02.32
De la Haba Rodríguez, Juan EP08.01-048
Delaney, Geoff EP04.01-025
De Langen, Adrianus J. EP08.02-019
De las Casas, Clara M. EP08.02-032
Delasos, Lukas MA13.05
Del Barco, Edel EP08.01-048, OA02.03
Del Barrio Díaz Aldagalan, Anabel EP08.02-070
Del Bene, Graziana P2.10-05
Del Conte, Alessandro EP08.02-104
De León-Cruz, Alejandro EP16.03-026
Deleuze, Jean-Francois MA01.09
Delfanti, Sara EP07.01-004
Delgado Cruz, Tatiana OA09.05
Delibasic, Victoria EP04.01-027, EP10.01-004
Deligianni, Elena EP10.01-006, EP10.01-007
De Lima, Vladimir C. EP03.01-003
Delimar, Petra EP14.01-011
Della Beffa, Eleonora EP02.03-006, EP02.03-007
Dell'Anna, Vladimiro EP14.02-001
Dellepiane, Chiara EP08.01-088
Dellerba, Davide P2.04-03
Del Mastro, Lucia EP04.01-005
Delmonte, Angelo EP02.04-001, EP08.01-030, EP08.02-048, P2.14-02
Del Rey Vergara, Raúl EP14.05-002
De Maglio, Giovanna EP11.01-004
De Maria, Andrea EP08.01-088
De Marinis, Filippo EP05.03-008, EP08.02-048, EP08.02-140, P1.16-04, P2.14-02
DeMarinis, Filippo EP14.05-009
De Massimi, Alessia R. EP07.01-017
Demedts, Ingel P1.15-11
De Miguel, Maria OA03.04
de Miguel, Maria Jose EP08.02-041
de Miguel Perez, Diego EP07.01-001, P2.13-01
de Miguel-Perez, Diego EP16.03-002
Demir, Bilgin EP16.04-005
Demirci, Buket EP16.04-005
Demirci, Dilara EP08.02-022
Demirkazık, Ahmet EP08.01-024
De Monte, Lavinia EP08.03-007
Dempsey, Naomi OA07.06
Dempsey, Paul W. EP01.01-010
Deng, Chao EP08.01-092
Deng, Jia-Ying EP08.01-085, WS08.09
Deng, Jiajun EP02.01-003, MA06.09
Deng, Lei EP02.04-006, EP08.01-050
Deng, Qianyue EP05.01-027, EP05.01-028
Deng, Qinghua EP16.04-030
Deng, Yu PL03.09
de Nijs, Koen OA05.04
de Oliveira, Fernando N. EP03.01-003
de Oro-Pulido, Fidel EP08.01-065
De Perrot, Marc IBS06.02
de Petris, Luigi P2.13-03
Deppen, Stephen A. EP01.05-010
Deppen, Steve EP01.05-008, EP01.05-009
De Rappard-Yuswack, Georgia EP08.02-055
Dercle, Laurent P2.12-03
Derks, Jules MA01.09
De Ruvo, Marianna P1.15-06
De Ruysscher, Dirk EP14.01-014, MA06.08, P1.15-01
De Ruysscher, Dirk K. EP08.01-026
Desai, Jayesh OA03.04
Desai, Shruti S. OA09.04
Desai, Sujal EP06.01-008, P1.12-05
De Sande, Luis Miguel EP05.02-002, EP05.02-003
Descallar, Joseph EP04.01-025
Deshayes, Sophie EP16.04-019
De Simone, Irene EP07.01-004
Desmeules, Patrice EP16.03-020
De Sousa, Paulo EP01.07-006, EP02.03-002, P1.12-05
Dessain, Scott EP08.02-015
De Stanchina, Elisa MA13.05
De Summa, Simona P2.10-05
Desvallees, Thomas E P16.02-004
De Toma, Alessandro EP07.01-021, EP08.01-006, MA10.07, P1.15-02
Detterbeck, Frank MA04.06
Devaraj, Anand EP06.01-008, EP11.03-003, OA05.07, P1.12-05
Devarakonda, Siddhartha EP08.01-013, EP08.02-116
Devbhandari, Mohan EP02.03-002
de Vries, Jeltje F. OA04.06
Dew, Rosie OA01.05
Dezso, Katalin MA01.04
Dhanasopon, Andrew P. EP14.05-021
Dhar, Arindam P1.11-01
Dharia, Neekesh V. OA03.04
D'Hondt, Erik EP08.02-135
Diao, Lixia MA01.03
Dias, Margarida EP04.01-003, EP08.01-008
Diaz, Pablo EP16.01-031
Diaz-Garcia, Diego EP16.03-023, WS07.04
Díaz López, Sebastián EP14.05-005
DiCarlo, Brian MA07.05
Di Ciano-Oliveira, Caterina EP16.03-015
Dick, Steven EP05.01-021
Dickson, Franco EP05.01-001
DiCostanzo, Dominic EP05.01-021, EP08.01-098
Dieckmann, Karin ES24.02, MA14.06
Dieguez, Gabriela EP14.05-011, EP14.05-012, EP14.05-013
Diehn, Maximilian OA14.04
Dienstmann, Rodrigo EP04.01-022, EP07.01-022, EP07.01-023, EP08.02-056, WS07.06
Dientsmann, Rodrigo IBS03.01
Diez, Patricia EP08.03-005
Diez, Victor EP08.02-102
Di Fazio, Giuseppina R. EP08.02-046
Digby, Geneviève C. EP04.01-024, EP13.01-012
Di Genova, Alex MA01.09, MA02.03, OA04.05
Di Gregorio, Settimio EP08.01-006
Dilege, Sukru EP05.02-004, EP05.02-005, EP05.03-007
Dillon, Magnus ES29.06
Di Martino, Marco EP07.01-017
Di Mauro, Debora EP10.01-019
Di Mauro, Maria Rosa EP08.01-006
Di Mauro, Rosa MA10.07
Dimitrakopoulos, Foteinos-Ioannis EP08.01-072

Dimou, Anastasios EP05.01-011, EP08.02-037, EP08.02-118, MA13.09
Din, Azra OA14.05
D'Incalci, Maurizio EP07.01-004
Ding, Beiying EP02.04-005
Ding, Cuimin EP08.02-139
ding, lingyu EP16.04-030
Ding, Luyin EP08.01-081
Ding, Michelle P1.16-04
Ding, Peng EP08.01-100, MA09.04
Dingemans, Anne-Marie MA01.09, PL02.03, WS03.05
Diniz, Gulden EP16.04-005
Diniz, Paulo Henrique C. EP08.02-056
Di Nucci, Agnese EP07.01-021, EP08.01-006
Di Pace, Brian P1.11-01
Di Rienzo, Gaetano EP14.02-001
Dirksen, Uta EP07.01-026
Di Scala, Lilla EP08.02-016
Disel, Umut EP08.01-014
Dissing, Julie G. EP08.01-084
Dive, Caroline EP05.01-007, ES39.03
Divis, Paolo EP14.01-005
Dix, Daniel EP01.01-003
Dixon, Scott EP08.02-055
Diz, Pilar EP08.01-029, EP08.02-131
Dizbay Sak, Serpil EP13.01-002, EP16.01-004
Diz Taín, Pilar EP05.02-002, EP05.02-003
Djaballah, Hakim EP08.02-055
Djekic Malbasa, Jelena EP03.01-017
Do, Nhan EP08.01-045
Do, Trevor P2.07-01
Doake, Ruth OA15.04
Docherty, Catherine EP01.07-006
Dodd, Rachael EP01.03-006
Dodd, Rachael H. EP01.02-004, EP01.03-012
Dodi, Alessandra EP10.01-011
Dodlek, Nikolina P2.04-01
Doebele, Robert EP16.03-012
Doger, Bernard EP08.01-109
Doherty, Mark EP04.01-027
Dokuni, Ryota EP14.05-022
Dolev, Yardena EP08.01-011
Dome, Balazs EP07.02-001, EP14.02-002
Döme, Balazs EP14.02-003
Dome, Balazs EP14.02-006, MA01.04
Domenech, Marta OA06.04
Dómine, Manuel EP08.01-029
Domine, Manuel MA13.07
Dómine, Manuel OA02.03
Domine, Manuel P1.09-03
Dómine, Manuel P1.15-09
Domine, Manuel P2.07-02
Dómine Gómez, Manuel EP08.02-070
Dominguez, Barbara EP08.01-023
Donaldson, Dusty P2.08-07
Dong, Jiyan EP11.03-002, EP14.02-007, MA01.05
Dong, Lucy EP08.01-098
Dong, Qi EP08.02-109
Dong, Xiao Rong EP08.02-078
Dong, Xiaorong EP08.01-099, EP08.01-100, EP08.02-063, EP08.05-002, EP16.01-027, MA09.04, OA03.07, OA11.06, WS08.13, WS08.18
Dong, Xiaowei EP16.03-006
Donnelly, Edwin P1.03-01
Donnelly, Paul MA09.05, P1.10-02, P2.03-01
Dønnem, Tom EP01.01-005
D'Onofrio, Mirko EP10.01-011
Doroshow, Deborah B. P2.12-05
Dorta, Miriam EP08.02-149, P1.16-02
Dortch, Kourtney EP02.03-022, MA03.08
Dou, Xuejun EP16.03-008
Douma, Li-Anne H. OA04.06
Dowlati, Afshin EP14.01-004, OA12.05
Draeger, Tyler EP02.03-012
Dressler, Danielle EP04.01-007, EP04.01-008
Dressman, Marlene OA15.05
Drilon, Alexander EP08.02-041, EP08.02-148, HOD03.03, MA13.04
Driscoll, Chiny EP01.06-004
Drokin, Ivan MA11.09, WS07.05
Dropkin, Lisa MA08.04
Drudi, Alessandro EP10.01-011
Drusbosky, Leylah EP16.02-018
Drusbosky, Leylah M. EP16.03-016, EP16.03-019, MA07.07
D'Silva, Adrijana EP04.02-001, EP08.02-112
D'souza, Desmond P1.03-01
Du, Lei-ya EP08.05-004
Du, Pengyao EP01.01-012
Du, Robyn EP08.02-163
du, yajing EP02.02-001
Duan, Huaxin EP08.02-158, WS08.14
Duarte, Flávia A. EP08.02-056
Duarte Paes, Rafael EP04.01-022, WS07.06
Dubey, Arbind EP08.02-024
Dubois, Frederic EP08.01-021
Dudley, Andrew EP08.02-093
Dudnik, Elizabeth EP08.02-047, EP08.02-122
Dudnik, Julia EP08.02-047
Duffy, Mary EP04.01-023, EP09.01-001, EP14.05-016
Duffy, Stephen W. EP01.06-006
Dufton, Polly D. OA08.06
Dugan, Margaret EP08.02-031, EP08.02-106
Duggirala, Krishna Babu MA07.08
Dujardin, Philip EP16.04-002
Dülger, Zeynep Selin EP06.01-007
Duma, Narjust ES04.06, MA14.04, OA06.06
Dumais, Katerine EP16.02-018, EP16.03-022, P1.16-03
Dumais, Katerine EP08.02-107
Dumas, Megan EP08.04-002, EP16.03-005
Dumitrascu, Andra Diana EP08.01-006, P1.15-02
Dunlop, Kate L. EP01.03-006
Dunne, Simon ES14.03
Durcinoska, Ivana EP04.01-025
Durden, Kelly P2.08-07, P2.08-09
Durgeshwar, Gopal EP08.04-004
Durm, Greg A. MA06.05
Durm, Gregory A. EP14.05-004, OA03.06
Dutra, Carolina EP03.01-003
Dvorkin, Mikhail EP08.01-014
Dvortsin, Evgeni P1.02-03
Dy Buncio, Anne OA13.03
Dyer, Debra S. EP01.07-002
Dziadziuszko, Rafal MA13.04

E

Eastep, Christine P1.03-01
Eastwood, Mark EP07.03-005
Eaton, Kiefer MA12.05
Eberhardt, Wilfried EP05.01-030, ES02.06
Eberhardt, Wilfried E. EP04.02-005, MA06.08
Eberhardt, Wilfried Ernst Erich EP04.01-016
Eberl, Marian EP03.01-013
Ebert, Peter OA14.06
Ebiana, Victoria OA03.06
Eboulet, Eric I. EP16.01-018, MA12.04
Echepare, Mirari EP16.01-009
Edatt, Lincy EP08.02-093, EP16.04-017
Ede, Nicholas P1.15-08
Egger, Felix EP14.02-003
Egger, Robert P2.07-01
Eguchi, Takashi MA03.07, P2.12-02
Ehlers, Jeanette EP01.07-001
Eichholz, Jordan EP05.01-014
Eichhorn, Florian EP08.01-031
Eickhoff, Jens P2.02-02
Eiros Bachiller, Rocío EP08.01-048
Eisenhauer, Elizabeth EP04.01-024, EP13.01-012
Eisert, Anna EP08.02-106, EP08.02-114, EP08.02-162
Ekman, Simon EP08.01-083, EP16.02-008, P2.13-03, WS03.07
Elamin, Yasir EP08.02-019, EP08.02-041, EP08.02-045
Elchebly, Mounib EP11.03-001
El-edwan, Ahed EP14.05-018
Elegbede, Anifat EP02.04-003, EP04.02-001, EP05.02-001, EP08.01-004, EP08.02-014, EP08.02-071
Elegbede, Anifat A. EP08.02-112
Elegbede, Anifat J. EP08.02-013
Eletti, Luca EP10.01-015
El Founini, Younes EP16.03-045
Elfving, Hedvig MA05.04
Elian, Razan EP01.02-002, P2.11-01
Elio, Javier OA13.04
Elkins, Ivy MA14.04
Elkkari, Abdulbaset EP03.01-010
El-Koha, Omran EP03.01-010
Elkouly, Ehab EP16.03-005
Elkrief, Arielle EP08.01-043
Ellerbeck, Edward F. OA10.04
Elliot, Mitchell J. EP08.01-067
Ellison, David EP08.02-111
Elmas, Hatice EP16.01-011
El Mzibri, Mohammed EP16.03-045
El-Osta, Hazem OA12.06
Elsayed, Asmaa G. EP09.01-001
Elshami, Mohamedraed EP01.02-002, EP05.02-012, EP07.01-025, P2.11-01
Elshiaty, Mariam EP08.01-031, EP08.01-072

Ely, Sora EP14.05-021
Emard, Nick P2.08-09
Emmerson, Amber EP08.03-005
Emond, Bruno MA12.05
Emoto, Katsura EP07.03-007
Şen, Erdem EP08.01-024
Endo, Makoto EP02.03-024, EP05.03-009
English, John MA11.08, P1.04-02
Enon, Serkan EP08.03-004
Enrico, Diego EP08.02-097, EP16.03-002
Enriquez, Rita EP08.02-141, EP16.03-035
Šepac, Ana EP14.01-011, EP14.01-012
Epaillard, Nicolas P1.12-04
Erefai, ouassima EP14.01-018, EP16.04-018
Ergin, Tiffany M. EP02.03-027, EP13.01-014
Ergin, Tiffany Melissa EP02.03-026
Ergonul, Ayse G. EP02.03-026, EP02.03-027, EP13.01-014
Erhunmwunsee, Loretta ES33.04
Erhunmwunsee, Loretta J. EP10.01-012
Erickson, Brett EP02.02-006
Eris, Sude EP08.02-022
Erkmen, Cherie P. P1.12-01
Ermer, Theresa OA11.03
Ernani, Vinicius EP05.01-011, EP08.01-076, EP14.05-001, MA13.09
Ersen, Ezel EP02.03-001, EP05.03-001, P2.06-01
Ertürk, Ismail EP08.01-024
Erus, Suat EP05.02-004, EP05.02-005, EP05.03-007
Esakia, Tamar EP01.03-013
Escudero, Vicente EP04.01-002
Esparré, Carlos EP08.02-120
Espenschied, Carin MA07.03
Espiga de Macedo, Joana EP01.01-007, EP16.02-011, EP16.02-012
Espino-Hernández, Gabriela P1.02-01
Esteban, Patricia EP16.01-014
Esteban González, Emilio EP16.01-031
Esteban Martínez, Fátima EP08.01-048
Esteban Rodríguez, Isabel EP08.02-088, EP16.01-007, EP16.02-014
Esteban-Rodriguez, Isabel P2.07-02
Esteban-Villarrubia, Jorge EP08.02-149
Estecio, Marcos R. MA01.03
Estephan, Jérôme EP07.01-007
Estevinho, Fernanda EP03.01-009, EP04.01-011, EP05.03-006, EP08.02-053
Estival, Anna OA06.04
Ettinger, David EP02.04-007
Ettinger, David S. MA03.04
Eubanks, Richard EP02.03-022
Evangelou, George EP14.01-022
Evans, Bill K. OA10.05
Evans, Sue EP04.01-023
Evans, Tracey EP08.02-015
Evans, William ES37.06
Evison, Matt IBS11.01
Evrard, Solène EP11.01-005
Ewara, Emmanuel MA12.05
Exner, Jan-Philipp EP04.01-016
Exner, Jan-Philipp H. EP04.02-005
Exposito Hernandez, Jose P2.13-01
Eyles, Emily EP04.01-021
Ezeife, Doreen EP04.02-004
Ezer, Nicole E P05.02-019

F

Fabikan, Hannah EP02.01-008, EP08.02-122
Fabre, Elizabeth OA07.06
Fabrizio, David EP08.02-084
Facilissimo, Ivan EP05.01-024, EP06.01-006
Fadel, Elie E P07.01-007, MA10.08
Fagan-Solis, Katerina EP16.04-017
Fahy, Darren P2.07-01
Faisal, Wasek EP14.05-016
Faivre-Finn, Corinne EP05.01-007, EP05.01-012, EP08.03-005, IBS15.01, PL03.14
Falchook, Gerald OA03.03
Falchook, Gerald S. OA03.06
Falcon, Alejandro OA03.04
Fan, Hui Jie EP08.02-078
Fan, Xiao-Jun EP16.01-025, WS08.21
Fan, Xiaojun EP01.01-011
Fan, Ye EP16.01-001
Fan, Yun EP07.02-006, EP08.01-014, EP08.01-032, EP08.01-033, EP08.01-042, EP08.02-029, EP08.02-051, EP08.02-052, EP08.02-078, EP08.02-092, EP08.02-165, MA13.04, PL03.09
Fang, Bruno EP08.02-081
Fang, Jian EP08.01-042, EP08.02029, EP08.02-063, EP08.02-139, OA02.05, OA03.07
Fang, shencun EP08.02-050
Fang, Vincent W. EP08.03-006
Fang, Wade EP08.02-151
Fang, Wentao ES18.02, MA04.05
Fang, Yong EP08.02-160
Fang, Yujia EP08.01-097
Fanti, Stefano MA01.08
Fanton Aita, Fiorella EP08.02-103
Farag, Sheima EP08.02-065
Faria, Ana EP04.01-011
Farias, Igor E. EP02.03-010
Faris, Nicholas E P01.06-007, EP02.03-022
Faris, Nick MA03.08
Farnsworth, Dylan EP08.02-055
Faseru, Babalola OA10.04
Fasola, Gianpiero EP11.01-004
Fassan, Matteo P1.15-06
Fathi, Joelle EP08.02-043, ES37.05, P2.08-01, P2.08-09
Faull, Iris A07.07
Favato Barcelos, Isabella EP04.01-022, WS07.06
Feathers, Ryan P2.14-03
Febbraro, Michela EP04.01-018
Fediuk, Melanie EP02.01-008
Fedrigo, Elena EP14.01-005
Fehnel, Carrie EP01.06-007, EP02.03-022, MA03.08
Fei, Cong EP08.01-070, EP08.01-071, WS08.15
Feigenberg, Steven EP08.01-018
Fein, Luis EP03.01-003
Feldman, Jill MA08.01, MA14.04, P2.08-07, P2.08-09
Feldman, Lawrence EP02.02-002, MA06.05
Feldman, MD, Lawrence EP10.01-014
Feliciano, Josephine EP02.04-007, EP08.01-086
Felip, Enriqueta EP07.01-022, EP07.01-023, EP08.01-078, EP08.01-109, EP08.02-041, EP08.02-081, EP16.03-011, ES36.03, MA13.07, OA03.05, OA15.03, P1.11-01, P2.07-02, PL03.09, WS01.04
Felip, Eudald OA06.04
Felizardo, Margarida EP03.01-009, EP04.01-011, EP05.03-006, EP08.02-141, EP16.03-035
Felley-Bosco, Emanuela EP07.02-004
Fellous, Marc EP08.02-148
Femia, Federico EP02.03-006, EP02.03-007
Fenemore, Jackie MA08.07, P2.08-05, P2.08-06
Feng, Jifeng EP08.01-080
Feng, Lingxin EP08.02-057
Feng, Xiaoshuang P1.01-01
Feng, Yu EP07.03-003, EP16.02-017
Feng, Yuqian EP05.02-020
Fennell, Dean ES13.05
Fennell, Dean A. WS04.11
Fenouil, Tanguy EP11.01-005
Fenton, Paul OA08.05
Ferencz, Bence EP14.02-003, MA01.04
Ferguson, Katelyn EP01.04-004
Ferguson, Sarah EP14.05-004, OA12.04
Fernandes, Ana EP04.01-011
Fernandes, Gabriela EP03.01-009, EP05.03-006
Fernandes, Roxanne EP04.02-004
Fernandez, Elena EP04.01-002
Fernández, Natalia P1.15-09
Fernández Carcaño, Marta EP14.05-005
Fernandez-Cuesta, Lynnette MA01.07, MA01.09, MA02.03, OA04.05
Fernández Pérez, Elisa M. EP14.05-005
Fernandez-Vega Martinez, Grisel EP04.01-010
Fernando, Hiran Chrishantha IBS02.02
Fernando, Nelumka EP08.02-098
Ferrara, Roberto EP05.01-024, EP07.01-021, EP08.01-006, MA10.07, P1.15-02
Ferrarello, Tommaso EP02.03-019
Ferrarone, John EP08.02-055
Ferreira, Carlos Gil M. OA08.03
Ferreira, Luís EP04.01-011, EP08.02-054
Ferreira, Lurdes EP03.01-009, EP04.01-011, EP05.03-006
Ferreira, Yamila EP08.02-097
Ferrell, Betty EP10.01-012
Ferri, Lorenzo EP05.02-015, EP05.02-019
Ferrigno, Pia EP08.03-007
Ferris, Andrea EP04.01-004, MA08.04
Ferro, Alessandra EP08.01-012, EP08.02-104, P1.15-06

Ferro, Filipa EP08.02-132
Ficarra, Giovanni EP10.01-019
Ficken, Catherine EP16.04-011
Ficorella, Corrado EP14.01-006
Fidalgo, Paula EP04.01-011
Fidler, Mary J. EP08.01-037, EP08.02-119
Fidler, Mary Jo MA06.05, MA14.04
Field, John EP01.04-005, MA11.07, P1.02-02
Field, John K. EP01.06-006, WS02.38
Field, John K. IBS01.01
Fifer, Simon EP10.01-003
Figueiredo, Ana EP04.01-011
Figueiredo, Catarina EP05.03-003
Figueiredo, Maria EP04.01-011
Figueiredo, Maria M. EP05.03-006
Figueiredo, Sara EP03.01-009, EP05.03-006
Filetti, Marco EP08.02-046
Filipello, Federica MA12.08
Filipits, Martin ES35.01, WS08.08
Fillinger, Janos EP14.02-003, MA01.04
Fillmore, Nathanael EP08.01-045
Filosso, Pier Luigi EP02.03-006
Finch, Jonathan EP11.03-003, P1.12-05
Fine, Alexander D. EP16.02-002
Fine, Leah EP08.02-043, P1.12-01, P2.08-01
Finley, Christian EP04.02-002, ES37.07, P1.02-01
Finn, Stephen P. EP02.01-002
Fiorentino, Michelangelo EP02.03-019
Firat, Pinar EP05.02-004, EP05.02-005
Fischer, Barbara M. EP01.07-001
Fischer, Berthold MA06.08
Fischer, Brigitte EP15.01-001
Fischer, Claire EP14.04-002
Fischer, Rieke EP08.02-106, EP08.02-114
Fiset, Pierre-Olivier EP05.02-019, OA06.07
Fisher, Scott EP07.01-024
Fishman, Elliot K. MA03.04
Fitzgerald, Bailey P2.12-05
Fitzgerald, Kelly EP05.01-025
Fitzmaurice, Gerard J. EP02.01-002
Fitzpatrick, Peggy EP08.01-086
Fitzpatrick, Sarah EP08.02-019
Flehberger, Daniela EP07.01-014
Fletcher, James EP04.01-013
Fleurimont, BS, MPH, Judes EP10.01-014
Flippen, Carrie EP16.02-003
Flora, Daniel OA06.06
Flores, Raja M. EP03.01-008, OA02.01
Florescu, Marie EP04.01-020, EP07.03-002
Flores-Estrada, Diana MA14.03, WS07.03
Florez, Narjust IBS18.03, IBS18.05
Florez-Arango, Juan MA10.08
Foggetti, Giorgia EP08.02-125
Folitar, Ilya EP14.01-020
Foll, Matthieu MA01.07, MA01.09, MA02.03, OA04.05
Follador, Alessandro EP11.01-004, EP14.01-006
Fong, Kam Weng P2.13-02
Fong, Kwun ES20.03, MA11.03
Fonio, Paolo EP02.03-007
Fonseca, Ana EP04.01-003, EP08.01-008
Fontaine, Jacques P. EP02.03-005, EP02.03-012
Fontana, Elisa Carla EP02.03-006
Fontanini, Gabriella EP08.02-048
Forcina, Giovanni EP08.02-055
Forde, Patrick EP02.04-007, EP08.01-086
Forde, Patrick M. LA01.05, MA03.04, OA15.05
Ford-Sahibzada, Chelsea EP04.02-001, EP08.02-112
Forsblom, Marjo MA08.08
Forster, Martin EP05.01-007, EP08.01-109, OA03.04
Fortin, Dalilah EP02.01-013, OA06.07
Forti Parri, Sergio Nicola EP02.03-019
Fortunati, Emilia MA01.08
Fossella, Frank V. EP08.01-059
Fotopoulos, Ioannis EP01.01-009, MA11.04
Fox, Jesme MA08.07, P2.08-05, P2.08-06
Frampton, Garrett EP08.02-084
Franceschini, Juliana P. MA11.09, WS07.05
Franchetto, Meagan EP06.01-015
Franchina, Tindara EP10.01-019
Franchina, Veronica EP10.01-019
Franchini, Fanny EP08.02-061
Franco, Fernando EP06.01-017, EP13.01-016, P1.15-09
Frank, Ingrid R. EP02.01-001
Frank, MSc, Pauline P1.09-01
Frankart, Andrew EP05.02-013
Frankel, Paul MA13.08
Franklin, Peter OA13.06
Franklin, Wilbur MA03.04
Franks, Kevin EP05.01-007, ES19.03
Fransson, Susanne EP16.03-012
Franzen, Bo P2.13-03
Fraser, Anne EP01.03-001, EP06.01-002, ES14.01, IBS04.02, LA03.04
Fraser, Richard EP05.02-019
Frassoldati, Antonio EP14.01-006
Frega, Stefano EP08.01-012, EP08.02-104, P1.15-06
Frei, Christopher R. EP05.02-013
Freitas, Helano EP16.03-002
French, Benjamin OA06.06
French, Conor EP11.02-001
French, Daniel EP02.03-020
French, Dorothy P2.07-01
Fresquet, Judith EP16.04-019
Friboulet, Luc EP08.02-020
Fridman, Brandon EP01.02-006, EP01.02-007
Friedberg, Joseph EP07.01-001
Friedel, Godehard MA06.08
Friedes, Cole EP08.01-018
Friedmann, Jennifer E. EP06.01-001
Friedrich, Lea EP08.01-108
Frigola, Joan EP07.01-022, EP07.01-023, EP08.01-078
Frost, Matilde T. EP08.02-105
Frost, Nikolaj EP14.01-008
Frowen, Jacqui OA08.07
Frumovitz, Michael P2.10-01
Ftanou, Maria ES06.06
Fu, Jie OA14.04
Fu, Junke EP05.02-018,
Fu, Ping EP08.02-038
Fu, Pingfu EP05.02-022
Fu, Rui EP05.02-006, EP16.01-025, EP16.02-024, WS08.21
Fu, Shuai E P08.02-038
Fu, Wei OA12.06
Fu, Xiangning EP01.03-011
Fu, Xiaolong EP05.03-012
Fuentes Pradera, José EP14.05-005
Fugazzotto, Domenico EP10.01-019
Fujino, Toshio EP08.02-085, EP08.02-146
Fujioka, Naomi MA06.05
Fujisaka, Yasuhito EP08.02-133
Fujiwara, Yutaka EP08.02-116, EP08.02-118
Fukuda, Kiyoko EP14.05-022
Fukuda, Minoru EP08.01-064, EP08.04-005
Fukuda, Satoshi OA07.03
Fukui, Mariko EP02.03-025
Fukumitsu, Kensuke OA07.03
Fukumoto, Koichi EP02.01-015
Fukuoka, Junya EP11.02-002
Fulfaro, Fabio EP16.01-013
Fulgenzi, Claudia EP08.01-043
Fung, Andrea S. EP03.01-016, EP14.04-001, EP14.05-020
Fung, Andrea S EP14.05-010
Furedy, Amy EP08.02-117
Furnback, Wesley EP08.01-016
Furrer, Katarzyna EP08.03-006, P2.11-03
Furtado, Sofia T. EP08.02-141, EP16.03-035
Furukawa, Kinya EP16.03-029, EP16.03-037, EP16.04-009
Furuya, Naoki EP08.02-113
Fusamoto, Aya EP02.03-017

G

G, Poornachandra EP16.03-024
Gaba, Lydia EP03.01-012, P1.07-02
Gabay, Carolina EP04.01-006
Gabayan, Afshin E. EP08.02-118
Gabe, Rhian EP01.06-006, PL03.03
Gabrielson, Edward MA03.04
Gadgeel, Shirish EP08.02-019, EP08.02-041
Gai, Yun-Zu EP16.03-007
Gaissmaier, Lena EP08.01-031
Gajewski, Byron OA10.04
Galateau-Salle, Françoise OA04.05 ES13.03
Galera, Mar EP08.02-110
Galetta, Domenico EP02.04-001, EP08.02-048, EP08.02-101, EP16.03-040, P2.10-05, P2.14-02
Galffy, Gabriella MA01.04, P1.1511
Galindo-Campos, Miguel Alejandro EP14.05-002
Gallagher, Ryan P1.03-01
Galli, Edoardo Gregorio EP08.01-006
Galli, Francesca MA10.07

Galli, Giulia EP07.01-021, EP08.01-006, MA10.07
Gallo, Martina EP02.03-006
Galpin, Kirsty P1.12-02
Galvan, Patricia EP08.02-102
Galvano, Antonio EP08.03-007, EP16.01-013
Galvez, Eva M EP16.01-014
Gamez, Tatiana EP16.03-002, EP16.03-003
Gan, Bin EP08.01-085, WS08.09
Gan, Gregory EP14.03-001
Gan, Xin EP08.01-081
Gandara, David R. ES17.02, MA13.08, OA03.02
Gandara, David R. P2.12-03
Gandhi, Yash EP08.01-020
Ganesh, Ashwin EP02.02-002
Gangrieddy, Mounika P. EP08.02-015
Ganguly, Sandip EP06.01-005, EP08.02-040, EP16.02-006
Ganju, Vinod EP08.02-109
Gans, Steven J. P1.15-11
Ganti, Apar MA06.05
Ganti, Apar K. EP14.05-023, EP16.03-024
Ganzinelli, Monica EP07.01-021, EP08.01-006, MA10.07
Gao, Bo EP08.01-071, EP08.02-029
Gao, Boning EP08.02-130
Gao, Chao EP16.01-017
Gao, Chi EP02.03-009
Gao, Grace P1.16-01
Gao, Guanghui EP08.01-035, EP08.01-107, EP16.01-005, WS08.16
Gao, Jiani EP11.01-001
Gao, Jin EP08.01-080
Gao, Rang EP08.01-073
Gao, Robert W. EP05.01-011
Gao, Shugeng EP08.01-055, EP16.01-023, MA05.03, WS08.17, WS08.20
Gao, Xiohong EP07.03-005
Gao, Yanfei EP01.06-008
Gao, Yang EP05.02-010
Gao, Zhuolin EP14.01-016
Garassino, Marina EP08.01-020, ES02.01, MA10.07, OA03.05
Garassino, Marina C. EP07.01-021, EP08.02-108, OA06.01, OA06.08, P1.16-04
Garassino, Marina C. OA15.06
Garassino, Marina Chiara EP08.01-006, P1.15-02
Garbo, Edoardo EP08.02-101
Garces, Yolanda I. EP05.01-011
García, Beatriz EP08.02-120
García, Javier EP08.01-029
Garcia, Jorge P2.07-02
Garcia, Katherine EP16.04-012
Garcia, Miguel EP02.04-009, EP03.01-002, EP04.01-001, EP08.02-082, EP08.02-110, OA13.04
Garcia Benito, Carmen PL03.12
García Campelo, Maria R. EP08.02-171
Garcia Campelo, Rosario EP08.02-060
García- Campelo, María del Rosario OA02.03
Garcia-Campelo, Mª Rosario P1.09-03
García-Campelo, Rosario EP08.02-131
Garcia-Campelo, Rosario OA07.06
Garcia Casabal, Florencia EP08.02-032
Garcia de Herreros, Marta EP08.02-102, MA07.07, OA13.04, P1.16-02
Garcia-Diaz, Abel P2.13-01
García–Gómez, Juan M. EP10.01-017
García González, Guillermo EP14.05-005
Garcia-Illescas, David EP07.01-022, EP08.01-078
Garcia Palomo, Andres EP05.02-002, EP05.02-003
García-Peláez, Beatriz EP08.02-032
Garcia-Reina, Samuel EP01.03-002, EP01.05-001
Garcia-Robledo, Juan B. EP16.03-002
Garcia-Robledo, Juan E. EP05.01-001, EP16.03-003
García Rodríguez, Sonia EP14.05-005
García-Román, Silvia EP08.02-120 EP08.02-135
García- Sastre, Adolfo OA06.03
Gard, Grace EP08.04-002, EP16.03-005
Garde-Noguera, Javier EP08.02-149
Garelli, Elena EP02.03-019
Gargoum, Ali EP03.01-010
Garitaonaindía Díaz, Yago EP06.01-017, EP13.01-016, EP16.04-014
Garon, Edward OA12.03
Garon, Edward B. EP08.01-027, EP08.02098, MA07.05, OA15.04
Garralda, Elena OA03.04
Garrett, Joseph EP02.03-012
Garrett, Joseph R. EP02.03-005
Garrido, Maria Luisa EP05.02-002, EP05.02-003
Garrido, Pilar EP08.02-131, OA07.02, OA15.01, P2.07-02
Garrido Fernandez, Alberto MA06.03
Garrido López, Pilar EP08.02-070
Garrido Lopez, Pilar P1.11-01
Garrone, Pamela EP02.03-007
Gärtner-Pelham, Claudia EP16.01-018
Garzón Ibañez, Mónica EP08.02-032
Gasche, Nikolaus EP16.01-015
Gascón- Ruiz, Marta EP16.01-014
Gaspar, Bernard MA08.07, P2.08-05, P2.08-06
Gastala, MD, Nicole EP10.01-014
Gately, Kathy A. EP02.01-002
Gaudreau, Pierre-Olivier EP14.05-010
Gaudreault, Nathalie EP16.02-027, EP16.03-020
Gauler, Thomas C. EP04.02-005, MA06.08
Gauler, Thomas Christoph EP04.01-016
Gauntner, Timothy EP08.01-062
Gausachs, Mireia EP16.03-027
Gauto, Diana M. OA03.06
Gauvin, Camille EP07.03-002
Gavira, Javier P1.12-04
Gavrielatou, Niki P2.12-01
Gay, Carl M. MA01.03, P2.10-01
Gazzah, Anas P1.16-02
Gazzera, Carlo EP02.03-007
Ge, Jia EP05.01-015
Ge, Xiao Song EP08.02-078
Geater, Sarayut L. OA15.04
Geater, Sarayut Lucien EP08.01-027
Gee, Harriet OA14.04
Gelatti, Ana C. EP03.01-003
Gelblum, Daphna Y. EP05.01-014, EP05.01-025, P1.05-02
Geleff, Silvana EP02.01-009
Gelibter, Alain EP08.01-007
Gelibter, Alain J. EP08.02-046
Gelsomino, Francesco EP02.04-001, EP08.01-007, EP14.01-006
Gemma, Akihiko EP08.01-005
Gencheva, Radosveta P2.13-03
Geng, di EP08.02-069
Genova, Carlo EP02.04-001, EP04.01-005, EP08.01-007, EP08.01-088, EP08.02-046, EP08.02-101, EP14.01-006, EP16.03-040
Gensheimer, Michael OA14.04
Gerard, Ian J. OA06.07
Gerard, Roger L. EP02.03-005
Gerber, David E. OA06.03
Gerke, Oke EP01.07-001
Gesualdo, Monica P2.10-05
Gettinger, Scott EP08.02-125
Ghanim, Obaida EP01.02-002, P2.11-01
Ghanta, Ravi P1.14-02
Ghantous, Akram MA01.09, OA04.05
Gharaibeh, azza EP07.01-016
Ghattas, Christian P1.03-01
Ghefter, Mario MA11.09, WS07.05
Ghosh, Adity EP16.03-024
Ghosh, Joydeep EP06.01-005, EP08.02-040, EP16.02-006
Ghosh, Sudip EP08.04-004
Ghoshal, Avik EP01.05-002
Giacometti, Valentina P1.10-03
Gianetta, Martina P2.04-03
Gianino, Nicole P2.12-01
Giannarelli, Diana EP08.01-030, EP08.02-048, P2.14-02
Giannetta, Laura G. EP08.02-046
Giardina, Donatella EP14.01-006
Gibbard, Jamie EP12.01-001
Gibbs, Peter EP08.04-002, EP16.03-005
Gibson, Amanda EP02.04-003, EP04.02-001, EP05.02-001, EP08.01-004, EP08.02-013, EP08.02-014, EP08.02-071
Gibson, Amanda J.W. EP08.02-112
Gibson, Neil EP08.02-049
Gierada, David EP01.01-002
Gieske, Michael R. EP01.04-004, EP01.07-002
Gil, Debora EP01.05-001
Gil, Nuno EP03.01-009, EP04.01-011
Giladi, Moshe EP16.01-016, EP16.03-028
Gil Barturen, Mariana EP06.01-017
Gil-Bazo, Ignacio EP08.02-070, MA02.08
Gilbert, Alexandra EP05.01-007
Gilbert, Christopher R. MA14.09
Gilja, Shivee OA02.04
Gill, Ritu ES18.04, P1.1302
Gill, Ritu R. EP07.01-018
Gilligan, David EP08.02-150
Gimenez Capitán, Ana EP08.02-032
Giménez-Capitán, Ana EP08.02-135, EP16.02-007
Gini, Beatrice EP08.02-147
Ginsberg, MIchelle S. EP05.01-025
Ginzinger, David EP11.01-009

Giovanniello, Delia EP07.01-017
Gipson, Meghan EP16.02-025
Girard, Luc EP08.02-130
Girard, Nicolas EP08.01-021, EP08.02-016, EP08.02-060, MA01.09, MA02.03, OA04.05, P1.16-04
Girardi, Fabio EP08.01-012
Girgis, Afaf EP04.01-025
Girija, Aswathy EP08.04-004
Giroux, Dorothy J. MA04.05
Gitlitz, Barbara J. PL03.09
Giuliano, Claudio MA13.05
Giunta, Domenica EP08.03-007
Giusti, Raffaele EP05.01-024, EP06.01-006, EP08.02-046
Gkiozos, Ioannis EP14.01-022
Glaser, Megan EP16.03-024
Glaser, Moritz EP08.02-114
Glass, Benjamin P2.07-01
Glazer, Daniel EP13.01-006
Gleason, Charles R. OA06.03
Gleeson, Fergus PL04.04
Glez Larriba, Jose Luis MA06.03, PL03.12
Glover, Michael EP08.01-045
Gnetti, Letizia EP02.04-001
Gobbi, Giulia EP16.03-042
Godar, Gilles EP16.01-018, MA12.04
Godfrey, Caroline EP01.05-010
Godfrey, Virginia EP16.04-017
Goebeler, Maria-Elisabeth EP08.02-116
Goetze, Thorsten O. P1.11-01
Goff, Miranda P2.08-08
Goffin, John R. P1.15-10
Gogishvili, Miranda P1.15-12
Goh, Boon Cher EP08.01-101
Goldberg, Judith D. EP01.06-003
Goldberg, Sarah EP08.02-019, EP08.02-125
Goldberg, Sarah B. OA03.06, P1.10-01
Goldman, Jonathan MA07.05, OA12.03, P1.06-01
Goldmann, Torsten EP11.01-007, EP16.01-019
Goldrick, Amanda OA12.05
Goldsbury, David P1.08.01
Goldschmidt, Jerome EP05.01-002
Gomà, Carles EP02.02-007
Gomatou, Georgia EP14.01-022
Gomes, Rafaela EP03.01-003
Gomes, Rita EP04.01-011
Gomez, Daniel P2.12-03, PL02.08
Gomez, Daniel R. EP05.01-014, EP05.01-025, P1.05-02
Gomez, Jorge EP07.01-002
Gomez, Jorge C. OA06.03
Gomez, Jorge E. P2.12-05
Gomez Castella, Roser OA06.04
Gompelmann, Daniela EP02.01-009, EP05.02-007, ES34.04
Goncalves, Susana EP01.05-004
Gong, Liang EP08.02-010
Gong, Weida EP16.04-017
Gong, Yi OA03.07
Gong, You-ling EP08.05-004
Gong, Youling EP05.01-005, EP05.01-027, EP05.01-028, EP14.03-002, OA02.05
Gonsalves, Wilson I. MA13.08
Gonzalez, Adela EP01.03-002
Gonzalez-Aguado, Laura EP03.01-012, P1.07-02
Gonzalez Cao, Maria EP08.02-032
González González, Sara Cristina EP16.04-014
Gonzalez-Larriba, Jose Luis P1.09-03
Gonzalez Ojea, Clara OA02.03
Gonzalez Rivas, Diego ES09.06
González-Rumayor, Víctor EP16.02-007
González Sánchez, Alejandro EP08.01-066
Gonzalez-Sanchez, Alejandro EP06.01-017, EP13.01-016
Gonzalo, Javier EP07.01-022, EP07.01-023
Goo, Jin Mo EP01.03-005, EP01.04-003, ES34.03
Good, Anthony J P1.15-08
Goodman, Erin EP08.02-171
Gopinathan, Aarthi P1.10-01
Gorden, Jed A. MA14.09
Gordo, Rocío EP08.02-131
Gorgens, Ulrike P2.04-05
Gorguner, Fulden EP07.01-003
Görgüner, Fulden EP07.01-010
Gorguner, Fulden EP08.03-004
Gori, Stefania EP05.01-024, EP06.01-006, EP08.01-030, EP08.02-046, EP08.02-048
Gorría, Teresa EP03.01-012
Gorria, Teresa EP08.01-090, EP08.01-091, MA07.07, OA07.06, OA13.04
Gorría, Teresa P1.07-02
Gorria*, Teresa P1.12-04
Goss, Glenwood OA15.05
Gotfredsen, Ditte R. EP08.02-105
Goto, Koichi EP08.02-016, EP08.02-019, EP08.02-045, EP08.02-113, MA13.04
Goto, Yasushi EP07.03-004, EP08.01-005, EP08.02-115, ES36.01, MA13.07
Gottfried, Maya OA12.06
Gouran-Savadkoohi, Mohammad EP05.01-035
Govers, Tim M. EP04.01-026
Govindan, Ramaswamy E P08.01-013, OA03.06, OA12.05
Goyal, Akash EP05.01-021
Graf, Ryon P2.14-01
Grah, Christian EP05.01-030
Grainger, Elizabeth EP03.01-014
Grainger, Ellie P1.15-11
Grande, Ilaria EP07.01-021
Grandon, Anaïs EP16.04-001
Grant, Benjamin EP11.02-001
Grant, Michael EP08.02-125
Grasmuk-Siegl, Erwin ES20.05
Gray, Elin EP16.01-002
Gray, Jhanelle IBS18.10
Gray, Jhanelle E. EP01.03-008
Gray, Steven EP02.01-002
Grecea, Miruna P1.16-02
Grecula, John EP05.01-021
Green, Sheryl M. MA08.03
Green, Teresa MA07.03
Grefte, Annemarie MA12.08
Gregg, Jeffrey EP08.02-080
Gregorc, Vanesa EP05.01-024, EP06.01-006
Grenda, Anna EP01.01-008
Greystoke, Alastair EP05.01-007, OA01.05
Gridelli, Cesare EP05.01-024, EP06.01-006, EP08.02-048, P1.11-01, P2.14-02
Grier, William EP07.01-001
Griesinger, Frank EP04.01-014, EP05.01-030
Griffin, Michael P2.15-01
Grills, Inga ES38.03
Grindheim, Jessica OA14.06
Gristina, Valerio EP08.03-007, EP16.01-013
Groen, Harry J. P1.02-03
Groeschel, Andreas EP05.01-030
Grogan, Eric EP01.05-008, EP01.05-009
Grogan, Eric L. EP01.05-010
Grogan, Madison EP08.01-019, EP08.01-062
Grohe, Christian EP08.01-021, ES02.02, OA06.02, P1.15-05
Grønberg, Bjørn H. EP01.01-005
Gross, Jefferso L. EP02.03-010
Grossi, Francesco EP05.01-024, EP08.02-048
Grosso, Federica EP07.01-004
Grundberg, Oscar P2.13-03
Grüner, Barbara EP16.04-002
Grüner, Barbara M. EP16.03-004
Grusch, Michael EP05.02-007, EP07.01-014, EP07.02-001, EP14.02-002
Grynberg, Shirly EP08.02-047
Gu, Aiqin EP08.01-038
Gu, Aiqing EP05.01-36
Gu, Anxin EP05.02-022
Gu, LinPing EP16.03-031, EP16.03-032, EP16.03-033, WS08.23
Gu, Peng EP16.02-016, EP16.03-018
Gu, Qianqian EP14.01-016
Guaitoli, Giorgia EP02.04-001, EP14.01-006
Guarini, Attilio P2.10-05
Guarneri, Valentina EP08.01-012, EP08.02-104, P1.15-06
Guasch, Ignasi E P01.05-001
Guberina, Maja MA06.08
Guckenberger, Mathias PL02.04
Guckenberger, Matthias EP08.03-005, EP08.03-006
Guendaoui, Salma EP06.01-010
Guerrera, Francesco EP02.03-006, EP02.03-007
Guerrero Tejada, Rosario P2.13-01
Guessous, Fadila EP16.03-045
Guetz, Sylvia IBS12.01
Guggino, Gianluca EP05.03-008
Guha, Udayan EP08.02-055
Guida, Annalisa EP08.01-007
Guida, Florence MA11.05, P1.01-01
Guillaudeux, Thierry EP16.02-004
Guimaraes, Marcos MA11.09, WS07.05
Guimaraes De Sousa, Luana MA01.03
Guirado, Maria P1.09-03, P1.15-09
Guldbrandsen, Kasper EP01.07-001
Güler, Gökberk E P06.01-007, P2.06-01
Gullo, Giuseppe P1.15-12
Gulyas, Miklos EP11.01-007, MA05.04
Gümüş, Mahmut OA12.06, P1.15-12
Gumustepe, Esra EP13.01-002
Gunasekaran, Muthukumar P2.13-01
Guo, Changyuan C. EP02.01-011
Guo, Chao EP16.01-017
Guo, Chenchen EP14.02-005

Guo, Gang EP16.03-001
Guo, Janet EP08.01-062
Guo, Lanwei EP01.05-005, OA13.05
Guo, Lei EP02.01-011, EP11.01-014
Guo, Lianying MA05.07
Guo, Lin EP05.02-021
Guo, Matthew EP08.01-086
Guo, qianqian EP08.02-069
Guo, Renhong EP14.01-007
Guo, Renhua EP08.02-139
Guo, Sanxing EP08.02-069
Guo, Yiying EP14.02-007
Gupta, Gaorav EP16.04-017
Gupta, Ishan EP11.01-002
Gupta, Nalini EP11.01-002
Gupta, Neeraj EP08.02-109
Gupta, Parikshaa EP11.01-002
Gupta, Parul P2.09-02
Gupta, Yashdeep P2.02-03
Guramare, Maria P2.15-01
Gürbüz, Mustafa E P08.01-024
Gürler, Fatih EP08.01-024
Gursoy Coruh, Aysegul EP13.01-002, P1.12-03
Gurwitch, Annabelle PL01.05
Gutierrez, Martin EP08.01-044, P1.15-08
Gutierrez, Salvador MA09.09
Gutiérrez Sainz, Laura EP08.01-048, EP08.02-088, EP16.01-007
Gutiérrez-Sainz, Laura EP08.01-049, EP16.02-014
Gutierrez-Torres, Salvador MA14.03, WS07.03
Güven, Deniz C. EP08.01-024
Guzman, Arielle EP10.01-014
Gwon, Hye Ran EP13.01-004
Gyotoku, Hiroshi EP08.04-005

H

Haas, Rick EP05.01-009
Haber, Adi EP16.03-028
Haberberger, James P2.14-01
Habes, Haneen EP01.02-002, P2.11-01
Habes, Yousef EP01.02-002, P2.11-01
Haddad, Hussam EP07.01-016
Haddad, Philip A. EP07.01-006, EP14.05-006
Haderi, Artes EP01.03-004
Hafidi, Sara EP16.03-045
Hafizi, Hasan EP03.01-004
Haggstrom, Daniel EP08.02-041
Haglund, Karl EP05.01-021
Hahne, Sabine EP08.02-114
Hajj, Carla EP05.01-025
Hakozaki, Taiki EP08.01-104
Hall, Nicole P2.12-05
Hall, Richard EP08.01-034
Hallam, Matthew EP05.01-007
Hallberg, Bengt EP16.03-012
Hallet, Julie EP04.01-027
Halling, Kevin EP08.02-037
Halmos, Balazs MA05.08, P2.10-02
Hamada, Akira EP08.02-085, EP08.02-146
Hamada, Chizuru EP08.02-143
Hamaguchi, Naohiko EP08.02-143
Hamamoto, Ryuji MA04.04
Hamanaka, Kazutoshi MA03.07, P2.12-02
Hamann, Heidi P2.08-09
Hamatake, Motoharu EP08.02-144
Hamer-Wilson, Jill MA08.09
Hami, Hinde EP14.01-018, EP16.04-018
Hamlish, PhD, Tamara EP10.01-014
Hamm, Margaret EP02.03-008
Hammoud, Dalia EP14.05-006
Hamon, Rhys EP16.04-020
Hamouri, Shadi EP02.04-008, EP05.02-012, EP05.03-010, EP07.01-025, EP08.02-121
Hampe, Marcio P1.09-02
Han, Baohui EP01.03-010, EP05.01-36, EP08.01-042, EP08.01-052, EP08.01-102, EP08.01-103, EP16.01-032, EP16.02-023, EP16.02-028, OA05.05, P1.11-02, WS08.10
Han, Cuicui MA14.05
Han, Ji-Youn EP08.02-012, EP08.02-025, EP14.01-023, EP14.05-008, P1.16-01
Han, Joonhee EP13.01-003
Han, Li EP09.01-002
Han, Sae-Won OA03.04
Han, Summer EP08.01-045
Han, Sun EP05.02-022
Han, Xianwei EP08.05-003
Han, Yeonbi EP11.01-013
Han, Ying EP05.01-015
Han, Yuchen EP16.03-044, MA05.07
Hanaoka, Takaomi EP01.06-008
Handa, Hiroshi O. EP11.01-010
Hanefioui, Kawtar EP16.03-045
Hanley, Michael J. EP08.02-109
Hann, Christine EP02.04-007, EP08.01-086, ES30.03
Hanna, Gerard EP05.01-007, MA09.05
Hanna, Gerard G. EP05.01-023, EP08.03-005, P1.10-03
Hanna, Gerry P1.10-02, P2.03-01
Hanna, Nasser MA06.05
Hanna, Wael C. OA14.03
Hanna, Wael C. MA08.03
Hannon, Clare EP08.02-150
Hanriot, Rodrigo d. EP02.03-029
Hansen, Karin Holmskov EP08.02-099
Hantula, Spencer EP01.01-010
Hanvesakul, Raj P2.10-02
Hao, Desiree EP04.02-004, EP06.01-003, EP08.02-014, EP10.01-008
Hao, Xuezhi EP08.01-089, EP08.02-007, EP08.02-008, EP08.02-009, EP08.02-100, EP08.02-145, EP13.01-013
Hara, Jared EP14.03-001
Hara, Satoshi EP08.01-005
Harada, Guilherme EP08.02-059
Harada, Ken ES23.05
Haramati, Linda EP01.04-001
Haratani, Koji EP16.02-005
harb, ahmad EP14.05-018
Hardardottir, Hronn EP16.02-009, EP16.03-013
Hardcastle, Nicholas EP05.01-023
Harden, Susan EP04.01-023, EP14.05-016
Harden, Susan V. OA01.04
Hargrave, Joanne P1.13-01
Hargreaves, Sarah ES20.04
Haridas, Chinmay OA05.03
Haridas, Chinmay S. EP14.05-003
Hariharan, Ananya EP07.02-004
Harkin, Timothy P2.12-05
Harmsen, William EP05.01-011
Harpole, David MA03.06
Harris, Eric M. EP14.01-004
Harris, Faye P2.14-03
Harris, Margaret EP05.01-012
Harrison, Samantha EP04.02-002
Harrison, Sebron EP02.04-004
Harrow, Stephen EP05.01-007
Hartley, John EP05.01-007
Hartmaier, Ryan EP08.02-138, EP08.02-140
Hartman, Douglas PL04.03
Hasan, Haroon EP08.01-065
Hasegawa, Kazuo EP10.01-003
Hashemi, Sayed M. EP08.02-122
Hashemi Sadraei, Nooshin OA12.05
Hashimoto, Hiroya EP16.02-005
Hashimoto, Kazuki EP08.02-168
Hashimoto, Kohei EP02.01-006, EP02.01-014
Hashimoto, Takafumi EP08.02-123
hassan, Jouhadi EP06.01-010
Hassan, Raffit ES13.06
Hata, Akito EP08.01-005, EP08.02-133, EP10.01-003, EP16.02-005
Hataji, Osamu EP08.01-005
Hatakeyama, Yukihisa EP14.05-022
Hatamleh, Zaid EP08.02-121
Hattori, Aritoshi EP02.03-025
Hattori, Noboru EP08.01-064
Hautzel, Hubertus EP02.01-010, EP04.01-016, EP04.02-005
Hayakawa, Daisuke EP08.02-113, EP16.02-005
Hayasaka, Kazuki MA03.05
Hayashi, Fumiko EP08.04-005
Hayashi, Hidetoshi EP08.01-005, EP08.02-115, EP08.02-118, MA06.04
Hayenga, Jon P2.11-02
Hayes, Josie EP08.02-111
Hayes-Lattin, Brandon OA06.06
Hayoz, Stephanie EP16.01-018, MA12.04
Hazama, Daisuke EP16.02-005
He, Baimei EP05.02-010
He, chunyu EP08.03-001
He, Jianxing EP05.02-009
He, Jie EP16.01-023, P1.06-01, WS08.20
He, Kai EP08.01-062, EP08.01-098, EP14.05-004, OA12.04
He, Ruoxi EP05.02-010
He, Xuanyao P1.15-12
He, Yiming EP02.01-003
He, Yong EP08.02-064, EP08.02-108
He, Zhangyi EP16.04-011
He, Zhi Yong EP08.02-078
Hecker, Erich EP05.03-010
Hee, Yan Ting EP16.01-030
Heeke, Simon EP11.01-005, EP11.01-006, MA01.03
Hegde, Priti EP08.02-084
Hegde, Samarth P2.12-05
Hegedues, Balazs EP02.01-010
Hegedüs, Balazs EP16.03-004, EP16.04-002, P1.14-05

Hegedüs, Luca P1.14-05
Hegi-Johnson, Fiona ES29.01, MA09.05, P1.10-02, P2.03-01
Heigener, David EP16.01-011
Heineman, David J. OA06.05
Heinzen, Sophie EP14.01-008
Heisler, Christine MA14.04
Heitman, Kristen EP03.01-014
Hemmati, Mehdi EP01.04-002
Henderson, Brian D. EP02.01-002
Hendriks, Lizza EP14.01-014, ES19.01, OA07.06, P1.15-01
Hendriks, Lizza E. EP08.01-026
Henick, Brian P2.12-01
Hennequin, Clotilde P2.12-05
Hennessy, Cassandra OA06.06
Hennessy, Sean EP08.01-063
Hennink, Merel ES27.06, IBS09.02, MA08.07, P2.08-05, P2.08-06
Henry, Cyndi EP16.03-020
Henry, Valencia EP08.01-023
Henschke, Claudia EP01.04-005, EP01.05-011, EP02.03-011, MA11.07, P1.02-02
Henschke, Claudia I. EP01.01-002, EP01.06-009, EP01.07-003
Henschke, Claudia I. OA06.03
Hepp de los Rios, Rodrigo EP04.01-016, EP04.02-005, MA06.08
Herbst, Roy EP14.01-015
Herbst, Roy S. P2.12-03
Heredia, David EP07.01-011, EP08.02-035, EP16.03-023, MA09.09, MA14.03, WS07.03, WS07.04
Herman, Josh EP02.04-009, EP04.01-001
Herman, Joshua EP03.01-002
Hernández, Ainhoa EP08.01-029
Hernandez, Andrea P1.14-02
Hernández, Irene EP08.02-088, EP16.01-007, EP16.02-014
Hernandez, Susana P2.07-02
Hernández-Barajas, David EP16.03-026
Hernandez-Pedro, Norma EP07.01-011, EP16.03-023, WS07.04
Hernandez-Vargas, Hector OA04.05
Hernando Trancho, Florentino MA06.03, PL03.12
Hernando-Trancho, Florentino P1.09-03
Herrmann, Ken EP14.01-020
Herzig, Petra EP16.01-018, MA12.04
Herzog, Brett EP08.01-013
Hespanhol, Venceslau EP03.01-009
Hespanhol, Venceslau M. EP01.01-007, EP16.02-011, EP16.02-012
Heuer-Olewinski, Nadine EP16.01-011
Heukamp, Lukas C P2.14-02
Heuvelmans, Marjolein ES01.02, WS02.25
Heuvelmans, Marjolein A. EP01.05-006
Heymach, John EP08.02-049, EP08.02-163, PL02.05
Heymach, John V. EP02.04-005, MA01.03, OA15.05
Higgins, Chelsea EP08.01-016
Higgins, Kristin EP08.01-060, MA09.06, P2.04-05
Higgins, Kristin A. EP14.03-003, P1.10-04
Higuera, Oliver EP08.01-049, EP16.02-014
Higuera Gómez, Oliver EP08.01-048, EP08.02-088, EP16.01-007
Hijazo-Pechero, Sara P2.14-04
Hilberg, Ole EP01.07-001
Hiley, Crispin EP05.01-007, EP08.03-005
Hillinger, Sven P2.11-03
Hillmer, Axel EP08.02-031
Hillmer, Axel M. EP08.02-106
Hiltbrunner, Stefanie P1.14-01
Hilts, Annalise MA12.05
Hilz, Stephanie OA14.06
Hilzenrat, Roy A. EP02.01-001
Himpe, Ulrike EP08.02-162
Hines, Adam EP08.02-129
Hinrichsen, Laura B. EP06.01-011
Hipper, Annette EP05.01-030
Hirai, Yoshimitsu EP02.03-017
Hiret, Sandrine EP14.01-004
Hirsch, Fred MA01.04
Hirsch, Fred R. EP07.01-001, EP16.03-029, P2.12-05, P2.13-01
Hirsch, Fred R. IBS17.01, OA06.03
Hirsh, Vera EP05.02-019
Hishida, Tomoyuki EP07.03-007
Hlaing, Nwe Oo EP16.03-036
Ho, Cassandra S. EP16.03-004
Ho, Chao-Chi EP05.01-003, EP08.02-027, EP08.02-127
Ho, Cheryl EP03.01-016, EP08.01-074, EP08.01-075, EP08.02-089, EP14.04-001, EP14.05-017, EP14.05-020, P2.09-03
Ho, James C. EP03.01-011
HO, James Chung Man EP16.01-024
Ho, James Chung-Man EP07.01-008
Ho, James CM EP16.04-006
Ho, James, Chung Man EP05.02-020
Ho, Jia Min EP01.01-006
Hoang, Tuan EP08.01-067
Hobson, Rosalind OA15.05
Hochhegger, Bruno EP01.04-005, MA11.07, MA11.09, WS07.05
Hochmair, Maximilian EP16.01-015
Hochmair, Maximilian J. EP02.01-008, EP08.02-122
Hocum, Craig EP05.01-011, MA13.09
Hoda, Mir A. EP07.01-014, EP14.02-003
Hoda, Mir Ali Reza ES12.02
Hoda, Mir Alireza EP02.01-009, EP05.02-007, EP07.02-001, MA01.04, MA04.01
Hodgson, Darren EP16.02-027
Hoetzenecker, Konrad EP02.01-009, EP05.02-007, EP07.02-001, EP14.02-002, EP14.02-003, EP14.02-006, MA01.04
Hoffknecht, Petra EP05.01-030, EP08.01-057
Hoffmann, Andreas-Claudius EP04.01-016, EP04.02-005
Hoffmann, Hans ES03.02
Hoffmann, Lone EP05.01-017
Hofman, Michael S. EP05.01-023
Hofman, Paul EP11.01-005, EP11.01-006
Hofman, Véronique E P11.01-005, EP11.01-006
Hofmanninger, Johannes EP13.01-011
Hogan, Heather MA08.09
Hogg, Phil EP16.03-041
Hogg, Philip P1.12-02
Holland, Devin EP05.01-019
Holt, Gregory E. OA10.06
Holt, Marianne I. EP05.01-017
Holtzman, Liran EP08.02-047
Holz, Barbara EP08.02-031
Homer, Robert J. EP14.05-021
Honda, Akira EP16.04-009
Hong, David S. OA03.03
Hong, Hui-Zhao EP16.02-024
Hong, Huizhao EP05.02-006
Hong, Ilene EP08.02-062
Hong, Lingzhi EP08.02-163
Hong, Min Hee EP08.02-012
Hong, Min-Hee MA07.09
Hong, Sungyoul EP14.02-004
Hong, Wei EP08.01-032, EP16.03-005
Hopman, Wilma EP14.05-010
Hoppe, Bradford S. EP05.01-011
Horiike, Atsushi MA13.07
Horinouchi, Hidehito EP07.03-004
Horiuchi, Minoru OA07.03
Horn, Leora EP08.01-028
Horne, Ashley EP05.01-007
Horner, Andreas EP08.01-108
Horodniceanu, Erica EP04.01-004
Horowitz, Jeffery P1.03-01
Horrigan, Stephen K. EP08.02-130
Hosaka, Yoshinao EP16.04-025
Hosmer, Wylie OA06.06
Hosomi, Yukio EP08.01-104, EP08.01-105, EP14.05-007
Hou, Likun EP02.01-007
Hou, Liqiao EP05.01-033
Hou, Runping EP05.03-012
Hou, Ting MA02.05
hou, xiaoming EP08.02-033
Hou, Xinli EP08.02-033
Houben, Ruud EP14.01-014
Houck-Loomis,, Brian EP16.03-030
Hounsell, Alan R. P1.10-03
Hourani, Mohammad EP03.01-010
Housseau, Franck MA03.04
Howarth, Karen P1.16-02
Hoxha, Tedi EP02.04-009, EP04.01-001
Hoyd, Rebecca EP03.01-014, EP08.01-019
Hrinczenko, Borys MA06.05
Hsia, Te-Chun EP05.01-003
Hsiao, Susan EP08.02-117
Hsu, Athena EP01.06-004
Hsu, Chih-Yuan EP08.01-028, OA06.03
Hsu, Kuo-Hsuan EP08.02-155
Hsu, Ying-Han R. EP11.02-001
Hu, Chen EP02.04-007, EP07.01-018, EP14.03-005, MA03.04
Hu, Chunhong EP01.07-005, EP08.01-092
Hu, Desheng OA02.05
Hu, Eddie H. MA07.05
Hu, Fang E P08.01-038, EP08.01-039
Hu, Jian EP05.02-009
Hu, Jie WS08.07
Hu, Junjiao EP01.07-005
Hu, Ping WS02.27
Hu, Sheng EP08.01-014
Hu, Tao EP16.01-005, MA05.07
Hu, Xiaohan EP02.03-009, EP08.01-083, EP08.01-087, OA07.04
Hu, Xingsheng EP07.03-003, EP08.01-053, EP08.01-054, EP16.02-017

Hu, Xue MA05.05
Hu, Yan Ping EP08.02-078
Hu, Yan-Ping EP08.02-064
Hu, Yi EP05.02-018
Hu, Ying EP08.02-039
Hu, Zhibin ES22.05
Hua, Chung Chian EP05.01-003
Huang, Cheng OA02.05
Huang, Ding Zhi EP08.02-078
Huang, Dingzhi EP08.01-014, EP08.01-070, WS08.15
Huang, Holly K. MA07.05
Huang, Hsu-Ching EP16.01-003
Huang, Huayan EP08.03-008, OA11.05
Huang, Jie EP08.01-056, EP08.02-068, EP08.02-136, MA02.05
Huang, Jing EP14.01-016
Huang, Joanna EP14.05-016
Huang, Jun EP02.04-010
Huang, Meijuan EP08.02-067, EP14.03-002
Huang, Mengli EP14.01-001, EP14.01-007, EP14.01-024
Huang, Mingfeng EP08.01-082
Huang, Peng MA03.04, P1.04-02
Huang, Richard S. P2.14-01
Huang, siyuan EP08.02-069
Huang, Weiye MA02.05
Huang, Wen-Tsung EP08.02-029
Huang, Xiangning EP08.02-108, P1.06-01
Huang, Yan MA14.05
Huang, Yen Hsiang EP08.02-155
Huang, Ying EP08.01-107, WS08.16
Huang, Yiqing EP08.01-101
Huang, Yu MA09.04
Huang, Yunchao EP05.02-009, EP08.02-139
Huang, Zhicheng EP16.01-017
Huang, Zhiyu EP07.02-006, EP08.01-032, EP08.01-033
Huang, Zhonglu EP08.01-060
Hubbard, Caroline EP08.01-034
Hubbard, Rebecca A. EP08.01-063
Hubbard, Ruth E. EP04.01-013
Huber, Christoph PL01.06
Huber, Michael EP10.01-014
Huber, Rudolf P1.02-02
Huber, Rudolf M. MA04.10
Hueniken, Katrina EP02.04-009, EP03.01-002, EP04.01-001, EP14.01-019
Hughes, Brett EP16.03-005
Hughes, Rebecca EP01.06-005
Hughesman, Curtis EP02.01-001
Hui, Rina OA15.06
Hui, Zhenzhen OA09.03
Hulo, Pauline EP16.04-019
Hum, Yee Fang EP01.01-006
Hummel, Horst-Dieter OA12.05
Humphries, Michael J. EP08.02-156
Hung, Jen-Yu EP08.02-027
Hung, Rayjean ES22.01
Hung, Tiffany E P16.02-027
Husain, Hatim P2.14-01
Husain, Marium EP08.01-062
Hussein, Maen EP08.01-027, OA15.04, P1.15-11
Hutcheson, Tresza OA10.04
Hveem, Kristian P1.01-01
Hwalek, Ann E. EP02.03-008
Hwang, Clara OA06.06
Hwang, David MA12.07
Hwang, Wei-Ting P1.15-07
Hwang, Yoohwa EP16.03-034
Hydbring, Per EP16.02-008, P2.13-03
Hysko, Pellumb EP03.01-004

I

Iacono, Federica EP16.01-013
Iams, Wade EP08.01-109
Iams, Wade T. EP08.02-126, OA03.06
Ibáñez Cabeza, Borja EP08.01-048
Ibáñez de Cáceres, Inmaculada EP08.02-088, EP16.01-007 EP16.02-014
Ibi, Takayuki EP16.01-029
Ibrahim, Kareem EP02.03-023
Ibrahim, Mohsen EP01.06-001, EP05.03-002
Ibrahimov, Ferruh EP13.01-002
Ichinose, Junji EP02.01-006, EP02.01-014
Ide, Shogo MA03.07, P2.12-02
Idzko, Marco EP02.01-009
Iglesias, Marcelo d. EP06.01-011
Iguchi, Hideto EP02.03-017
Ihle, Rayan EP01.02-006, EP01.02-007
IJzerman, Maarten J. EP08.02-061 EP01.02-001
Ikeda, Norihiko EP02.01-017, EP16.03-029, EP16.03-037, EP16.04-009
Ikeno, Takashi EP02.01-005
Ikeya, Tomohiko EP16.01-029
Ilié, Marius EP11.01-005, EP11.01-006
Illei, Peter B. EP02.04-007 MA03.04
Illini, Oliver EP02.01-008, EP08.02-122
Imaizumi, Kazuyoshi EP08.02-115
Imamura, Satomi EP05.02-017
Imoto, Tomohiro EP07.03-007
Incharoen, Pimpin EP02.01-016
Incorvaia, Lorena EP16.01-013
Inculet, Richard EP02.01-013
Inculet, Richard I. OA06.07
Indraccolo, Stefano EP08.02-104
Infantine, Joshua MA07.03
Inguglia, Sara EP16.01-013
Innocenti, Beatrice P2.04-03
Inomata, Sho P1.15-13
Inoue, Akira EP10.01-003
Inoue, Hiromasa EP08.01-064
Inoue, Hiroyuki EP08.01-036
Inoue, Takashi EP05.02-017
Inoue, Takeo EP11.01-010
Insa, Amelia EP04.01-002, EP08.02-149, MA06.03, OA02.03, P2.07-02, PL03.12
Insalaco, Lavinia EP16.01-013
Internullo, Eveline HOD01.01
Iqbal, Afsheen N. EP05.01-025
Iranzo, Patricia EP07.01-022, EP07.01-023, EP08.01-029, EP08.01-078
Iranzo Gómez, Patricia EP08.02-070
Irem, Zenciye K. EP02.02-009
Ćirić, Eva EP05.01-013
Irie, Nanami EP16.04-025, EP16.04-026, EP16.04-027
Isaksson, Johan MA05.04
Isbell, James M. EP05.01-014
Ishihara, Takeaki MA06.04
Ishijima, Mikako EP08.02-168
Isla, Dolores EP16.01-014
Islam, Shahidul EP16.04-012
Ito, Hiroyuki EP02.01-017
Ito, Toshinari EP02.01-015
Ito, Yutaka OA07.03
Iwama, Eiji EP08.01-036
Iwano, Shingo EP02.01-015
Iwasawa, Shunichiro EP08.01-005
Iwaya, Mai MA03.07, P2.12-02
Iyer, Aparna EP04.01-009
Iyer, Sonia OA15.05
Izquierdo, Paola EP16.02-018
Izumi, Hiroki EP08.02-113, OA12.05

J

Jabbal, Iktej S. EP08.01-023
Jabbour, Salma MA06.05
Jacob, Natalia OA15.03
Jacobs, Francesca EP08.02-101, P2.14-02
Jacobs, Michael A. MA03.04
Jacobson, Blake P1.14-04
Jaenicke, Martina EP05.01-030
Jaffee, Elizabeth EP08.01-086
Jafri, Syed EP08.01-079
Jahanzeb, Mohammad EP08.02-156
Jain, Amit EP16.03-036, P2.13-02
Jain, Deepali EP03.01-005, EP03.01-006, EP11.01-002, EP11.01-011, MA12.02, MA12.07, P2.02-03
Jain, Suneil P1.10-03
Jajodia, Ankush ES34.02
Jakobsen, Erik EP04.02-002, EP08.02-105
Jakopović, Marko EP05.01-018, EP08.02-058
Jakopovic, Marko EP07.01-012, EP07.02-001, P2.04-01
Jakubowski, Debbie EP01.01-003
Jalal, Shadia MA06.05
Jaller, Elvira EP05.01-001, EP16.03-002, EP16.03-003
Janes, Sam ES01.05
Jang, Hee-Jin P1.14-02
Jang, Hyun Woo EP08.02-025
Jang, Jae-Hwi EP16.04-010
Jang, Seung Hun EP01.03-005, ES18.03
Jang, Tae Won EP08.02-142
Jangra, Kirti EP03.01-005
Jani, Chinmay OA06.06
Janke, Florian EP08.01-031
Jankharashvili, Natalia EP01.03-013
Jankowski, Grzegorz EP01.01-008
Jankowski, Tomasz EP01.01-008
Jänne, Pasi A. EP08.02-029 EP13.01-006, WS03.10, EP08.02-171, MA07.10
Janopaul-Naylor, James R. P1.10-04
Jansen, Christian EP16.01-015
Jansen, Sophie EP08.02-055
Jansriwong, Phichai EP02.01-016
Janssen, Tomas EP05.01-009
Janzen, Ian EP01.05-007
Japaridze, Nino EP01.03-013
Jarrett, Jennie EP10.01-014

Jarry, Ulric EP16.02-004
Jassem, Jacek ES06.07, ES37.04
Jaus, Massimo O. EP07.01-017
Javed, Syed Ashar P2.15-01
Jayasekera, Jinani OA10.03
Jazen, Ian P2.09-03
J. Cilento, Vanessa MA04.05
Jean, Didier OA04.05
Jeklin, Andrew T. P2.08-02
Jekunen, Antti EP04.01-012
Jelerčič, Staša EP05.01-013
Jelitto-Gorska, Malgorzata EP01.04-005, MA11.07
Jensen, Kristoffer J. EP08.02-105
Jeon, Hyeong-Eun P2.05-01
Jeon, Jae Hyun EP16.03-034
Jeon, Jihyoun OA10.03
Jeon, Yeong Jeong MA03.03
Jeon, Yunho EP02.03-013
Jeong, Sukin EP16.04-016
Jeong, Sungchan MA07.09
Jermann, Philip EP16.01-018, MA12.04
Jerusalem, Guy OA03.04
Jesus, Filipa EP08.02-054
Jheon, Sanghoon EP16.03-034
Ji, Hongbin EP14.02-005
Ji, Jinfeng EP08.01-081
Ji, Wonjun EP08.01-041, EP08.02-128
Ji, Xianxiu EP08.01-097, EP08.01-107, WS08.16
Ji, Yinghua EP08.01-001
Jia, Haijian EP05.01-033, EP08.05-003
Jia, Nan EP08.02-138
Jialei, Wang EP08.02-052
Jian, Hong EP08.02-139, OA03.07
Jian, Ou OA02.05
Jiang, Changchuan EP02.04-006, EP07.01-002, EP08.01-050
Jiang, Fenge EP08.02-076
Jiang, Guanming EP08.02-139
Jiang, Haiyi EP14.04-002
Jiang, Hong EP14.01-021
Jiang, Juan EP05.02-010
Jiang, Li-Yan EP08.02-064
Jiang, Liyan EP08.01-038, EP08.01-039, EP08.02-029, EP08.02-139, OA03.07
Jiang, Long P1.02-02
Jiang, Tao EP02.01-018, EP05.02-021, EP16.01-005
Jiang, Wenjuan EP05.02-021
Jiang, Xin EP16.04-020
Jiang, Xu EP16.01-017
Jiang, Yingjia EP01.07-005
Jiang, Zhuoxin EP08.02-080
Jianying, Zhou EP08.02-052
Jie, Yamin EP05.02-022
Jiménez-Bou, Diego EP08.01-049
Jimenez-Fuentes, Edgardo EP08.03-003
Jiménez Munarríz, Beatriz EP08.02-070
Jin, Bo EP08.02-073
Jin, Janet P2.07-01
Jin, Xiangming EP08.02-139
Jing, Xiaohui EP08.01-001
Jirapatnakul, Artit EP01.01-002
Jiwnani, Sabita EP06.01-014, MA10.03
Jo, Anna MA07.08
Joa, Kyung-Lim P2.05-01
Job, Bastien MA10.08
Jöckel, Karl-Heinz MA06.08
Johal, Sukhvinder EP14.04-002
Johansson, Mattias EP01.01-005, ES22.02, MA11.05, P1.01-01
Johansson, Mikael EP01.01-005, EP04.01-012, MA11.05, P1.01-01
John, Ani EP08.02-061
John, Thomas EP14.05-016
John, Tom MA09.05, P1.10-02, P2.03-01
Johnson, Ann EP04.01-017, OA14.06
Johnson, Bruce EP13.01-006
Johnson, Bruce E. EP02.04-005, OA14.06
Johnson, Fiona Hegi ES33.05
Johnson, Fraser EP08.02-055
Johnson, Melissa EP08.02-041, OA12.05
Johnson, Melissa L. EP02.04-005, EP08.01-027, EP08.02-111, OA15.04
Johnson, Melissa L. EP14.01-004
Johnson, Sarah H. P2.14-03
Johnson, Tirrell OA12.03
Jones, Ann-Marie OA08.05
Jones, David R PL03.06
Jones, Lauren EP08.02-089
Jones, Mike EP13.01-001
Jones, Robert EP05.01-007
Jones, Xavier EP05.02-013
Jonigk, Danny EP07.03-005
Jordan, Simon EP11.03-003, P1.12-05
Jordana, Núria EP08.02-120
Jordana-Ariza, Nuria EP08.02-135
Josan, Enambir P1.03-01
Joseph, Gregory EP08.01-060
Joseph, Vishwas EP16.03-024
Joshi, Kirti EP08.02-162
Joshua, Anthony EP16.03-041
Jost, Philipp J. EP02.01-008
Jouan, Florence EP16.02-004
Joubert, Philippe EP16.02-027, EP16.03-020
JOUHADI, Hassan EP06.01-012
Jovanoski, Nick EP04.01-017
Jové, María EP16.03-027
Joy, Awosika OA06.06
Ju, Young Seok EP16.03-017, EP16.04-013
Juan, Li EP08.02-052
Juan, Oscar P2.07-02
Juan-Cruz, Celia EP05.01-010
Juan-Vidal, Oscar EP08.01-029, EP14.01-004
Juergens, Rosalyn EP04.02-004, EP08.02-034
Jukich, Megan EP14.05-004, OA12.04
Juloori, Aditya EP14.03-001
Jun, Chen EP08.02-052
Jun, Ha Ra EP08.01-017
Jun, Zhao EP08.02-052
Jung, Chi Young EP08.02-142
Jung, Hyun-Ae MA07.09, MA07.09
Jung, Jae Seob EP08.02-128
Jung, Ji Eun MA07.08
Jung, Se Hee EP16.04-016
Jung, Sujin MA07.09
Jung, Woohyun EP16.03-034
Jung, Yoojin EP16.02-021

K

Kabus, Sven EP05.01-019
Kadkhoda, Haleh EP08.02-117
Kadomatsu, Yuka EP02.01-015
Kadrija, Dzenete EP10.01-011
Kaen, Diego L. EP03.01-003
Kagawa, Yusuke OA07.03
Kahn, Shannon EP14.03-003
Kahraman, Arda EP02.02-009
Kahraman Aydın, Seda EP02.03-026
Kahya, Yusuf EP07.01-003, EP07.01-010, EP08.03-004, EP10.01-013, EP13.01-002, EP16.01-004, P1.12-03
Kai, Yuichiro EP16.01-004
Kaiser, Bernhard EP08.01-108
Kaizer, Alex EP01.05-009
Kakumanu, Saranya EP08.02-024
Kalashnikova, Ekaterina P2.13-02
Kalemkerian, Gregory P. OA12.06
Kalinka, Ewa P1.15-11
Kalnicki, Shalom EP01.04-001
Kalofonos, Charalampos EP10.01-018
Kalofonos, Haralabos EP08.01-072
Kalra, Kaushal P2.02-03
Kalra, Manik EP08.02-053
Kamal, Khaled ES15.02
Kambartel, Kato EP08.01-057, P1.15-05
Kaminski, Michael F. OA11.03
Kamińska, Anna EP01.01-008
Kammer, Michael N. EP01.05-008, EP01.05-009
Kampschroeder, Amy MA08.05
Kan, Joshua EP03.01-011
Kan, Tal EP16.01-016, EP16.03-028
Kanamori, David OA12.03
Kanazu, Masaki EP08.02-168
Kanchi, Krishna L. EP16.03-025
Kandi, Maria EP05.01-017
Kanemitsu, Yoshihiro OA07.03
Kaneshiro, Kazumi EP14.05-022
Kanesvaran, Ravindran EP16.03-036, P2.13-02
Kang, Chang Hyun EP02.03-004, EP07.03-001, EP16.02-021
Kang, EunKyo EP01.03-005, EP01.04-003, EP01.05-003
Kang, Hye Seon P2.01-01
Kang, Jin-Hyoung EP08.01-073
Kang, Yoonmi EP08.02-128
Kanjanavithayakul, Yanisa EP08.02-164
Kanne, Jeffrey P. EP01.07-002
Kantathut, Narongrit EP02.01-016
Kantor, Sydney EP02.03-011
Kanzawa, Hiroya EP16.03-029, EP16.04-009
Kao, Steven EP16.03-005
Kapisyzi, Perlat EP03.01-004
Kapodistrias, Nikolaos EP10.01-018
Kapoor, Shweta EP16.03-024
Kapur, Dinesh P1.11-01
Kara, Hasan V. EP05.03-001
Kara, Hasan Volkan P2.06-01
Karaağaç, Mustafa EP08.01-024
Karabatic, Sandra EP07.01-012, P2.04-01
Karachaliou, Niki EP08.02-162
Karacosta, Loukia G. EP16.02-015
Karadurmuş, Nuri EP08.01-024
Karagouga, Giannoula P2.14-03
Karakulah, Gokhan EP08.02-022

Karashima, Takashi EP08.02-123
Kareff, Samuel EP04.01-010
Kargl, Michaela EP11.02-002
Karikios, Deme P1.08.01
Karim, Nazmul OA01.03
Karimundackal, George EP06.01-014, MA10.03
Karkouri, Mehdi EP16.03-045
Karp, Daniel D. EP08.01-059
Kärre, Klas MA05.04
Karthik, Venkataramani MA10.03
Kasahara-Kiritani, Mami EP10.01-003
Kasajima, Rika EP11.01-008
Kaseda, Kaoru EP07.03-007
Kasi, Anup OA06.06
Kasymjanova, Goulnar EP04.02-004, EP06.01-001, EP11.03-001
Katakami, Nobuyuki EP08.02-133
Katakura, Seigo EP11.01-008
Katara, Rahul EP11.01-012
Katcharava, Margarita EP01.03-013
Kato, Takahide EP08.02-143
Kato, Taketo EP02.01-015
Kato, Terufumi EP08.02-045, EP08.02-108, EP08.02-113, EP08.02-115, EP11.01-008, MA03.01, OA12.06
Katona, Eszter EP05.01-007
Katsandjian, Suzanne OA07.06
Katsurada, Masahiro EP14.05-022
Katsurada, Naoko EP14.05-022
Katsuya, Ryotaro EP02.01-015
Katzenmeier, Marianna EP08.02-114
Kauczor, Hans-Ulrich EP01.02-001, ES18.06
Kaufman, Jacob EP08.01-062, EP08.01-098, EP14.05-004, EP16.03-009, OA12.04
Kauke, Teresa EP04.01-015
Kaumaya, Pravin P1.15-08
Kaur, Harvinder EP16.01-030, EP16.02-013
Kaur, Maneet EP16.02-002
Kaushal, Rajiv EP06.01-014
Kavak, Kubra Alphan EP07.01-010, EP08.03-004, EP10.01-013
Kawa, Yoshitaka EP14.05-022
Kawaguchi, Yohei EP16.03-029
Kawamukai, Kenji EP02.03-019
Kawamura, Masafumi EP16.01-028, EP16.01-029
Kawase, Shigeo EP08.01-064
Kayı Cangır, Ayten EP07.01-010
Kayi Cangir, Ayten EP07.01-003, EP08.03-004, EP13.01-002, EP16.01-004, P1.12-03
Kaynak, Kamil EP02.03-001, EP05.03-001, EP06.01-007, P2.06-01
Kaywin, Paul EP07.03-006
Kazdal, Daniel EP08.01-031
Kazernooni, Ella P2.08-07
Kazerooni, Ella P1.02-02, P2.08-09
Kazerooni, Ella A. EP01.07002, OA05.02, WS02.03, WS02.07, WS02.10, WS02.31
Ke, Leiyu EP16.03-001
Keall, Paul EP05.01-019
Keam, Bhumsuk EP07.03-001
Keartland, Sarah I. EP02.01-002
Keating, Garret EP02.01-002
Kececi Ozgur, Gizem EP13.01-014
Kee, Adrian EP08.01-101
Keenan, Robert PL03.06
Kefas, Joanna EP08.01-109
Keller, Eveline EP16.01-018, MA12.04
Keller, Ralph EP08.01-057, P1.15-05
Kelley, Michael EP08.01-045
Kelly, Karen EP08.01-061, IBS18.11, P2.12-03, WS03.03, WS08.04
Kelly, Sharon EP04.02-004
Kelsey, Christopher EP02.02-006
Kemp, Samuel P1.12-05
Kemper, Suzanne EP01.02-006, EP01.02-007
Kendall, Jessica EP05.01-007
Kenmotsu, Hirokazu EP08.02-115
Kenmotsu, Hirotsugu EP16.02-005, PL03.09
Kennedy, Gregory T. OA14.05
Kentepozidis, Nikolaos EP10.01-018
Kepka, Lucyna ES06.05
Keren-Rosenberg, Shoshana EP08.02-122
Kern, Izidor EP11.02-002, MA01.04
Kern, Jens EP08.01-057
Kerns, Jessica L. EP01.04-004
Kerpel-Fronius, Anna MA11.01, P1.02-02
Kerr, Daniel L. EP08.02-147
Kerr, Keith ES10.01, MA12.07
Kersey, Gina OA01.06
Kesarwala, Aparna H. EP14.03-003, P1.10-04, P2.04-05
Ketpueak, Thanika EP08.02-026
Key, Brenda L. MA08.03
Khalil, Azza EP05.01-017
Khalil, Maryam EP16.04-015
Khalil, Sultanem EP06.01-001
Khan, Hamza MA03.04
Khan, Hina EP16.03-021, OA06.06
Khan, Khadeja EP04.01-010
Khan, Khaleeq EP02.04-009, EP03.01-002, EP03.01-016, EP04.01-001, EP08.02-082, EP14.04-001, EP14.05-020
Khan, Nida EP08.01-068
kharadze, Rusudan EP01.03-013
Khattra, Sukhinder EP01.05-007
Khiewngam, Khantong EP02.01-016
Khodos, Inna MA13.05
Khoo, Edwin P1.02-04
Khoudigian, Shoghag EP08.02-103
Khoury, John EP08.02-118
Khrizman, Polina EP08.02-081
Khurana, Sachin EP03.01-005, EP03.01-006, EP11.01-011, P2.02-03
Ki, Min Seo EP02.03-003
Kian, Waleed EP08.02-047, EP08.02-122
Kida, Hirotaka EP11.01-010
Kidane, Biniam EP04.01-027, EP16.02-019, OA06.07
Kido, Shoji EP13.01-007
Kiedrowski, Lesli EP04.02-004
Kiedrowski, Lesli A. EP16.03-019
Kielly-Carroll, Candice EP01.02-004
Kikkawa, Hironori EP08.02-115
Kilaru, Sindhu EP08.01-025
Kilburn, Lucy EP08.03-005
Kilickap, Saadettin P1.15-12
Killean, Angus J. EP02.02-003, EP05.01-008
Kim, Choonok MA07.08
Kim, Chu Hyun P2.09-01
Kim, Chul EP02.03-008, EP08.01-044, P2.02-02
Kim, Dong Kwan EP05.03-004
Kim, Dong-Wan EP08.02-025, P1.16-01
Kim, Edward S. MA13.03
Kim, Eun Young EP16.04-016
Kim, Hak Jae EP07.03-001
Kim, Harim P2.09-01
Kim, Hong Kwan MA03.03, MA10.09
Kim, Hyae Young EP01.03-005, EP01.04-003
Kim, Hye Ryun EP08.01-073, EP08.02-012, OA12.06, P1.11-01
Kim, Hye Sook EP14.05-008
Kim, Hyeong Ryul EP05.03-004, EP05.03-005
Kim, Hyojin EP11.01-013
Kim, Hyung Kyung EP11.01-013
Kim, Hyung-Jun EP13.01-008
Kim, Jae Y. EP10.01-012
Kim, Jhingook MA03.03, P2.09-01
Kim, Jihun EP05.01-034
Kim, Jin EP08.01-016
Kim, Jin Soo EP14.02-004
Kim, Jong Kwang EP14.05-008
Kim, Jonghoon P2.09-01
Kim, Joo-Hang EP08.02-025
Kim, Joon Young EP05.03-004
Kim, Joseph EP08.02-081
Kim, Julian O. OA06.07
Kim, Kwhanmien EP16.03-034
Kim, Kyung Hwan EP05.01-034, OA11.04
Kim, Leeseul EP05.03-011, EP08.02-062, EP16.02-022, P2.12-04
Kim, Mi young EP07.01-015, EP14.02-004
Kim, Samuel EP05.03-011
Kim, Sang-We EP08.01-027, EP08.02-025, EP08.02-140, OA15.04
Kim, Se Hyun EP08.01-073
Kim, Seojin EP02.03-028
Kim, Seung Joon EP08.02-142, P2.01-01
Kim, Sundong MA02.07
Kim, Sung-Hwan EP05.01-032
Kim, Tae M. EP08.02-016
Kim, Tae Min EP08.02-019, EP08.02-045, EP08.02-171, MA07.09
Kim, Tae Won OA03.04
Kim, Tae-Min EP08.02-140
Kim, Taewoo EP16.03-017
Kim, Won-Hyoung P2.05-01
Kim, Yeol EP01.03-005, EP01.04-003, EP01.05-003
Kim, Yeon Sil ES19.05
Kim, Yeon Wook EP13.01-008
Kim, Yeonsil EP05.01-032
Kim, Yong Man EP08.02-128
Kim, Yong-Hee EP05.03-004, EP07.01-015
Kim, Yonghyun EP01.04-003
Kim, Young Tae EP02.03-004, EP16.02-021, EP16.03-017, EP16.04-013, MA03.10
Kim, Young-Chul EP08.01-017, EP08.02-086, EP08.02-142
Kim, Yu Jung P1.11-01
Kim, Yun Ho EP16.02-021

Kimberley, Rebecca EP04.01-013
Kimbrough, Erin EP16.03-016
Kimmich, Martin MA06.08
Kindler, Hedy L. EP07.01-013, WS04.17
King, Jennifer MA14.04
King, Jennifer C. EP08.02-043, IBS04.01, MA08.05, P1.12-01, P2.08-01, P2.08-09
King, Jennifer C. OA06.03
King, Mark P1.03-01
King, Seema EP10.01-008
King-Kallimanis, Bellinda EP04.01-004, MA08.04, OA01.06
Kinoshita, Akitoshi EP08.04-005
Kirchner, Martina EP08.01-031
Kirimis, Evangelia MA07.05
Kirschner, Michaela B. EP07.02-002, EP16.04-010, OA04.04, P1.14-01
Kirschner, Michaela B EP07.02-003
Kislov, Nikolay P1.15-11
Kitadai, Rui EP08.01-104
Kitazono, Satoru EP02.01-006
Kittaneh, Rahaf EP01.02-002, P2.11-01
Kizhake, Smitha P2.14-03
Kılıç, Burcu EP06.01-007, P2.06-01
Kılıçkap, Saadettin EP08.01-024
Klein, Mark EP16.03-024
Klein-Goldberg, Anat EP16.01-016, EP16.03-028
Klemm, Anna EP16.04-001
Klikovits, Thomas EP05.02-007, EP07.02-001, EP14.02-003, MA01.04
Klingmueller, Ursula EP16.01-019
Kloecker, Goetz H. EP01.04-004
Kluetz, Paul EP04.01-004
Klug, Stefanie J. EP03.01-013
Knabl, Alexander E P16.01-015
Knap, Marianne M. EP05.01-017
Knegjens, Joost EP05.01-009
Kneidinger, Nikolaus EP04.01-015
Kneuertz, Peter P1.03-01
K. Nishimura, Katherine MA04.05
Knoblauch, Roland E. MA07.04, P1.16-01
Knol, Hans P. MA03.09
Knopp, Michael P1.03-01
Knudsen, Sofie H. EP08.01-084
Ko, Jen-Chung EP05.01-003, EP08.02-027
Ko, Stephen EP05.01-011
Kobayashi, Aki HOD03.01
Kobayashi, Jun EP13.01-010
Kobayashi, Shota MA03.07
Kobayashi, Takeshi EP01.04-005, MA11.07
Kobe, Hiroshi EP16.02-005
Kocaman, Gokhan EP07.01-003
Kocaman, Gökhan EP07.01-010
Kocaman, Gokhan EP08.03-004
Koche, Richard P. EP16.03-030
Kocherginsky, Masha EP04.01-007, EP04.01-008, EP08.02-028
Koczywas, Marianna MA13.07, MA13.08
Kodaganur Gopinath, Srinivas EP06.01-014
Kodaira, Takeshi MA06.04
Koegelenberg, Coenraad P1.02-02
Koelzer, Viktor H. MA12.04
Koers, Alex EP08.02-079
Koffijberg, Hendrik EP01.02-001
Koga, Takamasa EP08.02-079, EP08.02-146
Koh, Cloe EP08.01-016
Kohlmann, Milena EP08.01-027
Kohman, Leslie J PL03.06
Kohn, Nina EP08.01-068
Kohno, Takashi EP02.03-016, MA04.04
Koike, Hirofumi EP13.01-007
Koistinen, Hannu EP16.01-019
Kok, Peey Sei EP08.01-002
Koksoy, Elif Berna EP13.01-002
Koleczko, Sophia EP08.02-106
Kolff, M. W. MA03.09
Kollmeier, Jens EP08.01-057
Kolokotroni, Maria EP06.01-009
Koltun, Bella EP16.01-016, EP16.03-028
Kometani, Takuro EP08.02-144
Komurcuoglu, Berna EP16.04-005
Konda, Bhavana EP14.05-004, OA12.04
Kondo, Kimie MA01.03
Kondo, Tetsuro EP11.01-008
Kong, Feng Ming EP05.01-029
Kong, Feng-Ming EP05.02-022
Kong, Feng-Ming S. EP14.01-014
Kong, Feng-ming Spring ES38.01
Kong, Fengming EP16.04-032
Kong, Fengming S. EP05.01-015
Kong, Weidong EP04.01-024, EP13.01-012
Kong, Xiangrong MA03.04
Kong, Xiangshuo EP08.02-076
Kong, Yi EP08.01-093, EP08.01-094, EP08.01-095
König, David EP16.01-018, MA12.04
Konjic, Selma EP02.01-008
Kono, Satoko M A14.02
Kontogianni, Georgia EP16.02-004
Koo, Kendrick OA01.04
Kopp, Hans-Georg MA06.08
Koppe, Friederike L. MA03.09
Kops, Stephan EP04.01-026
Koren, Lilach EP16.01-016, EP16.03-028
Korkmaz Ekren, Pervin EP13.01-014
Kormany, William EP08.02-116
Korpics, Mark EP02.02-002
Kosari, Farhad P2.14-03
Koshy, Matthew EP02.02-002
Kosibaty, Zeinab P2.13-03
Kosmidis, Paris EP08.02-060, EP10.01-006, EP10.01-007
Kosmidis, Thanos EP10.01-006, EP10.01-007
Kosteva, John EP08.01-018
Kotagiri, Sonali EP01.01-003
Kotecha, Rupesh EP07.01-019, EP07.03-006, EP08.01-076
Kotecha, Rupesh R. EP05.01-025
Kotteas, Elias EP14.01-022
Kottorou, Anastasia EP08.01-072
Koul, Rashmi EP08.02-024
Koumarianou, Anna EP08.02-060, EP10.01-018
Koury, Albert EP02.03-022
Kouso, Hidenori EP08.02-144
Koutras, Angelos EP08.01-072
Kovacevic, Mile MA01.04
Kovacevic, Tomi EP03.01-017, EP04.02-006
Kovacs, Ildiko EP14.02-002
Kovàcs, Julia EP04.01-015
Kowalski, Dariusz OA15.03
Kowalski, Dariusz M. OA15.06
Kowol, Christian EP14.02-002
Kozono, David PL03.06
Kraft, Agnieszka EP07.02-003
Krainock, Michael EP16.02-003
Krammer, Florian OA06.03
Kratochvil, Leah B. EP05.01-014
Kratzke, Robert P1.14-04
Krauss, John C. OA03.03
Krawczyk, Paweł EP01.01-008
Kraywinkel, Klaus EP03.01-013
Krebs, Matthew EP05.01-007, EP08.01-109
Krebs, Matthew G. MA13.04, OA03.04
Krenbek, Dagmar EP08.02-122
Kris, Mark G. EP05.01-025, OA14.06
Krishnan, Karthik EP01.04-005, MA11.07
Krishnaraj, Arun EP08.01-034
Kristiansen, Charlotte EP01.07-001
Krochmal, Rebecca EP02.03-008
Kroeze, Stephanie ES16.03
Krokidis, Miltiadis PL02.09
Kron, Tomas EP05.01-023
Krug, Lee OA15.04
Krupar, Rosemarie EP11.01-007
Krzakowski, Maciej MA13.04
Krzyzanowska, Natalia EP01.01-008
Kshivets, Oleg EP16.02-020
Kubica, Sydney P2.14-03
Kubli, Shawn P. EP16.01-006
Kudou, Kentarou MA13.03
Kukava, Salome EP01.03-013
Kulasinghe, Arutha EP16.04-003, ES35.06
Kulkarni, Amit OA06.06
Kulkarni, Dakshayini EP08.02-108
Kulkarni, Shruthi EP16.03-024
Kumagai, Toru EP08.01-005, MA13.03
Kumar, Akash EP11.01-012
Kumar, Arvind OA02.04
Kumar, Chandan EP16.03-024
Kumar, Rajiv EP08.01-073
Kumar, Sachin EP03.01-006, P2.02-03
Kumar, Sameera ES36.05
Kumar, Sanjeevani OA02.04
Kumar, Sunil EP11.01-011
Kumarahuru, Rishi P2.08-02
Kumarasamy, Chellan EP01.03-003, OA13.06
Kummar, Shivaani EP08.02-148
Kunst, Peter W. EP08.01-026
Kunte, Siddarth MA13.05
Kuo, Chih-His EP08.02-027
Kuo, ChihHsi EP05.01-003
Kuon, Jonas EP08.01-031
Kurata, Takayasu EP08.02-115, MA06.04
Kurban, Lutfi EP03.01-010
Kurien, Elizabeth EP10.01-008
Kurose, Koji EP08.01-064
Kurowski, Krzysztof EP07.01-009
Kuruvilla, Sara EP02.01-013
Kushitani, Kei EP16.01-004
Kushner, David MA14.04
Kutuk, Tugce EP07.01-019, EP07.03-006
Kuyama, Shoichi EP08.02-115
Kvizhinadze, Giorgi EP01.03-009

Kwak, Sehyun EP13.01-005
Kwak, Yoo-Kang EP05.01-032
Kwiatkowski, David J. OA14.06
Kwint, Margriet EP05.01-009
Kwon, Byoung Soo EP13.01-008
Kwon, Hyun Jung EP11.01-013
Kwon, Soohyeon EP11.01-013

L

La, Jennifer EP08.01-045
Labbé, Catherine EP16.03-020
Laber, Damian EP14.01-013
Lacroix, Ludovic MA10.08
Lacroix, Ludovic Lacroix P1.16-02
Ladanyi, Marc MA13.05
Ladwa, Rahul EP04.01-013, EP08.04-002
Lafeuille, Marie-Hélène MA12.05
La Fleur, Linnéa MA05.04
Lafleur, Francois EP08.02-031, EP08.02-106
Lagani, Vincenzo EP01.01-009, MA11.04
Lage Alfranca, Yolanda EP08.02-070
Lager, Joanne EP08.01-021
Lagogianni, Christie EP10.01-006, EP10.01-007
Laguna, Juan C. EP08.02-149
Laguna, Juan Carlos EP03.01-012, MA07.07, OA13.04, P1.07-02
Lai, Gillianne EP16.03-036, P2.13-02
Lai, Jia-lu EP08.05-004
Lai, Victoria OA12.05
Lai, Wei-Chu V. MA13.08
Lai, Wei-Yun EP16.03-012
Lai, Yi P2.13-03
Lai, Zhongwu OA15.04, P1.15-11
Laidsaar-Powell, Rebekah EP10.01-005
Laisaar, Tanel EP06.01-016
Lakhani, Dhairya EP01.05-008
Lakhanpal, Shaily EP16.02-002
Lala, Deepak A. EP16.03-024
Lalezari, Ferry OA04.06
Lalvée, Salomé EP11.01-006
LAM, NGUYEN S. EP11.01-003
Lam, Stephen EP01.04-005, EP01.05-007, EP01.07-004, EP08.01-075, MA03.04, MA11.07, MA11.08, OA13.03, P1.02-02, P1.02-04, P1.04-02, P2.09-03, WS02.04, WS02.08, WS02.17, WS02.23
Lam, Sze Kwan EP05.02-020, EP07.01-008, EP16.01-024
Lam, Vincent EP02.04-007, EP08.01-086
Lam, Wan L. EP16.03-015
Lam, Wei-Sen EP08.02-162
La Mantia, Maria EP08.03-007, EP16.01-013
LaMarche, Nelson M. P2.12-05
Lamarre, Neil EP14.05-014
Lamaze, Fabien EP16.02-027
Lamberg, Kristina EP11.01-007, MA05.04
Lamberti, Giuseppe EP08.01-043, EP14.01-006, MA01.08, MA02.09, P1.15-03
Lambin, Philippe ES09.05
Lambotte, Olivier MA10.08
Lammers, Philip P2.10-02
Lamot, Sebastian EP01.05-004
Lampaki, Sofia EP08.02-060
Lamprecht, Bernd EP08.01-108
Lancaster, Harriet L. EP01.05-006
Land, Lotte H. EP01.07-001
Landi, Lorenza EP08.01-030, EP08.02-048, MA13.01, MA13.06, P2.14-02
Landi, Maria T. EP16.03-020
Landlinger-Schubert, Christine EP08.01-015
Landman, Bennett EP01.05-008
Landreneau, Rodney PL03.06
Lane, Jordan EP01.06-007
Lang, Christian EP14.02-002, EP14.02-003, EP14.02-006, MA01.04
Lang, David EP08.01-108
Lang, Joshua P2.02-02
Langdon, Robert EP08.02-111
Langer, Corey EP08.01-018, EP16.03-021
Langer, Corey J. EP08.01-076, OA03.03, P1.15-07
Langer, Deanna P1.02-01
Langfort, Renata EP16.03-014
Langhammer, Arnulf MA11.05, P1.01-01
Langlais, Blake EP14.05-001
Langleben, Adrian EP05.02-019
Langs, Georg EP13.01-011, PL04.06, WS02.28
Lanman, Richard EP04.02-004
Lantos, Andras EP14.02-003, MA01.04
Lantuejoul, Sylvie ES21.02, MA01.07, MA01.09, MA02.03, MA12.07, OA04.05
Lanza, Ian MA13.08
La Porta, Marilina EP02.03-019
Lara, Primo N. MA13.08
Lara-Mejia, Luis EP07.01-011
Lara-Mejía, Luis EP08.02-035
Lara-Mejia, Luis EP16.03-023
Lara-Mejía, Luis MA09.09, MA14.03, WS07.03
Lara-Mejia, Luis WS07.04
Lardon, Filip EP07.01-024
Larson, Timothy EP08.02-111
Laskin, Janessa EP04.02-004, EP08.02-108
Lassalle, Sandra EP11.01-005, EP11.01-006
Lassen, Ulrik N. EP08.02-148
Lastra, Rodrigo EP16.01-014
Laszlo, Viktoria MA01.04
Laštíkova, Simona EP08.02-087
Lau, Asa P. EP16.01-006
Lau, Brianna OA14.04
Lau, Dawn EP16.03-036
Lau, John EP15.01-001
Lau, Rainbow WH EP02.02-008
Lau, Sally C. EP08.01-067, MA14.08
Laufer Peerl, Michal EP08.01-010
Laure, Alexander P1.14-01
Laurent, MSc, Julie P1.09-01
Lauricella, Calogero EP08.02-046
Laurie, Scott EP04.02-004
Laursen, Christian B. EP01.07-001
Lausi, Paolo Olivo EP02.03-006, EP02.03-007
Law, Jennifer EP04.02-004
Lawler, William OA12.03
Lawrenson, Ross EP04.01-023
Lázaro, Conxi EP16.03-027
Lázaro Quintela, Martín EP08.02-070
Le, Anh EP16.03-012
Le, Khanh N. EP16.04-007
Le, Lisa EP04.02-004
Le, Xiuning EP08.02-018, EP08.02-162, EP08.02-163, OA03.05, P1.09-02
Lea, Robin EP08.02-147
Leal, Alessandro EP01.01-003
Leal, Ticiana EP14.03-003, MA06.05, P1.10-04, P2.02-02, P2.04-05, WS07.08
Leal, Ticiana A. EP08.02-019
Leal, Ticiana A. OA15.06
LeBerichel, Jessica P2.12-05
Lebow, Emily EP05.01-014
Lebow, Emily S. P1.05-02
Lecavalier-Barsoum, Magali EP06.01-001
Lechowicz, Urszula EP16.03-014
Ledda, Roberta Eufrasia P1.15-04
Ledger, Danielle P1.11-01
Leduc, Charles EP04.01-020, EP07.03-002
Lee, Benjamin EP02.04-004
Lee, Chang Geol OA11.04
Lee, Chee Khoon EP08.02-029
Lee, Choon-Taek EP01.03-005, EP13.01-008
Lee, Chung-Shien EP08.01-068, EP08.02-129
Lee, Dae Ho OA15.03
Lee, Eungbae EP02.03-013
Lee, Eunhye EP13.01-005
Lee, Geon Kook EP14.01-023
Lee, Geun Dong EP05.03-004
Lee, Geundong EP07.01-015
Lee, Grace Y. EP08.02-062
Lee, Gyeong-Won EP08.01-073, EP08.02-025
Lee, Ho Yun MA03.03, P2.09-01
Lee, Hyun Joo EP16.02-021
Lee, Hyun-Sung P1.14-02
Lee, Jae EP04.01-001
Lee, Jae Cheol EP08.01-041, EP08.02-128
Lee, Jae Chul EP08.01-017
Lee, Jae Ho EP13.01-008
Lee, Jae Yun EP08.02-082
Lee, Janet EP04.01-017
Lee, Jay EP02.04-007
Lee, Jay M. EP02.04-005, OA14.06
Lee, Jeong Eun EP08.01-017, EP08.02-142
Lee, Jeong Hyeon Lee EP02.03-028
Lee, Jeonghyo EP11.01-013
Lee, Ji-Young EP08.01-017
Lee, Jii Bum B. MA13.02
Lee, Jin Wee E P01.01-006
Lee, Jong OA03.04
Lee, Jong Seok EP08.02-140
Lee, Jong Woo MA02.07
Lee, Jong-Seok P1.16-01
Lee, Jonghoo EP13.01-003
Lee, Joongyo EP05.01-034
Lee, Joonseok EP16.03-034
Lee, Juehea MA14.08
Lee, Junghee MA03.03
Lee, Kathryn OA08.06
Lee, Ki H. EP08.02-159
Lee, Ki Hyeong EP08.02-025, P1.16-01
Lee, Kwangho MA07.08

Lee, Kye Young EP08.02-142
Lee, Michelle P1.13-01
Lee, Na Mi EP08.02-025
Lee, Na-Young EP01.03-005, EP01.05-003
Lee, Nayoung EP01.04-003
Lee, Onyou EP16.02-021
Lee, Percy ES16.05
Lee, Richard EP01.06-002
Lee, Sang Haak P2.01-01
Lee, Sang Hoon EP02.03-003, EP08.02-142
Lee, Sang-Yoon MA07.09
Lee, Se-hoon EP08.02-016, MA07.04, P1.16-01
Lee, Sejoon EP11.01-013
Lee, Seoyoung EP08.02-012
Lee, Seung Hyeun EP16.02-010
Lee, Shi EP01.02-003
Lee, Shin Yup EP08.01-017, EP08.02-142
Lee, Soo-Hyun EP14.01-023
Lee, Sooyun OA06.03
Lee, Suheon EP06.01-015
Lee, Sung Sook EP08.02-025
Lee, Sung Yong EP08.01-017, EP08.02-142
Lee, Sungho EP02.03-028
Lee, Wai Chung Kirsty EP08.02-162
Lee, Yeon Joo EP13.01-008
Lee, Yong-Hee MA07.09
Lee, Yoon-Hee EP05.01-032
Lee, Youngjoo EP08.02-012, EP14.01-023
Lee, Yun-Gyoo EP08.02-025
Lefebvre, Patrick MA12.05
LeFresne, Shilo ES29.05
Lehman, Margot ES29.04
Lei, Lei EP08.01-107, WS08.16
Lei, Tianyao EP08.02-152, EP16.04-024
Leiby, Melanie A. OA15.06
Leigh, Lillian EP04.01-023
Leighl, Natasha EP02.04-009, EP03.01-002, EP04.02-004, EP08.01-067, EP08.02-016, EP08.02-080, EP08.02-082, EP14.05-009, OA13.04
Leighl, Natasha B. EP04.01-001, MA14.08
Lemech, Charlotte R. OA03.06
Léna, Hervé EP16.02-004
Lengel, Harry MA05.09
Lennes, Inga EP13.01-017
Leo, Ludovica P1.15-04
León, Luis P1.15-09
Leonards, Katharina EP16.01-018, MA12.04
Leonetti, Alessandro E P02.04-001, EP06.01-006, EP08.01-007, P1.15-04
Leong, David EP04.01-023
Leong, Tracey EP04.01-023
Le Quesne, John EP16.04-011
Lerner, Ariel EP02.03-009
Lesage, Jacqueline EP14.05-016
Leshem, Yasmin EP08.01-011, MA14.07
Lespinet-Fabre, Virginie EP11.01-005, EP11.01-006
Le Stang, Nolwenn OA04.05
Leung, Bonnie EP03.01-016, EP08.01-074, EP08.02-089, EP14.04-001, EP14.05-017, EP14.05-020
Leung, Maria EP02.03-002
Leung, Yvonne OA10.05, P1.02-01
Leuzzi, Giovanni EP05.03-008
Leventakos, Konstantinos EP05.01-011, EP14.05-001, MA13.07, MA13.09
Levi, Paul MA03.08
Levin, William EP08.01-018
Levy, Antonin EP14.01-014
Levy, Ben EP02.04-007
Levy, Benjamin EP08.01-086, MA13.07
Levy, David OA10.03
Levy, Paul EP02.03-022
Levy, Ralph P1.16-03
Lewensohn, Rolf EP16.02-008, P2.13-03
Lewis, Sarah PL03.03
Lewis, Whitney E. EP08.02-163, MA01.03
Leyvraz, Serge EP08.02-148
Li, Andrew X. OA11.03
Li, Bob T. EP05.01-014, OA03.03, OA03.06
Li, Bob T. ES05.05
Li, Bowen EP16.01-017
Li, Dana EP13.01-001
Li, Dianming EP08.02-139
Li, Fangyong EP08.02-125
Li, Feng EP08.01-009, EP08.01-035, EP16.02-016
Li, Gerald P2.14-01
Li, Guanghui OA02.05
Li, Guixiang EP08.02-033
Li, Haifu EP08.02-052
Li, Heng EP16.03-001
Li, Hongling EP08.02-033
Li, Hongmei EP08.02-038
Li, Hui EP08.01-032, EP08.01-070, EP08.01-071, WS08.15
Li, Huihui EP14.01-016
Li, Janice J. EP14.01-019
Li, Jessica P2.09-03
Li, Ji EP16.01-017
Li, Jia EP08.01-093, EP08.01-094, EP08.01-095, EP08.02-158, EP08.02-161, WS08.14
Li, Jingchang EP08.02-063
Li, Jinglong EP02.03-015
Li, Jingyi EP08.02-080
Li, Jinlong EP01.01-012
Li, Juan EP08.01-033, EP08.02-159
Li, Junling EP08.01-089, EP08.02-007, EP08.02-008, EP08.02-009, EP08.02-091, EP08.02-100, EP08.02-145, EP08.02-159, EP13.01-013, MA01.05
Li, Junxia EP08.02-076
Li, Kang EP08.01-093, EP08.01-094, EP08.01-095, EP08.02-158, EP08.02-161, WS08.14
Li, Li EP10.01-002
Li, Lin EP02.01-011
Li, Ling EP01.01-012, EP08.02-003, EP16.03-008, EP16.03-043
Li, Linlin EP08.02-069
Li, Mengmeng EP08.02-005, EP08.02-006
Li, Min EP05.02-010
Li, Mingjia EP08.01-062
Li, Na EP07.02-006, EP08.02-092
Li, Peng EP01.01-012
Li, Pengfei EP01.05-011
Li, Qian EP16.01-005
Li, Qingshan EP08.02-139
Li, Quan EP08.02-079, EP16.03-015
Li, Shanqing EP16.01-017
Li, Shaolei EP05.02-014, WS08.22
Li, Shasha EP05.01-015
Li, Shenduo EP08.01-051
Li, Shenghui EP02.01-007, EP13.01-009
Li, Shengting MA07.04
Li, Shujun EP08.02-154
Li, Shuling MA09.08
Li, Songzi EP08.01-014
Li, Tengfei OA10.03
Li, Tianhong EP08.01-061
Li, Tracy EP08.02-016
Li, Wei EP16.01-005, EP16.03-043
Li, Weihua EP11.01-014, EP16.02-017
Li, Wenbin EP08.01-055, MA05.03, WS08.17
Li, Wensheng EP16.01-012
Li, Wenvan P2.10-02
Li, Wenyan EP14.05-023
Li, Wenyuan EP01.06-003
Li, Xiang EP02.03-018, EP05.02-014, WS08.22
Li, Xiaofei EP05.02-018, WS08.11
Li, Xiaoling EP08.02-139
Li, Xin EP08.01-056, EP08.01-070, EP08.01-071, EP08.02-136, WS08.15
Li, Xingya EP08.02-069
Li, Xuanzong EP16.01-021, EP16.01-022
Li, Xuefei EP08.01-035
Li, Yan EP08.02-009, EP08.02-091
Li, Yang EP05.02-022
Li, YanWei EP08.02-003
Li, Yanying EP14.03-002
Li, Yizheng EP08.01-092
li, Yong EP14.01-002
Li, Youquan P2.13-02
Li, Yuan EP16.01-023, WS08.20
Li, Yujie MA14.05
Li, Zeng EP08.02-033
Li, Zhang EP08.02-052
Li, Zhen EP08.01-061
Li, Zhengguo EP08.02-033
Li, Zhonglin EP16.03-020
Li, Zuofeng EP07.01-018
Liang, Hong EP08.01-023
Liang, Jun EP05.01-015, EP05.02-022
Liang, Naixin EP05.02-009, EP16.01-017
Liang, Shi-meng EP08.05-004
Liang, Wenhua EP05.02-009
Liang, Xiangwei EP08.01-054
Liang, Yi EP05.02-009, EP16.01-025, WS08.21

Liang, Yuepei EP16.03-046
Liang, Zhu EP05.02-009
Liang, Zong-An EP08.02-064
Liao, Bin-Chi EP08.02-127
Liao, Wei EP01.06-007
Liao, Wei-Yu EP08.02-127
Liberman, Moishe EP07.03-002
Lim, Chloe EP10.01-005
Lim, Eric EP01.07-006, EP02.03-002, EP11.03-003, P1.12-05, PL02.10, PL03.02
Lim, Eun Jin EP14.01-023
Lim, Farah Louise EP08.01-027, EP08.02-081, OA15.04
Lim, Jeong Uk P2.01-01
Lim, Jing Shan EP01.01-006
Lim, Kiat Hon EP16.03-036
Lim, Steffany EP08.01-061
Lim, Sun Min EP08.02-012, EP08.02-045, MA07.09, OA08.02
Lim, Sung Yoon EP13.01-008
Lim, Vun-Sin WS01.07
Lim, Wan-Teck EP16.03-036, P2.13-02
Limongelli, Alessandro EP08.01-088
Lin, Chia-Chi EP08.02-045, EP08.02-116
Lin, Chien-Chung EP08.02-027
Lin, Emily P. EP08.01-028
Lin, Gen EP08.01-094, EP08.02-094
Lin, Guomin EP16.02-016, EP16.03-018
Lin, Huamao M. EP08.02-156, EP08.02-171
Lin, Jessica J. EP08.02-041, EP08.02-148
Lin, Jianxin OA15.06
Lin, Jie EP08.01-094
Lin, Jules EP02.04-005
Lin, Ling EP14.01-016
Lin, Mark O A03.04
Lin, Muwen EP08.02-154
Lin, Qin OA02.05
Lin, Stephanie EP04.02-003
Lin, Wan-Hsin P2.14-03
Lin, Wenxia EP14.01-016
Lin, Xiwu EP08.02-016
Lin, Yao-Bin EP05.02-011, WS08.19
Lin, Yingcheng OA02.05
Lin, Yuxiao EP16.01-017
Lin, Zhi-Bo EP10.01-010
Linardou, Helen EP16.03-011
Linardou, Helena ES05.02, OA03.08
Lindberg, Amanda EP16.04-001
Lindenmann, Jörg EP02.01-008
Lindqvist, Jonatan EP04.01-012
Lindskog, Cecilia MA05.04
Ling, Xuxinyi E P08.01-052, WS08.10
Ling, Yun EP02.01-011
Linke, Rolf EP08.02-159
Liotta, Rosa EP08.03-007
Liou, Douglas OA02.04
Liptay, Michael EP11.01-009
Lissenberg-Witte, Birgit MA12.07
Listì, Angela EP16.03-011, EP16.03-040
Listiandoko, Raden Dicky W. EP01.01-004
Litt, Ishjot EP02.04-003, EP08.02-071
Litt, Ishjott EP08.02-014
Liu, Alex EP14.05-001
Liu, Alvin EP08.02-055
Liu, Anwen EP08.01-003, OA02.05
Liu, Bao Gang EP08.02-078
Liu, Bingchun EP16.03-043
Liu, Chuan EP01.01-012
Liu, Chuang EP01.01-012, EP16.03-008, EP16.03-043
Liu, Chunling EP08.01-033, EP08.02-095
Liu, Chunxu EP08.02-116
Liu, Geoff EP08.02-034
Liu, Geoffrey EP02.04-009, EP03.01-002, EP03.01-016, EP04.01-001, EP08.01-067, EP08.02-082, EP08.02-118, EP11.02-001, EP14.01-019, EP14.04-001, EP14.05-020, MA14.08
Liu, Hongxiang EP08.02-150
Liu, Hua EP08.02-033
Liu, Jia EP08.05-004
Liu, Jiali EP05.01-015, EP16.04-032
Liu, Jichun EP05.02-018,
Liu, Jie EP08.02-038
Liu, Jun EP01.07-005
Liu, Junfeng EP05.02-009
Liu, Junqi EP01.07-005, EP08.01-092
Liu, Laiyu EP08.02-063
Liu, Li EP05.02-021, EP11.03-002, EP14.02-007, MA01.05
Kiu, Lirong EP14.01-002
Liu, Liuyu EP08.01-093, EP08.02-161
Liu, Lunxu EP05.02-018
Liu, Meilian EP08.02-154
Liu, Pengfei P1.12-03
Liu, Ping EP08.01-095
Liu, Qianqian MA14.05
Liu, Qun EP08.02-078
Liu, Shubin EP08.01-003
Liu, Si-yang EP05.02-006, EP08.01-085, WS08.09
Liu, Stephen EP02.03-008, EP08.01-087, EP08.02-041, EP14.01-020, EP16.03-021, IBS07.01, LA02.05, OA07.04
Liu, Stephen V. EP08.01-044, EP08.02-098, EP14.01-015
Liu, Stephen V. MA05.08
Liu, Steven Y. P1.16-04
Liu, Wenjin EP16.02-016, EP16.03-006
Liu, Wenlei P1.11-01
Liu, Xi EP08.01-081
Liu, Xia EP08.02-169
Liu, Xianling EP08.01-092
Liu, Xiao-qin EP08.05-004
Liu, Xiaohan E P01.07-005
Liu, Xiaoli MA05.05
Liu, Xiaoping EP08.02-033
Liu, Xinyu EP16.01-017
Liu, Yang EP16.04-022
Liu, Ying EP08.02-078
Liu, Yongmei EP08.02-148, EP14.03-002
Liu, Yu L. EP08.01-095
Liu, Yunpeng EP08.01-014, EP08.01-070, EP08.01-071, EP08.02-139, OA02.05, WS08.15
Liu, Yutao EP07.03-003, EP08.01-053, EP08.01-054, EP16.02-017
Liu, Yuxuan EP08.02-157
Liu, Zhaoqian EP05.02-010
Liu, Zhe EP08.02-139
Liu, Zhi Fang EP08.02-078
Liu, Zhihai EP02.03-015
Liu, Zhihua EP08.01-014, OA02.05
Liu, Zhisheng EP14.01-024
Liuru, Taiyang EP02.03-015
Livingston, Eric EP16.04-017
Ljubicic, Lidija EP07.01-012
Lo, Ying-Chun EP08.02-037
Lobo, Tania OA10.03
Lobreglio, Giambattista EP14.02-001
Lo Certo, Giuseppe EP05.01-024
Lockwood, William EP08.02-055
Lockwood, William W. EP16.03-039
Lococo, Filippo EP05.03-008, EP16.03-042
Logan, Diane EP02.01-013
Logan, Jacqueline EP01.04-005, MA11.07
Logotheti, Marianthi EP16.02-004
Lohinai, Zoltan MA01.04
Lok, Benjamin H. EP03.01-016, EP14.01-019, EP14.04-001, EP14.05-020
Lombardo, Fiorella EP14.01-005
Long, Hao EP05.02-011, WS08.19
Long-Mira, Elodie EP11.01-005, EP11.01-006
Iongo, Vito P2.10-05
Loo, Billy ES23.01, OA14.04
Loong, Herbert EP03.01-011
Loong, Herbert H. MA13.04
Lopes, Danilo EP01.05-004
Lopes, Gilberto EP04.01-010, EP08.01-090, EP08.01-091, EP08.02-041, EP16.03-021, ES17.03, OA06.06, OA15.06
Lopes, José EP04.01-011
Lopes, José A. EP03.01-009, EP05.03-006
Lopes, Miguel EP04.01-011, EP05.03-006
Lopes Jr, Gilberto L. EP08.02-042
Lopez, Ana EP05.02-002
López, Ana EP05.02-003
Lopez, Angel EP16.04-020
López, Dennis MA14.03, WS07.03
Lopez, Gabriella EP08.01-062
López, Inés MA02.08
Lopez, James S. EP07.01-006
López, Laura EP05.02-002, EP05.02-003
López, Mariana EP05.02-002
Lopez, Mariana EP05.02-003
Lopez, Pilar G. EP08.01-020
Lopez-Bigas, Nuria OA04.05
López-Brea, Marta EP08.02-131
López Brea Piqueras, Marta EP08.01-065
Lopez Castro, Rafael MA06.03, OA13.04
López Castro, Rafael PL03.12
López-Castro, Rafael EP08.01-029
Lopez-Castro, Rafael EP08.02-070, OA07.06
López-Castro, Rafael P1.12-04
Lopez-Cohen, Alejandro EP16.02-018
López Fernández, Teresa EP08.01-048
Lopez Lisbona, Rossa EP01.07-004
López-Paradís, Assumpció OA06.04

Lopez-Rios, Fernando HOD03.02, P2.07-02
Lopez-Segui, Francesc EP01.03-002
Lopez-Vilaro, Laura P2.07-02
López Vivanco, Guillermo MA06.03, PL03.12
López-Vivanco, Guillermo OA02.03
Lorente, Jose Antonio P2.13-01
Lorenzi, Martina EP08.01-012, EP08.02-104, P1.15-06
Lo Russo, Giuseppe EP07.01-021, EP08.01-006, EP08.02-046, EP08.02-060, MA10.07, P1.15-02
Lorusso, Bruno P1.15-04
LoRusso, Patricia OA03.04
Losantos, Itsaso EP08.02-088, EP16.01-007, EP16.02-014
Lou, Yanyan EP05.01-011, EP08.01-051, EP16.03-016, MA13.07, MA13.09
Lou, Yuqing EP16.01-032, OA05.05
Louie, Alexander EP05.01-020, ES11.01, ES23.06
Louie, Alexander V. EP04.01-027, EP08.05-001, EP10.01-004
Louie, Karly EP08.02-105
Louie-Gao, Melinda EP08.02-019, EP08.02-045
Lourenzo Aguilera, Gloria EP14.05-005
Lovati, Emanuela MA13.05
Lovly, Christine M. EP16.03-019
Lozano, Teresa EP08.01-048
Lu, Binbin EP08.02-153
Lu, Daniel EP08.02-055
Lu, Fang-Liang EP05.02-008
Lu, Jingyu EP07.03-003
Lu, Jun EP05.01-36, EP16.01-032
Lu, Junguo OA03.07
Lu, Leilei EP16.03-046
Lu, Shun EP05.02-018, EP08.01-009, EP08.01-073, EP08.01-081, EP08.01-082, EP08.02-064, EP08.02-137, EP08.02-138, EP08.02-139, EP08.03-008, EP16.03-031, EP16.03-032, EP16.03-033, EP16.03-044, OA03.07, OA11.05, WS08.23
Lu, Tianyi EP14.05-023
Lu, Tong EP16.01-010
Lu, Weiqiang EP16.03-008
Lu, Xiaotong EP05.01-016
Lu, You EP08.02-064, EP14.03-002
Lu, Yue C. MA13.05
Lucarelli, Alessandra MA10.07
Lucchi, Marco EP02.03-019
Ludwig, Paula EP05.01-030
Luetke Brintrup, Diana MA06.08
Luft, Alexander EP08.01-027, OA12.06, OA15.04
Lugini, Antonio EP05.01-024, EP06.01-006
Lui, Allan J. MA13.05
Luís, Filomena EP08.02-054
Luk, Eric EP07.01-019
Lukić Franolić, Ivana EP08.02-058
lungNEN network, NA MA01.09
Lunkes, Eduarda B. EP02.03-010
Luo, Jia EP13.01-006
Luo, Xian EP08.02-063
Luo, Xuerui EP08.01-073
Luo, Yipin EP08.02-154
Luo, Yung-Hung EP08.02-134, EP08.02-151, EP16.01-003
Luo, Yuxi EP08.01-003
Lupichuk, Sasha EP06.01-003
Lupinacci, Lorena EP08.02-097
Lusky, Fabienne EP08.01-031
Luta, George OA10.03
Lutz, Christina M. EP05.01-017
Lutzow, Lynde K. P1.12-01
Luu, Jennifer EP08.02-055
Lv, Chao EP02.03-018, EP05.02-008, EP05.02-014, WS08.22
Lv, Dongqing EP08.01-033, EP08.02-139, EP14.01-016
Lv, Xin EP01.01-011
Ly, Fabrice P1.12-05
Lyberis, Paraskevas EP02.03-006, EP02.03-007
Lynch, Charlotte EP04.02-002
Lynch, Fiona ES31.05

M

Ma, Di EP08.02-091
Ma, Gina EP05.01-021
Ma, Grace X. P1.12-01
Ma, Ning EP16.04-003
Ma, Patrick C. MA05.08
Ma, Qing EP08.02-169
Ma, Rui EP08.02-078, OA03.05, OA03.07
Ma, Runyang EP16.03-008
Ma, Shenglin EP05.01-031, EP08.01-056, EP08.02-021, EP08.02-136, EP08.02-167, EP10.01-001, EP14.01-021, EP16.04-030
Ma, Xiangyu EP10.01-009
Ma, Yu EP02.01-018, EP16.01-012, MA06.07
Ma, Yujie EP08.01-054
Ma, Yutong EP08.02-073
Ma, Zhiyong EP08.01-001, EP08.01-014, EP08.01-070, EP08.01-071, EP08.02-005, EP08.02-006, OA02.05, WS08.15
Ma, Zhongxia EP08.02-158, WS08.14
MacAulay, Calum EP01.05-007, EP08.01-075, P2.09-03
Maccora, Jordan P2.08-02
Macerelli, Marianna EP05.01-024, EP06.01-006
MacEwan, Joanna P. EP14.05-015
Machado, José Carlos M. EP01.01-007, EP16.02-011, EP16.02-012
Machuca, Tiago N. OA14.03
Maciel, João EP05.03-003
MacIntyre, Jessica EP04.01-010
Mack, Philip C. OA06.03
MacMahon, Suzanne EP08.02-065, EP11.03-003, MA12.09
MacManus, Michael EP14.05-016, MA09.05, P1.10-02, P2.03-01
Maconi, Antonio EP07.01-004
Macpherson, Michele D. EP16.03-024
Madan Mohan, Aravind EP01.01-006
Madžarac, Goran EP14.01-012
Maddala, Tara EP01.01-003
Madison, Russell EP16.02-002
Madison, Russell W. P2.14-01
Maduka, Richard C. OA11.03
Maeda, Chihaya EP07.03-007
Maeda, Sumiko EP05.02-017
Maeda, Tadashi EP08.02-115
Maeno, Ken OA07.03
Maenz, Martin EP08.01-057, P1.15-05
Maes, Philip EP10.01-014
Maestu-Maiques, Inmaculada EP10.01-017
Magaudda, Ludovico EP10.01-019
Magdub, Sulaman EP03.01-010
Magee, Lavina MA08.08, PL02.11
Maglakelidze, Marian EP01.03-013
Maglietta, Giuseppe EP08.01-007
Maguire, Paula EP02.01-002
Mahadevan, Navin R. P2.10-04
Mahadevia, Parthiv EP08.02-016
Mahaffey, Nichole EP05.01-019
Mahajan, Swati EP11.01-002
Mahapatra, Shayan EP01.05-008, EP01.05-009
Mahar, Alyson EP04.01-027
Mahmoudpour, Hamid EP08.02-126
Mai, Vicky EP02.04-009, EP03.01-002, EP04.01-001, EP08.02-082
Mai, Xiao-Mei EP01.01-005
Maier, Barbara P2.12-05
Maimon Rabinovich, Natalie EP08.02-047
Mairinger, Fabian P1.14-05
Maisonneuve, Patrick P1.04-03
Maity, Alisha P. EP08.02-015
Majeed, Umair E P05.01-011
Majem, Margarita EP08.01-109, EP08.02-131, OA02.03, P1.06-01, P2.07-02
Majem Tarruella, Margarita EP08.02-070
Majumdar, Saroj Kumar Das EP08.04-004
Mak, David Y. EP08.05-001
Mak, Tak W. EP16.01-006
Makarem, Maisam EP08.01-067
Makatsoris, Thomas EP08.01-072
Maki, Robert EP08.02-116
Makropoulos, Antonis EP13.01-011
Malapelle, Umberto EP08.02-101, EP16.03-002, EP16.03-003, EP16.03-040, ES39.01, OA09.02, OA09.07
Maldonado, Fabien EP01.05-008
Maldonado-Magos, Federico EP08.03-003
Malec, Monica EP07.01-013
Maletić, Olivera EP05.01-018
Maletic, Olivera EP07.01-012
Malhotra, Jyoti P2.02-02
Malik, Prabhat S. EP03.01-005, EP11.01-011, P2.02-03
Malik, Prabhat Singh EP03.01-006
Malinky, Melissa P1.03-01
Mallapelle, Umberto EP07.01-001
Malling, Charlotte P2.08-09
Mallison, Georgia EP05.01-007
Malthaner, Richard EP02.01-013
Malthaner, Richard A. OA06.07
Mamdani, Hirva MA06.05
Mamidi, Srikanth G. EP08.04-004
Mammadov, Rza EP02.03-027
Mamtani, Ronac EP08.01-063
Mancheño, Nuria P2.07-02

Mandal, Nabanita IBS09.05
Mandani, Hirva EP16.03-021
Mandelblatt, Jeanne OA10.03
Mander, Kimberley EP10.01-005
Manders, Peter M. EP05.01-026
Mandlekar, Sandhya OA03.04
Maneenil, Kunlatida EP08.02-083
Mangiameli, Giuseppe EP05.03-008
Mangiante, Lise MA01.09, MA02.03, OA04.05
Manglaviti, Sara EP06.01-006, EP07.01-021, EP08.01-006, MA10.07, P1.15-02
Maniarasu, Vindhya EP06.01-004
Mann, Helen EP08.01-027, EP08.01-042, P1.10-01
Mannarino, Laura EP07.01-004
Manochakian, Rami EP08.01-051, EP14.05-001, EP16.03-016, MA13.09
Mansfield, Aaron EP05.01-011, MA13.09, P2.14-03
Mansfield, Aaron S. EP08.02-037
Mansour, Ahmad EP01.02-002
Mansour, Ahmad A. P2.11-01
Manst, MD, MPH, Deborah EP10.01-014
Mansur, Arian OA05.06
Mantovani, Sara EP07.01-017
Manzaneque, Alba EP04.01-002
Manzo, Anna EP08.01-007
Manzo, Massimiliano EP16.01-018, MA12.04
Mao, Weimin EP07.02-005
Mao, Xiaowei EP08.01-038, EP08.01-039
Mar, Brenton G. MA07.03
Marchetti, Paolo EP07.01-021
Marchini, Sergio EP07.01-004
Marconi, Silvia EP08.01-088
Marcq, Elly EP07.01-024
Mardanzai, Khaled EP02.01-010
Marech, Ilaria P2.10-05
Marfatia, Isvita OA14.05
Margaritora, Stefano EP05.03-008
Margolis, Marc EP02.03-008
Mariamidze, Elene EP01.03-013
Marijanović, Drago EP14.01-011
Marin, Elba EP08.02-102
Marín, Elba EP08.02-120
Marín, Raul P2.14-04
Marinacci, Roberto EP08.01-006
Marin-Acevedo, Julian A. EP16.03-016
Marinato, Gianmarco EP08.01-012
Markaki, Maria EP01.01-005, EP01.01-009, MA11.04
Markman, Ben EP08.04-002, EP16.03-005
Marko-Varga, Gyorgy MA01.04
Markowitz, Geoffrey OA09.05
Marks, Jennifer MA05.08
Marks, Randolph EP05.01-011, MA13.09
Marmarelis, Melina EP08.01-018
Marmarelis, Melina E. EP08.01-063, MA05.08, MA07.04, P1.15-07
Marom, Edith ES18.01
Marques, Edouard MA04.05
Marquette, Charles-Hugo EP11.01-005, EP11.01-006
Márquez Rodas, Iván EP08.01-048
Marron, Thomas U. P2.12-05
Marrone, Kristen EP02.04-007, EP08.01-086
Marrone, Kristen A. OA03.03
Marsé, Raquel P1.15-09
Marshall, Henry EP01.02-004, EP01.03-012, EP04.01-023, EP15.01-001, MA11.03
Marshall, Henry M. EP01.03-006
Martín, Claudio EP05.01-001 EP07.01-011, EP08.02-097 EP16.03-002, EP16.03-003 MA09.09
Martin, Jasmine EP08.02-090
Martin, Linda OA02.06
Martin, Linda W. OA05.03
Martin, Monty EP08.01-075
Martin, Paloma P2.07-02
Martinetto, Simone EP10.01-015
Martínez, Alex EP04.01-002
Martinez, Cristina OA02.03
Martínez, Daniel EP03.01-012
Martinez, Daniel EP08.02-102
Martínez, Daniel P1.07-02
Martinez, Elia P1.15-09
Martinez, Iñigo EP08.02-110
Martinez, Maria José OA06.04
Martinez, Rebeca P2.07-02
Martínez Banaclocha, Natividad EP08.01-048
Martínez Cutillas, Marta EP16.04-014
Martínez-Cutillas, Marta EP06.01-017, EP13.01-016
Martinez-Iniesta, María P2.14-04
Martinez-Lostao, Luis EP16.01-014
Martinez-Marti, Alex EP07.01-022, EP07.01-023, EP08.01-078
Martínez-Martí, Alex MA06.03, OA02.03
Martinez-Marti, Alex PL03.09
Martínez-Martí, Alex PL03.12
Martínez-Valenciano, Juan M. EP16.03-026
Martín Fernández, Pilar EP08.01-048
Martín García, Ana EP08.01-048
Martin-Romano, Patricia P1.16-02
Martins, Sara EP08.02-036
Martins de Marchi, Pedro EP04.01-022, WS07.06
Martinsson, Tommy EP16.03-012
Martin-Ucar, Antonio EP06.01-009
Martín-Ureste, María EP10.01-017
Martomo, Stella OA09.05
Marwitz, Sebastian EP16.01-019
Más, Luis EP05.01-001, EP16.03-002, EP16.03-003
Masai, Kyohei EP07.03-007
Mascarenhas, Eldsamira EP03.01-003, EP03.01-007
Mascaux, Celine MA06.02
Masciari, Serena EP08.02-111
Masfarré, Laura EP14.05-002
Massa, Davide P1.15-06
Massard, Christophe P1.16-02
Massarelli, Erminia MA13.08, OA03.04
Massutí, Bartomeu MA06.03, OA02.03, P1.09-03, P1.15-09
Massuti, Bartomeu P2.07-02
Massutí, Bartomeu PL03.12
Mastrokalou, Chara EP16.02-004
Masuda, Ken EP07.03-004
Masuda, Takeshi EP08.01-064, EP16.02-005
Mate, Jose Luis EP01.05-001
Mathew, Divij P1.15-07
Mathey-Andrews, Camille OA05.03, OA05.06
Mathey-Andrews, Camille A. MA04.09
Mathian, émilie MA01.07
Mathian, Emilie MA02.03
Mathias, Clarissa EP03.01-003, ES17.04, IBS18.08, LA03.05, PL05.02, WS03.11, WS07.01
Matías-Guiu, Xavier EP16.03-027
Matijašević, Leo EP14.01-011
Matos, Cristina EP04.01-011
Matsas, Silvio EP08.02-042
Matsubara, Taisuke EP16.03-037, EP16.04-009
Matsubayashi, Jun EP16.03-037
Matsumoto, Masataka EP14.05-022
Matsumoto, Shingo EP08.02-113
Matsumoto, Yuji EP07.03-004
Matsumura, Kanoko EP14.05-022
Matsumura, Yuki MA03.05, P1.15-13
Matsunaga, Takeshi EP02.03-025
Matsuoka, Shunichiro MA03.07, P2.12-02
Matsuura, Yosuke EP02.01-006, EP02.01-014
Mattar, Marissa S. MA13.05
Matter, Alessandra EP08.03-006
Mattiuz, Raphael P2.12-05
Mattsson, Johanna EP11.01-007
Mattsson, Johanna S. M. MA05.04
Matuszek, Jolanta Iwona EP07.01-009
Maurizi, Giulio EP01.06-001, EP05.03-002
Mavroudis, Dimitrios EP10.01-018
Mayans, Javi MA08.07, P2.08-05, P2.08-06
Mayo, John EP01.05-007, EP01.07-004, MA11.08, P1.04-02
Mayo-de-Las-Casas, Clara EP16.02-007
Mazal, Juraj EP08.02-087
Mazi, Fatma Aybuke EP08.02-022
Mazieres, Julien EP08.02-162
Mazières, Julien EP11.01-005
Mazieres, Julien OA03.05, OA12.06
Mazilu, Laura EP16.03-011
Mazzaschi, Giulia P1.15-04
Mazzeo, Laura EP07.01-021, EP08.01-006, EP08.02-046, MA10.07, P1.15-02
Mazzola, Emanuele EP13.01-006, P1.13-02
Mazzone, Peter J. EP01.01-003
Mazzoni, Francesca EP02.04-001, EP08.02-046, EP08.02-048, EP14.01-006
Mazzoni, Lucia EP02.03-021
Mbanugo, Ebele IBS09.03
Mbuagbaw, Lawrence MA08.03
McAleese, Jonathan EP04.02-002
McArthur, Eric EP02.01-013, EP16.02-025
McCall, Neal P2.04-05
Mccall, Neal S. EP14.03-003, P1.10-04
McCann, Conor P1.10-03
McCloy, Rachael EP16.03-041
McConechy, Melissa K. EP02.01-001
McCulloch, Tine EP01.07-001, EP08.02-099
McCullough, Sue EP01.03-006, EP01.03-012
McCune, Alexa P2.14-03
McCune, Steve L. EP14.01-004

McCutchan, Grace PL03.03
McDonald, Fiona E P08.03-005, EP11.03-003, ES11.02, IBS05.01, P1.12-05
McDougall, Carey R. EP16.03-019
McElrea, April EP16.02-019
McGarry, Caitlan OA10.05
McGarry, Caitlin P1.02-01
McGarry, Conor K. P1.10-03
McGinnis, Hamilton S. P1.10-04
McGraw, Timothy EP02.04-004
McGregor, Deborah EP01.02-004
McGreivy, Jesse S. EP14.01-004
McGuire, Anna L. EP01.07-004, EP02.01-001
McKay, Charlotte EP08.01-002
McKay, Rana OA06.06
Mckinnon, Mathieu EP03.01-016, EP14.04-001, EP14.05-020
McLaren, Duncan B. EP02.02-003
McLeod, Melissa EP01.03-009
McNally, Virginia PL03.09
McNamara, Aoife MA08.07, P2.08-05, P2.08-06
Mc Neil, Rob EP01.03-001
McTavish, Sloane EP08.01-034
McWilliam, Alan EP05.01-012
McWilliams, Annette EP01.03-012, EP01.04-005, EP04.02-002, ES01.04, MA11.03, MA11.07
McWilliams, Annette M. WS02.05, WS02.16, WS02.35
McWilliams, Lorna ES14.06
Meano, Ken EP16.02-005
Meço, Başak C. EP10.01-013
Medeci, João P. EP02.03-010
Mederos Alfonso, Nuria N. EP08.01-069
Medina, Soledad EP05.02-002, EP05.02-003
Meem, Mahbuba EP14.05-010
Meerang, Mayura EP07.02-002, EP07.02-003
Meggyesy, Austin MA14.09
Megyesfalvi, Zsolt EP14.02-002, EP14.02-003, EP14.02-006, MA01.04
Mehra, Ranee EP07.01-001
Mehta, Anurag EP16.03-047
Mehta, Minesh P. EP07.03-006
Mei, Lei EP16.03-006
Mei, Ting EP05.01-005
Meijer, Ruben P. OA14.05
Mejia, Sergio EP16.03-002, EP16.03-003
Mekan, Sabeen F. EP08.02-098, P1.16-04
Mekhail, Tarek EP08.02-171
Melchior, Linea C. EP08.02-044, EP08.02-075
Melder, Angela EP01.02-003, EP04.01-021
Meldgaard, Peter EP03.01-015, EP08.01-084, EP08.02-099
Mele, Maria Cristina EP10.01-011
Meleiro, António EP03.01-009, EP04.01-011, EP05.03-006
Melin, Beatrice P1.01-01
Melkadze, Tamar EP01.03-013
Mella, Giulia MA10.07
Mellerick, Angela OA08.06
Mellidez, Juan EP04.01-011
Meloni, Alison R. OA03.03, OA03.06
Melosky, Barb EP08.01-075, P2.09-03
Melosky, Barbra OA13.03
Melton, Collin EP16.02-027
Memmott, Regan EP08.01-062, EP08.01-098, EP14.05-004, OA12.04
Menchaca, Martha EP01.07-002
Mendenhall, Melody OA12.03
Mendez Garcia, Miriam EP04.01-019
Méndez García, Miriam EP08.01-066, EP16.04-014
Meng, Fan Lu EP08.02-169
Meng, Fanfan EP01.01-012
Meng, Lingbin EP14.01-013
Meng, Weilin OA07.04
Meng, Yinnan EP05.01-015, EP05.01-033, EP05.02-022, EP16.04-032, MA09.08
Menis, Jessica EP10.01-011
Menna, Edoardo EP05.03-008
Menon, Nandini EP08.03-002
Menon, Roopika P2.14-02
Mensi, Carolina EP07.01-005
Merad, Miriam P2.12-05
Mercier, Olaf EP07.01-007, MA10.08
Merimsky, Ofer EP08.01-010, EP08.01-011, EP08.04-001
Merkelbach-Bruse, Sabine EP08.02-031, EP08.02-106, EP08.02-114
Merlin, Céline EP07.01-024
Merlio, Jean Philippe EP11.01-005
Merrell, Kenneth W. EP05.01-011
Merritt, Robert P1.03-01
Mesa Rubio, Dolores EP08.01-048
Mesci, Aruz EP05.01-035
Meshulami, Noy OA06.03
Mesobank, Mesopath/ OA04.05
Messina, Cristina EP08.01-020
Meti, Nicholas EP14.01-019
Metro, Giulio EP02.04-001, EP08.01-030, EP08.02-046, EP08.02-060, EP08.02-140
Metzenmacher, Martin EP04.01-016, EP04.02-005, MA06.08
Meyer, Christian N. EP01.07-001
Meyer, Michael G. P2.11-02
Meyer, Thomas EP02.03-023
Meyers, Renelle EP01.07-004, EP16.02-019
Meza, Rafael OA10.03
Mezheyeuski, Artur MA05.04
Mezquita, Laura EP03.01-012, EP08.01-090, EP08.01-091, EP08.02-074, EP08.02-102, EP08.02-149, MA07.06, MA07.07, OA07.06, OA13.04, P1.07-02, P1.12-04, P1.16-02
Mhizha, Nyaradzayi EP01.07-006
Miah, Abdul EP08.01-062
Miao, Libin EP16.03-008
Michael, Kesi EP13.01-006
Michaeli, Tal P2.01-02
Michelotti, Anna EP11.01-004
Michels, Sebastian EP08.02-106, EP08.02-114
Micke, Patrick EP11.01-007, EP16.04-001, IBS10.02, MA05.04, OA09.06
Mielgo, Xabier P1.12-04
Migas, John P2.10-02
Migliorino, Maria R. EP08.02-159, EP16.03-040
Migliorino, Maria Rita EP02.04-001
Mihic Góngora, Luka EP16.01-031
Mikov, Ivan EP04.02-006
Milanese, Gianluca P1.15-04
Milanowski, Janusz EP01.01-008
Milella, Michele EP10.01-011, EP14.01-005
Milicevic, Jasminka P2.04-01
Milione, Massimo MA01.07
Miller, Beth P1.02-01
Miller, Eric EP05.01-021
Miller, Jarred EP01.03-008
Miller Jr., Wilson H. OA03.04
Millett, Ralph P2.02-02
Millward, Michael EP08.02-029, EP16.01-002, EP16.03-005
Milne, Roger L. MA11.05, P1.01-01
Milner-Watts, Charlotte EP08.02-065, MA12.09
Milton, Denai R. EP08.01-059
Min, Xu Hong EP08.02-078
Min, Xuhong EP08.02-063
Min, Young Joo EP08.02-025
Minami, Yuko ES07.02, MA02.06, MA12.07
Minari, Roberta EP02.04-001, P1.15-04
Minata, Jose N. EP16.03-002
Minatta, Jose N. EP08.02-097
Minatta, José Nicolas P1.12-04
Minatta, Nicolás J. EP16.02-029
Minchom, Anna EP08.02-065, EP08.02-124, MA12.09
Mine, Hayato P1.15-13
Mineshita, Masamichi EP11.01-010
Minhas, Fayyaz EP07.03-005
Minn, Andy J. P1.15-07
Minna, John D. EP08.02-130
Minna, John D. OA06.03
Minnella, Enrico M. EP05.02-015
Mino-Kenudson, Mari MA12.07, MA12.10
Minotti, Vincenzo EP08.02-048
Minuti, Gabriele EP08.01-030, P2.14-02
Miranda, José EP14.01-009
Misako, Nagasaka EP08.02-118
Mishima, Shuji MA03.07, P2.12-02
Mishra, Pritinanda EP08.04-004
Mishra, Sanjay OA06.06
Mistry, Amita P2.07-01
Misumi, Toshihiro EP08.01-005
Mitchell, Paul EP08.02-029, EP14.05-016
Mithoowani, Hamid EP08.02-034
Mitola, Giulia EP16.03-042
Mitsudomi, Tetsuya EP08.01-005, EP08.02-085, EP08.02-146, WS03.01
Mitsui, Masafumi EP08.02-133
Mittak, Marcel MA01.04
Mittal, Abhenil EP04.01-001
Mittal, Vivek OA09.05
Mittmann, Nicole EP04.01-027
Miura, Kentaro MA03.07, P2.12-02
Miura, Naoko EP08.02-144
Miura, Satoru EP08.01-005
Miyagi, Yohei EP11.01-008
Miyamoto, Shingo EP08.02-113
Miyata, Yoshihiro EP02.01-017, EP16.01-004
Miyawaki, Michiyo EP08.02-123
Miyazaki, Teruo EP16.03-029, EP16.03-037, EP16.04-009

Miyoshi, Seigo EP08.02-143
Miyoshi, Tomohiro EP02.01-005
Mizuno, Keiko EP08.01-064
Mizuta, Hayato EP08.02-020
Mjelle, Robin EP01.01-005, EP01.01-009
Mo, Xiaokui EP05.01-021, EP08.01-098
Moehler, Thomas EP04.01-006
Moes-Sosnowska, Joanna EP16.03-014
Moffat, Miriam EP07.03-005
Moffatt, Miriam F. EP11.03-003, P1.12-05
Moffett, Jenesse N. EP05.01-011
Moffett, Nicole MA13.09
Mohamed, Islam P1.05-01
Mohamed Hoesein, Firdaus A. EP01.05-006
Mohan, Anant EP03.01-005, EP03.01-006, EP11.01-011
Mohanty, Sambit K. EP11.01-012
Mohapatra, Prasanta R. EP08.04-004
Mohindra, Nisha A. EP04.01-007, EP04.01-008, EP08.02-028
Mohindra, Pranshu EP07.01-001
Mohorcic, Katja EP08.02-122, EP16.03-011
Moita, Catarina P. EP05.03-003
Moital, Inês EP08.02-053
Mok, Tony EP08.01-027, EP08.01-042, MA13.03, OA15.04
Mok, Tony S. EP08.02-098, EP08.02-159
Mok, Tony S. K. OA15.06
Mok, Tony SK EP02.02-008
Mokhtari, Abdelrhani EP14.01-018, EP16.04-018
Moldovan, Nataliya EP16.02-019
Moldvay, Judit MA01.04
Molina, Gaspar EP07.01-022, EP08.01-078
Molina, Julian EP05.01-011, MA13.09
Molina, Mariel MA08.04
Molina, Miguel Ángel EP08.02-011, EP16.02-007
Molina, Thierry MA10.08
Molinas Mandel, Nil EP05.02-004, EP05.02-005, EP05.03-007
Molina-Vila, Miguel Angel EP08.02-032, EP08.02-120, EP08.02-135
Mollà, Meritxell EP02.02-007
Møller, Ditte S. EP05.01-017
Möller, Miriam EP14.01-008
Molyneaux, Philip L. P1.12-05
Mondal, Debapriya EP06.01-005, EP08.02-040, EP16.02-006
Mondal, Sudipto EP08.02-053
Monjazeb, Arta EP08.01-061
Monkman, James EP16.04-003
Monmano, Nanamon EP02.01-016
Montagna, Sara P2.10-05
Montague, Debra EP08.02-066
Montalto, Michael P2.15-01
Montella, Tatiane C. OA01.07, OA08.03
Montero Fernandez, Angeles EP07.03-005
Montesion, Meagan EP08.02-084
Monte Tenório Taveira, Gabriela EP04.01-022, WS07.06
Montrone, Michele EP05.01-024, EP06.01-006, EP08.01-007, P2.10-05
Montuenga, Luis M. EP16.01-009
Moodie, Carla EP02.03-012
Moodie, Carla C. EP02.03-005
Moonen, Laura MA01.09
Mooradian, Ariana EP16.03-016
Moore, Alison EP02.04-009, EP03.01-002, EP04.01-001
Moore, Amanda EP05.02-013
Moore, Amy MA14.04, OA06.03
Moore, Elizabeth EP08.01-061
Moore, Sara M. EP03.01-016, EP14.04-001, EP14.05-020
Morabito, Alessandro EP05.01-024, EP06.01-006, EP08.02-048
Moracci, Laura EP07.01-004
Moraes, Fabio O A14.02
Morales-Garcia, Mariana EP16.03-023, WS07.04
Moran, Angel EP05.01-019
Moran, Teresa MA06.03, OA06.04, PL03.12
Morandi, Paolo EP08.01-012
Morbeck, Igor EP03.01-003
Moreira, Andre ES10.06, MA12.07
Moreira, Gisele F. OA08.03
Moreira Ferreira, Carlos Gil EP04.01-022, WS07.06
Morellato, Juliana B. EP02.03-010
Morelli, Anna M. EP10.01-015
Moreno, Lorena EP03.01-012, P1.07-02
Moreno, Victor EP08.02-148
Morganstein, Neil EP07.01-019
Morgensztern, Daniel EP08.01-013
Mori, Masahide EP08.02-168
Mori, Yuta OA07.03
Morikawa, Kei EP11.01-010
Morin, Gregg EP08.02-055
MORISHITA, YUKIO EP16.03-029, EP16.04-009
Morita, Ryo EP08.02-133
Morita, Satoshi EP08.02-133
Mornex, Francoise IBS18.01, IBS18.09, PL02.01
Moron Dalla Tor, Lucas P1.15-04
Morooka, Hiroaki EP16.01-029
Morris, Clive P1.16-02
Morris, Stefanie EP14.01-015
Morrison, Laura MA12.05
Mortensen, Lise S. EP01.07-001
Moscatelli, Paolo EP04.01-005
Moskovitz, Mor EP08.02-047
Mosleh, Berta EP02.01-009, EP05.02-007, EP07.02-001
Mosquera, Joaquín EP08.01-029
Mosquera, Joaquin M A06.03, PL03.12
Mosteiro Lamas, Miguel EP16.03-027
Motoi, Noriko MA12.07
Motola-Kuba, Daniel EP07.01-011
Mott, Frank E. EP08.01-059
Moudgalya, Hita EP08.01-037
Mountain, Victoria P2.15-01
Mountzios, Giannis EP08.02-060, ES05.03
Mourino, Rocio EP01.03-002
Mu, Yuxin EP08.02-091
Muanza, Thierry OA07.06
Mueller, Christian EP08.01-109
Mukae, Hiroshi EP08.01-064, EP08.04-005
Mukhopadhyay, Ayesha EP01.06-007
Mulargiu, Cristiana EP08.01-012, P1.15-06
Mulder, David EP05.02-015, EP05.02-019
Muley, Thomas EP16.01-019
Müller, Heimo EP11.02-002
Mullet, Timothy P2.08-09
Mulrooney, Tiernan EP05.02-013
Mulshine, James EP01.04-005, MA11.07
Mummudi, Naveen EP08.03-002, MA09.03
Mun, Mingyon EP02.01-006, EP02.01-014
Mundkur, Nirjhar EP16.03-024
Munker, Dieter EP04.01-015
Munné, Marta EP01.03-002
Muñoz, Wendy EP07.01-011
Muñoz Martín, Andrés J. EP08.02-070
Muñoz-Pinedo, Cristina P2.14-04
Munoz-Schuffenegger, Pablo OA11.01
Munthum, Dittapol EP02.01-016
Munuganti, Ravi EP08.02-055
Murakami, Haruyasu MA13.04
Murakami, Kasumi EP08.02-143
Murakami, Shuji EP08.02-115, EP11.01-008
Muraoka, Yuji EP02.03-016, MA04.04
Murauer, Christoph EP11.02-002
Muriana, Piergiorgio P1.04-03
Murphy, John EP05.01-002
Murphy, Neal EP15.01-002
Murray, Conor EP01.03-003
Murray, James EP01.07-006
Murray, Joseph EP02.04-007, EP08.01-086
Murray, Rachael EP01.02-005, PL03.03
Murugesan, Karthikeyan EP08.02-084
Musca, Marco MA10.07
Mushonga, Melinda EP05.01-020
Mussi, Chiara E. EP08.02-148
Mussot, Sacha MA10.08
Mussulman, Laura OA10.04
Muto, Satoshi P1.15-13
Muyang, He EP02.02-001
Myers, Renelle EP01.05-007, MA11.08, P1.04-02
Myers, Renelle L. OA13.03
Myers, Sara W. EP16.03-019
Mynard, Nathan EP02.04-004

N

Na, Bubse EP16.02-021
Na, Feifei EP14.03-002
Na, Kwon Joong EP02.03-004, EP16.02-021, EP16.03-017, EP16.04-013
Naban, Chadi EP16.03-021
Nackaerts, Kristiaan EP01.05-006
Nadal, Ernest EP08.01-029, EP08.01-090, EP08.01-091, EP16.03-027, MA06.03, OA02.03, OA07.06, P1.09-03, P2.07-02, P2.14-04, PL03.12
Nadal Alforja, Ernest EP08.02-070
Nadeem, Bilal OA14.05
Nadjm, Sascha EP04.01-016, EP04.02-005
Nadon, Tara EP04.02-004
Nagarkar, Deepti OA14.06
Nagarkar, Rajnish P1.15-11
Nagasaka, Misako EP01.06-008, EP16.03-021
Nagashima, Seiji EP08.04-005
Nagata, Yasushi ES16.01
Nagayasu, Takeshi EP13.01-007

Nagelberg, Amy EP08.02-055
Nagelberg, Amy L. EP16.03-039
Nagovski, Neil EP16.02-003
Nahleh, Zeina EP08.01-023
Naicker, Kirsha EP08.01-042
Naidoo, Jarushka MA06.05, WS03.04
Nailon, William H. EP02.02-003
Naing, Aung EP08.01-059
Nair, Arjun EP01.06-002, EP08.03-005, MA11.10, OA05.01
Nair, Prashant R. EP16.03-024
Nair, Sandhya EP08.02-016
Nairoukh, Roba EP01.02-002, P2.11-01
Nait Ajjou, Myriam EP04.01-020
Najmeh, Sara EP05.02-015, EP05.02-019
Nakagawa, Kazuhiko EP08.02-159, EP16.02-005, MA06.04
Nakagawa, Kazuo EP02.03-014, EP02.03-016, MA04.04
Nakagawa, Shintaro EP08.01-005
Nakahashi, Kenta EP02.03-024, EP05.03-009
Nakajima, Eiji EP16.03-029, EP16.03-037, EP16.04-009
Nakajima, Jun MA10.04
Nakajima, Takahiro EP05.02-017
Nakamura, Shota EP02.01-015
Nakamura, Yukihiro EP08.02-143
Nakanishi, Keita EP02.01-015
Nakanishi, Ryoichi MA10.04
Nakao, Masayuki EP02.01-006, EP02.01-014
Nakata, Kyosuke EP14.05-022
Nakata, Masao EP08.01-064
Nakatani, Koichi EP08.01-005
Nakatomi, Katsumi EP08.01-064, EP08.04-005
Nakayama, Haruhiko EP02.01-017
Nakayama, Yuko LA02.04
Naldrett, Michael J. P2.14-03
Naltet, Charles P1.16-02
Nambirajan, Aruna EP03.01-005, EP11.01-002, EP11.01-011
Namikawa-Kanai, Haruka EP16.04-009
Nano, MD, Olger EP08.02-107
Naqib, Ankur EP08.02-119
Nardini, Marco P1.13-01
Naruka, Vinci EP01.07-006
Narvekar, Yugandhara EP16.03-024
Nascimento, Lucas EP03.01-007
Nash, Amanda P1.14-02
Nasit, Kampanat EP08.02-026
Natal, Rebeca EP08.02-054
Natarajan, Amarnath P2.14-03
Nathany, Shrinidhi EP16.03-047
Natkunam, Yasodha MA10.05
Nauroth, Julie EP08.01-086
Navani, Neal EP01.06-002
Navarro, Alejandro EP07.01-022, EP07.01-023, EP08.01-078, OA12.06
Navarro, Valentí EP08.01-029
Navarro, Victor EP07.01-022, EP07.01-023
Navarro-Gorro, Nil EP14.05-002
Naveh, Navit P2.10-02
Naves, Dwayne MA12.03
Nayak, Rahul EP02.01-013
Nazir, Niaman OA10.04
Neal, Joel W. EP08.02-081, EP08.02-098, EP16.02-015
Neal, Richard PL03.03
Neal, Robert EP02.04-002
Nechushtan, Hovav P2.01-02
Neesanun, Sunee EP08.04-006
Negi, Amit EP11.01-012
Negrao, Marcelo V. EP08.02-163
Negri, Antonio P2.10-05
Neitzert, Luca EP02.03-007
Nelson, Alan C. P2.11-02
NEN Network, L MA01.07
NEN Network, Lung MA02.03
Nensa, Felix EP02.01-010
Nestle, Ursula ES16.02, MA09.10
Neuberger, Manfred OA10.02
Neumann, Melissa EP15.01-002, EP15.01-002
Neves, Fátima EP14.01-009
Neves, Maria C. EP03.01-009
Newman, Edward MA13.08
Newman, James EP08.01-068
Newton, Michael P1.10-01
Ng, Calvin SH EP02.02-008
Ng, Pak For EP03.01-011
Ng, Quan Sing EP16.03-036, P2.13-02
Ng, Ryan EP08.02-103
Ng, Thomas EP02.03-022, MA03.08
Ng, Victor P1.05-02
Ng, Wee Loon P2.13-02
Ngiam, Celina EP02.04-005
Ngo, Preston MA11.03, P1.08.01
Ngodngamtaweesuk, Montien EP02.01-016
Nguyen, Aiden EP08.02-130
Nguyen, Brandon MA10.05
Nguyen, Caroline EP04.01-017
Nguyen, Danny EP08.02-018, EP08.02-171
Nguyen, Kathy P1.02-01
Nguyen, Olav Toai Duc EP01.01-009, MA11.04
Nguyen, Tom EP13.01-006
Ni, jianjiao P2.10-03
Ni, Jie EP14.01-001
Ni, Shuai MA02.05
Nian, Weiqi EP08.02-029
Niaura, Raymond OA10.03
Nicholas, Alan OA14.06
Nicholls, Danielle EP11.02-001
Nicholson, Andrew ES10.03, MA12.07
Nicholson, Andrew G. EP11.03-003, P1.12-05
Nicholson, Siobhan EP02.01-002
Nicotra, Claudio P1.16-02
Niedbala, Michael EP08.02-079
Niedzwiecki, Donna EP02.02-006
Nieto, Beatriz EP05.02-002, EP05.02-003
Nieva, Jorge EP08.02-118, EP16.03-021, MA13.08
Niho, Seiji EP08.02-159
Nii, Kazuhito EP08.01-046
Niimi, Akio OA07.03
Nikolaidou, Vasiliki EP14.01-022
Nikolakopoulos, Achilleas EP10.01-018
Nilsson, Monique B. MA01.03
Nishimura, Yoshiharu EP02.03-017
Nishino, Kazumi EP08.02-113
Nishio, Makoto EP02.01-006, EP08.01-005, EP08.02-115, MA13.03
Nishiyama, Akihiro EP08.02-113
Niu, Xiaomin EP08.01-009
Niu, Yanjie EP08.01-038, EP08.01-039
Niu, Yuanyuan EP08.01-001, EP08.02-005, EP08.02-006
Nixon, Bonnie P1.15-08
Niyogi, Devayani EP06.01-014, MA03.02, MA10.03, MA14.10
Nogami, Naoyuki EP08.02-143, OA15.06
Nogova, Lucia EP08.02-106, EP08.02-114
Noguchi, Masayuki MA12.07
Nogueira, Isabel EP01.05-001
Noh, Jae Myoung EP02.02-004, EP02.02-005
Nomura, Aya EP05.02-017
Nong, Yang EP08.02-052
Noonan, Elise EP13.01-017
Noor, Zorawar MA07.05
Noordhof, Anneloes L. EP08.01-026
Nooruddin, Zohra EP05.02-013
Nordling, Sofia OA09.06
Norenberg, Ricarda EP08.02-148
Noriega-Aguirre, Lorena EP01.05-004
Norman, Ina EP08.04-002
Norman, Ruthann O. EP14.05-004, OA12.04
Noronha, Vanita EP08.03-002
Norris, Ruth P. OA01.05
Nosaki, Kaname EP08.02-113, EP08.02-118
Nøst, Therese H. EP01.01-005
Nøst, Therese Haugdahl EP01.01-009, MA11.04
Notario, Lucia OA06.04
Nott, Louise EP16.03-005
Nouriany, Nazanin ES31.01
Novegil, Veronica Y. P2.10-01
Novello, Silvia EP05.01-024, EP06.01-006, EP08.02-101, EP08.02-140, EP10.01-015, EP16.03-011, EP16.03-040, IBS18.02, IBS18.07, OA15.06, P1.11-01, PL01.01
Novicoff, Wendy EP08.01-034
Nowack, Miriam MA12.04
Nowak, Anna EP07.01-024, WS04.05
Ntambwe, Ives EP05.02-018
Nuerlan, Saiteer. EP08.02-095
Nugent, Zoann EP16.02-019
Nuñez, Anna EP01.03-002
Núñez García, Beatriz EP04.01-019
Nuñez García, Beatriz EP08.01-066
Núñez García, Beatriz EP16.04-014
Nuredini, Ornela EP03.01-004
Nürnberg, Peter MA01.09
Nusch, Arnd EP05.01-030
Nwadozi, Emmanuel OA09.06
Nyman, Jan HOD02.02

O

Oancea, Blanca EP06.01-009
Obeid, Zeinab EP07.01-016, EP14.05-018
Oberley, Matthew MA05.08
Oberndorfer, Felicitas EP14.02-003, MA01.04
O'Brate, Aurora OA03.05
O'Brien, Mary EP08.02-065, EP08.02-124, MA12.09

O'Brien, Timothy EP02.04-002
O'Brien, Mary EP08.01-021
O'Byrne, Ken EP16.04-003
O'Byrne, Kenneth J. MA01.06, WS04.01
Ocariz, Maitane EP16.01-014
Occhipinti, Mario EP07.01-021, EP08.01-006, MA10.07, P1.15-02
O'Connor, John P1.10-03
Odintsov, Igor MA13.05
O'Dowd, Emma EP01.02-005
O'Dowd, Niamh EP16.04-004
Oeck, Sebastian EP16.03-004, EP16.04-002
Oedegaard, Cecilie EP08.02-047
Oezkan, Filiz EP04.01-016, EP04.02-005, ES25.03, MA06.08, OA14.06
Officer, Leah EP16.04-011
Offin, Michael D. EP05.01-025
Offman, Judith EP07.03-005
Ofiara, Linda EP05.02-015, EP05.02-019
Oga, Toru EP08.01-064
Ogale, Sarika EP04.01-017
Ogata, Ryosuke EP08.04-005
Ogrady, Daniel P2.12-05
Oguri, Tetsuya OA07.03
Oh, Hyung-Joo EP08.01-017, EP08.02-086
Oh, In-Jae EP08.01-017, EP08.02-086, EP08.02-142
Oh, Jaewon EP05.01-034
Oh, Youjin EP08.02-023, EP08.02-062, EP16.02-022, P2.12-04
Ohara, Shuta EP08.02-085, EP08.02-146
Ohashi, Kadoaki EP08.02-113
Ohashi, Takuya EP02.03-017
Ohe, Yuichiro EP07.03-004, EP08.02-016, EP08.02-118
Ohira, Tatsuo EP16.03-037
Ohira, Tetsuya MA03.05
Ohkubo, Hirotsugu OA07.03
Öhman, Ronny EP08.02-122
Oi, Hajime EP08.02-113
Oizumi, Satoshi EP08.02-113
Oka, Mikio EP08.01-064
Oka, Naoyuki EP07.03-007
Okabe, Naoyuki P1.15-13
Okabe, Takafumi EP16.02-005
Okada, Morihito EP02.01-017, EP16.01-004
Okada, Yoshinori MA03.05
Okado, Shoji EP02.01-015
Okahisa, Masanobu EP08.02-113
Okamoto, Isaumu EP08.01-036
Okamoto, Tatsuro EP08.02-118, EP08.02-144
Okamura, Koji EP08.01-036
Oki, Masahide EP16.02-005
Okimoto, Tamio EP08.01-019
Oksen, Dina EP08.02-126
Okubo, Yu EP07.03-007
Okuma, Yusuke EP07.03-004
Okumura, Meinoshin MA10.04
Okumura, Sakae EP02.01-006, EP02.01-014
Okumus, Oezlem EP02.01-010
Okumus, Özlem P1.14-05
Okura, Masayuki EP08.02-115
Olazagasti, Coral EP04.01-010
Olesen, Inger EP14.05-016
Olevsky, Olga MA07.05
Oliva, Dolores M. P1.15-11
Oliveira, Júlio EP04.01-011
Oliveira, Marcos EP08.02-054
Oliver, Thomas EP05.01-011
Olivier, Kenneth R. EP05.01-011
Olmedo, María MA02.08
Olmedo-García, Eugenia EP08.02-149
Olmetto, Emanuela EP06.01-006
Olshan, Perry EP16.02-003
Olson, Sara EP08.01-065
Olteanu, Gheorghe-Emilian EP07.01-004
Oltvai, Zoltan N. EP16.04-025, EP16.04-026, EP16.04-027
Omar, Ola EP01.02-002, P2.11-01
Omura, Kenshiro EP02.01-014
On, Phu Vinh EP08.02-103
O'Neil, Bert EP08.02-116
O'Neill, Eric J. EP16.04-008
Onn, Amir EP08.02-047
Ono, Shotaro EP16.03-029, EP16.04-009
Onodera, Ken EP02.01-005
Onwuka, Justina P1.01-01
Opalecky, Buerkley EP07.01-013
Opdam, Frans EP08.02-049
Opitz, Isabelle EP07.02-002, EP07.02-003, EP07.02-004, EP08.03-006, EP16.04-010, ES03.06, LA02.03, OA04.04, P1.14-01, WS04.16
Opitz, Lennart P1.14-01
Orain, Michèle EP16.02-027
Ordman, Robyn EP10.01-003
Ordoñez-Reyes, Camila EP05.01-001, EP16.03-002, EP16.03-003
Orecchioni, Stefania EP16.03-042
Oresti, Sara EP08.02-046
Orhan, Kaan EP13.01-002, P1.12-03
Orlandi, Francisco J. OA12.06
Orlov, Sergey EP08.02-108
Orlowski, Tadeusz EP16.03-014
Orlowski, Vanessa EP07.02-002, OA04.04
Orozco, Mario EP08.02-035
Orozco-Morales, Mario EP07.01-011
Ortega, Ana L. P1.15-09
Ortega, Ana Laura EP08.01-029
Ortega, Francisco Gabriel P2.13-01
Ortiz, David EP01.04-001
Ortiz-Cuaran, Sandra ES07.04
Osarogiagbon, Raymond U. EP02.03-022 MA03.08, EP01.06-007, LA01.03, WS02.34
Osborne, Edward OA14.06
Oshita, Kazuki EP08.02-143
Osmon, Elizabeth EP08.02-107
Osoegawa, Atsushi EP08.02-123
Ostoros, Gyula IBS15.02, OA01.01
Ostroff, Jamie P2.08-07, P2.08-09
Osugi, Jun EP08.02-133
O'Sullivan, Hazel M. EP08.02-065, MA12.09
O'Sullivan, Maeve MA08.08
O'Sullvan, Hazel EP08.02-124
Ota, Keiichi EP08.01-036
Ota, Takahiro EP08.02-133
Otero, Jorge EP16.03-002, EP16.03-003
Otsubo, Kohei EP16.02-005
Otten, Leila-Sophie EP08.02-090
Ottersbach, Michelle P1.03-01
Otterson, Greg EP08.01-062, EP08.01-098
Otterson, Gregory A. E P14.05-004, EP16.03-009, OA12.04
Otto, Gordon EP08.02-126, OA03.05
Otxozoria, Nana EP01.03-013
Ou, Qiuxiang EP08.02-073
Ou, Sai-Hong I. E P01.06-003, EP01.06-008, EP08.02-118, MA07.04, MA07.09, MA13.03, WS08.12
Ou, Sai-Hong Ignatius EP08.02-041
Oudkerk, Mathijs ES04.03, WS02.20
Oudkerk, Matthijs EP01.05-006, OA05.04, P1.02-03
Oughton, Jamie B. EP05.01-007
Owen, Dawn EP05.01-011, MA06.10
Owen, Dwight EP08.01-019, EP08.01-062
Owen, Dwight H. EP08.01-098, EP14.05-004, EP16.03-009, OA12.04, OA14.06
Owen, Scott EP05.02-015, EP05.02-019
Owen, Scott P. EP08.02-098
Owonikoko, Taofeek OA12.05
Oxnard, Geoff EP08.02-084
Oxnard, Geoff R. P2.14-01
Oxnard, Geoffrey R. EP16.02-002
Oyebanji, Tunde N. EP06.01-004
Oyervides-Juárez, Víctor M. EP16.03-026
Ozaez, Irene EP08.02-088, EP16.01-007, EP16.02-014
Ozaki, Tomohiro EP16.02-005
Ozakinci, Hilal EP13.01-002, EP16.01-004
Özçıbık, Gizem EP05.03-001
Ozcibik, Gizem EP02.03-001
Özdemir, Nuriye EP08.01-024
Ozdil, Ali EP02.03-026, EP02.03-027, EP13.01-014
Ozeki, Naoki EP02.01-015
Ozer, Kadir B. EP05.02-004, EP05.02-005, EP05.03-007
Özet, Ahmet EP08.01-024
Özgüroğlu, Mustafa EP14.05-009, OA15.03, P1.15-12

P

Paakkola, Nelly-Maria D. EP04.01-012
Pabani, Aliyah EP02.04-003, EP05.02-001, EP06.01-003, EP08.01-004, EP08.02-013, EP08.02-014, EP08.02-071, EP10.01-008
Pacchiana Parravicini, Maria Vittoria EP16.03-011
Pacheco, Alicia EP01.06-007, EP02.03-022, MA03.08
Pacheco, Patrícia EP03.01-003
Pacheco-Barcia, Vilma EP08.01-040
Paci, Massimiliano EP16.03-042
Padda, Sukhmani MA10.05
Padley, Simon EP06.01-008, P1.12-05
Padmaja, Mantha S. EP08.04-004
Padrosa, Joan EP08.02-102
Paez, Rafael EP01.05-009
Paggio, Angela MA10.07
Pagni, Fabio MA01.01, MA05.06
Paik, Paul MA13.08, OA03.05
Paku, Sandor MA01.04
Pal, Navdeep EP08.01-065
Pal, Prodipto EP11.02-001
Palanca, Sarai P2.07-02
Pall, Georg EP08.02-122
Palma, David A. OA06.07
Palmares, Abigail EP02.03-002
Palmer, Ruth H. EP16.03-012
Palmero, Ramón EP08.02-131, EP16.03-027

Palmero, Ramon MA06.03
Palmero, Ramón P2.14-04, PL03.12
Palmieri, Luciano EP02.03-007
Palsuledesai, Charuta C. EP16.02-003
Palti, Yoram EP16.01-016, EP16.03-028
Paluch, Peter EP08.02-087
Pan, Banzhou EP08.01-080
Pan, Fang EP08.02-159
Pan, Kaicheng EP10.01-001
Pan, Max OA05.03
Pan, Minghong MA04.07
Pan, Weijia EP14.01-016
Pan, Xuanqi P1.02-03
Pan, Yi OA02.05
Pan, Yue EP01.07-005
Pan, Yue Yin EP08.02-078
Pan, Yue-Yin EP08.02-064
Pan, Yueyin EP08.02-139
Pan, Zhan Yu EP08.02-003
Panandtigri, Souleymane EP06.01-012
Pancirer, Dani EP16.02-015
Pandey, Prashant EP16.02-006
Pang, Dazhi EP02.03-015
Pang, Jiaohui EP16.03-044
Panigrahi, Manoj K. EP08.04-004
Pannu, Jasleen EP01.03-007
Pannu, Jasleen K. P1.03-01
Paño, José Ramón EP16.01-014
Pantel, Klaus EP16.01-011
Pantelas, James P2.08-07
Pantelas, Jim P2.08-09
Paoloni, Francesco EP08.01-007
Paone, Julie EP14.05-023
Papadakis, Andreas EP11.03-001
Papafili, Anastasia EP14.01-022
Papakotoulas, Pavlos EP10.01-018
Papandreou, Christos EP10.01-018
Papi, Maximilian EP08.01-030
Papotti, Mauro ES21.03, MA12.07
Paracchini, Lara EP07.01-004
Parakh, Sagun OA08.06
Paratore, Chiara P2.04-03
Pardo, Julián EP16.01-014
Pardo, Nuria EP07.01-022, EP07.01-023, EP08.01-078
Paredes, Alfredo EP08.02-131
Parejo, Consuelo EP16.04-014
Parente, Bárbara EP03.01-009, EP04.01-011, EP05.03-006
Parente, Phil EP14.05-016
Parente, Phillip EP08.04-002
Parepally, Jagan EP08.02-018, EP08.02-019, EP08.02-045
Parikh, Kaushal EP08.01-044
Parisi, Francesca EP08.01-088
Park, Chan Kwon P2.01-01
Park, Cheol-Kyu EP08.01-017, EP08.02-086
Park, Hyungjun EP08.02-128
Park, Il Yeong EP08.02-086
Park, In Kyu EP02.03-004, EP16.02-021, ES08.06
Park, Ji Young EP08.02-142
Park, John J. P1.15-08
Park, Jong Sun EP13.01-008
Park, Joo Hee EP16.02-022, P2.12-04
Park, Josiah V. EP08.02-130
Park, Keunchil ES25.05, LA01.01, OA15.03
Park, Kisung EP02.03-013
Park, Matthew D. P2.12-05
Park, Samina EP02.03-004, EP16.02-021
Park, Seung-Il EP05.03-004
Park, SoHee EP07.01-015
Parker, Christopher M. EP04.01-024, EP13.01-012
Parker, Jennifer EP04.01-001
Parker, Joel S. EP16.03-025
Parker, Mark S. EP01.07-002
Parker, Patricia P2.08-09
Parlagreco, Elena P2.04-03
Parmar, Ambica EP10.01-004
Parmar, Ambika EP04.01-027, EP08.05-001
Parrott, Steve PL03.03
Parthasarathy, Sriram EP01.06-004
Parvez, Wadood EP13.01-001
Pascal, Mariona EP08.01-090, EP08.01-091
Pasello, Giulia EP02.04-001, EP05.01-024, EP06.01-006, EP08.01-007, EP08.01-012, EP08.02-104, EP14.01-006, MA05.10, MA10.07, P1.15-06
Pasquarella, Anthony V. EP16.04-012
Pasquinelli, Mary EP02.02-002
Pasquinelli, DNP, Mary EP10.01-014
Pass, Harvey I. EP02.04-005
Passiglia, Francesco EP02.04-001, EP08.01-007, EP08.02-101, EP16.03-011, EP16.03-040, ES25.06
Passlick, Bernward EP05.01-030
Passmann, Elke EP08.02-114
Passone, Erika EP02.03-006
Passos Coelho, José EP08.02-141, EP16.03-035
Pastis, Nicholas P1.03-01
Pastor, Belén EP03.01-012, MA07.07, P1.07-02
Pastorello, Julia EP03.01-003
Pastori, Chiara EP02.04-002
Pastorino, Ugo EP01.04-005, ES27.02, MA11.07
Patel, Anant EP01.07-006, EP02.03-002
Patel, Dainik EP04.01-023
Patel, Devalban MA14.08
Patel, Devalben EP03.01-016, EP04.01-001, EP14.01-019, EP14.04-001, EP14.05-020
Patel, Hetal EP02.03-022
Patel, Jeegar OA09.05
Patel, Jyoti EP04.01-007, EP04.01-008, EP08.02-028, EP14.03-001
Patel, Jyoti D. EP08.02-074, EP08.02-148, MA07.07
Patel, Khushbu EP01.05-008
Patel, Krishna H. EP08.01-047
Patel, Manali EP04.02-003
Patel, Manish P1.14-04
Patel, Manish R. OA03.04
Patel, Priyanka EP08.03-005
Patel, Raj A. EP02.03-005
Patel, Riddhi P1.16-04
Patel, Sandip EP08.01-062, EP08.01-098
Patel, Sanjana EP16.03-024
Patel, Sanjay EP08.02-018
Patel, Yogita S. MA08.03, OA14.03
Pathak, Rashmi EP01.03-008
Patil, Vijay EP08.03-002
Patnaik, Amita EP08.02-116
Patrizia, Frosch OA10.07
Paudel, Nitika EP02.03-008
Paul, Dion P2.08-02
Paulsen, Erna-Elise EP01.01-005
Paulus, Rebecca EP07.01-018
Pauwels, Patrick EP07.01-024
Pavan, Alberto EP08.01-012, EP08.02-104
Pavlakis, Nick EP04.01-023, EP08.02-109, EP16.03-005
Payapwattanawong, Songwit EP08.02-083
Paz, Rom EP16.01-016, EP16.03-028
Paz Ares, Luis EP14.01-020, EP16.03-011
Paz-Ares, Luis EP08.01-029, EP14.01-015, MA05.01, MA13.07, OA02.02, OA12.05, P1.16-04, P2.07-02
Paz-Ares Rodriguez, Luis OA03.04
Pecci, Federica EP08.01-043, MA02.09, P1.15-03
Pecot, Chad V. EP08.02-093, EP16.03-025, EP16.04-017
Pedeux, Rémy EP16.02-004
Pedica, Benedetta EP08.01-006
Pedraza, Manuela EP05.02-002, EP05.02-003
Pedrazzoli, Paolo EP10.01-015
Pedrocchi, Alessandra Laura Giulia EP08.01-006
Pego, Alice EP04.01-011
Peguero, Julio EP08.01-109
Pei, Yuquan EP02.03-018
Pei, Zhihua EP08.01-055, WS08.17
Peikert, Tobias EP07.01-018
Pek, Michelle EP16.02-013
Peled, Nir EP08.02-047, EP08.02-122, OA15.06, PL05.04
Pèlegrin, André OA14.05
Pelish, Henry EP08.02-020
Pelish, Henry E. EP08.02-041
Pelizzari, Giacomo EP11.01-004
Peloquin, François EP08.02-103
Pelosi, Giuseppe MA12.07
Pemberton, Laura EP05.01-012
Peña-López, Jesús EP08.01-049
Pencz, Alec EP02.01-013
Pender, Alexandra EP08.01-074, EP08.02-089
Peng, Duanyang EP08.01-003
Peng, Feng EP14.03-002
Peng, Jin EP08.01-038, EP08.01-039
Peng, Ling EP08.01-099, WS08.13
Peng, Yurong EP01.07-005
Peng, Zhongming EP05.02-009
Penkov, Konstantin P1.11-01
Pennell, Nathan EP08.02-118
Penpa, Serena EP07.01-004
Pepe, Carmela EP05.02-019, EP06.01-001, EP11.03-001
Pepe, Francesco EP07.01-001, EP16.03-040
Peposhi, Ilir EP03.01-004
Perdikouri, Eleni-Isidora EP08.02-060
Pereira, Allan A. EP08.02-059
Pereira da Silva, Fernando EP08.02-054
Peres, Stela V. EP02.03-029
Peres, Wilza OA08.03
Perez, Alessandro EP16.01-013
Pérez-Gracia, José L. EP08.02-149
Perez-Morales, Jaileene EP01.03-008
Pérez Parente, Diego EP08.01-065
Pérez Ramírez, Sara EP08.01-048

Perimbeti, Stuthi EP02.04-006, EP08.01-050
Perner, Sven EP16.01-011
Peroukidis, Stavros EP10.01-018
Perrino, Matteo MA10.07
Perrone, Antonella P2.10-05
Perrone, Carola EP08.01-088
Perrone, Fabiana EP08.01-007
Persson, Gitte EP01.07-001
Pertejo, Ana EP08.01-049
Pesenti, Mattia EP08.01-006
Pesola, Francesco P2.10-05
Peters, Cheryl EP04.02-001
Peters, Jane OA15.05
Peters, Matthew ES27.05, WS02.12
Peters, Solange EP08.01-027, EP14.01-015, IBS17.02, OA06.06, OA12.06, OA15.04, WS04.04
Petersen, Tonny S. EP08.02-105
Peterson, Christine B. P2.13-01
Petricca, Jessica EP11.02-001
Petrillo, Patrizia P2.10-05
Petrini, Iacopo EP08.02-162, MA10.07
Petruzelka, Lubos OA07.01
Petursdottir, Vigdis EP16.03-013
Petzold, Anne EP16.04-002
Peyton, Michael EP08.02-130
Pezzuto, Federica EP07.01-004
Pham, Nhu-An EP08.02-079, EP16.03-015, EP16.04-015
Phan, Tri Guang P1.15-08
Philip, Jennifer EP04.01-023, EP14.05-016
Philip, Vivek EP14.01-019
Phillip, Rachel EP05.01-007
Phillips, Iain MA09.07
Phillips, Iain D. EP02.02-003, EP05.01-008
Piana, Simonetta EP16.03-042
Pianarosa, Emilie EP03.01-002
Piantedosi, Franco EP08.01-030
Pichert, Matthew D. OA11.03
Pickering, Ed M. EP07.01-001
Piekarz, Richard MA13.08
Pienkowski, Martha EP02.04-009
Pienta, Kenneth J. MA03.04
Piet, Berber EP08.02-090
Pietanza, M. Catherine OA15.06
Pignataro, Daniele EP16.03-011
Pignatelli, Pasquale EP14.02-001
Pignatti, Francesco PL05.05
Pijuán, Lara EP16.03-027
Pilcher, Carly EP14.05-004, OA12.04
Pilon, Yohann EP05.02-015, EP05.02-019
Pilotto, Sara EP02.04-001, EP05.01-024, EP06.01-006, EP08.01-030, EP08.02-046, EP08.02-048, EP08.02-104, EP10.01-011, EP16.03-040, ES15.04, P1.12-04
Pina, Adela EP08.02-109
Pinato, David EP08.01-090, EP08.01-091
Pinato, David J. EP08.01-043, OA07.06
Pinto, Carmine WS04.03
Pinto, Clóvis A. EP02.03-010
Pinweha, Pannapa EP16.01-030
Piotrowska, Zofia EP08.02-045
Piovano, Pier Luigi EP05.01-024, EP06.01-006
Pipek, Orsolya MA01.04
Pipinikas, Christodoulos P1.16-02
Pircher, Chiara MA10.07, P1.15-02
Pircher, Chiara C. EP07.01-021
Pircher, Chiara Carlotta EP08.01-006
Pirker, Christine EP07.01-014
Pirker, Robert PL01.02
Pisapia, Pasquale EP16.03-040
Pitcher, Bethany MA13.04
Piton, Nicolas EP11.01-005
Pitson, Stuart M. EP16.04-020
Pizzolitto, Stefano EP11.01-004
Pizzutilo, Elio Gregory EP08.02-046
Pizzutilo, Pamela P2.10-05
Planchard, David EP08.01-091, EP08.02-060, EP14.01-020, ES15.03, P1.16-02
Planck, Maria EP16.03-010
Plass, Markus EP11.02-002
Platania, Marco EP07.01-021
Pless, Miklos EP16.01-018, MA12.04
Pleština, Sanja EP05.01-018
Plevritis, Sylvia K. EP16.02-015
Ploenes, Till EP02.01-010
Plönes, Till EP04.01-016, EP04.02-005, P1.14-05
Pluchino, Monica P1.15-04
Pluzanski, Adam EP08.02-159
Poddubskaya, Elena EP08.01-014
Poettgen, Christoph EP04.02-005, MA06.08
Poghosyan, Hermine EP01.03-007
Poh, Jonathan EP16.02-013
Pøhl, Mette EP01.07-001
Polacheck, William EP08.02-093
Poleri, Claudia MA12.07
Poletes, Christopher EP08.01-067, MA14.08
Politi, Katerina EP08.02-125
Polo, Carolina EP16.03-002
Polo, Valentina EP08.02-104
Pomp, Jacqueline MA03.09
Pompili, Cecilia HOD02.01
Ponce, Santiago MA06.03, PL03.12
Pond, Gregory R. EP05.01-035, P1.15-10
Pons, Aina EP02.03-002
Pons-Tostivint, Elvire EP16.04-019
Ponte, Carmen EP05.02-002, EP05.02-003
Pontén, Fredrik MA05.04
Poole, Lynne EP08.02-140
Poon, Charlotte EP01.03-004
Poon, Ian EP08.05-001
poon, ian C. EP05.01-020
Popat, Sanjay EP07.03-005, EP08.02-065, EP08.02-124, EP08.02-171, EP08.03-005, EP11.03-003, ES25.02, MA12.09, P1.12-05
Popiel, Delfina E P16.03-014
Popper, Helmut EP11.02-002, ES07.06, MA01.04
Porciuncula, Angelo P2.12-01
Porcu, Luca P1.15-02
Port, Jeffrey EP02.04-004, PL03.06
Portugal, Gonçalo EP08.02-132
Postel-Vinay, Sophie EP08.02-116
Postma, Maarten J. P1.02-03
Postmus, Pieter MA04.02
Potluri, Ravi EP08.02-016
Potrony, Miriam EP03.01-012, P1.07-02
Potter, Alexandra MA04.09, OA02.04, OA05.03, OA05.06
Potter, Alexandra L. EP14.05-003
Potter, Ashley EP05.01-011, MA13.09
Potter, Vanessa EP08.02-108
Pöttgen, Christoph EP04.01-016
Pous, Anna OA06.04
Powell, Joseph EP16.03-041
Powery, Herman EP16.02-018, P1.16-03
Pozadzides, Jenny EP08.02-163
Pozo, Fernando EP08.01-040
Prabhash, Kumar EP08.03-002
Prakash, Vineet EP08.03-005
Pramesh, C S MA10.03
Pramesh, CS EP06.01-014
Prasad, Samiksha A. EP16.03-024
Prasongsook, Naiyarat EP08.02-164
Prat, Aleix EP03.01-012, EP08.01-091, EP08.02-102, MA07.07, OA13.04, P1.07-02, P1.12-04
Pratapa, Aditya EP16.04-003
Pratt, Angus MA08.09
Preeshagul, Isabel R. EP05.01-025
Preiss, Jordan EP16.02-015
Prelaj, Arsela EP07.01-021, EP08.01-006, EP08.02-060, MA10.07, P1.15-02
Prenen, Hans EP08.02-116, OA03.04
Presley, Carolyn EP08.01-019, EP08.01-062, EP08.01-098
Presley, Carolyn J. EP01.03-007, EP14.05-004, OA12.04
Pretelli, Giulia E P08.01-012, P1.15-06
Pretorius, Lauren ES27.07, MA08.07, P2.08-05, P2.08-06
Pretre, Vincent P1.09-02
Priano, Ilaria EP08.01-078
Price-Gallagher, Colton EP06.01-001
Prince, Patricia EP14.05-023
Prochaska, Judith J. PL03.04
Prodduturvar, Pranitha EP05.01-011
Proescholdt, Christina EP08.01-016
Proli, Chiara EP01.07-006, EP02.03-002
Pronzato, Paolo EP04.01-005
Prophet, Elisabeth EP02.04-007
Prosch, Helmut EP01.04-006, EP02.01-009, PL04.02
Proto, Claudia EP05.03-008, EP07.01-021, EP08.01-006, EP08.02-046, EP08.02-140, MA10.07, P1.15-02
Provencio, Mariano EP04.01-019, EP06.01-017, EP08.01-029, EP08.01-065, EP08.01-066, EP13.01-016, EP16.02-007, ES28.02, MA06.03, OA02.03, P1.09-03, P2.07-02, PL03.12
Provencio Pulla, Mariano EP16.04-014
Provencio-Pulla, Mariano P1.15-09
Psyrri, Amanda EP10.01-018
Pu, Xiang X. EP08.01-095
Pu, Xingxiang EP08.01-093, EP08.01-094, EP08.02-158, EP08.02-159, EP08.02-161, WS08.14
Pu, Yue OA09.03

Puc, Matthew OA06.06
Pugazenthi, Aarthi P1.14-02
Puig-Butillé, Joan Anton EP03.01-012
Puig-Butille, Joan Anton MA07.07
Puig-Butillé, Joan Anton P1.07-02
Pujol, Jean-Louis WS01.05
Pulla, Mariano P. MA13.07
Puntoni, Matteo EP08.01-007
Puparelli, Carmen EP08.02-097
Pushpam, Deepam EP03.01-006, P2.02-03
Putora, Paul Martin ES03.04
Puyalto, Ander MA02.08
Pyo, Hongryull EP02.02-004, EP02.02-005
Pyrousis, Ioannis EP08.01-072

Q

Qassem, Shahd EP01.02-002, P2.11-01
Qi, Lihong EP05.01-019, EP08.01-061
Qi, Qi EP08.02-057
Qi, Weihong EP07.02-004
Qi, Yi-Fan EP02.01-012
Qiabi, Mehdi EP02.01-013
Qian, Fangfei EP01.03-010, EP16.02-023, OA05.05
Qiao, Rong EP08.01-102, EP08.01-103
Qin, Haixia EP16.03-024
Qing, Gefei EP16.02-019, OA06.07
Qiong Wu, Christine MA08.09
Qiu, Liqing EP16.04-030
Qiu, Zhen-Bin EP02.01-012, EP16.01-025, WS08.21
Qiu, Zhenghua EP08.01-092
Qu, Huajun EP08.02-076
Qu, Rirong EP01.03-011
Qu, Xin EP14.01-002
Quah, Gaik Tin EP08.04-002
Quaife, Samantha PL03.03
Quaini, Federico P1.15-04
Quan, Kimmen EP05.01-035
Qudratullah, Qudratullah EP04.01-009
Queiroga, Henrique EP04.01-011
Quek, Ruben G. P1.15-12
Querner, Alessandro S. EP14.02-003
Quilez, Elisa EP16.01-014
Quinn, Gwendolyn P. EP01.03-008
Quinn-Scoggins, Harriet PL03.03
Quiñones-Hinojosa, Alfredo P2.14-03
Quintanal-Villalonga, Alvaro EP16.03-030
Quirant, Bibiana OA06.04
Quiroga, Alicia EP03.01-003
Quist, Morten ES31.02
Qureshi, Talat EP01.06-007

R

Rabeneck, Linda OA10.05, P1.02-01
Rabin, Michael EP13.01-006
Rabinel, Pierre EP02.03-021
Radonic, Teodora ES21.05, MA12.03, MA12.08
Radulovich, Nikolina EP08.02-079
Raez, Luis EP16.03-002, EP16.03-003
Raez, Luis E. EP05.01-001, EP08.02-118, EP16.02-018, EP16.03-021, EP16.03-022, P1.16-03
Raez, Luis EP08.02-107, WS07.10
Ragam, Avanthi EP04.01-007, EP04.01-008
Rahai, Neloufar EP14.05-023
Rahman, Husneara EP08.01-068
Rahman, Rifaquat IBS13.01
Rahmim, Arman MA03.04
Rahsepar, Bahar P2.07-01
Rai, Pragya EP08.01-087
Rajagopal, Chaketh EP01.06-004
Rajagopalan, Swaminathan EP16.03-024
Rajan, Deepta P2.07-01
Rajasekaran, Tanujaa EP16.03-036, P2.13-02
Rajer, Mirjana ES24.05, IBS08.02
Rakshit, Sagar MA13.09
Ramaesh, Rishi EP02.02-003
Ramaker, Dianne P1.02-03
Ramalingam, Suresh EP08.02-108
Ramalingam, Suresh S. EP08.01-060, EP08.02-171, EP14.03-003, MA05.08, MA07.03, OA03.06, P1.10-04
Ramanujam, Sangeetha EP16.03-005
Rambousek, Vanessa EP08.01-108
Ramella, Sara EP05.01-024, EP06.01-006, ES06.02, ES11.06
Ramesh, Vidhyalakshmi OA06.06
Ramfidis, Vasilis EP14.01-022
Rami-Porta, Ramon ES34.05
Ramirez, Ariel EP16.01-014
Ramirez, Larisa EP01.05-004
Ramirez, Robert EP14.05-014, EP14.05-015
Ramirez, Robert A. EP14.05-011, EP14.05-012, EP14.05-013, EP14.05-019
Ramkumar, Kavya P2.10-01
Ramlau, Rodryg EP08.02-072
Ramos, Rodolfo EP01.06-007
Ramos, Suyen EP07.03-006
Ramos-Ramirez, Maritza EP07.01-011
Ramos-Ramírez, Maritza EP08.02-035
Ramos-Ramirez, Maritza EP08.03-003, EP16.03-023, WS07.04
Ramos-Vegue, Arturo J. EP04.01-019
Rampinelli, Cristiano P1.04-03
Rana, Sandeep P2.14-03
Ranft, Andreas EP07.01-026
Rankin, Nicole EP04.01-023, EP04.01-025, EP10.01-005
Rankin, Nicole M. EP01.02-004, EP01.03-006, EP01.03-012
Rao, Bing-Yu EP05.02-011, WS08.19
Rao, Sanjay P1.05-01
Raphael, Ari EP08.02-047
Raphael, Jacques EP02.01-013
Raskin, Ariel OA06.03
Raskin, Jo OA03.05
Rasmussen, Torben R. EP01.07-001
Raso, Maria Gabriela MA01.03
Rastelli, Francesca EP08.01-007
Rathod, Shrinivas EP08.02-024
Rathor, Amber EP11.01-011
Raubenheimer, Hilgardt EP02.03-002
Ravina, Alberto Ruano ES22.04
Rawal, Bhavin EP06.01-008
Rawat, Siddhartha MA13.07
Ray, Meredith EP01.06-007, EP02.03-022, MA03.08
Rayes, Roni EP05.02-015
Rayes, Roni F. EP05.02-019
Raz, Dan J. EP10.01-012
Reale, Maria L. EP10.01-015, EP16.03-040
Reale, Maria Lucia EP08.02-101, EP16.03-011
Rebelatto, Taiane F. EP03.01-003
Reck, Martin EP05.01-030, EP08.01-020, EP08.01-057, EP08.02-060, EP08.02-098, EP14.01-015, EP16.01-011, ES25.01, OA15.03, OA15.06, P1.15-05
Reckamp, Karen L. EP08.02-019, EP08.02-045
Recondo, Gonzalo EP05.01-001, EP16.03-002, EP16.03-003
Recondo (h), Gonzalo EP16.02-029
Reddy, Chandana EP02.02-010
Reddy Mallareddy, Jayapal P2.14-03
Redín, Esther EP16.01-009
Redman, Mary W. P2.12-03
Redmond, Karen EP04.02-002
Redrado, Miriam EP16.01-009
Redway, Andrea MA08.09
Redway, Lydia MA08.04
Refaat, Tamer EP07.01-019
Reggiani, Francesca EP16.03-042
Reguart, Noemí EP03.01-012, EP08.01-090, EP08.01-091
Reguart, Noemi EP08.02-102, EP08.02-120, MA06.03, MA07.07, OA12.05, OA13.04, P1.07-02 P2.07-02, PL03.12
Reguart Aransay, Noemí EP08.02-070
Rehrauer, Hubert EP07.02-004
Rei, Joana EP14.01-009
Reich, Mark EP04.01-021
Reichow, Sandro L. EP03.01-003
Reid, Anna EP16.01-002
Reid, Glen OA04.04
Reid, Joel M. MA13.08
Reid, Karen EP08.02-117
Reid, Natasha EP04.01-013
Reinbolt, Raquel P1.03-01
Reinhold, Florencia EP01.05-004
Reinmuth, Niels EP08.01-027, EP14.01-008, EP14.05-009, HOD01.04, OA15.04, P1.15-05, P1.16-04
Reis, João E. EP05.03-003
Reiser, Marcel EP05.01-030
Rekhtman, Natasha EP16.03-030, ES21.04
Remick, Adam J. MA13.08
Ren, Dewang EP16.03-008
Ren, Kaili EP08.02-156
Ren, Shengxiang EP16.01-005
Ren, Wei EP01.01-011
Ren, Xiubao OA09.03
Renaud, Claire EP02.03-021
Rendina, Erino A. EP01.06-001, EP05.03-002
Rendle, Katharine ES01.06
Rengarajan, Badri EP14.05-023
Renyi-Vamos, Ferenc EP14.02-003, MA01.04
Resi, Maria Vittoria EP08.01-012, P1.15-06
Resnick, Murray P2.15-01
Restelli, Marcello EP08.01-006
Reuben, Alexandre OA14.06
Reungwetwattana, Thanyanan EP02.01-016, EP08.02-108
Reuss, Joshua EP08.01-044

Reuss, Joshua E. EP02.03-008
Reuter, Sebastian P1.14-05
Revel, Marie-Pierre EP01.02-001
Reveles, Kelly R. EP05.02-013
Revelo, Alberto P1.03-01
Rey, Michelle OA10.05, P1.02-01
Reyes, Edgar MA14.03, WS07.03
Reyes, Monica EP01.03-008
Reyes, Roxana EP03.01-012, EP08.01-090, EP08.01-091, EP08.02-070, EP08.02-102, MA07.07, OA07.06, OA13.04, P1.07-02, P1.16-02
Reymen, Bart J.MA03.09
Reyna-De La Garza, Roberto A. EP16.03-026
Reynolds, John OA01.04
Reynolds, Paul N. EP16.04-020
Rezeli, Melinda EP14.02-002, EP14.02-006, MA01.04
Reznick, Douglas P1.16-04
Rhee, Joel EP01.03-006, EP01.03-012
Ribeiro, Joana EP08.02-054
Riboldi, Luciano EP07.01-005
Ricardi, Umberto ES02.05
Ricaurte, Luisa EP16.03-002, EP16.03-003
Riccardi, Ferdinando EP14.01-006
Ricciardi, Sara EP07.01-017
Ricciuti, Biagio EP08.01-043, MA02.09, P1.15-03
Rice, Alexandra EP11.03-003, P1.12-05
Richard, William G. P1.13-02
Richardson, Gary E. P1.15-08
Richartz, Vanessa EP08.02-031
Richman, Ilana EP01.03-007
Richter, Kimber OA10.04
Richtmann, Sarah EP16.01-019
Ricordel, Charles EP16.02-004
Ridai, Mohamed EP16.03-045
Riddell, Angela EP08.03-005
Ridge, Carole EP06.01-008, ES33.03, MA11.06
Ridge, Carole A. P1.12-05
Riedel, Richard EP08.02-106, EP08.02-114
Riedl, Ken EP03.01-014
Riely, Gregory J. EP08.02-171
Riemer, Joanne EP08.01-086
Ries, Alexander EP07.01-014
Riess, Jonathan EP08.01-061, MA10.05, MA13.08
Riess, Jonathan W. OA06.06
Rietschel, Petra P1.15-12
Righi, Luisella EP16.03-011, EP16.03-040
Rigney, Maureen MA08.05, MA08.07, P2.08-05, P2.08-06, P2.08-08, P2.08-09
Rigutto, Angelica P1.14-01
Rihawi, Karim EP14.01-006
Rijavec, Erika EP06.01-006
Riley, Gosia EP08.02-041
Riley, Joanne EP05.01-012
Riley, Mark EP01.06-004
Rimm, David L. ES35.03, P2.12-01
Rimner, Andreas EP05.01-014, EP05.01-025, EP07.01-018, IBS06.03, P1.05-02, WS04.15
Rinaldi, Arturo EP07.01-021
Rincones, Orlando EP04.01-025
Rios-Hoyo, Alejandro EP14.05-002
Rios-Perez, Jorge Arturo EP14.01-004
Rittberg, Rebekah EP03.01-016, EP08.01-074, EP08.02-089, EP14.04-001, EP14.05-017, EP14.05-020
Rittmeyer, Achim EP14.01-004, P1.15-05
Riudavets, Mariona EP08.02-060, OA13.04, P1.16-02
Rivalland, Gareth EP08.01-014
Rivard, Christopher MA01.04
Rivera, Carlos EP08.01-023
Rivera Concepcion, Joel EP05.01-011
Rixe, Olivier MA13.07
Rizzo, Manglio EP08.02-097
Rizzo, Manglio M. EP16.02-029
Rizzo, Sergio EP08.03-007
Rizzolo, Angelo EP06.01-001
Roa, Diana EP08.02-149
Robado de Lope, Lucía EP16.02-007
Robbins, Edward T. MA03.08
Robbins, Hilary ES01.03, OA13.02, WS02.26
Robbins, Hilary A. MA11.05, P1.01-01
Robbins, Todd EP01.06-007, EP02.03-022
Roberts-Thomson, Rachel EP16.03-005
Robertus, Jan Lukas EP07.03-005, EP11.03-003, P1.12-05
Robinson, Andrew EP14.05-010
Robinson, Andrew G. OA15.06
Robinson, Clifford ES19.04
Robinson, Irina EP16.01-015
Robinson, Kyle EP08.01-018
Roca, Elisa EP08.02-046, EP14.01-005, EP16.03-011
Rocco, Danilo EP02.04-001, EP05.01-024, EP06.01-006
Rocco, Gaetano ES33.02
Rocha, Daniel EP08.02-036
Rocha, Pedro EP14.05-002
Rochand, Adrien OA07.06
Roden, Anja ES26.03, MA12.07, P2.14-03
Rodig, Scott P2.10-04
Rodilla, Ananda OA06.03
Rodríguez, Angel EP05.02-002, EP05.02-003
Rodríguez, Delvys EP08.01-029
Rodriguez, Estelamari EP04.01-010
Rodriguez, Jose R. EP02.01-004
Rodríguez, Jose de los Reyes EP05.02-002
Rodriguez, Jose de los Reyes EP05.02-003
Rodríguez, July EP16.03-002, EP16.03-003
Rodríguez, Marta P1.12-04
Rodríguez, Zulema EP05.02-002, EP05.02-003
Rodriguez, Mitchelle EP08.02-107
Rodríguez-Abreu, Delvys EP08.01-065, EP08.02-131, ES25.04, MA06.03, OA02.03, OA12.06, OA15.06, P1.09-03, PL03.12
Rodríguez Antolín, Carlos EP08.02-088, EP16.01-007
Rodríguez-Antolín, Carlos EP16.02-014
Rodriguez Carrillo, Jose Luis P2.07-02
Rodriguez Esteban, Marina OA06.04
Rodríguez González, Adán EP16.01-031
Rodriguez-Mayoral, Oscar MA14.03, WS07.03
Rodríguez-Pérez, Ángel Ricardo EP08.02-070
Rodríguez-Remírez, María MA02.08
Røe, Oluf D. EP01.01-005, EP01.01-009
Røe, Oluf Dimitri MA11.04
Roediger, Alexander EP01.03-004
Roelke, Theresa EP01.02-008
Roeper, Julia EP04.01-014
Roffinella, Matteo EP02.03-006
Rogado, Jacobo EP08.01-040
Rogerson, Suzanne PL03.03
Rohde, Gernod EP14.01-008
Rohs, Nicholas OA06.03, P2.12-05
Rojas, Leonardo EP05.01-001
Rojas, Mariam EP05.02-002, EP05.02-003
Rojo, Federico P2.07-02
Rokah, Merav EP05.02-015, EP05.02-019
Rolando, Chiara EP11.01-009
Rolfo, Christian EP05.01-001, EP16.03-002, EP16.03-003, ES39.04, P2.12-05, P2.13-01
Rolfo, Christian D. EP07.01-001, ES39.02
Rolfo, Christian D. OA06.03
Román, Ruth EP08.02-120
Romano, Francesco EP05.03-008
Romano, Gianpiero EP05.01-024, EP06.01-006
Romee, Rizwan P2.10-04
Romeo, Margarita OA06.04
Romero, Atocha EP16.02-007, MA06.03, PL03.12
Romero, Heather EP08.02-171
Romero, Laura EP07.01-022
Romero-Laorden, Nuria EP08.01-040
Roncari, Barbara EP06.01-006
Ronner, Manuel EP07.02-004
Rosado, Joel EP07.01-022
Rosamilia, Gabriel d. EP02.03-029
Rosas Alonso, Rocío EP08.02-088, EP16.01-007
Rosas-Alonso, Rocío EP16.02-014
Rosboch, Giulio Luca EP02.03-007
Rosell, Antoni EP01.03-002, EP01.05-001, EP01.07-004
Rosell, Rafael EP05.01-001, EP08.02-011, EP08.02-032, EP08.02-120, EP08.02-135, EP08.02-159, EP16.02-007, EP16.03-003, MA02.02
Roselt, Peter MA09.05, P1.10-02, P2.03-01
Rosen, Joshua EP08.02-079
Rosen, Lee EP08.02-148
Rosenthal, Lauren P2.08-07, P2.08-09
Rosery, Vivian EP14.01-008
Rosner, Samuel EP02.04-007, EP08.01-086
Ross, Patrick EP02.03-023
Ross, Sally EP08.01-021
Ross, Sarah EP08.02-079
Rossell, Rafael EP16.03-002
Rossetti, Maura EP08.01-021
Rossi, Giovanni EP08.01-088
Rossi, Giulio EP08.01-030
Rossi, Maddalena M. EP05.01-010
Rossi, Sabrina EP05.01-024, EP06.01-006

Rotem, Ofer EP08.02-122
Rotenberg, Yakir P2.01-02
Rothbaum, Wayne P. EP14.01-004
Rothenstein, Jeff EP08.02-034
Rothschild, Sacha I. EP16.01-018, MA12.04
Rothwell, Dominic EP05.01-007
Roti, Giovanni P1.15-04
Rotow, Julia EP08.02-019, EP08.02-045, ES28.06
Rouch, Axel EP02.03-021
Routman, David EP05.01-011
Routy, Bertrand EP04.01-020, EP07.03-002, EP08.01-090, EP08.01-091, OA07.06
Rovers, Maroeska M. EP04.01-026
Rovers, Sophie EP07.01-024
Rovitsky, Yulia EP08.02-122
Roxburgh, Patricia EP08.01-109
Roy, Kunal G. EP16.03-024
Roy, Somnath EP06.01-005, EP08.02-040, EP16.02-006
Royer Joo, Stephanie OA03.04
Roy-Ghanta, Sumita EP08.01-020
Royuela, Ana EP04.01-019
Rozy, Adrianna EP16.03-014
Ruckdeschel, John C. EP01.06-004
Rudd, Stacey MA09.05, P1.10-02, P2.03-01
Rudin, Charles ES38.04
Rudin, Charles M. EP16.03-030, OA12.06
Rudzinski, Piotr EP16.03-014
Ruel, Louis-Jacques EP16.03-020
Ruffinelli, Jose C EP08.01-091
Ruffinelli, José Carlos EP16.03-027
Ruffinelli Rodríguez, José Carlos EP08.02-070
Ruffini, Enrico EP02.03-006, EP02.03-007, ES26.04
Rugarli, Sabrina EP07.01-005
Ruiter, Gerrina WS04.08
Ruiz de Castilla, Karla IBS09.04
Ruiz de Domingo, Diana EP06.01-017, EP08.01-066, EP13.01-016
Ruiz-Felix, Omar A. EP08.03-003
Ruiz-Giménez, Leticia EP08.01-049
Ruiz Gracia, Pedro EP08.01-065
Ruiz-Gutiérrez, Icíar EP08.01-049
Ruiz-Patiño, Alejandro EP05.01-001, EP16.03-002, EP16.03-003
Rukhadze, Tamar EP01.03-013
Rulli, Eliana MA10.07, P1.15-02
Rupji, Manali EP08.01-060
Rupp, Martin EP08.02-103
Rusch, Valerie ES12.04
Rusch, Valerie W. EP07.01-018, OA14.06
Russano, Marco EP08.02-046
Russo, Alessandro EP06.01-006, EP07.01-001, EP16.03-002, P2.13-01, WS03.12
Russo, Antonio EP08.03-007, EP16.01-013
Rybstein, Marissa EP16.04-012
Rychwicka-Kielek, Beata A. EP01.07-001
Ryszka, Aleks MA12.01
Ryu, Jeong Seon EP08.02-142
Rzyman, Witold EP01.04-005, MA11.07

S

Saad, Akram EP08.02-122
Saalfeld, Felix C. EP14.01-008
Saar, Annika EP06.01-016
Saavedra Armero, Victoria EP16.02-027
Sabari, Joshua EP08.02-016
Sabouhanian, Amir EP02.04-009, EP03.01-002, EP04.01-001
Sabourin, Jean-Christophe EP11.01-005
Sacco, Gianluca EP08.01-088
Sacdalan, Danielle EP14.01-019
Sachdeva, Ashutosh EP07.01-001
Sachdeva, Robin EP02.01-013
Sacher, Adrian EP02.04-009, EP03.01-002, EP08.01-067, EP08.02-079, EP08.02-082, EP08.02-116, OA03.04
Sacher, Adrian G. EP04.01-001, MA14.08
Sadeesh K. Srinathan EP16.02-019
Sadeghirad, Behnam EP08.02-059
Sadjadian, Parvis EP08.01-057, P1.15-05
Sadow, Sam EP14.05-009
Sadrolhefazi, Behbood EP08.02-049
Sae-Lim, Pakatorn EP02.01-016
Sætrom, Pål EP01.01-005, EP01.01-009
Saez, Daniel MA08.05
Saez, Daniel A. EP08.02-043, P2.08-01
Safavi, Amir H. EP10.01-004
Safavi, Farnoush EP08.02-098
Saghir, Zaigham EP01.07-001
Saha, Jayati EP08.02-074
Sahraoui, Souha EP06.01-010, EP06.01-012
Sahu, Diwyanshu EP16.03-024
Saichaemchan, Siriwimon EP08.02-164
Saigi, Maria EP01.03-002, OA06.04
Saigi Morgui, María EP08.02-070
Sailem, Heba EP07.03-005
Sainz, Cristina EP16.01-009
Saito, Haruhiro EP08.01-027, EP11.01-008, OA15.04
Saito, Masao EP13.01-010
Saito, Yuichi EP16.01-028, EP16.01-029
Saji, Hisashi PL03.07
Sajnic, Andreja P2.04-01
Sakaeda, Kanako EP08.01-064
Sakai, Hiroshi OA03.05
Sakai, Tetsuya EP08.02-113
Sakai, Yumiko EP08.01-064
Sakao, Yukinori EP16.01-028, EP16.01-029
Salah, Myriam EP11.01-006
Sağlam, Ömer Faruk P2.06-01
Salas, Clara P2.07-02
Saleh, Mohamed M. EP08.02-106
Saleh, Sara EP08.02-121
Salem, Ahmed EP05.01-012
Salemi, Domenico EP08.03-007
Sales dos Santos, Ricardo P1.02-02
Sales Santos, Ricardo ES04.02, WS07.09
Salomonsson, Stina EP08.01-083
Salvadori, Lorenzo EP07.01-017
Sam, Janette P1.02-04
Samantas, Epaminondas EP10.01-018
Samaraweera, Leleesha EP08.02-081
Samaržija, Miroslav EP05.01-018, EP08.02-058
Samarzija, Miroslav EP07.01-012
Samelis, Georgios EP10.01-018
Samitas, Konstantinos EP08.02-060
Samkari, Ayman EP02.03-009, OA07.04
Samnani, Sunil EP06.01-003
Samtani, Suraj EP05.01-001, EP16.03-002, EP16.03-003
Samuel, Evangeline EP14.05-016
Sanatani, Michael EP02.01-013
Sánchez, Alfredo EP08.01-029 P1.09-03, P1.15-09
Sanchez, Enrique EP05.02-002, EP05.02-003
Sánchez, José Miguel P1.15-09
Sanchez, Leire EP07.01-022
Sánchez-Cabrero, Darío EP08.01-049
Sanchez del Corral, Maria EP04.01-019
Sanchez del Corral, Maria Matilde EP06.01-017, EP13.01-016
Sánchez–García, Ángel EP10.01-017
Sánchez-Gastaldo, Amparo EP08.02-149
Sánchez González, Juan Cristóbal EP04.01-019, EP08.01-066, EP16.04-014
Sánchez González, Marcelo EP02.02-007
Sánchez-Herrero, Estela EP16.02-007
Sánchez Mauriño, Pedro EP08.01-048
Sánchez Pablo, Clara EP08.01-048
Sanchez-Ramos, Carles EP01.05-001
Sánchez Torres, José Miguel EP08.02-070, EP08.02-131
Sánchez-Torres, José Miguel EP08.01-040
Sancisi, Valentina EP16.03-042
Sandanger, Torkjel M. EP01.01-005
Sandanger, Torkjel Manning EP01.01-009
Sandiford, Peter EP01.03-009
Sands, Jacob EP14.05-003
Sandy, Beth EP09.01-001
Sangiorgi, Sara EP08.02-104
Sa-nguansai, Sunatee EP08.02-083
Sanmamed, Miguel F. OA09.04
Sansano, Irene P2.07-02
Santana, Maria EP10.01-008
Santarpia, Mariacarmela EP08.02-104
Santini, Fernando C. EP05.01-025
Santo, Antonio EP14.01-005
Santoni-Rugiu, Eric EP08.02-044, EP08.02-075
Santoro, Alessandra EP08.03-007
Santoro, Armando EP08.02-081
Santos, Edgardo S. EP16.02-018
Santos, Ricardo EP01.04-005, MA11.07
Santos, Ricardo S. MA11.09, WS07.05
Santoyo, Nicolas EP16.03-002, EP16.03-003
Sanz-Moreno, Sandra EP16.02-007
Sarachai, Nidchakarn EP02.01-016
Sarana, Bruno EP06.01-016
Saravia, Diana EP08.01-023
Sarbay, Ismail EP02.03-001, EP05.03-001, EP06.01-007, EP11.04-002, P2.06-01
Sardo, Delia EP16.01-013
Sarich, Peter MA11.03
Sarihan, Süreyya EP02.02-009
Sarkar, Subho EP08.04-004
Sarris, Ahmad EP08.02-117
Sart, Joan OA13.04
Sartore-Bianchi, Andrea EP08.02-046
Sasage, Takayuki EP05.03-009
Sathya, Sneha G. OA10.06
Sato, Keiyu EP02.01-015
Sato, Yuki MA06.04

Satouchi, Miyako EP14.05-022, HOD02.04, MA06.04
Sauliner, Patrick MA10.08
Saulsberry, Andrea EP02.03-022, MA03.08
Sauta, Elisabetta EP16.03-042
Sauter, Jennifer WS04.13
Savardekar, Himanshu EP14.05-004, OA12.04
Savarino, Edoardo Vincenzo P1.15-06
Savic Prince, Spasenija EP16.01-018, MA12.04
Savvides, Panayiotis MA13.07, P1.15-08
Savvides, Panayiotis S. EP05.01-011
Savvides, Panos MA13.09
Saw, Stephanie P2.13-02
Saw, Stephanie P. EP16.03-036
Sawafta, Nawras EP01.02-002, P2.11-01
Sbrana, Andrea MA10.07
Scagliotti, Giorgio EP08.01-060, EP16.03-011, ES30.01, LA02.02, PL05.03
Scattolin, Daniela EP08.02-104
Schabath, Matthew B. EP01.03-008
Schaefer-Klein, Janet P2.14-03
Schaeffer, Marcy EP08.02-016
Schafer, Johanna EP08.01-062
Schäfer, Lisa V. EP14.01-008
Schalper, Kurt A. OA09.01, OA09.04, P2.12-01
Scharnetzki, Elizabeth P2.08-07
Scharpenseel, Heather EP08.02-106
Scharpf, Robert B. EP01.01-003
Schaufler, Diana EP08.02-114
Scheel, Andreas H. EP08.02-031, EP08.02-106
Scheffler, Matthias EP08.02-031, EP08.02-106, EP08.02-114
Schehr, Jennifer P2.02-02
Schelch, Karin EP07.01-014, EP07.02-001, EP14.02-002, EP14.02-003, EP14.02-006, MA01.04
Schenker, Matthew EP13.01-006
Scherpereel, Arnaud WS04.02, WS04.14
Scheuermann, Taneisha OA10.04
Schiena, Elena ES14.05
Schild, Steven E. EP05.01-011
Schilder, Bodien OA04.06
Schildhaus, Hans-Ulrich EP16.03-004
Schiller, Joan P2.08-09
Schimd, Sabine EP04.01-001
Schinagl, Alexander EP08.01-015
Schinagl, Dominic A. MA03.09
Schindler, Hannah EP08.01-031
Schläpfer, Fabian EP07.02-002, OA04.04
Schlintl, Verena EP02.01-008
Schmid, Dominic EP16.01-018, MA12.04
Schmid, Sabine EP14.01-019
Schmid, Severin EP05.02-015
Schmidberger, Heinz MA06.08
Schmidt, Heidi P1.02-01
Schmidt, Hjørdis H. EP05.01-017
Schmidt, Milena EP16.01-011
Schmitt, Gary M. EP01.04-004
Schmitt, Matthias EP05.01-012
Schmitt-Opitz, Isabelle P2.11-03
Schmitz, Jaqueline EP08.02-114
Schneider, Christian EP04.01-015
Schneider, Gabriela F. EP06.01-011
Schneider, Jeffrey EP16.04-012
Schneider, Marc A. EP08.01-031, EP16.01-019
Schneider, Martina EP16.01-018, MA12.04
Schneiders, Famke IBS02.01
Schneiter, Didier P2.11-03
Schnepp, Robert W. P1.16-01
Schoenfeld, Adam J. EP08.01-043
Schol, Pieter P2.10-04
Schramm, Alexander EP16.03-004, EP16.04-002
Schreurs, Hermien W. OA06.05
Schrock, Alexa B. P2.14-01
Schuler, Martin EP02.01-010, EP04.01-016, EP04.02-005, EP16.03-004, EP16.04-002, MA06.08, P1.14-05
Schulte, Christina EP04.01-016, EP04.02-005, MA06.08
Schulze, Katja EP02.04-005, EP16.02-002, OA14.06
Schumacher, Michael EP08.02-122
Schutzman, Jennifer OA03.04
Schuurbiers, Olga C. OA06.05
Schuurmans, Macé P2.11-03
Schwaner, Signe H. EP01.07-001
Schwartz, Lawrence H. P2.12-03
Schwarz, Emily EP14.05-004, OA12.04
Schwarzenberger, Paul EP08.01-087
Schwecke, Anna MA13.09
Schwecke, Anna J. EP05.01-011
Schwendenwein, Anna EP14.02-002, EP14.02-003, EP14.02-006, MA01.04
Scilla, Katherine A. EP07.01-001
Scoazec, Jean-Yves MA10.08
Scobie, Micaela EP08.01-045
Scott, Andrew MA09.05, P1.10-02, P2.03-01
Scott, Julie - A. EP08.01-109
Scott, Susan EP08.01-086
Scott, Susan C. E P02.04-007
Scotti, Vieri EP05.01-024
Seaborne, Lori MA14.04
Seah, Ethan MA07.08
Sebag-Montefiore, David EP05.01-007
Sebastian, Martin EP05.01-030, EP08.01-057, EP14.01-008, P1.15-05
Secen, Nevena EP16.03-011, ES38.02
Secor, Austin EP08.01-062
Seder, Christopher EP11.01-009
Seetharamu, Nagashree EP08.01-068, EP08.02-129
Segale, Miriam P1.15-02
Segota, Zdenka E. EP16.02-003
Seguí, Elia P1.12-04
Seike, Masahiro EP08.01-005
Seiwerth, Fran EP05.01-018, EP07.01-012, EP08.02-058, EP14.01-011, EP14.01-012
Seiwerth, Sven EP14.01-011, EP14.01-012
Sekido, Yoshitaka WS04.07
Selbie, Lisa EP05.01-023
Selcukbiricik, Fatih EP05.02-004, EP05.02-005, EP05.03-007
Sellmer, Laura EP04.01-015
Sen, Triparna EP16.03-030, ES07.05, MA02.04, OA04.03
Sena, Susana N. EP16.02-029
Senabouth, Anne EP16.03-041
Senan, Suresh ES09.03
Sendler, Andrea P1.15-05
Sengottuvel, Nisitha EP08.02-093, EP16.04-017
Senju, Hiroaki EP08.04-005
Senthi, Sasha OA01.04
Senthil, Priyanka OA05.06
Senturk, Serif EP08.02-022
Sepesi, Boris EP02.04-005
Sequist, Lecia EP08.01-060, EP08.02-140
Sereno, Marco EP16.04-011
Sergi, Concetta EP05.01-024, EP06.01-006
Serio, Giovanni EP14.02-001
Serna, Roberto MA06.03, PL03.12
Serna-Blasco, Roberto EP16.02-007
Serra, Josep EP08.02-049
Serrano, Diego EP16.01-009
Serrano, Maria EP01.04-001
Serrano, Maria Jose P2.13-01
Sesma, Andrea EP16.01-014
Sethakorn, Nan P2.02-02
Seto, Takashi EP08.02-118
Setyawan, Ungky A. EP01.01-004
Seu, Rie EP01.04-001
Seweryn, Michal OA14.06
Sexton Oates, Alexandra MA01.07
Sexton-Oates, Alexandra ES21.06, MA01.09, MA02.03, OA04.05
Seyyedi, Saeed EP01.05-007
Sezer, Ahmet OA15.03, P1.15-12
Shacham-Shmueli, Einat OA03.04
Shackelford, David MA13.08
Shafique, Michael EP14.01-013, P2.02-02
Shah, Manisha OA12.04
Shah, Mohsin EP08.01-063
Shah, Pallav L. EP11.03-003, P1.12-05
Shah, Pratik V. EP08.02-129
Shah, Rajiv EP08.01-031
Shah, Roma EP08.02-061
Shalata, Walid EP08.02-060
Shamai, Sivan EP08.01-010, EP08.04-001
Shamrai, Volodymyr OA15.03
Shan, Li EP08.01-042
Shanbhag, Lucinda EP04.02-003
Shang, Zhanxian EP16.03-044
Shannies, Tariq B. EP14.05-018
Shantzer, Lindsey EP08.01-034
Shao, Changjian EP13.01-015, MA04.07
Shao, Guangqiang EP02.03-015
Shao, Jinchen MA05.07
Shao, Yang EP01.01-011, EP08.02-073, EP16.01-025, EP16.02-024, EP16.03-044, WS08.21
Shargall, Yaron OA14.03
Shariati-Ievari, Shiva EP16.02-019
Sharma, Arushi EP08.02-103
Sharma, Deepak EP11.01-012
Sharma, Mansi EP16.03-047
Sharma, Sanjeev K. EP11.01-012
Sharma, Shivani EP11.01-012
Sharma, Sohat EP02.01-001
Sharman, Ashleigh R. EP01.02-004, EP01.03-006, EP01.03-012
Sharman Moser, Sarah EP08.02-017

Sharp, Linda OA01.05
Shau, Wen-Yi EP08.02-151
Shaver, Adam P1.03-01
Shaverdian, Narek EP05.01-025, P1.05-02
Shaw, Paul EP05.01-007
She, Yunlang EP02.01-007, MA06.09
Sheeka, Alexander EP06.01-008
Sheffield, Brandon MA12.05
Sheikh, Hamid EP05.01-012
Sheils, Orla EP16.04-004
Shelton, Joseph W. EP14.03-003, P1.10-04
Shen, Bo EP08.01-080
Shen, Chen EP08.03-006
Shen, Chia-I EP16.01-003
Shen, Hua EP08.02-153
Shen, Juan EP08.02-136
Shen, Lan EP16.03-031, EP16.03-032, EP16.03-033, WS08.23
Shen, Lin EP08.02-148
Shen, Megan P2.08-09
Sheng, Jiamin EP07.02-006
Shepherd, Annemarie F. EP05.01-014, EP05.01-025, P1.05-02
Shepherd, Frances EP03.01-002, LA02.01
Shepherd, Frances A. EP02.04-009, EP04.01-001, EP08.01-067, EP08.02-082, MA14.08
Shepherd, Paula ES31.04
Shergina, Elena OA10.04
Sherlock, Stuart EP11.03-003
Sheverdian, Narek EP05.01-014
Sheybani, Arshin EP07.01-019
Shi, Anhui OA02.05
Shi, Jianhua OA02.05, OA03.07
Shi, Lin EP08.01-080, EP14.01-007
Shi, Rocky EP08.02-055, EP16.03-039
Shi, Shenghao EP01.07-005
Shi, Xiaojin EP08.01-027, P1.15-11
Shi, Xiaoliang EP16.03-006
Shi, Xinying EP08.01-055, WS08.17
Shi, Yuan-Kai EP08.02-064
Shi, Yuankai EP16.02-017, ES17.05
Shi, Zhe OA03.07
Shi, Zhen OA03.04
Shiarli, Anna Maria EP08.02-150
Shibata, Yuji EP08.02-113
Shieh, Benjamin EP05.02-015, EP05.02-019
Shields, Peter EP08.01-062, EP08.01-098, EP14.05-004, OA12.04
Shigefuku, Shunsuke EP16.04-009
Shih, Beatrice EP16.03-034
Shih, Ie-Ming MA03.04
Shih, Jin-Yuan EP08.02-127, EP08.02-151
Shilo, Shani ES27.04
Shim, Byoung Yong P1.15-11
Shim, Byoung-Yong EP08.01-073
Shim, Young Mog MA03.03
Shimada, Midori EP08.04-005
Shimada, Naoko EP08.02-115
Shimada, Yoshihisa EP02.01-017
Shimizu, Junichi EP08.02-115
Shimizu, Katsuhiko EP08.01-064
Shimizu, Kimihiro MA03.07, MA10.04, P2.12-02
Shimizu, Yoshihiko EP16.01-029
Shimoji, Masaki EP08.02-146
Shimokawa, Mototsugu MA06.04
Shin, Ah Young P2.01-01
Shin, Hyun Joo EP13.01-005
Shin, Jacob Y. EP05.01-014, EP05.01-025
Shin, Ju Hye EP16.04-016
Shin, Sumin MA03.03, MA10.09, P2.09-01
Shinada, Kanako EP11.01-008
Shinno, Yuki EP07.03-004, MA04.04
Shintani, Yasushi MA10.04
Shio, Yutaka P1.15-13
Shiono, Satoshi EP02.03-024, EP05.03-009, MA03.05
Shipe, Maren E. EP01.05-010
Shiraishi, Kouya EP02.03-016, MA04.04
Shiraishi, Yoshimasa MA06.04
Shiraiwa, Naoko EP08.02-115
Shire, Norah EP08.01-042
Shirgaonkar, Rohit B. EP08.04-004
Shirt, Lisa EP10.01-008
Shochat, Tzippy EP08.02-047
Shokoohi, Aria EP08.01-074, EP08.02-089
Sholl, Lynette M. MA02.09
Shookoohi, Aria EP04.02-004
Shrager, Joseph B. EP16.02-015
Shu, Yongqian EP08.01-014
Shum, Elaine EP01.06-003, EP01.06-008, EP08.02-019, EP08.02-045
Shurrab, Hanan EP01.02-002, P2.11-01
Shyr, Yu EP08.01-028, OA06.03
Si, Haojie MA04.03, P1.14-03
Si, Xiaoyan EP16.01-017
Sidawy, Mary K. EP02.03-008
Siddiqui, Madeena EP14.01-015
Sidiqi, Baho P1.05-02
Siegelmann-Danieli, Nava EP08.02-017
Siena, Salvatore EP08.02-046, MA13.04
Sierra-Rodero, Belen OA02.03
Signorelli, Diego EP08.02-046
Signorovitch, James EP02.03-009
Sihoe, Alan ES12.03
Sihota, Tianna EP08.02-055
Sihota, Tianna S. EP16.03-039
Sihvo, Eero EP04.01-012
Silberman, Philip EP04.01-007, EP04.01-008
Silipigni, Sonia EP05.01-024, EP06.01-006
Silva, Adriana N. EP02.03-010
Silva, Adriano EP03.01-003
Silva, Eloisa EP04.01-003
Silva, Eloísa EP08.01-008
Silva, Mario EP01.02-001, EP01.04-006, ES01.01
Silva, Sofia C. EP08.02-141, EP16.03-035
Silva, Sónia EP04.01-011
Silva, Vinícius G. EP02.03-029
Silver, Alexandra EP08.01-075
Silvestrini, Matthew EP02.04-002
Simes, John EP16.03-041, P1.12-02
Simionato, Francesca EP08.01-012
Simkin, Jonathan P1.02-04
Simmonds, Shanique EP06.01-009
Simmons, Vani N. EP01.03-008
Simó, Marta EP08.01-029
Simon, Jessica EP10.01-008
Simon, Viviana OA06.03
Simone 2nd, Charles B. P1.05-02
Simone II, Charles B. EP05.01-014, EP05.01-025, EP07.01-018
Simoni, Lucia EP05.01-024
Singaravelou, Ajay EP06.01-008
Singh, Aditi EP08.01-018, P1.15-07
Singh, Ajay EP08.03-002
Singh, Arshdeep OA09.05
Singh, Divya EP16.03-024
Singh, Navneet ES15.01, OA07.07, P2.09-02
Singh, Pawan Kumar ES32.03
Singh, Sarbjit P2.14-03
Singh, Varsha P2.02-03
Singhal, Nimit EP04.01-023
Singhal, Sunil OA14.05
Sini, Claudio EP16.03-011
Sinn, Katharina EP02.01-009, EP05.02-007, EP07.02-001
Sinnarajah, Aynharan EP10.01-008
Sio, Terence T. EP05.01-011
Siow, Tian Rui P2.13-02
Siringo, Marco EP08.02-046
Sirois, Christian EP05.02-015, EP05.02-019, EP06.01-001
Sit, Christina IBS09.06, MA08.09
Sithara, Smitha MA09.05
Siu, Lillian ES39.06
Siva, Shankar EP05.01-023, ES19.02
Sivarasan, Nishanth EP06.01-008
Skabla, Patsy EP02.03-023
Skanderup, Anders EP16.03-036
Skanderup, Anders J. P2.13-02
Skarda, Jozef MA01.04
Skenduli, Ilir EP03.01-004
Skinner, Lawrie OA14.04
Skipworth, Richard J. EP10.01-016
Skog, Johan K. EP16.02-008
Skogholt, Anne H. EP01.01-005
Skougaard, Kristin EP01.07-001
Skoulidis, Ferdinandos EP08.02-163, MA01.02, OA03.06
Skronska, Paulina EP16.03-014
Skuladottir, Halla EP01.07-001
Skupinska, Monika EP16.03-014
Sladek, Barbara EP16.01-015
Slamon, Dennis MA07.05, OA12.03
Slater, Dennis P2.10-02
Sliwinski, Pawel EP08.02-072
Slobogian, Vanessa E P10.01-008
Slomowitz, Samuel MA07.05
Smadbeck, James P2.14-03
Smajima, Joji EP02.01-005
Small, Andrew EP08.02-117
Small, David EP06.01-001, EP11.03-001
Smeltzer, Matthew EP01.06-007, EP02.03-022, MA03.08
Smesseim, Illaa OA04.06
Smit, Egbert ES30.06, OA03.05

Smit, Hans J. OA06.05
Smith, Cardinale B. P2.12-05
Smith, Kellie EP02.04-007, EP08.01-086, ES35.04
Smith, Kellie N. EP08.01-044
Smith, Laney OA10.03
Smith, Rebecca A. EP14.05-011, EP14.05-012, EP14.05-013
Smith, Robert P2.08-07, WS02.11
Smith, Shantelle EP04.01-023, EP14.05-016, OA01.03
Smith-Byrne, Karl MA11.05, P1.01-01
Smits, Evelien EP07.01-024
Smits, koen EP05.01-009
Smokovich, Anna EP13.01-006
Snider, Jeremy P2.14-01
Snoeckx, Annemiek MA11.02
Snow, Stephanie EP03.01-016, EP14.04-001, EP14.05-020
Snow, Tamara D. P2.14-01
Snyder, Wendy J. OA03.06
Soares, Marta EP03.01-009, EP04.01-011
Soberanis, Pamela EP05.01-001
Soberanis-Piña, Pamela D. EP08.03-003, EP16.03-023, WS07.04
Soberanis-Piña, Pamela Denisse EP07.01-011
Sobottka, Bettina MA12.04
Sobrero, Alberto EP04.01-005
Socinsky, Mark A. EP16.03-021
Soda, Hiroshi EP08.04-005
Soh, Junichi EP08.02-085, EP08.02-146
Sohoni, Sophia EP08.02-111
Solanes, Ares EP16.03-027
Solari, Maria Leticia EP04.01-006
Soldato, Davide OA07.06
Solé, Xavier P2.14-04
Solem, Espen J. EP08.02-105
Soler, Jorge EP08.02-149
Solís Hernández, María del Pilar EP16.01-031
Solitro, Federica EP10.01-015
Solli, Piergiorgio EP02.03-019
Solomon, Ben ES03.05
Solomon, Benjamin EP08.02-061, EP08.02-148, EP16.03-005
Solomon, Sheila R. EP16.03-019
Somwar, Romel EP08.02-055, MA13.05
Son, Seok-Hyun E P05.01-032
Sone, Kazuki OA07.03
Sonett, Joshua IBS12.02
Song, Feixue EP08.02-033
Song, Ji-Youn EP01.04-003
Song, Meng EP14.01-001
Song, Mengmeng EP16.01-017
Song, Myung Jin EP13.01-008
Song, Peng EP08.01-055, EP16.01-023, MA05.03, WS08.17, WS08.20
Song, Wen Jie EP08.02-078
Song, Xinyu EP16.01-020
Song, Yan EP02.03-009
Song, Yang EP16.01-017
Song, Yong EP08.02-064, EP08.02-139
Song, Zhengbo OA03.07
Sonke, Jan-Jakob EP05.01-009, EP05.01-010
Soo, Ross EP08.01-101, EP08.02-109, ES23.04, LA03.01, MA07.02, WS03.06
Soon, Yu Yang EP08.01-101, ES29.03
Soosman, Steffan EP13.01-006
Sørensen, Anne Mette S. EP08.02-105
Sorensen, Bo EP08.02-099
Sørensen, Boe S. EP01.07-001, EP08.01-084
Sørensen, Jens B. EP08.02-044, EP08.02-075, ES30.05
Sorensen, Poul EP08.02-055
Soria-Comes, Teresa EP10.01-017
Sorotsky, Hadas G. EP08.02-122
Sotelo, Carolina EP16.03-002, EP16.03-003
Sotiriou, Sotiris P2.14-03
Soto Parra, Hector EP02.04-001, EP16.03-040
Soufflet, Christine EP08.02-030
Soulaymani, Abdelmajid EP14.01-018, EP16.04-018
Sousa, Diana EP08.02-036
Sowers, Tina P1.03-01
Sozzi, Gabriella P1.02-02, P1.15-02
Spaggiari, Lorenzo EP05.03-008, P1.04-03
Spagnoli, Alessandra EP14.02-001
Spakowicz, Daniel EP03.01-014, EP08.01-019, EP08.01-062, EP14.05-004
Spatz, Alan EP06.01-001, EP11.03-001
Speel, Ernst-Jan MA01.09
Spencer, Kristen EP08.02-081
Spencer Miko, Sandra EP08.02-055
Spengler, Werner MA06.08
Sperduti, Isabella EP10.01-011
Spicer, Jonathan EP02.04-007, EP05.02-015, EP06.01-001, ES36.04, OA06.07
Spicer, Jonathan D. EP05.02-019
Spigel, David EP08.01-020, P1.15-11
Spigel, David R. EP08.02-019, EP08.02-045
Spigel, David R. EP08.01-073
Spinnato, Valeria EP16.01-013
Spira, Alexander EP08.02-018, EP08.02-019, EP08.02-041, EP08.02-111, OA03.06
Spira, Alexander I. MA07.04
Spoelstra, Femke O. MA03.09
Sposito, Marco EP10.01-011, EP14.01-005
Spotti, Martina EP08.02-097
Spotti, Martina P. EP16.02-029
Spring, Lisa EP05.01-030
Squillante, Christian EP07.01-019
Srdić, Dražena EP05.01-018
Sriuranpong, Virote EP08.04-003
Srivastava, Komal OA06.03
Srivastava, Shouryadeep EP08.01-021
Srivastava, Surabhi EP01.06-002
Sroczynski, Nicholas EP08.02-105
Staaf, Johan EP16.03-010
Stabile, Stefano EP08.02-046
Stam, Barbara EP05.01-009, EP05.01-010
Stamatis, Georgios EP04.01-016, EP04.02-005, MA06.08
Stanculeanu, Dana Lucia MA07.01
Stanic, Karmen EP05.01-013
Stanton, Cassandra OA10.03
Stares, Mark EP05.01-008, MA09.07
Stasi, Irene EP05.01-024, EP06.01-006
Steeghs, Neeltje OA12.05
Stefanizzi, Lavinia EP14.01-005
Stella, Simona EP07.01-005
Stelmach, Miroslaw EP08.02-099
Stensgaard, Simone EP08.01-084
Stenzinger, Albrecht EP08.01-031
Stephans, Kevin EP02.02-010
Stephen, Bettzy A. EP08.01-059
Stephens, Bob EP01.02-006, EP01.02-007
Stephenson, Philippe EP04.01-020
Stepniewska, Aneta EP16.03-014
Sterman, Daniel WS04.09
Stern, Tomer EP08.04-001
Steuer, Conor E. EP14.03-003, P1.10-04
Stevens, Victoria MA11.05
Stevens, Victoria L. P1.01-01
Stevenson, Daniel R. EP02.03-022
Stewart, Allison MA01.03
Stewart, C. Allison P2.10-01
Stewart, David J. EP05.01-006
Stewart, Ross OA15.04, P1.15-11
Stiles, Brendon EP01.04-001, OA14.07, P2.08-07
Stinchcombe, Thomas E PL03.06
Stirling, Robert G. EP04.01-023, EP14.05-016, OA01.03 EP01.02-003, EP04.01-021 OA01.04, P2.08-02
Stock, Gustavo T. EP08.02-059
Stockhammer, Paul EP08.02-125
Stoff, Ronen EP08.02-122
Stokes, Bill P2.04-05
Stokes, William A. EP14.03-003, P1.10-04
Stone, Emily E P01.02-004, EP01.03-006, EP01.03-012, EP04.01-023, EP10.01-005, IBS11.02
Stork, Theresa EP07.01-026
Storm, Evan EP04.01-001
Stragliotto, Giuseppe EP16.02-008
Stratmann, Jan A. EP14.01-008
Strell, Carina EP16.04-001, MA05.04, OA09.06
Stricker, Carrie EP04.02-003
Strickler, John H. OA03.03
Strollo, Sara EP01.02-006, EP01.02-007
Strom, Evan EP02.04-009, EP03.01-002
Strother, Eric EP02.03-008
Strum, Scott W. EP16.02-025
Studnicka, Michael EP08.02-122
Studts, Jamie P2.08-07, P2.08-09
Stupnik, Tomaz ES12.01
Stuschke, Martin EP02.01-010, EP04.01-016, EP04.02-005, EP05.01-030, MA06.08
Stylianou, Annie EP08.01-020
Su, Chunxia EP08.01-097, EP08.01-107, EP16.01-005, ES17.01, ES32.05, WS08.16
Su, Hang MA04.03, P1.14-03

Su, Jian EP05.01-003, EP08.01-085, EP08.02-027, EP16.01-025, WS08.09, WS08.21
Su, Po-Lan EP05.01-003, EP08.02-027
Su, Shu EP01.01-011
Su, Weiguo EP08.02-063
Su, Wu-Chou EP08.02-029, MA13.07
Suarez-Murias, Melanie EP07.03-006
Subbiah, Vivek EP08.02-081
Subramanian, Janakiraman EP08.02-080
Sud, Shelly EP05.02-015, EP05.02-019
Suda, Kenichi EP08.02-085, EP08.02-146
Sudhagoni, Ramu EP08.02-081
Sudhir, Rajini EP13.01-001
Suetsugu, Takayuki EP08.01-064
Sugasaki, Nanae EP08.04-005
Sugawara, Shunichi EP08.02-118, MA06.04, P1.15-11
Sugawara, Sunichi PL03.09
Sugimoto, Eiji EP08.02-143
Sugio, Kenji EP08.02-123
SUGITA, MICHIO EP16.03-029
Sugiura, Akihiro EP16.04-025
Sugiyama, Eri EP08.02-113
Sujaritvanichpong, Nantapa P2.02-01
Sukar, Nabil P1.16-03
Sukhadia, Bhoomika EP08.02-023
Sukrithan, Vineeth EP14.05-004, OA12.04
Suksomboonchaoren, Thatthan EP08.02-026
Sukumaran, Shawgi EP14.01-004
Sullivan, Ivana EP04.01-002, P1.09-03, P1.15-09
Sullivan, Richard OA15.03
Sültmann, Holger EP08.01-031
Suman, Shankar EP08.01-019
Sumi, Toshiyuki EP08.02-133
Sun, Dailin MA02.05
Sun, Dantong EP08.01-089
Sun, Fangdi EP08.02-147
Sun, Guoping EP08.02-139
Sun, Han EP05.01-015
Sun, Hui EP08.01-097
Sun, Jianguo EP08.01-042
Sun, Jingchao EP08.01-070, EP08.01-071, WS08.15
Sun, Lee Ming EP01.01-003
Sun, Lova EP08.01-018, EP08.02-018, P1.15-07
Sun, Meili EP08.01-070, EP08.01-071, EP08.01-073, EP08.01-081, WS08.15
Sun, Ning EP14.01-007
Sun, Ping EP08.02-076
Sun, Qi EP01.05-011
Sun, Shu Guang EP08.02-078
Sun, Si EP08.01-033, EP08.01-042
Sun, Sophie EP08.02-034
Sun, Suna EP07.02-004
Sun, Thomas Yang MA10.05
Sun, Virginia EP10.01-012
Sun, Wenjie MA02.05
Sun, xujie EP11.03-002, EP14.02-007, MA01.05
Sun, Yi-Qian EP01.01-005
Sun, Zequn EP04.01-007, EP04.01-008, EP08.02-028
Sun, Zhijuan EP02.03-015
Sunami, Kuniko ES10.05
Sung, Arthur W. EP16.02-015
Sung, Soo-Yoon EP05.01-032
Sung, MSN, Choa EP10.01-014
Sura, Sneha EP05.01-002
Surinach, Andy EP14.05-019
Surya, NItya EP08.01-062
Sutter, Jacquline EP02.03-023
Suyama, Takayuki EP08.04-005
Suzuki, Hiroyuki MA03.05, P1.15-13
Suzuki, Jun EP02.01-005
Suzuki, Kenji EP02.03-025
Suzuki, Takahiro EP07.03-007
Suzuki, Yuto OA07.03
Sverzellati, Nicola P1.15-04
Swalduz, Aurélie EP08.02-122
Swaminath, Anand EP04.02-002, EP05.01-035
Swart, Esther EP08.01-026
Swiniuch, Daria EP08.02-072
Switchenko, Jeffrey EP08.01-060
Switchenko, Jeffrey M. EP14.03-003
Syaj, Sebawe EP02.04-008, EP05.02-012, EP05.03-010, EP07.01-025, EP08.02-121
Syn, Nicholas L. EP01.06-008
Syrigos, Kostas OA12.02
Syrykh, Charlotte EP11.01-005
Szabo, Stephen M. EP14.03-003
Szalai, Zsuzsanna OA15.03
Szarf, Gilberto MA11.09, WS07.05
Szczepulska-Wojcik, Ewa EP16.03-014
Szmytke, Ewelina EP16.03-011, MA08.02, MA08.08
Szpechcinski, Adam EP08.02-072
Szwiec, Marek EP08.02-072

T

Tabbò, Fabrizio EP16.03-011
Tabone-Eglinger, Severine MA01.09, MA02.03
Tabung, Fred EP03.01-014
Tacchetto, Andrea EP07.01-021
Tachihara, Motoko EP14.05-022, MA06.04
Tadigotla, Vasisht EP16.02-008
Tadjalli Mehr, Keyvan OA15.03
Tae Kim, Young MA04.05
Tagliaferri, Piersandro EP05.01-024, EP06.01-006
Tagliamento, Marco EP08.01-088, P1.12-04
Taguchi, Yoshihiro EP08.02-143
Tahmeed, Tahseena EP08.03-002, MA09.03
Taioli, Emanuela EP03.01-008, EP07.01-002, EP08.01-047, P1.07-01
Tajiri, Tomoko OA07.03
Takada, Ikki EP16.03-037, EP16.04-009
Takahama, Takayuki EP08.02-115, IBS08.01
Takahashi, Michiko EP10.01-003
Takahashi, Nobumasa EP16.01-029
Takahashi, Toshiaki EP08.02-118
Takamiya, Rei EP14.05-022
Takamochi, Kazuya EP02.03-025
Takano, Angela EP16.03-036
Takeda, Norihisa OA07.03
Takeda, Tetsu MA03.07, P2.12-02
Takemoto, Shinnosuke EP08.01-064, EP08.04-005, EP16.02-005
Takemoto, Toshiki EP08.02-146
Takenaka, Tomoyoshi EP08.02-144
Takenoyama, Mitsuhiro EP08.02-144
Takeshima, Yukio EP16.01-004
Takumi, Yohei EP08.02-123
Talarico, Giovanna EP16.03-042
Talton, David EP02.03-022
Tamagawa, Satoru EP02.01-014
Tamakloe, Selorm EP02.04-002
Tamiya, Akihiro EP08.02-115
Tamiya, Motohiro EP08.02-115
Tammemagi, Martin IBS16.01, MA11.03, OA10.05, P1.02-01
Tammemägi, Martin P1.02-02
Tammemagi, Martin C. OA13.03
Tampellini, Marco EP10.01-015
Tan, Aaron EP16.03-036, P2.13-02
Tan, Daniel ES03.01
Tan, Daniel S. EP08.02-148, EP16.03-036, P2.13-02
Tan, Daniel S W. EP08.02-045
Tan, Dean EP08.02-023
Tan, Eng Huat EP16.03-036
Tan, Hendrick EP04.01-027
Tan, Jie EP08.02-002
Tan, Lawrence Tan EP16.02-019
Tan, Lisa EP08.02-147
Tan, Min Han EP01.01-006
Tan, Min-Han EP16.01-030
Tan, Shilei EP16.03-046
Tan, Sze Huey P2.13-02
Tan, Vivian S. EP04.01-027
Tan, Wan Ling EP16.03-036, P2.13-02
Tan, Weiwei EP08.02-159
Tan, Yali EP08.01-094
Tanabe, Miyuki EP08.02-143
Tanaka, Kentaro EP08.01-036
Tanaka, Luana F. EP03.01-013
Tancredi, Giorgia EP08.03-007
Tane, Kenta EP02.01-005
Tang, Cheng Y. EP08.01-095
Tang, Junfang EP08.02-063
Tang, Wen-Fang EP16.01-025, EP16.02-024, WS08.21
Tang, Ximing MA01.03
Tang, Xingni EP05.01-033
Tang, Yi EP08.02-021
Tang, Yiyun EP08.02-159
Tanga, Virginie EP11.01-005, EP11.01-006
Tangpeerachaikul, Anupong EP08.02-020
Taniguchi, Hirokazu EP08.02-115, EP16.03-030
Tanizaki, Junko ES39.05
Tanju, Serhan EP05.02-004, EP05.02-005, EP05.03-007
Tantraworasin, Apichat EP08.04-003
Tanwar, Pranay EP11.01-011
Tao, Lian-De EP10.01-002
Tapia, José Carlos P1.12-04
Tarannum, Mubin P2.10-04
Tarasenko, Elena OA08.06
Targato, Giada EP11.01-004
Tashi, Eritjan EP03.01-004
Tashiro, Jiro EP16.04-025, EP16.04-026
Taube, Christian EP04.01-016, EP04.02-005
Taus, Álvaro EP14.05-002
Tavara, Blanca EP05.02-002, EP05.02-003

Tavares, Mariana EP08.02-054
Taveira, Gabriela M. EP08.02-042
Tawalbeh, Ra'fat EP05.03-010
Tawfiq, Nezha EP06.01-010, EP06.01-012
Tay, Rebecca EP04.01-023
Tay, Sen Hee EP08.01-101
Taylor, Aliki EP08.02-080
Taylor, Kathryn L. OA10.03
Tcheou, Johnstone OA06.03
Teh, Yi Lin EP16.03-036
Tehfé, Mustapha EP04.01-020
Tehfe, Mustapha EP07.03-002
Teixeira, Encarnação EP04.01-011, EP08.02-053
Teixeira, Maria E. EP03.01-009, EP05.03-006
Teixidó, Cristina EP03.01-012, EP08.01-090, EP08.01-091
Teixido, Cristina EP08.02-102
Teixidó, Cristina EP08.02-149
Teixido, Cristina MA07.07, OA13.04
Teixidó, Cristina P1.07-02, P1.16-02
Teixido, Cristina P2.07-02
Tekneci, Ahmet K. EP02.03-027
Telaranta-Keerie, Aino EP08.02-138, EP08.02-140
Teles, Gustavo B. MA11.09, WS07.05
Temel, Jennifer ES24.03
Teng, Fei EP08.01-089, EP08.02-100, EP08.02-145, EP13.01-013
Teng, Jiajun OA05.05
ten Haaf, Kevin OA05.04
Teo, Lynette ES34.01
Teodòsio, Ana EP16.04-011
Terada, Kazuhiro EP11.04-001
Terán Brage, Eduardo EP08.01-048
Teraoka, Shunsuke EP16.02-005, MA06.04
Terbuch, Angelika EP02.01-008, EP08.02-116
Ter Heine, Rob EP08.02-090
Terjung, Inken EP08.02-114
Terol Espinosa de los Monteros, Belén EP08.01-048
Šteruský, Miroslav EP08.02-087
Ter Woerds, Desi K. MA04.08
Teteh, Dede EP10.01-012
Teulè, Alex EP16.03-027
Tew, Jenna EP02.03-012
Tew, Jenna R. EP02.03-005
Thabane, Lehana OA14.03
Thakral, Abhinav EP08.02-082, EP11.02-001
Thamrongjirapat, Thanaporn EP02.01-016
Thayu, Meena EP08.02-016, MA07.04, P1.16-01
Theegarten, Dirk EP02.01-010, EP04.01-016, EP04.02-005, P1.14-05
Theelen, Willemijin ES23.03
Theiveehathasan, Marius R. EP01.06-005
Theti, Davinder EP08.01-020
Thia, Tracy EP08.02-126
Thiagarajan, Anuradha P2.13-02
Thiele, Michael EP08.01-015
ThippuJayaprakash, Kamalram EP08.02-150
Thisaruban, Subashini EP01.07-001
Tho, Lye M. EP08.02-162
Thomaidou, Despina EP08.02-115
Thomas, Michael EP05.01-030, EP08.01-031, EP08.02-126, EP16.01-019, OA03.05, OA15.05
Thomas de Montpréville, Vincent MA10.08
Thompson, Jillian E. EP08.01-044
Thompson, Lisa EP11.03-003
Thomsen, Astrid EP08.01-084
Thomson, Carey EP01.07-002
Thongprasert, Sumitra ES30.04
Thor, Maria P1.10-03
Thorley, Rebecca EP01.02-005, PL03.03
Thorne, Leigh B. EP16.03-025
Thu, Kelsie L. EP16.01-006, EP16.03-015
Thunnissen, Erik MA02.01, MA12.07, MA12.08
Thurfjell, Viktoria EP11.01-007, EP16.04-001
Tian, Panwen EP08.02-139
Tian, Sibo EP14.03-003, P1.10-04, P2.04-05
Tian, Weiwei EP08.01-055, WS08.17
Tian, Zhenhuan EP16.01-017
Tiankui, Qiao EP02.02-001
Tibdewal, Anil EP08.03-002, MA09.03
Tiberi, David EP05.01-006
Tienchai, Kakanan EP08.02-083
Tienchaiananda, Piyawan EP08.02-083
Timelthaler, Gerald EP14.02-003
Timotheadou, Eleni EP10.01-018
Tincknell, Laura EP01.07-006
Tinivella, Marco EP10.01-015
Tirado, Victoria EP08.02-110
Tiseo, Marcello EP02.04-001, EP05.01-024, EP08.01-007, EP08.02-048, EP08.02-101, EP14.01-006, EP16.03-040, P1.15-04, P2.14-02
Tissera, Sanuki OA01.03
Tissing-Tan, Caroline J. MA03.09
Tiwari, Mani EP13.01-001
Tiwari, Virendra Kumar MA10.03
Tiwari, Virendrakumar EP06.01-014
Tjong, Michael C. EP04.01-027
Tochtermann, Giulia MA12.04
Todd, Adam OA01.05
Todd, Mary WS01.06
Todesco, Marco EP10.01-011
Tognazzi, Davide P1.15-04
Tognela, Annette EP08.01-002
Tognetto, Michele EP02.04-001, EP14.01-006
Tohidinezhad, Fariba P1.15-01
Tokaca, Nadza EP08.02-065, MA12.09
Tokuda, Yasuhiro EP05.02-017
Tolba, Khaled EP08.02-084, EP16.02-002, P2.14-01
Tolbert, Haley EP01.03-008
Tolcher, Anthony MA13.07
Tolosa, Ezequiel P2.14-03
Toloza, Eric M. EP02.03-005, EP02.03-012, EP02.04-005
Tom, Jennifer EP16.02-027
Tomono, Hiromi EP08.04-005
Toms, Christy EP08.03-005
Tong, Betty ES02.03
Tong, Fan EP08.01-099, EP08.01-100, EP08.05-002, MA09.04, OA11.06, WS08.13
Tong, Ruizhan EP14.03-002
Tong, Yan EP01.01-012
Tonneau, Marion OA07.06
Torasawa, Masahiro E P07.03-004
Torrents, Sophie EP04.01-010
Torres, Guillermo EP01.05-001
Torres, James EP01.04-001
Torres, Juan Manuel P1.12-04
Torres, Pere OA06.04
Torres, Tisdrey EP04.01-010
Torresan, Sara EP11.01-004
Torres-Cisneros, Eduardo R. EP16.03-026
Torres Jiménez, Javier EP08.01-090, EP08.01-090
Torres-Jiménez, Javier EP03.01-012, EP08.01-091, EP08.02-149, P1.07-02
Torres-Martínez, Alba EP08.02-149
Torres-Ramón, Irene EP16.01-014
Torricelli, Federica EP16.03-042
Tortora, Giampaolo EP10.01-011
Toschi, Luca EP02.04-001, EP05.03-008, EP08.01-007
Tosoni, Elena EP08.02-046, EP14.01-005
Totsukura, Masaya EP02.03-014
Toubia, John EP16.04-020
Toumazis, Iakovos EP01.04-002
Toya, Sophie EP08.02-111
Toyooka, Shin-ichi MA10.04
Toyozawa, Ryo EP08.02-113
Trachu, Narumol EP02.01-016
Trad, Diaeddine EP03.01-010
Tran, Hai MA01.03
Tran, Jessica H. EP07.01-002
Tran, Phuong EP05.02-018
Tran, Thi-Oanh EP16.04-007
Tran-Thanh, Danh EP04.01-020
Traseira, Cristina EP06.01-017, EP13.01-016
Traseira Puchol, Cristina EP16.04-014
Traverso, Alberto EP14.01-014, P1.15-01
Travis, Bill MA12.07
Traynor, Anne EP14.03-001
Treatman, Jacquelyn OA06.03
Treggiari, Stefano EP07.01-017
Tregnago, Daniela EP10.01-011
Trestini, Ilaria EP10.01-011, ES31.06
Triebel, Frederic EP08.01-109
Trimarchi, Fabio EP10.01-019
Triphuridet, Natthaya EP01.05-011, EP01.06-008, EP01.06-009, EP01.07-003, WS02.18
Troncone, Giancarlo EP07.01-001, EP08.02-101, EP16.03-040
Troost, Esther ES11.04
Troule, Kevin EP08.01-040
Trovo', Francesco EP08.01-006
Trudzinski, Franziska EP08.01-031
Trueb, Marta EP16.01-018, MA12.04
Truscott, Rebecca OA10.05
Tsai, Chen-Liang EP05.01-003
Tsai, Jill EP16.02-018
Tsai, Jill R. EP16.03-019
Tsai, Tzu-Hsiu EP08.02-127
Tsai, Yihsuan S. EP16.03-025
Tsakiridis, Theodoros EP05.01-035
Tsakonas, Georgios EP16.02-008, P2.13-03
Tsamardinos, Ioannis EP01.01-009, MA11.04

Tsang, Stella EP03.01-011
Tsao, Anne EP08.01-076, EP08.02-163, OA04.02
Tsao, May EP05.01-020, EP08.05-001
Tsao, Ming EP08.01-060, EP16.04-015, MA12.07
Tsao, Ming S. EP07.01-018, EP11.02-001, EP16.03-015
Tsao, Ming-Sound EP08.01-067, EP08.02-079, MA12.06
Tseng, Jeng-Sen EP08.02-027, EP08.02-155
Tsia, Kevin EP03.01-011
Tsiani, Evangelia EP16.04-008
Tsiouda, Dora EP08.02-060
Tsitsilashvili, Sophia EP01.03-013
Tsivtsivadze, Giorgi EP01.03-013
Tsou, Florencia EP08.02-097
Tsoukalas, Nikolaos EP10.01-018
Tsuboi, Masahiro EP02.01-005, ES08.01, MA10.04, PL03.13
Tsuchiya, Yuko IBS14.02
Tsujino, Kayoko MA06.04
Tsukazan, Maria Teresa EP06.01-011
Tsur, Eyal P2.01-02
Tsutani, Yasuhiro EP02.01-017, P1.06-01
Tsutsui, Shin EP13.01-007
Tsutsumi, Hirono EP08.01-036
Tu, Hai-Yan EP08.01-085, EP10.01-010, WS08.09
Tu, Janet EP08.01-059, EP08.02-163
Tucker, Sarah EP08.02-079
Tudor, Roxana EP04.02-001
Tudor, Roxana A. EP08.02-112
Tudor Marc, Silviu EP07.03-005
Tufail, Aisha MA09.07
Tufail, Muhammad EP13.01-001
Tufman, Amanda EP04.01-015, EP08.01-057, P1.11-01
Tula, Jonida EP03.01-004
Tuminello, Stephanie EP08.01-047
Tunc, Sema G. EP02.02-009
Tüns, Alicia I. EP16.03-004
Turcott, Jenny G. MA09.09, MA14.03, WS07.03
Turhal, Serdar EP08.01-024
Turhan, Kutsal EP02.03-026, EP02.03-027, EP13.01-014
Turna, Akif EP02.03-001, EP05.03-001, EP06.01-007, EP11.04-002, P2.06-01
Turnbull, Ronnie EP02.02-003
Turner, Michelle ES31.03
Turner, Michelle C. ES22.03
Tvilum, Marie EP05.01-017

U

Ubbels, J. F. MA03.09
Uchibori, Ken EP02.01-006
Uchida, Junji EP08.02-168
Uchida, Shinsuke EP02.03-025
Uchiyama, Ayumi EP08.02-115
Udagawa, Hibiki EP08.02-113
Udelsman, Brooks V. EP14.05-021
Udwan, Khalil EP16.03-015
Ueda, Hitoshi EP08.02-144
Ueda, So EP08.02-143
Uehara, Takechi MA03.07
Uehara, Yuji EP08.01-104, EP08.01-105, EP14.05-007
Uematsu, Mao EP07.03-004
Uemura, Takehiro EP16.02-005, OA07.03
Ueno, Harushi EP02.01-015
Uetani, Masataka EP13.01-007
Ugalde, Paula ES12.06
Ugalde, Paula A. OA05.03
Ugalde Figueroa, Paula A. MA04.05
Ul Haq, Sami EP14.01-019
Ulhøi, Maiken P. EP08.02-099
Ullal, Yashaswini S. EP16.03-024
Uluata Dayanc, Bengisu EP08.02-022
Umapathy, Ganesh EP16.03-012
Umeda, Syouta EP05.02-017
Umutlu, Lale EP04.01-016, EP04.02-005
Underhill, Craig EP14.05-016
Ung, Yee EP08.05-001
Ung, Yee C. EP05.01-020
Urban, Damien EP08.02-047
Urban, Susanna EP11.01-004
Urbano, Cristina P1.12-04
Urbanska, Edyta M. EP08.02-044, EP08.02-075
Urbarova, Ilona EP01.01-005
Urda, Michal EP08.02-087
Ursol, Grygorii EP08.01-027, OA15.04
Usio, Ryota EP11.01-008
Usrof, Faten P2.11-01
Usrof, Faten D. EP01.02-002

V

Vaccari, Stefania EP14.01-005
Vadvala, Harshna MA03.04
Vahrmeijer, Alexander L. OA14.05
Vakkalagadda, Chetan EP04.01-007, EP04.01-008, EP08.02-028
Valarezo, Joselyn EP08.02-032
Valaulikar, Ganpat EP02.03-022
Valbuena López, Silvia EP08.01-048
Valcárcel González, Sena EP16.01-031
Valdimarsdottir, Bryndis EP16.03-013
Valdimarsdottir, Unnur EP16.02-009, EP16.03-013
Valdivia, Augusto EP08.01-078
Valencia, Karmele EP16.01-009
Valencia-Velarde, Angel EP08.02-035, EP16.03-023, WS07.04
Valente, Maria La Salete EP08.02-036
Valente, Salete EP04.01-011
Valipou, Arschang EP16.01-015
Valipour, Arschang EP08.02-122
Valko, Zsuzsanna MA01.04
Valleggi, Simona MA10.07
Vallejo Pascual, Maria Eva EP05.02-002, EP05.02-003
Vallieres, Eric PL03.09
Vallome, Giacomo EP04.01-005
Vallone, Stefania EP16.03-011, IBS09.01
Vanakesa, Tõnu EP06.01-016
Van Bockel, Liselotte W. MA03.09
Van den Eynden, Jimmy EP16.03-012
Van den Heuvel, Michel M. EP08.02-090
Van der Aalst, Carlijn M. OA05.04
Van der Geest, A. M. MA03.09
Van der Gronde, Toon P1.06-01
Van der Heide, Stefan M. MA04.08
Van der Heijden, Erik H. EP04.01-026, MA04.08
Van der Horst, Joris EP04.02-002
Van de Rijn, Matt MA10.05
Van der Voort van Zijp, Noelle C. MA03.09
Van der Wekken, Anthonie J. EP08.02-041, EP08.02-109
Van der Wel, Antoinet M. MA03.09
Van Diessen, Judi EP05.01-009
Vaneckova, Pavla MA11.03
Van Ee, Thomas J. MA12.03
Van Es, Corine A. MA03.09
Van Geffen, Wouter H. EP08.01-026
Van Herk, Marcel EP05.01-012
Van Houtte, Paul MA10.02
Van Kampen, Daphne MA03.09
Van Kooyk, Yvette MA12.03
Van Maldegem, Febe MA12.03
Van Meerbeeck, Jan EP07.01-024
Vanni, Camilla EP01.06-001, EP05.03-002
Van Rossum, Peter EP05.01-009, EP05.01-010
Van Rossum, Peter S. MA03.09
Van Schil, Paul OA14.01
Van Til, Janine EP01.02-001
Varela, Mar EP16.03-027
Varela-Santoyo, Edgar EP08.02-035
Varesano, Niccolò P2.10-05
Vargas, Carlos EP16.03-002, EP16.03-003
Varmus, Harold EP08.02-055
Varriale, PhD, Pasquale P1.09-01
Varrieur, Tracy OA03.03
Varrieur, Tracy L. OA03.06
Vasconcelos, Andreina EP04.01-003
Vasmatzis, George P2.14-03
Vasseur, Damien OA13.04
Vasudevan, Anupama EP05.01-002
Vathiotis, Ioannis P2.12-01
Vattemi, Emanuela EP05.01-024, EP06.01-006
Vaz, Victor P1.15-03
Vaz, Victor R. EP08.01-043, MA02.09
Vázquez, Sergio EP08.01-029
Vázquez Estevez, Sergio EP08.02-070
V.d. Noort, V. OA04.06
Vegas, Lidia EP08.02-102
Veillon, Remi OA03.05
Veiseh, Omid P1.14-02
Vekkalagadda, Chetan EP08.02-074
Velasco Durántez, Verónica EP16.01-031
Velcheti, Vamsidhar EP08.01-021, MA02.10, P1.11-01
Velculescu, Victor EP01.01-003
Velez, Frank O. EP02.03-005
Velez, Maria A. OA12.03
Velikanova, Rimma P1.02-03
Veltri, Andrea EP10.01-015
Veluswamy, Rajwanth EP07.01-002, ES15.06, OA03.06, P2.12-05
Vendrell, Inês EP08.02-053
Venious, George P1.03-01
Venkatachalam, Palanisamy EP08.04-004
Ventura, Luigi P1.02-02, P1.13-01
Venugopal, Bindu K. EP08.02-024
Venuta, Federico EP01.06-001, EP05.03-002
Verderame, Francesco EP05.01-024, EP06.01-006
Vergé, Romain EP02.03-021
Verhagen, Ad F. MA04.08, OA06.05
Verhoeven, Roel L. EP04.01-026, MA04.08
Verma, Saurav P2.02-03
Vermeulen, Marrit OA04.06
Vermeulen, Robin J. EP04.01-026
Veronesi, Giulia ES12.05, P1.04-03

Verschraegen, Claire OA12.04
Verusio, Claudio EP07.01-005, P2.14-02
Verzè, Michela EP02.04-001, P1.15-04
Vibhakar, Pooja EP08.01-019
Vicent, Silve MA02.08
Vicente, David EP08.02-098, EP08.02-131
Vick, Joanna EP08.02-124
Vidal-Gutiérrez, Oscar EP16.03-026
Videtic, Gregory EP02.02-010
Vieni, Salvatore EP16.01-013
Vig, Chandra EP10.01-008
Vigier, Anna EP11.01-005
Vikström, Anders EP08.01-083, EP08.02-122
Viktorsson, Kristina P2.13-03
Vilalta, Anna MA02.08
Vilar-Compte, Diana OA06.06
Vilariça, Ana S. EP03.01-009
Vilariça, Ana Sofia EP08.02-132
Vilariño, Noelia EP16.03-027, P2.14-04
Villalón, Diego MA08.08
Villalona Calero, Miguel EP08.02-116
Villalona-Calero, Miguel MA13.08
Villanueva, Alberto P2.14-04
Villanueva, Emilio III Q. EP02.03-012
Villanueva, PharmD, Matthew EP08.02-107
Villanueva Palicio, Noemi EP16.01-031
Villatoro, Sergi EP16.03-027
Villena-Vargas, Jonathan EP02.04-004, OA09.05
Viñal, David EP08.01-049
Viñals, Pedro EP05.02-002, EP05.02-003
Vincent, Benjamin G. EP16.03-025
Vincent, Mark EP02.01-013, EP08.02-034, EP16.02-025
Vinod, Shalini EP04.01-023, EP04.01-025
Viñolas, Nuria EP03.01-012, EP08.01-090 EP08.01-091, EP08.02-102, MA07.07, OA13.04 P1.07-02, P1.16-02
Viola, Lucia EP01.05-004, EP16.03-002, EP16.03-003, P1.02-02, WS07.02, WS07.02
Viscardi, Giuseppe EP08.01-006
Visedo, Guillermo EP06.01-017, EP13.01-016
Visedo Ceballos, Guillermo EP16.04-014
Vita, Emanuele EP05.03-008, P10.01-011
Viteri, Santiago EP08.02-081, EP16.02-007, OA03.05
Viteri Ramirez, Santiago EP08.02-032
Vitorino, Rita EP04.01-011
Vitzthum, Lucas OA14.04
Viveiros, Pedro EP08.02-062
Vives, Marta EP08.02-120
Vives Usano, Marta EP08.02-032
Vlachavas, Efstathios-Iason EP16.02-004
Vlagea, Alexandru P1.12-04
Vlassak, Soetkin EP08.02-162
Vlastos, Dimitrios EP02.03-002
Vliegenthart, Rozemarijn EP01.02-001, EP01.05-006
Vodovotz, Yael EP03.01-014
Vodušek, Ana Lina EP05.01-013
Voegele, Catherine MA01.09, MA02.03, OA04.05
Voigt, Wieland EP01.04-006, ES09.02
Vojnic, Morana MA13.05
Vokes, Everett PL03.06
Voligny, Emma EP13.01-006
Vollmer Torrubiano, Ivan EP02.02-007
Volodin, Alexandra EP16.01-016, EP16.03-028
Voloshin, Tali EP16.01-016, EP16.03-028
Vonk, Ernest J. MA03.09
Von Levetzow, Cornelia EP08.02-114
Von Stackelberg, Oyunbileg EP01.02-001
Von Suchodoletz, Hanna P1.15-05
Voon, Pei Jye EP08.02-108
Voong, Khinh R. EP07.01-018
Vrankar, Martina EP05.01-013
Vulkan, Daniel EP01.06-006
Vynnychenko, Ihor O. PL03.09

W

Waddell, Thomas K. OA14.03
Wade, Stephen MA11.03, P1.08.01
Wagenius, Gunnar EP08.01-083
Wagner, Thomas EP01.07-006
Wahlroos, Sara EP08.02-116
Wainer-Katsir, Kerem EP16.03-028
Waissengrin, Barliz EP08.01-010, EP08.01-011, EP08.04-001, MA14.07
Wakabayashi, Masashi EP02.01-005
Wakeam, Elliot OA06.07
Wakefield, Nathan EP08.01-034
Wakeham, Andrew EP16.01-006
Wakelee, Heather EP16.02-015, IBS18.04, IBS18.06, MA10.05, PL03.01, PL03.09, WS03.02
Wakimoto, Shin EP16.01-029
Wakuda, Kazushige EP16.02-005
Wald, Joshua MA08.03
Walia, Preet EP02.04-009, EP03.01-002, EP04.01-001
Walji, Hasanali D. EP06.01-009
Walker, Damaal P1.16-03
Walker, Fiona EP05.01-007
Walker, Joshua EP07.01-019
Walker, Meghan OA10.05, P1.02-01
Walker, Michael EP02.03-023
Walker, Phillip MA05.08
Wallace, Alison EP02.03-020
Wallace, Andrew OA14.06
Waller, Cornelius P1.15-05
Waller, Cornelius F. EP14.01-008
Waller, David ES26.02, P1.13-01
Waller, Emanuel EP08.01-010
Walls, Gerard EP05.01-007
Walls, Gerard M. P1.10-03
Walpole, Euan EP04.01-013
Walpole, Imogen OA03.04
Walsh, Declan EP10.01-016
Walter, Joan E. EP01.05-006
Walter, Julia EP04.01-015
Walter, Thomas MA01.09
Wan, Yin EP08.02-156
Wan, Zi Yi EP16.01-030
Wanderwalde, Ari EP16.03-021
Wang, Alex EP16.03-005
Wang, Aodi EP16.02-016, EP16.03-006
Wang, Bin EP08.02-139
Wang, Bing EP08.02-021, EP08.02-136, EP10.01-001
Wang, Changli EP05.02-018, WS08.11
Wang, Cheng EP16.03-008
Wang, Chin-Chou EP05.01-003, EP08.02-027, EP08.02-151
Wang, Daquan EP16.02-026
Wang, Ding EP07.02-006
Wang, Dong EP01.01-012, EP08.01-087, OA02.05
Wang, Dongliang EP08.01-055, WS08.17
Wang, Donglin EP08.02-139
Wang, Fang MA04.03, P1.14-03
Wang, Guangsuo EP05.02-009
Wang, Hangjun EP06.01-001, EP11.03-001
Wang, Hao EP08.01-086
Wang, Hiuqi EP08.02-150
Wang, Hongtao EP02.01-018, EP16.01-012
Wang, Hongyu EP07.03-003
Wang, Huijuan EP08.01-001, EP08.02-004, EP08.02-005, EP08.02-006
Wang, Huimin EP16.01-032, OA05.05
Wang, Jia EP02.03-018, EP05.02-014, WS08.22
Wang, Jianghong EP08.02-063
Wang, Jianyang EP05.01-004
Wang, Jiaoli EP08.02-136, EP14.01-021
Wang, Jie EP08.01-014, EP08.02-077
Wang, Jin EP16.03-031, EP16.03-032, EP16.03-033, MA05.07, WS08.23
Wang, Jing EP08.01-051, EP08.02-057, MA01.03, P2.10-01
Wang, Jingyi EP08.01-093, EP08.02-161
Wang, Jinru OA02.05
Wang, Jun OA09.04
Wang, Junsheng EP08.01-001
Wang, Kai EP08.02-139
Wang, Kevin EP08.02-129
Wang, Le EP16.02-019
Wang, Lifeng EP01.01-011, EP08.01-071
Wang, Lijia EP14.01-015
Wang, Lijing EP05.02-010
Wang, Lin EP16.02-017
Wang, Lingjie EP01.01-012
Wang, Linlin EP16.01-021, EP16.01-022
Wang, Liwei EP16.03-006
Wang, Luhua EP05.01-016, EP14.03-005, EP16.02-026
Wang, Mengzhao EP08.02-029
Wang, Minghui EP05.02-009
Wang, Mingmin EP16.02-016, EP16.03-006
Wang, Mingzhao EP08.01-053, EP08.01-054, EP16.02-017
Wang, Pingli OA03.07
Wang, Qi EP08.01-097, EP08.02-100, MA01.03, OA09.03
Wang, Qian EP07.01-002, EP16.03-038, EP16.04-022, EP16.04-023, OA09.03
Wang, Qianyu MA02.05
Wang, Qianzhi EP08.01-093, EP08.01-094, EP08.02-158, EP08.02-161, WS08.14

Wang, Qichuan EP08.01-001
Wang, Qiming EP08.01-073
Wang, Qiu Ming EP08.02-078
Wang, Qun EP05.02-018
Wang, Renwei P1.01-01
Wang, Ruihua EP08.01-073
Wang, Rulan EP14.01-003
Wang, Runsheng P2.10-01
Wang, Sai EP01.01-012
Wang, Shouzheng EP08.02-091
Wang, Tao EP01.01-011, EP16.03-038, EP16.04-022, EP16.04-023, OA09.03
Wang, Ting EP14.01-003
Wang, Wei EP16.04-028, EP16.04-029
Wang, Wenchen MA06.07
Wang, Wenxiang EP05.02-018,
Wang, Xiangcai MA14.05
Wang, Xiaofei PL03.06
Wang, Xiaojuan EP08.01-054
Wang, Xiaolin EP08.02-111
Wang, XiaoZhe OA15.03
Wang, Xin EP08.02-169
Wang, Xinan EP08.01-043
Wang, Xintong EP07.01-002
Wang, Xue EP14.05-023
Wang, Yadong EP16.01-017
Wang, Yan EP08.01-014, EP16.03-001
Wang, Yang EP16.03-046
Wang, Yaolin OA03.07
Wang, Yaqi EP02.03-018
Wang, Yaxi EP11.01-014
Wang, Yi-Zhi EP05.02-011, WS08.19
Wang, Ying EP08.01-009, EP08.01-074, EP08.01-075, EP08.02-001, EP08.02-034, EP08.02-089, EP16.01-027, P1.01-01
Wang, Yiyang EP08.03-006
Wang, Yongjie EP01.01-012
Wang, Yu EP05.01-004, EP05.01-016, EP10.01-009
Wang, Yuanyong EP09.01-002, EP13.01-015, MA04.07
Wang, Yuning EP16.03-018
Wang, Yuzhao EP02.03-018, EP05.02-014, WS08.22
Wang, Zhaoxia EP08.02-152, EP08.02-153, EP16.04-024
Wang, Zhaoyang EP13.01-015
Wang, Zhehai EP08.01-070, EP08.01-071, WS08.15
Wang, Zhen EP10.01-010
Wang, Zhi Q. EP08.01-095
Wang, Zhiyuan EP16.03-008
Wang, Ziping EP08.01-014
Wannesson, Luciano EP08.02-122
Wapinski, Ilan P2.07-01, P2.15-01
Waqar, Saiama MA07.04
Waqar, Saiama N. EP08.01-013
Ward, Jeffrey P. EP08.01-013
Warita, Katsuhiko EP16.04-025, EP16.04-026, EP16.04-027
Warita, Tomoko EP16.04-025, EP16.04-026, EP16.04-027
Warkentin, Matthew OA13.01
Warner, Andrew EP08.05-001
Warner, Jeremy OA06.06
Waszak, Angela P1.11-01
Watanabe, Hirokazu MA04.04
Watanabe, Kageaki EP08.01-105, EP14.05-007
Watanabe, Masayuki P1.15-13
Watanabe, Shun-ichi EP02.03-014, EP02.03-016, MA04.04, MA10.04
Watkins, Neil EP16.03-041
Watson, Drew EP16.03-024
Watt, Colleeen PL03.06
Wawryko, Paul OA06.07
Webb, Maxine EP03.01-014
Weber, Jan-Phillip EP08.02-106, EP08.02-114
Weber, Marianne MA11.03, P1.08.01
Weder, Walter ES33.06
Wei, Chenchen EP08.02-152, EP08.02-153, EP16.04-024
Wei, Lai EP08.01-062, EP14.05-004, OA12.04
Wei, Li EP05.02-009
Wei, Shihong MA14.05
Wei, Yu-Feng EP08.02-027
Wei, Zihan MA14.04
Weinberg, Uri EP16.01-016, EP16.03-028
Weining, Tessa EP08.02-045
Weinlinger, Christoph EP02.01-008, EP08.02-122
Weipert, Caroline EP08.02-074
Weiss, Jessica EP08.01-067, EP08.02-079, EP16.03-015
Wekken, Anthonie v. EP08.02-162
Welch, Connor MA02.08
Welker, Lutz EP16.01-011
Welliver, Meng X. EP05.01-021, EP08.01-098
Welter, Stefan MA06.08
Welty, Valerie F. EP01.05-010
Wen, Lu EP08.01-099, MA09.04, WS08.13
Wen, Xiaoping EP08.01-094
Weng, Jie EP08.02-158, WS08.14
Wenga, Pawla EP08.01-086
Werner, Raphael S. EP08.03-006, EP16.04-010
Werner-Wasik, Maria ES19.06, MA14.01
Wert, Michael P1.03-01
Werutsky, Gustavo EP03.01-003
Wesam Almajd, Aabed P2.11-01
Wesolowski, Robert EP14.05-004, OA12.04
West, Howard EP02.03-009
West, Howard (Jack) ES20.06
Westeel, Virginie ES36.02, OA12.07, OA15.03
West III, William EP02.03-005
Weston, Michelle EP04.01-013
Whales, Amelia EP01.05-002
Whealon, Spencer EP02.03-023
Wheatley-Price, Paul EP03.01-016, EP08.02-034, EP14.04-001, EP14.05-020
Wheeler, Caroline EP03.01-014
Wheeler, Caroline E. EP08.01-019
Wherry, E. John P1.15-07
White, Charles S. EP01.07-002
Wichmann, Christian MA09.05, P1.10-02, P2.03-01
Widder, Joachim ES29.02
Wieczorek, Maciej EP16.03-014
Wiegman, Erwin M. MA03.09
Wiesweg, Marcel EP16.03-004, EP16.04-002
Wietecha, Delia EP16.02-018
Wiggins, Horace L. EP02.03-022
Wigle, Dennis PL03.06
Wikman, Harriet EP16.01-011
Wilbur, David C. P2.11-02
Wild, Robert EP08.02-031, EP08.02-106
Wiley, Joshua F. P2.08-02
Wilkinson, Samantha EP08.01-065
Williams, Niamh EP16.04-004
Williams, Nyelia EP03.01-014, EP08.01-019
Williams, Randi OA10.03
Williams, Sara C. EP01.06-007
Williamson, Timothy P2.08-09
Willimas, Terence EP05.01-021
Wilshire, Candice L. MA14.09
Wilson, Claire EP16.04-011
Wilson, Don EP01.07-004
Winder, Thomas EP08.02-122
Windsor, Morgan EP04.01-023
Wing, Shane EP08.01-079
Wing, Synne OA01.06
Winstone, Sarah MA08.07, P2.08-05, P2.08-06
Winter, Hauke EP16.01-019
Wipplinger, Martin EP07.02-004
Wirtz, Denis MA03.04
Wislon, Grace OA06.06
Wisnivesky, Juan P. EP07.01-002
Wistuba, Ignacio I. MA01.03, OA14.06
Withana, Nimali P. P1.15-08
Witlox, Willem EP14.01-014
Wojas-Krawczyk, Kamila EP01.01-008
Wojda, Emil EP08.02-072
Wolf, Adrea EP07.01-002
Wolf, Andrea EP07.01-001
Wolf, Brad EP02.03-022
Wolf, Ido EP08.01-010, EP08.01-011, MA14.07
Wolf, Jürgen EP08.02-031, EP08.02-106, EP08.02-114
Wolff, Jacqueline P2.10-04
Wolfhagen, Nienke EP05.01-009, MA03.09, OA06.05
Wollner, Mira EP08.02-017
Wollner, Mirjana OA12.06
Wömpner, Claudia EP08.02-114
Wong, Alvin EP08.01-101
Wong, Annick EP05.02-015, EP05.02-019
Wong, Chris EP03.01-011
Wong, Deborah J. MA07.05
Wong, Kwok-Kin EP01.06-003, EP08.02-084
Wong, Selina EP08.01-074, EP08.02-089
Wonser, Dann EP08.01-044
Woo, Hyeoksang EP02.03-004
Wood, Chris EP13.01-011
Woodard, Gavitt A. EP14.05-021
Woodcock, Joanna EP16.04-020
Woodcock, Mark EP16.03-025
Woodford, Katrina L. OA01.04
Woods, Allison EP16.04-017
Woods, Ryan P1.02-04
Woolf, David EP05.01-012
Woon, Beverly EP05.01-023
Worst, Michelle A. EP08.02-117
Wozniak, Antoinette EP16.03-021
Woznitza, Nicolas EP01.06-002
Wright, Cari EP05.01-019
Wright, Frances C. EP04.01-027, EP10.01-004
Wright, Gavin EP04.01-023
Wright, James R. EP05.01-035

Wright, Jeffrey EP01.06-007
Wroblewski, Kristen EP07.01-013
Wrona, Anna ES11.03, ES26.06
Wu, Abraham J. EP05.01-025, P1.05-02
Wu, Benson Z. EP16.03-015
Wu, Carol C. EP01.07-002
Wu, Chunyan EP02.01-003, P1.14-03
Wu, Fan PL03.09
Wu, Fang EP01.07-005, EP08.01-092, EP08.02-157
Wu, Fengying EP16.01-005
Wu, Gang EP08.01-042, EP08.02-064, EP08.02-139, OA02.05
Wu, Guixian EP14.01-016
Wu, Hongcheng EP08.02-063
Wu, Jing EP08.01-097
Wu, Jingxun EP08.01-071
Wu, Julie T. EP08.01-045
Wu, Jun EP16.01-032
Wu, Kan E P05.01-031, EP08.01-056, EP08.02-136
Wu, Lang EP08.01-075
Wu, Ligang EP16.02-023
Wu, Lihong EP08.01-107, WS08.16
Wu, Lin EP05.02-018, EP08.01-093, EP08.01-094, EP08.01-095, EP08.02-078, EP08.02-158, EP08.02-159, EP08.02-160, EP08.02-161, WS08.14
Wu, Linfang EP16.02-026
Wu, Meng EP07.01-013
Wu, Michael P1.04-02
Wu, Min EP16.01-025, EP16.02-024, WS08.21
Wu, Nan EP02.03-018, EP05.02-008, EP05.02-014, WS08.22
Wu, Pei-Hsun M A03.04
Wu, Ping OA03.07
Wu, Qi PL03.03
Wu, Qian EP08.02-073, EP16.03-044
Wu, Rong EP08.02-139, OA02.05
Wu, Wei EP08.02-147
Wu, Wen-Hsing P1.09-02
Wu, Wendy Y. P1.01-01
Wu, Xi MA01.05
Wu, Xiangfeng MA13.07
Wu, Xiaomai EP14.01-016
Wu, Xiaoxuan EP08.01-055, MA05.03, WS08.17
Wu, Xue EP08.02-073, EP16.01-025, WS08.21
Wu, Yanyu EP08.02-156
Wu, Yi-Long EP02.01-012, EP08.01-070, EP08.01-071, EP08.01-085, EP08.02-049, EP08.02-063, EP08.02-064, EP08.02-108, EP10.01-010, EP16.01-025, EP16.02-024, MA02.05, OA02.05, OA03.05, OA15.06, PL05.01, WS08.01, WS08.09, WS08.15, WS08.21
Wu, Yuan EP08.01-080
Wu, Yufan Fred OA14.04
Wu, Yuhua EP08.02-039
Wu, Yuzhi EP01.07-005
Wu, Zhijun EP08.02-158, WS08.14
Wujcik, Debra EP04.02-003
Wurm, Robert EP02.01-008, EP08.02-122
Wurtz, Anna EP08.02-125
Wusiman, Dilinaer EP10.01-009
Wynes, Murry EP01.04-005, EP08.01-060, MA11.07, P1.02-02

X

Xhemalaj, Daniela EP03.01-004
Xi, Yuanxin MA01.03, P2.10-01
Xia, Bing EP08.01-056, EP08.01-106, EP08.02-021, EP08.02-136, EP10.01-001, EP14.01-021
Xia, Guohao EP14.01-001
Xia, Liliang EP08.01-009
Xia, Xinhang EP16.04-028, EP16.04-029
Xiang, Chan EP16.03-044, MA05.07
Xiang, Ziyong OA03.07
Xiao, Desheng EP05.02-010
Xiao, Liang M. EP08.01-095
Xiao, Lizhi EP01.07-005
Xiao, Maoliang EP08.01-094, EP08.02-158, WS08.14
Xiao, Shanshan EP16.03-038, EP16.04-022, EP16.04-023, OA09.03
Xiao, Zemin EP08.02-158, WS08.14
Xie, Chao EP08.02-038
Xie, Dong P1.14-03
Xie, Fajun EP08.01-032
Xie, Feng OA14.03
Xie, John P1.16-01
Xie, Mengqing EP08.01-097
Xie, Mingran EP05.02-009
Xie, Xiaofeng MA04.03, P1.14-03
Xing, Puyuan EP07.03-003, EP08.01-089, EP08.02-007, EP08.02-008, EP08.02-009, EP08.02-091, EP08.02-100, EP08.02-145, EP11.03-002, EP13.01-013, EP14.02-007
Xing, Ruyue EP08.02-005, EP08.02-006
Xiong, Anning EP08.01-096
Xiong, Anwen EP16.01-005
Xiong, Huiling OA15.03
Xiong, Yanlu MA06.07
Xiong, Yi EP05.02-021
Xiong, Yuanyuan EP16.01-017
Xiu, Joanne MA05.08
Xu, Bing-Fei EP10.01-010
Xu, Enwu EP05.02-009
Xu, Fang EP08.01-093, EP08.01-094, EP08.01-095, EP08.02-161
Xu, Fei EP08.02-063, EP08.02-078
Xu, Jianlin EP08.01-096, EP08.01-102, EP08.01-103
Xu, Li EP08.01-093, EP08.01-095, EP08.02-161
Xu, Lin EP05.02-009
Xu, Mian EP08.01-009
Xu, Ran EP16.01-010
Xu, Shaohua EP16.04-023
Xu, Shun EP05.02-009, EP08.02-073
Xu, Song EP05.02-009
Xu, Tianwei EP08.02-152, EP08.02-153, EP16.04-024
Xu, Wanning EP08.02-138, EP08.02-140
Xu, Wei EP02.04-009
Xu, Xiao EP08.02-021, EP10.01-001
Xu, Xiaoling EP07.02-005, EP07.02-006, EP08.02-092, EP08.02-165
Xu, Xinhua OA02.05
Xu, Yan EP08.01-093, EP08.01-094, EP08.01-095, EP08.02-158, EP08.02-161, WS08.14
Xu, Yanjun EP08.01-032
Xu, Yasi EP08.02-167
Xu, Yiting EP01.07-005
Xu, Yong EP14.03-002
Xu, Yuan EP16.01-017
Xu, Yunhua EP16.03-044
Xu, Zhangwendi EP08.03-008, OA11.05
Xu, Ziyi EP08.02-091, EP08.02-100, EP13.01-013
Xuan, Yulong EP01.01-011
Xue, Jianchao EP16.01-017
Xue, Jianxin EP14.03-002
Xue, Xinying MA04.07

Y

Yachnin, Jeffrey EP08.02-148
Yadav, Mahesh OA14.06
Yadav, Ryan EP01.04-004
Yaghi, Marita EP08.01-023
Yamagata, Hiroshi EP02.01-004
Yamaguchi, Hiroyuki EP08.01-064, EP08.04-005
Yamaguchi, Masafumi MA06.04
Yamaguchi, Osamu EP08.02-143
Yamaguchi, Teppei EP16.02-005
Yamaguchi, Toshihiko EP08.02-168
Yamamichi, Takashi EP02.01-014
Yamamoto, Noboru EP07.03-004, EP08.02-049, MA10.01
Yamamoto, Nobuyuki EP16.02-005, MA06.04, MA13.03
Yamamoto, Shoichiro EP08.02-143
Yamamoto, Tokihiro EP05.01-019
Yamamoto, Yasuto EP16.01-028
Yamauchi, Yoshikane EP16.01-028, EP16.01-029
Yamazaki, Koji EP08.02-144
Yan, Cihui OA09.03
Yan, Hong-Hong EP08.01-085, WS08.09
Yan, Hua P1.12-03
Yan, Li EP08.02-033
Yan, Ling EP16.03-046
Yan, Michael EP03.01-016, EP04.01-027, EP08.05-001, EP14.04-001, EP14.05-020
Yan, Ningning EP08.02-069
Yan, Sheng EP05.02-020, EP07.01-008, EP16.01-024
Yan, Shi EP02.03-018, EP05.02-008, EP05.02-014, WS08.22
Yan, Shuangquan EP14.01-016
Yan, Xiangtao EP08.01-001
Yan, Xiaolong EP13.01-015, MA04.07
Yan, Xuejun EP08.01-094
Yan, Yu EP08.02-052

Yanagitani, Noriko EP02.01-006, EP08.01-005, EP08.02-115, EP08.02-118
Yang, Chen EP08.02-078
Yang, Cheng-Ta EP08.01-027, OA15.04
Yang, Chi-Fu Jeffrey EP14.05-003, MA04.05, MA04.09, OA02.04, OA05.03, OA05.06
Yang, Ching-Yao EP08.02-127
Yang, Cindy MA02.07
Yang, Dawei P1.02-02
Yang, Dian EP08.01-081
Yang, Dong EP16.03-016
Yang, Gowoon EP05.01-034, OA11.04
Yang, Haihua EP05.01-015, EP05.01-033, EP08.05-003, EP16.04-028, EP16.04-029, EP16.04-032, MA09.08
Yang, Haiyan EP05.02-021
Yang, Huaping EP05.02-010
Yang, Huaxia EP16.01-017
Yang, Hui MA13.03
Yang, James CH EP08.02-140
Yang, James Chih-Hsin EP08.01-028, EP08.02-029, EP08.02-127, OA03.05, OA12.06, OA15.03
Yang, Jason OA02.05
Yang, Jin-Ji EP08.01-085, WS08.09
Yang, Junquan EP08.02-139
Yang, Kyungmi EP02.02-004, EP02.02-005
Yang, Lei EP08.02-033
Yang, Lin EP08.02-063, EP11.03-002, EP14.02-007, MA01.05, P2.14-03
Yang, Ling-Ling EP16.02-024
Yang, Luxi EP08.02-111
Yang, Ming-Yi EP08.01-085, WS08.09
Yang, Nong EP05.02-021, OA02.05, OA03.07
Yang, Pan Chyr ES04.04, WS02.09
Yang, Pan-Chyr EP08.01-028
Yang, Ronghua EP01.01-012
Yang, Runxiang MA14.05
Yang, Sei Hoon EP08.02-142
Yang, Shaoyu EP08.01-056, EP08.02-136, EP08.02-166
Yang, Tsung Ying EP08.02-151
Yang, Tsung-Ying EP05.01-003, EP08.01-073, EP08.02-029, EP08.02-155, EP08.02-162, MA13.07
Yang, Wookyeom MA07.08
yang, xi P2.10-03
Yang, Xiaoying EP16.01-017
Yang, Xin EP05.02-008, EP05.02-014, WS08.22
Yang, Xue EP08.02-038, EP08.02-057, EP08.02-169
Yang, Yan EP08.02-139
Yang, Yin EP05.01-016
Yang, Yue EP02.03-018, EP05.02-014, WS08.22
Yang, Yufan EP05.01-016
Yang, Yunpeng EP08.02-068
Yang, Zhixiong EP08.02-154
Yankelevitz, David EP01.04-005, EP01.05-011, EP02.03-011, MA11.07, P1.02-02, P2.12-05
Yankelevitz, David F. EP01.01-002, EP01.06-009, EP01.07-003
Yankelevitz, David F. OA06.03
Yano, Kaito EP07.03-007
Yano, Tokujiro EP08.02-144
Yano, Yukihiro EP08.02-168
Yao, Chao EP08.01-035
Yao, Fei EP16.03-031, EP16.03-032, EP16.03-033, WS08.23
Yao, Guangyin EP16.02-017
Yao, Jicheng EP16.02-016
Yao, Wen Xiu EP08.02-078
Yap, Mei Ling EP01.03-012
Yap, Swee Peng P2.13-02
Yarden, Yosef MA07.05
Yasufuku, Kazuhiro OA14.03
Yata, Yumi EP02.03-017
Yatabe, Yasushi EP02.03-016, ES28.04, MA04.04, P1.06-01
Yates, Paul OA08.06
Yavuz, Hasan EP02.03-026, EP13.01-014
Yazaki, Yuki EP16.03-037
Yazaki, Yuuki EP05.02-017
Yazici, Ozan EP08.01-024
Ye, Darwin P1.15-07
Ye, Fen P1.09-02
Ye, Jian EP14.01-021
Ye, Monica EP08.01-075
Ye, Nicholas EP01.02-003
Ye, Qian EP01.07-004
Ye, Xianghua EP05.01-015
Yee, John EP01.07-004, EP02.01-001, MA11.08, OA13.03, P1.04-02
Yegya-Raman, Nikhil EP08.01-018
Yenigun, Bulent Mustafa EP07.01-003, EP08.03-004
Yeo, Chang Dong P2.01-01
Yeong, Joe EP16.03-036
Yi, Eunjue EP02.03-028
Yi, Tienan EP08.02-063, EP08.02-139
Yi, Yali EP08.01-003
Yilmaz, Asim Egemen EP07.01-003
Yilmaz, Bulent EP08.01-059
Yilmaz, Kaan Can EP07.01-003
Yim, Eunsil MA07.09
Yin, Jun MA05.08
Yin, Zihao EP16.04-030
Ying, Jianming EP02.01-011, EP08.02-009, EP08.02-091, EP11.01-014, MA01.05, MA05.03
Ying, Kejing EP05.02-018
Yip, Connie P2.13-02
Yip, Po Yee EP08.01-002
Yip, Rowena EP01.01-002, EP01.05-011, EP01.06-009, EP01.07-003, EP02.03-011
Yip, Stephen EP02.01-001
Yiu, Harry H. OA07.05
Yiu, Wing San EP05.01-029
Yıldırım Güçlü, Çiğdem EP10.01-013
Yoh, Kiyotaka EP08.02-049, EP08.02-113
Yokose, Tomoyuki EP11.01-008
Yokote, Fumi EP16.01-028
Yokoyama, Toshihide EP08.02-115, EP16.02-005
Yomota, Makiko EP08.01-105
Yoneshima, Yasuto EP08.01-036
Yoon, Dong Wok MA10.09
Yoon, Dong Woog P2.09-01
Yoon, Hong In EP05.01-034, OA11.04
Yoon, Ju-Yoon EP16.03-015
Yoon, Seong Hoon EP08.02-142
Yoon, Seung Hwan EP16.03-034
Yoon, Sung Hoon EP08.01-017
Yoon, Sung Mi EP16.02-022, P2.12-04
Yorke, Ellen D. EP07.01-018
Yorulmaz Çakmak, Refika EP08.01-024
Yoshida, Tatsuya EP07.03-004, MA13.03
Yoshida, Yukihiro EP02.03-014, EP02.03-016, MA04.04
Yoshikawa, Aki EP08.02-168
Yoshikawa, Toyofumi MA10.04
Yoshimura, Sho EP14.05-022
Yoshino, Ichiro EP08.01-005, MA10.04
Yoshioka, Hiroshige EP08.02-133
Yoshizawa, Akihiko EP11.04-001
Yotsukura, Masaya EP02.03-016, MA04.04
You, Dong EP08.01-035, EP16.03-001
You, Jian OA09.03
Younes, Riad N. EP02.03-029
Young, Jane EP10.01-005, EP16.03-041, P1.12-02
Young, Robin EP05.01-007
Younus, Jawaid EP02.01-013
Yousaf, Nadia EP08.02-065, EP08.02-124, MA12.09
Yousif, Ali EP03.01-010
Yu, Changhui EP05.01-033, EP08.05-003
Yu, Chong-Jen EP08.02-127
Yu, Cunjing EP08.01-014
Yu, Guo Hua EP08.02-078
Yu, Guohua EP08.01-073
Yu, Helena EP08.02-018, EP08.02-019
Yu, Helena A. EP16.03-030
Yu, Hui EP16.04-001
Yu, Huiqing EP10.01-020, EP10.01-020
Yu, Jie EP08.02-063
Yu, Jin-Ming EP08.02-064
Yu, Junhua MA07.03
Yu, Lian EP08.01-102, EP08.01-103
Yu, Min EP14.03-002
YU, Nathan Y. EP05.01-011, EP14.05-001
Yu, Qitao EP08.02-139
Yu, Shaorong EP14.01-001
Yu, Wei EP16.02-008
Yu, Xin EP08.01-097
Yu, Xinmin EP08.01-014
Yu, Yan EP08.01-033, MA14.05
Yu, Yongfeng EP08.03-008, EP16.03-031, EP16.03-032, EP16.03-033, OA11.05, WS08.23
Yu, Zhuang EP08.02-057, EP08.02-139
Yuan, Hong EP16.04-017
Yuan, Jian-Min MA11.05, P1.01-01
Yuan, Meng EP01.03-004
Yuan, Pei EP02.01-011
Yuan, Ren EP01.05-007, EP08.01-075, MA11.08, P1.04-02, P2.09-03

Yuan, Shaohua EP16.03-006
Yuanyuan, Zhao EP08.02-052
Yubero, Alfonso EP16.01-014
Yue, Jing EP16.04-030
Yuksel, Cabir EP07.01-003, EP08.03-004
Yuksel, Seher EP16.01-004
Yumuk, Fulden EP08.01-024
Yun, Jae Kwang EP05.03-004, EP05.03-005
Yun, Nicole EP08.02-119

Z

Zacharek, Sima P2.12-01
Zacharias, Martin EP02.01-008, EP11.02-002
Zacher, Angela P2.14-02
Zahed, Hana MA11.05, P1.01-01
Zahid, Muhammad P2.14-03
Zaidi, Malaika S. MA04.09
Zaidi, Neeha EP08.01-086
Zaitoun, Alaa EP08.02-121
Zalcberg, John EP04.01-023, EP14.05-016, MA11.03, OA01.03
Zalutskaya, Alena EP08.02-018, EP08.02-019, EP08.02-045
Zanelli, Francesca EP05.01-024, EP05.03-008, EP06.01-006
Zanetti, Eleonora EP16.03-042
Zang, Aimin EP08.02-139
Zaouit, Maryam EP05.01-022
Zapata, María EP16.01-014
Zaric, Bojan EP03.01-017, EP04.02-006
Zarzana, Maria Antonietta EP10.01-019
Zatarain-Barrón, Lucia EP05.01-001, EP16.03-002, EP16.03-003, MA14.03, WS07.03
Zatarain Nicolás, Eduardo EP08.01-048
Zauderer, Marjorie G. EP07.01-018
Zaw, Catherine OA10.06
Zeck, Jay EP08.01-044
Zelifan, Arash EP11.02-001
Zellino, Carolina EP07.01-005
Zemanova, Milada MA09.01
Zemer-Tov, Efrat EP16.01-016, EP16.03-028
Zeng, Aiping EP08.02-063, MA14.05
Zeng, Haiyan EP14.01-014
Zeng, Hao EP08.05-002, OA11.06
Zeng, Jun EP05.02-010
Zeng, Liang EP05.02-021
Zeng, Xiaoli EP08.01-003
Zeng, Yanwu EP16.03-046
Zeng, Yue EP01.07-005, EP08.01-092
Zeng, Zhimin EP08.01-003
Zenke, Yoshitaka EP08.02-113, MA13.07
Zer, Alona EP08.02-047, EP08.02-122
Zeuner, Harald MA13.04
Zhai, Wen-Yu E P05.02-011, WS08.19
Zhan, Luna EP08.02-082, EP11.02-001
Zhan, Luna J. EP02.04-009, EP03.01-002, EP03.01-016, EP04.01-001, EP14.01-019, EP14.04-001, EP14.05-020, MA14.08
Zhan, Peter L. OA11.03
Zhan, Yingqian A. EP16.03-030
Zhang, Baihua EP05.02-021
Zhang, Bingnan MA01.03
Zhang, Bo EP08.02-159
Zhang, Chao EP05.02-006, EP16.02-024, MA02.05
Zhang, Chenchen EP05.03-012
Zhang, Christopher Z. EP16.03-015
Zhang, Chuanwu OA10.04
Zhang, Chunfang EP05.02-018
Zhang, Cui-Ying EP08.02-064, EP08.02-064
Zhang, Guangjian E P05.02-009
Zhang, Guifang EP08.01-001
Zhang, Guojun EP08.02-139
Zhang, Guowei EP08.01-001, EP08.02-005
Zhang, Haibo EP14.01-002
Zhang, He-Long EP08.02-064
Zhang, Helong MA14.05
Zhang, hongfang EP16.04-030
Zhang, Hui EP08.02-018, EP08.02-158, WS08.14
Zhang, Huixian EP08.02-069
Zhang, Jane P1.15-07
Zhang, Jia-Tao WS08.05
Zhang, Jian EP08.02-139
Zhang, Jian Jun EP08.01-075, EP08.02-163, MA01.03, OA14.06
Zhang, Jiexia EP08.01-082
Zhang, Jijun EP08.02-038
Zhang, Jinyao EP08.02-159
Zhang, Jitian EP02.03-015
Zhang, Juan EP08.01-070, EP08.01-071, WS08.15
Zhang, Jun EP07.01-019, EP14.03-001
Zhang, Junling EP14.01-001, EP14.01-007, EP14.01-024
Zhang, Junping EP08.01-082
Zhang, Ke EP16.04-030
Zhang, Li EP08.02-068, EP16.01-017, MA14.05
Zhang, Ling OA03.07
Zhang, LinLin EP08.02-169
Zhang, Linyou EP16.01-010
Zhang, Liying EP05.01-020
Zhang, Lulu EP16.02-017
Zhang, Mina EP08.01-001, EP08.02-005, EP08.02-006
Zhang, Minna EP08.02-021, EP08.02-136, EP14.01-021, EP16.04-030
Zhang, Moyan EP16.01-023, WS08.20
Zhang, Nancy P1.15-07
Zhang, Nicole EP08.02-074, MA07.03
Zhang, Niu EP08.02-152, EP16.04-024
Zhang, Pingkuan EP08.02-156
Zhang, Pinkuang MA13.03
Zhang, Qing EP03.01-001
Zhang, Ruiguang MA09.04
Zhang, Shannon S. EP01.06-008
Zhang, Shucai EP08.02-039, EP08.02-139
Zhang, Steven EP08.02-109
Zhang, Su EP02.03-009
Zhang, Suning EP05.02-009
Zhang, Tao EP05.01-004
Zhang, Tongwu EP16.03-020
Zhang, Wei OA05.05
Zhang, Wen MA01.05
Zhang, Xiangyu EP05.02-021
Zhang, Xiaojuan EP08.02-005, EP08.02-006
Zhang, Xin EP16.03-001
Zhang, Xinyong EP08.02-039
Zhang, Xu EP08.02-055
Zhang, Xu-Chao EP08.01-085, WS08.09
Zhang, Yan EP08.02-139, EP14.03-002
Zhang, Yaning EP07.01-002
Zhang, Yanwei EP01.03-010, EP16.02-023, OA05.05
Zhang, Yaxuan EP01.01-012
Zhang, Ye EP08.01-053
Zhang, Yi-Ping EP08.02-064
Zhang, Yiping EP08.02-139, MA14.05, OA03.07
Zhang, Yiran OA12.05
Zhang, Yongchang EP05.02-021
Zhang, Yu EP05.02-016, EP08.02-003, EP08.02-033
Zhang, Yu Zhi EP11.03-003, P1.12-05
Zhang, Yucheng EP11.02-001
Zhang, Zhifeng EP05.02-009
Zhang, Zhigang EP05.01-025
Zhao, Amy OA10.03
Zhao, Bin OA12.06
Zhao, Binsheng P2.12-03
Zhao, Chao EP08.01-035
Zhao, Chen ES26.05
Zhao, Da EP08.02-033
Zhao, Dachuan EP02.03-018
Zhao, Deping EP02.01-007
Zhao, Hui EP08.02-139
Zhao, Jian EP05.02-009, EP05.02-018,
Zhao, Jikai EP16.03-044
Zhao, Jing EP08.01-033, EP08.01-097, EP08.01-107, WS08.16
Zhao, Jingjing EP14.03-005
Zhao, Joseph J. EP01.06-008, EP08.01-101
Zhao, Jun EP08.01-070, EP08.01-071, EP08.01-082, OA02.05, OA03.05, WS08.15
Zhao, Mengmeng EP01.01-001, EP13.01-009
Zhao, Min EP08.02-139
Zhao, Ming Fang WS08.24
Zhao, Pengjun EP08.02-136
Zhao, Ruiying EP16.03-044
Zhao, Shengnan EP11.01-001, EP11.03-004
Zhao, Songzhu EP08.01-062
Zhao, Wei EP01.07-005
Zhao, Weirong EP08.01-009
Zhao, Yanqiu EP08.02-029, OA03.07
Zhao, Yihua EP16.02-002
Zhao, Yizhuo EP08.01-038, EP08.01-039
Zhao, Yuansheng EP08.01-081
Zhao, Yujie EP08.01-051, EP16.03-016, MA13.09
Zhehai, Wang EP08.02-052
Zheng, Bin EP05.02-009
Zheng, Danyang EP14.01-014
Zheng, Hao EP08.01-073

Zheng, Li EP08.02-029
Zheng, Liuqing EP16.03-038
Zheng, Min EP16.03-046
Zheng, Xin EP16.02-016
Zheng, Xinyu EP16.02-016
Zheng, Yating MA05.05
zheng, zhiqin P2.10-03
Zhi, Xiuyi EP08.02-139
Zhong, Chenghua EP05.02-009
Zhong, Dian Sheng EP08.02-169
Zhong, Diansheng EP08.01-073, EP08.02-063
Zhong, Hua EP05.01-36, EP08.01-102, EP08.01-103, EP16.01-032, EP16.02-028, OA05.05
Zhong, Runbo EP08.01-052, EP08.01-102, EP08.01-103, WS08.10
Zhong, Wen-Zhao EP16.01-025, EP16.02-024, EP16.03-007, ES36.06, WS08.21
Zhong, Wenzhao EP05.02-006, LA01.04
Zhong, Yifan MA06.09
Zhong, Wen-Zhao EP02.01-012
Zhor, Areen P2.11-01
Zhou, Cai-Cun EP08.02-064
Zhou, Caicun EP05.02-021, EP08.01-014, EP08.01-035, EP08.02-171, EP16.01-005, ES05.01, PL03.09, WS08.03
Zhou, Chao EP05.01-033, EP08.05-003
Zhou, Fei EP16.01-005
Zhou, Hongrui EP16.02-016
Zhou, Jianying EP08.02-029, EP08.02-139, OA03.07
Zhou, Juan EP08.01-097, EP08.01-107, WS08.16
Zhou, Lin EP08.05-004, EP14.03-002
Zhou, Ming EP02.04-010
Zhou, Qing EP08.01-042, EP08.01-085, EP08.02-063, EP08.02-064, EP10.01-010, OA02.05, WS08.09
Zhou, Qinghua EP14.01-003
Zhou, Xiangdong EP08.02-159
Zhou, Yan EP16.02-028
Zhou, Yanwu EP05.02-010
Zhou, Yaxuan EP16.04-025, EP16.04-026, EP16.04-027
Zhou, Yuling EP05.02-021
Zhou, Yuxi MA02.05
Zhou, Zhipeng EP16.01-017
Zhou, Zichao EP07.02-006
Zhou, Zizi EP16.04-031
Zhu, Changbin EP16.01-005, EP16.03-031, EP16.03-032, EP16.03-033, MA05.07, WS08.23
Zhu, Chuan OA02.05
Zhu, Haohua EP07.03-003
Zhu, Hongge EP08.02-095
Zhu, Jeffrey EP02.03-011
Zhu, Jianfei EP02.01-018, EP16.01-012, MA06.07
Zhu, Jiang EP08.05-004, EP14.03-002
Zhu, Kai EP09.01-002
Zhu, Lei MA05.07
Zhu, Lucheng EP08.01-106, EP08.02-021, EP08.02-167, EP10.01-001
Zhu, Qian EP02.04-005
Zhu, Tong EP08.02-052
Zhu, Viola EP08.02-029
Zhu, Viola W. EP08.02-041
Zhu, Yeqing EP01.05-011
Zhu, Yixiang EP08.01-053, EP08.02-091
Zhu, Zhengfei P2.10-03
Zhuang, Wu EP08.02-139, OA03.07
Zhuang, Yan EP14.01-007
Zhuo, Ming-Lei EP05.02-008
Zhuo, Minglei EP08.01-082
Zhuo, Wen-Lei EP08.02-064
Zippelius, Alfred EP16.01-018, MA12.04
Znati, Kaoutar EP16.04-018
Zo, Jae Ill MA03.03
Zou, Benkun P1.11-02
Zou, Binwen EP14.03-002
Zou, Xiaoke EP10.01-012
Zou, Xiaoteng EP08.02-152, EP16.04-024
Zou, Zihua EP08.02-007, EP08.02-008, EP08.02-009
Zucali, Paolo MA10.07
Zugazagoitia, Jon P2.12-01
Zuhour, Areen EP01.02-002
Zukin, Mauro EP03.01-003
Zullo, Lodovica EP08.01-088
Zulueta, Javier P1.02-02
Zuniga, Richard EP16.02-002



11 MAPS & FLOOR PLANS

MAPS & FLOOR PLANS

Messe Wien Exhibition and Congress Center

MAPS & FLOOR PLANS

Foyer D and Hall C



FOYER D | REGISTRATION, HELP DESK, COAT & BAGGAGE CHECK

HALL C | SESSION ROOMS

VIP LOUNGE D | SPEAKER PREVIEW ROOM & LOUNGE



MAPS & FLOOR PLANS

Congress Center



CONGRESS CENTER | SESSION ROOMS
PRESS MEDIA ROOM
SPONSOR MEETING ROOMS

CONGRESS CENTER ▶ GROUND LEVEL



CONGRESS CENTER ▶ UPPER LEVEL



12 EXHIBIT & SUPPORTER INFORMATION

EXHIBIT & SUPPORTER INFORMATION

Conference Supporters

Diamond Level

Gold Level

Silver Level

Bronze Level

Destination Supporter

IASLC 2022 WCLC Official Mobile App

Charging Station Supporter

Collaborator Meeting Space Supporter

Delegate Lounge Supporter

Exhibit Information Desk Supporter

Patient Advocacy Lounge Supporter

Poster Supporter

Welcome Reception Supporter

International Lung Cancer Foundation Benefit Supporting Early Career Researchers Supporter

EXHIBIT FLOOR PLAN



CHARGING STATION

FOOD & BEVERAGES

COLLABORATIVE MEETING SPACE

EXHIBITOR INFOMATION DESK

DELEGATE LOUNGE

INTERNET CAFE

EXHIBITOR LISTINGS

Exhibitors By Name

SPONSOR	BOOTH #
Amgen Inc	410
Amoy Diagnostics Co., Ltd.	307
Arcus Biosciences	310
AstraZeneca	300
Blueprint Medicines	313
Bristol Myers Squibb	319
Caris Life Sciences	503
Context Flow / RevealDx	404
Coreline Soft Co., Ltd.	408
Daiichi Sankyo, Inc.	200
DaSH Global	305
Eli Lilly And Company	401
Exelixis	406
Global Lung Cancer Coalition	507
GSK	308
IASLC	423
Janssen Pharmaceuticals	309
KRAS Kickers	403
Lung Ambition Alliance	301
Lung Cancer Europe	409
Medscape LLC	312
Merck KGaA Darmstadt, Germany	303
Mesothelioma UK	306
MeVis Medical Solutions AG	405
Mirati Therapeutics	315
MSD	311
Novartis	314
Novocure Inc.	201
Optellum	506
Pfizer	500
Sanofi	400
Sanofi Genzyme	400
Scanlan International, Inc.	402
Spectrum Pharmaceuticals, Inc.	504
Takeda	502
Thermo Fisher Scientific	322
Turning Point Therapeutics (TP)	501
Wisepress Ltd	600

Exhibitors By Booth Number

SPONSOR	BOOTH #
Daiichi Sankyo, Inc.	200
Novocure Inc.	201
AstraZeneca	300
Lung Ambition Alliance	301
Merck KGaA Darmstadt, Germany	303
DaSH Global	305
Mesothelioma UK	306
Amoy Diagnostics Co., Ltd.	307
GSK	308
Janssen Pharmaceuticals	309
Arcus Biosciences	310
Merck (MSD)	311
Medscape LLC	312
Blueprint Medicines	313
Novartis	314
Mirati Therapeutics	315
Bristol Myers Squibb	319
Thermo Fisher Scientific	322
Sanofi	400
Sanofi Genzyme	400
Eli Lilly And Company	401
Scanlan International, Inc.	402
KRAS Kickers	403
Context Flow / RevealDx	404
MeVis Medical Solutions AG	405
Exelixis	406
Coreline Soft Co., Ltd.	408
Lung Cancer Europe	409
Amgen Inc	410
IASLC	423
Pfizer	500
Turning Point Therapeutics (TP)	501
Takeda	502
Caris Life Sciences	503
Spectrum Pharmaceuticals, Inc.	504
Optellum	506
Global Lung Cancer Coalition	507
Wisepress Ltd	600

EXHIBITOR & SUPPORTER DESCRIPTIONS

For information, please visit our website:
www.abbvie.com/our-science/therapeutic-focus-areas/oncology.html

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit **www.amgen.com** and follow us on **www.twitter.com/amgen**.

Amoy Diagnostics Co., Ltd. (SZSE: 300685) is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe. For more information, please visit **www.amoydiagnostics.com**.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, please visit **www.arcusbio.com** or follow us on Twitter.

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Bayer is committed to delivering ***SCIENCE FOR A BETTER LIFE*** by advancing a portfolio of innovative treatments. The company has the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes six marketed products across various indications and several compounds in different stages of clinical development. Bayer focuses its research activities on first-in-class innovations across the following scientific platforms: Precision Molecular Oncology, Targeted Alpha Therapies, and Immuno-Oncology. The company's approach to research prioritizes targets and pathways with the potential to impact the way that cancer is treated.

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide.

Blueprint Medicines is a global precision therapy company that aims to invent medicines for people with cancer and hematologic disorders.

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients' lives through science.

Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit **www.CarisLifeSciences.com** or follow us on Twitter **(@CarisLS)**.

Contextflow is your comprehensive solution for all things lung CT: ILD, COPD, and lung cancer. Its clinical decision support system (SEARCH Lung CT), offers quantitative and qualitative analysis of 8 key image patterns and lung nodule detection, segmentation and quantification. By integrating new technology from partner RevealDx, nodules can be further characterized, detecting lung cancer earlier and reducing costs (publication forthcoming).

Contextflow SEARCH Lung CT includes a TIMELINE feature that even quantifies and visualizes nodules over time, allowing physicians to follow treatment progress easily and efficiently. Fully integrated into the radiologist's workflow, our preliminary research shows average reading time is 31% shorter when Contextflow SEARCH Lung CT is available for use (publication forthcoming). See beyond a single case at **contextflow.com**.

Coreline Soft Ltd. was founded in the year 2012 and has its headquarter in Seoul, South Korea.

In September 2020 we founded Coreline Europe in Frankfurt, Germany in order to support the fast-growing European business.
Coreline develops AI based thorax specialized imaging diagnosis package, lung cancer screening (LCS), COPD quantification, and coronary artery calcification (CAC). These modules, so called "Big3", cover the three big diseases of thoracic imaging.

More complex lung modules are part of our portfolio as well, such as texture analysis for ILD/IPF and unique pneumonia detection software including COVID-19. Coreline became official solution provider of 4-IN-THE-LUNG-RUN (4ITLR) project, initiated and led by the Nelson Team (Erasmus MC and iDNA in the Netherlands). 4-IN-THE-LUNG-RUN has set up the goal to establish strategies that lead to cost-efficient lung cancer screening within reach for Europe. Coreline also became the official solution provider for the largest German LCS Study, HANSE Study in Germany initiated by Medizinische Hochschule Hannover- MHH. Besides MHH, there are two additional hospitals taking part in this study: Lungenclinic Grosshansdorf and University Hospital Schleswig-Holstein am Campus Lübeck.

Another remarkable reference where Coreline´s software was chosen is K-LUKAS, Korean Lung Cancer Screening Project. Korea is the second country, followed by USA to adopt the national lung cancer screening program. The Full-Out Screening, started in 2019, involves 270 thousand examinees per year and 300 hospitals.

Most recent achievement for Coreline is beginning to work for the Italian Lung Screening Project (ILSP). Coreline´s goal is not only to contribute to the field of treatment and management, but ideally to the area of prevention and diagnosis also.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

DaSH Global supports the drug approval process through the power of delivering cost-efficient, timely and precise evidence from unique real-world research methodologies. Specialising in MedTech strategies & products through our vision of building collaborative 'disruptive' transformational research platforms from 'joined up' health care.

DaSH Global has launched the Digital Assessment Xchange (DAX) research platform in Lung Cancer & Mesothelioma
www.dash-global.com

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.

To learn more about Lilly's commitment to people with cancer, please visit **www.LillyOncology.com**.

Exelixis is an oncology-focused biotechnology company striving to accelerate discovery, development, and commercialization of new products for difficult-to-treat cancers. Clinical development focuses on continued evaluation of approved products and investigational pipeline. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

Roche is also the world leader in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

For more information, please visit **roche.com**.

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

GSK is focused on maximising patient survival through transformational medicines. GSK's pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination. International Association for the Study of Lung Cancer

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit **www.iaslc.org** for more information.

At Janssen Oncology, our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those living with cancer begins with a very considered step forwards. Whether it's finding a novel solution, a new indication approval, or even just reaching one more patient. That's The Power of Purpose™.

KRAS Kickers is a patient founded organization that connects people to current research, resources, and community to kick cancer's KRAS. KRAS Kickers operates under the Dusty Joy Foundation, a 501(c)(3) nonprofit organization with the mission of advancing education, early detection, optimal care, and empathy to people impacted by lung cancer and other cancers triggered by specific biomarkers.

Terri Conneran, who has been battling lung cancer since 2017, founded KRAS Kickers to create a network for patients and families in search of KRAS information and support. KRAS Kickers focuses on people with any KRAS oncogene cancer including patients, survivors, and all who care. Within KRAS Kickers, members engage with leading doctors, researchers, and advocates, build community, and share their stories to give hope to all with a KRAS biomarker.

The KRAS Kickers community believes that hope shared is hope multiplied. The organization actively monitors and shares KRAS-related research developments, information, and clinical trials to help patients find answers, explore treatment options, and connect with others on a similar journey.
To learn more about KRAS Kickers, visit **KRASKickers.org**, connect on Facebook, or join the conversation on Twitter.

LuCE is the voice of Europeans impacted by lung cancer with a core purpose to Represent common interests of the lung cancer patient community in Europe.

We Collaborate with members and other stakeholders to Strengthen the voice of the lung cancer patient community and work to destigmatising the disease to ensure that those impactad by lung cancer get the care they need to achieve the best possible outcomes. We Act to address common problems by mobilising and leading collective action together with LuCE members, empowering them to ensure strong and effective lung cancer patient advocacy and to Amplify the patient voice by collaborating with all stakeholders with the power to improve the lives of people affected by lung cancer across Europe.

As a community we prioritise the needs and interests of those living with lung cancer, by working together to drive the changes needed to improve lung cancer outcomes. Our solidarity creates a strong community that is committed to helping each other achieve our common goals and to be as representative as possible of the European lung cancer patient community

Our organizational values ensure that we work in a professional, respectful, ethical manner with integrity and are accountable for all that we do.

Medscape is the leading source of clinical news, health information, medical education and point-of-care tools for health care professionals across more than 30 specialty areas. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools.

Merck KGaA, Darmstadt, Germany is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at **www.merckgrouponcology.com**.

Mesothelioma UK is the national charity for anyone affected by mesothelioma. We exist to support people with mesothelioma to live better and live longer and to prevent mesothelioma happening to future generations. We will do this by advocating for better treatment and care, enhancing quality of life, supporting research and amplifying the patient's voice.

The focus of our charitable activity since our foundation has been to provide access to specialist nurses at the point of need, in local hospitals across the UK. Mesothelioma Clinical Nurse Specialists provide a large range of benefits including; specialist expertise available to patients, increased access to clinical trials, an increase in the number of patients accessing treatment, a lower rate of unplanned admissions, better management of symptoms and an overall increase in the quality of life for patients.

At Mesothelioma UK, we also provide a number of other services to support anyone affected by mesothelioma. These include a Freephone Support Line, three specialist benefits advisors, a travel grant to support the cost of accessing clinical trials, a dedicated research centre at Sheffield University and a comprehensive information service accredited by the Patient Information Forum. Services such as this helped us directly support 1900 patients or carers in 2020/21 and reach a further ~500 people indirectly.

We understand that people diagnosed with mesothelioma feel very strongly about preventing future cases. That is why we work closely with partner organisations to raise awareness of asbestos and to shine a light on the devastating impact of mesothelioma.

MeVis Medical Solutions AG develops software for the analysis and processing of medical imaging data. Focus is the image-based early detection of cancer. Its state-of-the-art software solutions support the image-based early detection of lung cancer with dedicated reading software and how it can be used in lung cancer screening settings.

Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer.

At MSD, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at **https://www.novartis.com**

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields, TTFields. TTFields are electric fields that disrupt cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Optellum is a commercial-stage lung health company providing Artificial Intelligence decision support software that assists physicians in early diagnosis and optimal treatment for their patients. The company was founded so that every lung disease patient is diagnosed and treated at the earliest possible stage, when chances of cure are the highest. Optellum's roadmap extends beyond lung cancer diagnosis and treatment to other deadly diseases of the lungs, including interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD). Optellum has headquarters at the Oxford Centre for Innovation in Oxford, United Kingdom and a U.S. office at the Texas Medical Center in Houston, TX. Optellum has received grant funding from InnovateUK, the National Institute for Health Research (NIHR), the NHS AI Lab, The Accelerated Access Collaborative (AAC), MedCity and EIT Health. For more information, visit optellum.com, or follow us LinkedIn and Twitter.

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.

RMEI Medical Education, LLC (RMEI) is an established US-based provider of accredited continuing education, founded in 2005. With an emphasis on rigorous learner data analytics to inform course design, delivery, and assessment, RMEI works to elevate the dialogue on what makes for effective education. By creating original and evidence-based educational designs, such as Clinical Convergence®, Clinical Consults®, and the Care Team Forum®, RMEI seeks to foster greater collaboration within multidisciplinary care teams and a stronger commitment to patient engagement. RMEI is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Sanofi's Specialty Care business is committed to meeting significant unmet medical needs. In oncology, we are building on a rich legacy with a strong pipeline and a continued commitment to contribute meaningful solutions for patients with cancer. Through rigorous drug discovery and development rooted in cutting-edge science and innovative technologies, we are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at **www.sanofi.com.**

Since 2007, Sanofi and Regeneron have collaborated to help people with conditions that are often difficult to diagnose and treat, using innovative technology platforms. Sanofi is an innovative global healthcare company that provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally. Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions..

Celebrating 100 Years of Excellence ...and Our Journey Continues!
The highest quality surgical instruments have been designed and manufactured by the Scanlan Family since 1921.

Experience the Scanlan Difference at **Exhibit #402**

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit **www.sppirx.com**.

Takeda Oncology is structured to ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to market. Built on a legacy foundation and structured for agility, our leaders have proven experience to drive future growth.

We've demonstrated leadership in the treatment of hematologic cancers and solid tumors, and we're now leveraging that expertise to advance cutting-edge science through multiple platforms, partnerships and therapeutic approaches. We are focused on collaborating with leading scientific teams around the globe to accelerate remarkable innovation, including by leveraging the power of innate immunity to enhance and broaden the impact of immunotherapy.

We complement our deep in-house expertise with a network of symbiotic external partnerships to unlock the most promising science wherever it emerges. We fuel our relationships with academic, biotechnology and pharmaceutical partners with mutual respect, shared knowledge, scientific rigor and agility to find the best way to attack cancer. We are structured to ensure a tight connection from research to development to commercialization to rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients.

Takeda Oncology: *We aspire to cure cancer with inspiration from patients and innovation from everywhere*.

For more information, visit **www.takedaoncology.com**

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner, and safer. Our clinical next-generation sequencing (NGS) division focuses on delivering simple, fast and cost effective NGS technology for a range of applications. We are enabling precision oncology with easily implementable Oncomine™ assays. Our latest development, the Ion Torrent™ Genexus™ system, provides a highly automated end-to-end workflow allowing laboratories to deliver NGS results in as little as one day.

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. Its lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. The company's current pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC; TPX-0046, targeting RET; and TPX-0131, a next-generation ALK inhibitor. To learn more, visit **www.tptherapeutics.com**.

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

13 INDUSTRY SYMPOSIA

Saturday, August 6, 2022

10:45 - 11:45
IS01 Industry Sponsored Symposium by Abbvie Global: c-Met Dysregulation: Targeted Agents and Their Emerging Role in Advanced NSCLC

HALL C7

Chair: Jair Bar, Israel

10:45 - 10:50
IS01.01 Introduction and Opening Remarks
Jair Bar, Israel

10:50 - 11:05
IS01.02 c-Met Testing and Challenges Associated with Biomarker Testing in NSCLC Patients
Jair Bar, Israel

11:05 - 11:20
IS01.03 Role of c-MET Dysregulation in NSCLC
Shobhit Baijal, United Kingdom

11:20 - 11:35
IS01.04 Clinical Data Available on Agents Targeting c-Met Dysregulation in NSCLC
Alona Zer, Israel

11:35 - 11:40
IS01.05 Live Q&A

11:40 - 11:45
IS01.06 Conclusion and Evaluation
Jair Bar, Israel

12:00 - 13:00
IS03 Industry Sponsored Symposium by Mirati Therapeutics: Future Directions in NSCLC: Tailoring Treatment Options

HALL C2 | LIGHT LUNCH REFRESHMENTS PROVIDED

Chair: David Planchard, France

12:00 - 12:05
IS03.01 Welcome and and Introduction
David Planchard, France

12:05 - 12:15
IS03.02 The Changing Landscape in NSCLC
David Planchard, France

12:15 - 12:30
IS03.03 New Approaches for Overcoming CPI Resistance in NSCLC
David Carbone, United States

12:30 - 12:50
IS03.04 Targeting KRAS: Novel Opportunities for KRASG12C-Driven NSCLC
Marina Garassino, United States

12:55 - 13:00
IS03.05 Summary and Q&A

12:00 - 13:00
IS04 Industry Sponsored Symposium by Novartis: Novel Anti–PD-(L) 1/anti-TIGIT Combinations: Are these Breaking New Ground in NSCLC?

HALL C1 | LIGHT LUNCH REFRESHMENTS PROVIDED

Chair: Barbara Melosky, Canada

12:00 - 12:05
IS04.01 Welcome and Program Overview
Barbara Melosky, Canada

12:05 - 12:20
IS04.02 Laying the Foundation: The Need to Go Further with IO in Advanced NSCLC
Riyaz Shah, United Kingdom

12:20 - 12:35
IS04.03 Building Upward: Emerging Anti-PD-(L)1/ Anti-TIGIT Combinations in NSCLC
Giorgio Scagliotti, Italy

12:35 - 12:50
IS04.04 Panel Discussion: How to Break New Ground with Anti-TIGIT Combinations

12:50 - 13:00
IS04.05 Q&A Session

13:15 - 14:15
IS05 Industry Sponsored Symposium by Merck KGaA Darmstadt: Decisive Moments in the Treatment of MET Exon 14 Skipping NSCLC

HALL C7 | LIGHT LUNCH REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Sanjay Popat, United Kingdom

13:15 - 13:20
IS05.01 A Moment to Welcome You
Sanjay Popat, United Kingdom

13:20 - 13:25
IS05.02 Take A Moment to Consider Identification and Treatment
Sanjay Popat, United Kingdom, Sonja Loges, Germany, Paul Paik, United States, Enriqueta Felip, Spain

13: 25 - 13:40
IS05.03 A Moment of Clarity: Has Our VISION1 for Metex14 Skipping Become a Reality?
Sanjay Popat, United Kingdom, Sonja Loges, Germany, Paul Paik, United States, Enriqueta Felip, Spain

13:40 - 13:55
IS05.04 Seize The Moment: The Benefits of Early Treatment
Sanjay Popat, United Kingdom, Sonja Loges, Germany, Paul Paik, United States, Enriqueta Felip, Spain

13:55 - 14:10
IS05.05 Make Every Moment Matter: Optimising Treatment
Sanjay Popat, United Kingdom, Sonja Loges, Germany, Paul Paik, United States, Enriqueta Felip, Spain

14:10 - 14:15
IS05.06 A Moment to Reflect on METex14 Skipping
Sanjay Popat, United Kingdom

13:15 - 14:15
IS06 Industry Sponsored Symposium by Takeda: Precision Medicine in Lung Cancer: Learnings from Established and Emerging Targets

HALL C8 | LIGHT LUNCH REFRESHMENTS PROVIDED

Chair: Jyoti D. Patel, United States

13:15 - 13:20
IS06.01 Welcome and Introduction
Jyoti D. Patel, United States

13:20 - 13:30
IS06.02 Success, Challenges, and Lessons Learned in the Evolution of Precision Medicine
Jyoti D. Patel, United States

13:30 - 13:50
IS06.03 Treatment Selection in ALK-Positive Metastatic NSCLC: Navigating Treatment for an Established Biomarker
Stephen V. Liu, United States

13:50 - 14:05
IS06.04 Current and Emerging Treatment Standards in EGFR Exon 20 Insertion+Metastatic NSCLC
Daniel Shao-Weng Tan, Singapore

14:05 - 14:15
IS06.05 Panel Discussion and Q&A

14:30 - 15:30
IS07 Satellite CME Symposium by Liberum IME, supported by Bayer, Eli Lilly and Illumina: Optimizing Biomarker-Driven Therapy in NSCLC

CME ACCREDITED BY OTHER PROVIDER

HALL C1 | LIGHT REFRESHMENTS PROVIDED

Chair: Fernando López-Ríos, Spain

14:30 - 14:35
IS07.01 Welcome, Pre-activity Information & Pre-assessment
Fernando López-Ríos, Spain

14:35 - 14:45
IS07.02 Implementation and Interpretation of Biomarker Testing in NSCLC
Fernando López-Ríos, Spain

14:45 - 14:55
IS07.03 Biomarker-driven Approaches: Combined Prevalence and Individual Outcomes
Robin Cornelissen, Netherlands

14:55 - 15:00
IS07.04 How to Use Classroom to Clinic™
Fernando López-Ríos, Spain

15:00 - 15:15
IS07.05 Workshop: Applying Guideline Best Practice to Case Studies

15:15 - 15:18
IS07.06 Post-assessment and Commitment to Change

15:18 – 15:25
IS07.07 Q&A Session

15:25 – 15:30
IS07.08 Close
Fernando López-Ríos, Spain

14:30 - 15:30
IS08 Industry Sponsored Symposium by Pfizer: Is it Time to Raise the Bar for ALK+ NSCLC Patients?

HALL C2 | LIGHT REFRESHMENTS PROVIDED

Chair: Justin Gainor, United States

14:30 - 14:35
IS08.01 Welcome and Introduction
Justin Gainor, United States

14:35 - 14:45
IS08.02 New Data and Updated Expectations for First-Line Therapy
Alessandra Bearz, Italy

14:45 - 14:55
IS08.03 Managing Aes and Keeping Patients on Treatment
Rosario Garcia Campelo, Spain

14:55 – 15:05
IS08.04 What Next? Options After Progression on 2nd- and 3rd-Generation TKIs
Alesandra Bearz, Italy

15:05 – 15:15
IS08.05 The Future of ALK+ NSCLC
Justin Gainor, United States

15:15 - 15:25
IS08.06 Live Q&A

15:25 - 15:30
IS08.07 Summary and Close
Justin Gainor, United States

15:45 - 16:45
IS09 Industry Sponsored Symposium by AstraZeneca: Embarking on The Next Chapter in SCLC: Challenges and Opportunities

HALL C7 | LIGHT REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Lauren Byers, United States

15:45 - 15:50
IS09.01 Introduction
Lauren Byers, United States

15:50 - 16:05
IS09.02 Current Treatment Landscape for ES-SCLC and the Unmet Need
Andrea Ardizzoni, Italy

16:05 - 16:25
IS09.03 Panel Discussion: Improving Outcomes for Patients with SCLC – Today and Tomorrow
Lauren Byers, United States, Andrea Ardizzoni, Italy, Taofeek Owonikoko, United States, Keunchil Park, South Korea

16:25 - 16:40
IS09.04 Audience Q&A

16:40 - 16:45
IS09.05 Closing Remarks
Lauren Byers, United States

15:45 - 16:45
IS10 Industry Sponsored Symposium by Sanofi: A New Frontier: Emerging Biomarkers and Antibody-Drug Conjugates in Advanced NSCLC

HALL C8 | LIGHT REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: David R. Gandara, United States

15:45 - 16:00
IS10.01 Welcome and Overview of the Current Treatment Algorithms for Patients with NSCLC
David R. Gandara, United States

16:00 - 16:15
IS10.02 What, How, and Where Do We Test Emerging Biomarkers?
Ming Tsao, Canada

16:15 - 16:30
IS10.03 Emerging and Novel Therapies in Patients Without Driver Mutations
Alastair Greystoke, United Kingdom

16:30 - 16:40
IS10.04 Roundtable Discussion

16:40 - 16:45
IS10.05 Final Remarks
David R. Gandara, United States

INDUSTRY SYMPOSIA - SUNDAY, AUGUST 7, 2022

Sunday, August 7, 2022

13:15 - 14:15
IS11 Industry Sponsored Symposium by Amgen Inc.: Driving Advancements in the Treatment of Lung Cancer

HALL C8 | LIGHT LUNCH REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Luis Paz-Ares, Spain

13:15 - 13:30
IS11.01 Welcome and Introduction to Innovative Treatments for New Targets in Lung Cancer
Luis Paz-Ares, Spain

13:30 - 13:45
IS11.02 A Step Forward: KRASG12C Inhibitors in NSCLC Today and in the Future
Natasha Leighl, Canada

13:45 - 14:00
IS11.03 Striving for Improvement in SCLC: Off-the-shelf T Cell Engaging Therapies Targeting DLL3
Michael Boyer, Australia

14:00 - 14:15
IS11.04 Panel Discussion and Q&A

13:15 - 14:15
IS12 Industry Sponsored Symposium by AstraZeneca: Expanding Horizons in Metastatic NSCLC: Unmet Need and Future Directions

HALL C7 | LIGHT LUNCH REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: John Heymach, United States

13:15 - 13:20
IS12.01 Welcome and Introduction
John Heymach, United States

13:20 - 13:35
IS12.02 Biomarker Identification of Hard-to-treat Patients: Shining a Spotlight on Unmet Need
Niels, Reinmuth, Germany

13:35 - 13:50
IS12.03 Seeing the Unseen: Techniques and Practical Strategies for Broad Molecular Profiling
Elena Guerini-Rocco, Italy

13:50 - 14:15
IS12.04 Panel Discussion and Q&A

13:15 - 14:15
IS13 Industry Sponsored Symposium by Janssen Pharmaceuticals: Expanding Horizons for the Targeted Management of EGFR-Mutant NSCLC

STRAUSS 3 | LIGHT LUNCH REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Martin Reck, Germany

13:15 - 13:17
IS13.01 Weclome and Introduction
Martin Reck, Germany

13:17 - 13:32
IS13.02/IS13.03 What's New in Molecular Diagnostics for EGFR-Mutant NSCLC?
Umberto Malapelle, Italy, Sabine Merkelbach-Bruse, Germany

13:32 - 13:47
IS13.04 EGFR Exon 20 Insertion Mutations: A New Target for an Old Mutation
Maximilian Hochmair, Austria

13:47 – 14:02
IS13.04 Novel Approaches in Treatment-Resistant Advanced EGFR-Mutant NSCLC
Jordi Remon, Spain

14:02 – 14:12
IS13.06 Live Q&A

14:12 - 14:15
IS13.07 Key Learnings and Closing Remarks
Martin Reck, Germany

18:00 - 19:00
IS14 - Industry Sponsored Symposium by RMEI, Supported by Regeneron and Sanofi: Harnessing the Full Potential of Immunotherapy in Frontline Treatment of Locally Advanced or Metastatic NSCLC

HALL C7 | LIGHT REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Jared Weiss, United States

18:00 - 18:05
IS14.01 Opening Ceremonies
Jared Weiss, United States

18:05 - 18:20
IS14.02 Use of Biomarker Testing in Advanced NSCLC
Aleš Ryška, Czech Republic

18:20 - 18:35
IS14.03 Selecting Frontline Immunotherapy in Advanced NSCLC
Jared Weiss, United States

18:35 - 18:50
IS14.04 Managing Immunotherapy-Related Adverse Events in NSCLC
Mihaela Aldea, France

18:50 -19:00
IS14.05 Closing Ceremonies
Jared Weiss, United States

Monday, August 8, 2022

13:30 - 14:30
IS20 Industry Sponsored Symposium by AstraZeneca: Current and Future Management of Patients with Advanced EGFRm NSCLC Progressing on Third-generation EGFR-TKIs

HALL C7 | LIGHT LUNCH REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Pasi Jänne, United States

13:30 - 13:33
IS20.01 Welcome and Introductions
Pasi Jänne, United States

13:33 - 13:43
IS20.02 Current Management of Patients Progressing on Third-Generation EGFR-TKIs
Myung-Ju Ahn, South Korea

13:43 - 13:58
IS20.03 Evolving Treatment Landscape for Patients with Advanced EGFRm NSCLC and c-MET Driven Resistance to Third-Generation EGFR-TKIs
Pasi Jänne, United States

13:58 – 14:13
IS20.04 Optimal Biomarker Testing to Identify Patients with MET-Driven Resistance
Michelle Shiller, United States

14:13 – 14:28
IS20.05 Panel Discussion and Live Q&A

14:28 – 14:30
IS20.06 Summary and Close
Pasi Jänne, United States

13:30 - 14:30
IS21 Industry Sponsored Symposium by Daiichi Sankyo, Inc.: The Expanding Toolbox: Key Updates for ADCs in Lung Cancer

STRAUSS 3 | LIGHT LUNCH REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Michael Thomas, Germany

13:30 - 13:32
IS21.01 Welcome and Introduction
Michael Thomas, Germany

13:32 - 13:52
IS21.02 Emerging Targets for Therapeutic Strategies
Michael Thomas, Germany

13:52 - 14:12
IS21.03 Key Data Releases for ADCs in NSCLC
Tony Mok, Hong Kong

14:12 - 14:22
IS21.04 Implications of Emerging Data for SCLC
Charles Rudin, United States

14:22 - 14:30
IS21.05 Q&A

13:30 - 14:30
IS22 Industry Sponsored Symposium by Sanofi Regeneron Alliance - Breaking Barriers with Immunotherapy in Squamous Cell Carcinoma of the Lung: Challenges and Opportunities in Management

HALL C8 | LIGHT LUNCH REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Federico Cappuzzo, Italy

13:30 - 13:35
IS22.01 Welcome and Introductions
Federico Cappuzzo, Italy

13:35 - 13:50
IS22.02 Focusing on the Challenge of Squamous Lung Cancer
Jürgen Wolf, Netherlands

13:50 -14:05
IS22.03 Immunotherapy Outcomes for Advanced Squamous Cancers of the Lung
Johan Vansteenkiste, Belgium

14:05 - 14:30
IS22.04 Case Study Panel Discussion, Ask the Faculty and Concluding Remarks

18:00 - 19:00
IS23 Satellite CME Symposium by Medscape Oncology Global, supported by Daiichi Sankyo: The Potential of Antibody-Drug Conjugates in Non-Small Cell Lung Cancer - From Mechanism to Action

CME ACCREDITED BY OTHER PROVIDER

STRAUSS 3 | LIGHT LUNCH REFRESHMENTS PROVIDED | LIVE-STREAM

Chair: Hossein Borghaei, United States

18:00 - 18:03
IS23.01 Welcome and Introductions
Hossein Borghaei, United States

18:03 - 18:18
IS23.02 Mechanism of Action and Targets of ADCs in NSCLC
Antonio Passaro, Italy

18:18 - 18:35
IS23.03 ADCs in NSCLC: What Do the Data Show?
Hossein Borghaei, United States

18:35 - 18:50
IS23.04 ADCs in the Clinic: Challenges and Perspectives
Ticiana Leal, United States

18:50 - 18:59
IS23.05 Audience Q&A

18:59 - 19:00
IS23.06 Concluding Remarks
Hossein Borghaei, United States

18:00 - 19:00
IS24 Industry Sponsored Symposium by MSD: New Frontiers in the Management of NSCLC

HALL C7 | **LIGHT REFRESHMENTS PROVIDED**

Chair: Solange Peters, Switzerland

18:00 - 18:05
IS24.01 Welcome and Introductions
Solange Peters, Switzerland

18:05 - 18:15
IS24.02 Evolving Treatment Landscape in Metastatic NSCLC
Solange Peters, Switzerland

18:15 - 18:30
IS24.03 Emergence of Immuno-Oncology in Early Stage Operable NSCLC
Benjamin Besse, France

18:30 - 18:45
IS24.04 A Surgeon's Perspective on Treatment in Early-Stage Operable NSCLC
David J. Finey, United States

18:45 - 18:59
IS24.05 Panel Discussion and Q&A

18:59 - 19:00
IS24.06 Closing Remarks
Solange Peters, Switzerland

www.iaslc.org #WCLC23

2023 World Conference on Lung Cancer

SEPTEMBER 9-12, 2023 | SINGAPORE

IASLC

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

Conquering Thoracic Cancers Worldwide

TTFIELDS

TUMOR TREATING FIELDS THERAPY

EXPANDING THE POSSIBILITIES **BOOTH #201**

The Queen, in chess, holds the most versatile range of possible strategic moves.

Solid tumor treatment calls for an innovative versatile modality.
TTFields are electric fields that disrupt multiple cellular processes critical for cancer cell viability and tumor progression.

Please visit tumortreatingfieldstherapy.com to discover more

©2022 Novocure GmbH. All rights reserved. Novocure is a trademark of Novocure GmbH. GLB-OPT-00083 August 2022

novocure®
patientforward